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ABSTRACT 
 
1. Background. Paediatric neuroimmunology is a rapidly evolving field both as regards clinical-
radiological phenotyping, biomarker development, and therapeutic possibilities. In this latter aspect, 
while a growing armamentarium of treating agents is becoming available, this is not mirrored by quality 
evidence and definite recommendations on treatment strategies, drugs’ efficacy and tolerability. This is 
especially true in paediatric age, where most data is derived from adult studies.  
Objective. To investigate clinical and therapeutic aspects of decision making in paediatric autoimmune 
and immune-mediated inflammatory conditions. In particular, the aims of this work include: exploring 
the available immune therapeutic agents and their mechanisms of action; investigating the use of 
immune therapy in autoimmune encephalitis; investigating the use, efficacy and tolerability of 
individual immune therapeutic agents in different clinical situations in paediatric neurology 
(intravenous immunoglobulin in Sydenham’s chorea; intravenous immunoglobulin in paediatric 
neurology; therapeutic plasma exchange in anti-N-methyl-D-aspartate receptor (anti-NMDAR) 
encephalitis; rituximab in neuromyelitis optica spectrum disorders; mycophenolate mofetil, azathioprine 
and methotrexate in anti-NMDAR encephalitis; mycophenolate mofetil in paediatric autoimmune and 
immune-mediated central nervous system (CNS) conditions).  
2. Methods. The present PhD thesis is articulated into sub-projects carried out at the Department of 
Women's and Children's Health in Padua, Italy, and at the Children's Hospital at Westmead, Sydney, 
Australia. Study designs include six literature reviews (available immune therapeutic agents and their 
mechanisms of action; immune therapy in autoimmune encephalitis; immune therapy in herpes simplex 
virus-induced anti-NMDAR encephalitis; intravenous immunoglobulin in Sydenham’s chorea; 
therapeutic plasma exchange in paediatric anti-NMDAR encephalitis; mycophenolate mofetil, 
azathioprine and methotrexate in paediatric anti-NMDAR encephalitis) and four original studies with 
observational retrospective design (immune therapy in paediatric anti-NMDAR encephalitis; 
intravenous immunoglobulin in paediatric neurology; rituximab in neuromyelitis optica spectrum 
disorders; mycophenolate mofetil in paediatric autoimmune and immune-mediated CNS conditions). Of 
these latter original studies, one includes an Italian population (immune therapy in paediatric anti-
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NMDAR encephalitis), one a single-center Australian population (intravenous immunoglobulin in 
paediatric neurology), and two include an international cohort of paediatric patients (rituximab in 
neuromyelitis optica spectrum disorders; mycophenolate mofetil in paediatric autoimmune and immune-
mediated CNS conditions). Most of the projects have been concluded, whereas two are in their final 
phases (mycophenolate mofetil, azathioprine and methotrexate in paediatric anti-NMDAR encephalitis; 
mycophenolate mofetil in paediatric autoimmune and immune-mediated CNS conditions). 
3. Results. Key findings are presented for the main study objectives. 
3.1 Immune therapeutic agents and their mechanisms of action.  
3.1.1 Immune therapeutic agents and their mechanisms of action (literature review). First-line 
treatments typically include corticosteroids, intravenous immunoglobulin, and plasmapheresis, while 
for severe disease second-line ‘induction’ agents such as rituximab or cyclophosphamide are used. 
Steroid-sparing agents such as mycophenolate mofetil, azathioprine or methotrexate are often used 
in potentially relapsing or corticosteroid-dependent diseases. Lessons from adult neuroimmunology 
and rheumatology could be translated into pediatric autoimmune CNS disease in the future, 
including the potential utility of monoclonal antibodies targeting lymphocytes, adhesion molecules 
for lymphocytic migration, cytokines or their receptors, or complement. Finally, many agents used in 
other fields have multiple mechanisms of action, including immunomodulation, with potential utility 
in neuroimmunology, such as antibiotics, psychotropic drugs, probiotics, gut health, and ketogenic 
diet.  
3.2 Immune therapy in autoimmune encephalitis.  
3.2.1 Autoimmune encephalitis with antibodies targeting neuronal surface antigens (systematic 
literature review). Most studies on immune therapy in autoimmune encephalitis associated with 
antibodies to cell surface antigens are retrospective cohorts, and there are no randomised controlled 
trials. Most clinicians use first-line therapy (steroids, intravenous immunoglobulin, plasma 
exchange), and if severe or refractory, second-line therapy (rituximab, cyclophosphamide). When 
present, tumours should be removed. There are common therapeutic themes emerging. Firstly, 
patients given immune therapy do better and relapse less than patients given no treatment. Secondly, 
patients given early treatment do better. And thirdly, when patients fail first-line therapy, second-line 
5 
 
therapy improves outcomes and reduces relapses. Given the retrospective uncontrolled data, the 
literature has inherent bias, including severity and reporting bias.  
3.2.2 Clinical and therapeutic aspects of the Italian cohort of paediatric anti-NMDAR encephalitis 
(national retrospective observational study). We described a new case series of 20 children (50% 
females), with anti-NMDAR encephalitis referred by 13 Italian centers (mean age at onset 8 years, 
range 3-17). Onset was with neurological symptoms in 70%, and with behavioral/psychiatric 
disturbances in 30%. Most patients developed a severe clinical picture (90%), and 41% experienced 
medical complications; children 12-18 years old seemed to be more severe and symptomatic than 
younger patients. All children received first-line immune therapy; second-line treatment was 
administered to 45%. Relapses occurred in 15%. At last follow-up (mean 23.9 months, range 5-82), 
85% patients had modified Rankin Scale (mRS) 0-1; this rate was higher among older patients, and 
in those receiving first immune therapy within 1 month.  
3.2.3 Herpes simplex virus-induced anti-NMDAR encephalitis (systematic literature review). 43 
patients with herpes simplex encephalitis (HSE) followed by anti-NMDAR encephalitis were 
identified in the literature (31 children). Latency between HSE and anti-NMDAR encephalitis was 
significantly shorter in children than adults (median 24 vs. 40.5 days; p=0.0057). Compared to the 
HSE phase, anti-NMDAR encephalitis was characterized by significantly higher frequency of 
movement disorder (2.5% in HSE, vs. 75% in anti-NMDAR encephalitis; p<.0001), and by 
significantly lower rate of seizures (70% in HSE, vs. 30% in anti-NMDAR encephalitis; p=0.0011). 
Compared to adults, during anti-NMDAR encephalitis children had significantly more movement 
disorder (86.7% in children, vs. 40% in adults; p=0.0064) and less psychiatric symptoms (41.9% in 
children, vs. 90% in adults; p=0.0251). Children also had a slightly higher median mRS than adults 
during the acute phase of anti-NMDAR encephalitis (5 vs. 4; p=0.0146). During anti-NMDAR 
encephalitis, 84.6% patients received acyclovir (for ≤7 days in 22.7%; long-term antivirals in 18% 
only), and 92.7% immune therapy, but none had recurrence of HSE clinically or using CSF HSV-
PCR (median follow-up 7 months).  
3.3 Modes of use, efficacy and tolerability of individual immune therapeutic agents in different clinical 
situations in paediatric neurology. 
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3.3.1 Intravenous immunoglobulin in Sydenham’s chorea (systematic literature review). The studies 
reviewed on intravenous immunoglobulin in Sydenham’s chorea demonstrate a short-term benefit in 
symptomatic improvement. However, they do not clarify an optimum timing and duration for use of 
intravenous immunoglobulin, and do not provide data on the effect on long-term neurological and 
psychiatric complications. 
3.3.2 Intravenous immunoglobulin in paediatric neurology (single-center retrospective 
observational study). 196 children received intravenous immunoglobulin for neuroimmunological 
indications at the Children’s Hospital at Westmead, Australia, between 2000 and 2014 (28.1% had 
Guillain-Barré syndrome) (15.5% of all hospital indications). In total, 1669 intravenous 
immunoglobulin courses were administered (total 57221 g, median 78 g/patient, range 12-5748 g). 
Highest median number of courses was in chronic inflammatory demyelinating polyneuropathies, 
opsoclonus-myoclonus-ataxia, suspected immune-mediated epilepsies and Rasmussen’s 
encephalitis. Adverse reactions occurred in 25.5%, mostly minor. Outcome at follow-up was best in 
anti-NMDAR encephalitis, Guillain-Barré syndrome and myasthenia gravis, and worst in 
Rasmussen’s encephalitis and epilepsies. The total cost for intravenous immunoglobulin was 
2,595,907 American dollars (median $3,538/patient, range $544-260,766). 45.4%-57.1% patients 
received intravenous immunoglobulin for ‘weak’ indications or ‘not listed’ in international 
guidelines. Some entities frequently treated with intravenous immunoglobulin in current practice, 
such as anti-NMDAR encephalitis and transverse myelitis, are not listed in most guidelines. 
3.3.3 Therapeutic plasma exchange in anti-NMDAR encephalitis (systematic literature review). 71 
articles were identified (mostly retrospective), reporting a total of 242 children treated with 
therapeutic plasma exchange for anti-NMDAR encephalitis (73.2%, 93/127 females; median age at 
onset 12 years, range 1-18). Median time to immunotherapy was 21 days (range 0-190). In most 
cases, therapeutic plasma exchange was given with steroids and intravenous immunoglobulin 
(69.5%, 89/128), or steroids only (18%, 23/128); in a minority, it was associated with intravenous 
immunoglobulin only (7%, 9/128), or was the only first-line treatment (5.5%, 7/128). In 54.5% 
(65/119), therapeutic plasma exchange was the third treatment after steroids and intravenous 
immunoglobulin, in 31.1% (37/119) the second after steroids or intravenous immunoglobulin; only 
in 14.3% (17/119) was it the first treatment. Second-line immunotherapies were administered in 
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71.9% (100/139). Higher rates of full/substantial recovery at follow-up were observed with 
immunotherapy given ≤30 days from onset (69.4%, 25/36) compared to later (59.2%, 16/27), and 
when therapeutic plasma exchange was associated with steroids (66.7%, 70/105) rather than not 
(46.7%, 7/15). Significant adverse reactions to therapeutic plasma exchange were reported in 6 
patients. 
3.3.4 Rituximab in paediatric neuromyelitis optica spectrum disorders (international retrospective 
observational study). 16 patients treated with at least two courses of rituximab for neuromyelitis 
optica were included (14 females; mean age 9.6 years, range 1.8-15.3). The patients had a mean of 
6.1 events (range 1-11) during a mean follow-up of 6.1 years (range 1.6-13.6), and received a total of 
76 rituximab courses (mean 4.7, range 2-9) in 42.6-year cohort treatment. Before rituximab, 62.5% 
received azathioprine, mycophenolate mofetil or cyclophosphamide. Mean time from rituximab to 
last documented B cell depletion and first repopulation was 4.5 and 6.8 months respectively, with 
large inter-patient variability. Earliest repopulations (2.7 and 2.9 months) occurred with the lowest 
rituximab doses. Significant reduction between pre and post rituximab annualized relapse rate 
(ARR) was observed (p=0.003). During rituximab, 6 patients were relapse-free, although 21 relapses 
occurred in 10 patients, including 13 ‘repopulation’, 3 ‘depletion’, and 4 ‘depletion failure-related 
relapses’. Of the 13 ‘repopulation relapses’, 4 had CD19 10-50x106cells/L, 10 inadequate 
monitoring (≤1 CD19 in the 4 months before relapses), and 5 delayed re-dosing ≥10 days after 
repopulation detection. 
3.3.5 Mycophenolate mofetil, azathioprine and methotrexate in anti-NMDAR encephalitis 
(systematic literature review). 76 patients treated with mycophenolate 
mofetil/azathioprine/methotrexate for paediatric-onset anti-NMDAR encephalitis were included (age 
range at onset 0.8-18 years; 69.7% females; 49.1% had ≥1 relapse), reported in 37 articles. 
Mycophenolate mofetil was used in 53.9%, azathioprine in 25%, methotrexate in 15.8%; an 
additional 5.3% received two among mycophenolate mofetil/azathioprine/methotrexate. 
Mycophenolate mofetil/azathioprine/methotrexate were not preceded by any second-line therapy 
(rituximab/cyclophosphamide) in 47.7%, and were administered only after relapses in 46.8%. 
Among the subgroup treated with mycophenolate mofetil/azathioprine/methotrexate after the first 
event, relapses occurred in 8.3% only. Time on mycophenolate mofetil/azathioprine/methotrexate 
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was median 9 months (range 1-48). Median annualised relapse rate was 0.45 (mean 1, range 0-6.67) 
before mycophenolate mofetil/azathioprine/methotrexate (excluding onset), and 0 (mean 0.06, range 
0-1.3) during/after mycophenolate mofetil/azathioprine/methotrexate. Adverse reactions were 
reported only for mycophenolate mofetil (cytomegalovirus colitis and respiratory infection; grade 3 
Common Terminology Criteria for Adverse Events v4.0). Relapse rate was significantly higher in 
patients started on first immune therapy (any) >30 days after onset (85.7%) compared to those 
treated early (31.2% (p=0.0272). 
3.3.6 Mycophenolate mofetil in paediatric autoimmune and immune-mediated central nervous 
system conditions (international retrospective observational study). 44 children were included 
(30/44, 68.2% females). 43.2% (19/44) had proven or suspected autoimmune encephalitis, 31.8% 
(14/44) autoimmune inflammatory demyelinating CNS diseases, and 25% (11/44) other 
autoimmune/immune-mediated CNS conditions. Worst mRS was median 4 (range 2-6). Disease 
course was relapsing in 52.3% (23/44), monophasic in 38.6% (17/44), and chronic/chronic-
progressive in 9.1% (4/44). Before mycophenolate mofetil, all patients received first-line (steroids: 
44/44, 100%; intravenous immunoglobulin: 23/44, 52.3%; plasma exchange: 14/44, 31.8%) and 
38.6% (17/44) second-line immune therapies (cyclophosphamide: 12/44, 27.3%; rituximab: 6/44, 
13.6%). Median age at mycophenolate mofetil commencement was 9.3 years (range 1.4-16.4). 
Mycophenolate mofetil was started at median 9.5 months from onset (range 1-127; ≤6 months in 
31.8%, 14/44). In 55% (22/40) of patients, mycophenolate mofetil was started only after ≥2 events 
had occurred. Median duration of treatment with mycophenolate mofetil was 18 months (mean 23.2, 
range 0.3-73). Median annualised relapse rate (excluding patients with chronic/chronic-progressive 
disease) was 0.52 (mean 0.86, range 0-3) before mycophenolate mofetil (excluding first events), and 
0 (mean 0.36, range 0-4.64) during mycophenolate mofetil. 20.5% (8/39) patients relapsed during 
mycophenolate mofetil; compared to patients who did not relapse (31/49, 79.5%), these patients 
were younger (median age at onset 4.2 years versus 7.6), were more frequently females (8/8, 100% 
versus 21/31, 67.7%), had lower rate of second-line treatments before mycophenolate mofetil (1/8, 
12.5% versus 15/31, 48.4%), a later commencement of mycophenolate mofetil (>6 months after 
onset in 7/8, 87.5% versus 22/35, 58.1%), and more frequently they were started on mycophenolate 
mofetil only after ≥2 events had occurred (7/8, 87.5% versus 14/35, 45.2%). Adverse reactions to 
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mycophenolate mofetil occurred in 18.2% (8/44) of cases (6/8: grade 2, 2/8: grade 3 Common 
Terminology Criteria for Adverse Events v4.0). 
4. Conclusion. The present thesis is a collection of ten works exploring several aspects of the clinical 
and therapeutic decision-making in paediatric autoimmune and immune-mediated inflammatory 
conditions. A growing array of immune therapies are becoming available in paediatric neurology, also 
derived from the experience in immune modulation from other fields of paediatrics and in adult patients. 
While quality data and definite recommendations are generally lacking, there are common themes 
emerging, such as the utility of early and aggressive immune therapy in certain clinical situations, such 
as in autoimmune encephalitis. The use of immune therapy is still characterised by a great heterogeneity 
between physicians in many neurological conditions, for examples as regards therapeutic plasma 
exchange and steroid sparers in anti-NMDAR encephalitis, reflecting not only the lack of definite 
recommendations, but also different treating habits and potential practical difficulties, such as with 
therapeutic plasma exchange in children and uncooperative patients. Even when recommendations do 
exist, such as for the use of intravenous immunoglobulin in neurology, current practice is not always 
adherent to the guidelines, suggesting both the need for greater adherence to existing recommendations 
and the need for recommendations to be updated to accommodate emerging indications. In other cases, 
finally, the utility and safety of treatments such as steroid sparing agents warrants further investigations 
in several fields of paediatric neurology, such as in anti-NMDAR encephalitis. In all cases, both 
currently accepted and future potential agents have adverse effects, which can be severe. A 
comprehensive understanding of the therapeutic aspects should not go without the ability to understand 
each clinical situation in all its facets, taking into considerations not only potential effects, adverse 
reactions and mechanisms of treatment agents, but also the pathophysiology, the severity of the acute 
disease, the risk of relapses and of permanent disability, in a complex ‘risk-versus-benefit’ 
determination and a tailored approach 
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LIST OF ACRONYMS AND ABBREVIATIONS 
 
Ab = antibody 
AchR = acetylcholine receptor 
AED = antiepileptic drugs 
AMPAR = α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 
ANA = antinuclear antibodies  
Anti-NMDAR = anti-N-methyl-D-aspartate receptor  
ARR = annualised relapse rate 
AQP4 = aquaporin-4 
AZA = azathioprine 
Caspr2 = contactin-associated protein-2 
CNS = central nervous system 
CRMP5 = collapsin response-mediator protein 5 
CSF = cerebrospinal fluid 
CTCAE = Common Terminology Criteria for Adverse Events 
CYC or CPA = cyclophosphamide 
D2R = dopamine-2 receptor 
DNET = dysembryoplastic neuroepithelial tumour 
DPPX = dipeptidyl-peptidase-like protein-6 
EDSS = Kurtzke Expanded Disability Status Scale 
EE = epileptic encephalopathy 
EEG = electroencephalogram 
F = females 
FBDS = faciobrachial dystonic seizures 
GABAAR = γ-aminobutyric acid-A receptor  
GABABR = γ-aminobutyric acid-B receptor  
GAD = glutamic acid decarboxylase 
GC = glucocorticoid 
GlyR = glycine receptor  
GR = glucocorticoid receptor 
HEK293 = human embryonic kidney cells 
HSE = herpes simplex encephalitis 
HSV = herpes simplex virus 
IL = interleukin 
IT = immune therapy 
IVIG = intravenous immunoglobulin 
IVMP = intravenous methylprednisolone 
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LE = limbic encephalitis 
LGI1 = leucine-rich, glioma-inactivated protein-1  
M = males 
MG = myasthenia gravis 
mGluR5 = metabotropic glutamate receptor 5 
MMF = mycophenolate mofetil 
MOG = myelin oligodendrocyte glycoprotein 
MRI = magnetic resonance imaging 
mRS = modified Rankin Scale 
MS = multiple sclerosis 
MTX = methotrexate 
MUSK = muscle-specific tyrosine kinase 
n.a. = not available 
ON = optic neuritis 
OP = oral prednisone 
PCR = polymerase chain reaction 
PERM = progressive encephalomyelitis with rigidity and myoclonus 
RRMS = relapsing-remitting multiple sclerosis 
RTX = rituximab 
SCLC = small cell lung cancer 
SOX1 = Sry-like high mobility group box 1 
SPS = stiff-person-syndrome 
TNF-α = tumor necrosis factor α 
TPE = therapeutic plasma exchange 
TPO = thyroid peroxidase 
VGCC = voltage-gated calcium channels 
VGKC = voltage-gated potassium channel  
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1. INTRODUCTION 
 
1.1 Context 
 
This PhD thesis is the final result of an interest in the field of paediatric neuroimmunology started 
during the training in paediatric neurology at the Department of Women's and Children's Health in 
Padua, Italy (2010-2015), and developed during my PhD at the University of Padua, Italy, and at the 
Children's Hospital at Westmead, Sydney, Australia (2014-2017).  
During my training in paediatric neurology in Padua, I was first exposed to the diagnostic challenges 
and the therapeutic decision making for children with autoimmune and immune-mediated neurological 
disease, in a field that was moving forward quickly - as it still is - in terms of disease definition and 
classification, biomarker identification, and therapeutic possibilities. In particular, the opportunity to 
take care of the first few patients with anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis 
in our Department during my first years of training ended up being a clinical experience that would 
stick with me later on. Thereafter, a research interest in paediatric neuroimmunology, also led by my 
mentor Dr. Stefano Sartori, naturally sprouted, and rooted itself into my PhD project, which started in 
November 2014. Dr. Stefano Sartori has been sharing with me his broad knowledge in paediatric 
neurology and neuroimmunology, his intuitions, his enthusiasm and any research opportunities he 
could. In this context, I also had the invaluable opportunity to spend nearly two years under the 
supervision of prof. Russell C. Dale in Sydney, Australia, where I gained experience in clinical and 
research aspects in paediatric neuroimmunology. This deepened and developed the theme of immune 
therapy, which runs through my thesis. Most important of all - and not irrelevant to the scientific work - 
in Sydney I was overwhelmed by the generosity and support provided by prof. Russell C. Dale and his 
peers. I gratefully consider him to be my second mentor. 
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1.2 Introduction to the content of the thesis 
 
Paediatric neuroimmunology is a rapidly evolving field in a lot of ways. Firstly, clinical-radiological 
phenotyping and biomarker development have been allowing for re-discussion and re-classification of 
old clinical entities, and characterisation of new clinical forms. For example, the identification of 
neuromyelitis optica (NMO) IgG in 2004 [Lennon, 2004] confirmed the clinical suspicion that NMO 
was a different disease to multiple sclerosis, as initially thought. On the other hand, autoantibodies 
targeting neuronal cell surface proteins have been identified in the last years in cases of encephalitis 
which were previously unexplained. The first of this novel class was identified in 2007, targeting the 
NMDAR [Dalmau, 2007], and was followed by the subsequent identification of antibodies against a 
vast array of other neuronal surface antigens. Similarly, a new subclass of acquired central nervous 
system (CNS) demyelinating syndromes is being delineated thanks to the identification of myelin 
oligodendrocyte glycoprotein (MOG) antibodies [Hacohen, 2015; Hennes, 2017]. 
Moreover, the expanding field of immunotherapeutics represents the natural counterpart to the efforts in 
clinical-radiological and biomarker phenotyping in autoimmune and immune-mediated diseases. A 
rapidly growing armamentarium is indeed now available in this field, especially with regards to the 
advent of new drugs such as monoclonal antibodies. However, there are some constraints in this 
context. Namely, the limited knowledge of the pathophysiology for several autoimmune and immune-
mediated diseases, as well as of the complete mechanisms of action for many of these immune therapy 
agents. Besides, since autoimmune and immune-mediated conditions are relatively rare and, as said 
before, many have been described only recently, literature is lacking of quality, solid data on efficacy 
and tolerability of immune therapy in these conditions, especially in paediatric age. 
In this context, the present PhD thesis is meant to explore the field of clinical and therapeutic decision 
making in paediatric autoimmune and immune-mediated disease. Specifically, the thesis is articulated 
through a collection of ten works exploring three main areas, covered in sections 3.1 to 3.3: 
- Section 3.1: available immunotherapeutic agents and their mechanisms of action;  
- Section 3.2: immune therapy in autoimmune encephalitis: in particular, investigating the 
available evidence in the literature on the use of immune therapy in autoimmune encephalitis 
(section 3.2.1), the clinical characteristics and outcome, also with regards to treatment, in the 
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Italian cohort of paediatric anti-NMDAR encephalitis (section 3.2.2), and those of the literature 
cohort of patients with anti-NMDAR encephalitis occurring after herpes virus encephalitis 
(section 3.2.3); 
- Section 3.3: modes of use, efficacy and tolerability of individual immune therapeutic agents in 
different clinical situations in paediatric neurology: intravenous immunoglobulin in 
Sydenham’s chorea (section 3.3.1); intravenous immunoglobulin in paediatric neurology 
(section 3.3.2); therapeutic plasma exchange in anti-NMDAR encephalitis (section 3.3.3); 
rituximab in neuromyelitis optica spectrum disorders (section 3.3.4); mycophenolate mofetil, 
azathioprine and methotrexate in anti-NMDAR encephalitis (section 3.3.5); mycophenolate 
mofetil in paediatric autoimmune and immune-mediated CNS conditions (section 3.3.6). 
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2. METHODS 
 
The present PhD thesis is articulated into sub-projects that explore the theme of clinical and therapeutic 
decision making in paediatric autoimmune and immune-mediated disease, as illustrated in sections 3.1 
to 3.3.  
Study period and setting. The studies were carried out between 2014 and 2017 at the Department of 
Women's and Children's Health in Padua, Italy, under the supervision of Dr. Stefano Sartori and of Prof. 
Giorgio Perilongo, and at the Children's Hospital at Westmead, Sydney, Australia, under the supervision 
of Prof. Russell C. Dale. 
Study designs. The study design of the projects include six literature reviews (sections 3.1, 3.2, 3.4, 3.5, 
3.7, 3.9) and four original studies with observational retrospective design (sections 3.3, 3.6, 3.8, 3.10). 
The study designs are detailed below for each individual project: 
- Section 3.1.1: Immune therapeutic agents and their mechanisms of action: literature review. 
- Section 3.2.1: Autoimmune encephalitis with antibodies targeting neuronal surface antigens: 
systematic literature review. 
- Section 3.2.2: Clinical and therapeutic aspects of the Italian cohort of paediatric anti-NMDAR 
encephalitis: national retrospective observational study. 
- Section 3.2.3: Herpes simplex virus-induced anti-NMDAR encephalitis: systematic literature 
review. 
- Section 3.3.1: Intravenous immunoglobulin in Sydenham’s chorea: systematic literature review. 
- Section 3.3.2: Intravenous immunoglobulin in paediatric neurology: single-center retrospective 
observational study. 
- Section 3.3.3: Therapeutic plasma exchange in anti-NMDAR encephalitis: systematic literature 
review. 
- Section 3.3.4: Rituximab in neuromyelitis optica spectrum disorders: international retrospective 
observational study. 
- Section 3.3.5: Mycophenolate mofetil, azathioprine and methotrexate in anti-NMDAR encephalitis: 
systematic literature review.  
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- Section 3.3.6: Mycophenolate mofetil in paediatric autoimmune and immune-mediated central 
nervous system conditions: international retrospective observational study. 
Statistical analysis. Statistical analysis was carried out when appropriate, as specified in the Methods 
section for each individual study (Section 3.2.3: Herpes simplex virus-induced anti-NMDAR 
encephalitis; Section 3.3.4: Rituximab in neuromyelitis optica spectrum disorders).   
Ethics approval. Ethics committee was involved when appropriate (Section 3.3.2: Intravenous 
immunoglobulin in paediatric neurology; Section 3.3.4: Rituximab in neuromyelitis optica spectrum 
disorders). 
State of advancement of the projects. Most of the projects have been concluded (sections 3.1.1 to 3.3.4) 
[Nosadini, 2017; Nosadini, 2015; Sartori, 2015; Nosadini, 2017; Mohammad, 2015; Nosadini, 2016; 
Suppiej, 2016; Nosadini, 2016], whereas the systematic literature review on mycophenolate mofetil, 
azathioprine and methotrexate in paediatric anti-NMDAR encephalitis (section 3.3.5) and the original 
study on children with paediatric CNS autoimmune or immune-mediated inflammatory diseases treated 
with mycophenolate mofetil (section 3.3.6) are still in progress.  
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Immunotherapeutics in Pediatric
Autoimmune Central Nervous System
Disease: Agents and Mechanisms
MargheritaNosadini,MD,*,†StefanoSartori,MD,PhD,†Suvasini Sharma,MD,‡
and Russell C. Dale, MBChB, MRCP, MSc, PhD*
Beyond the major advances produced by careful clinical-radiological phenotyping and
biomarker development in autoimmune central nervous system disorders, a comprehensive
knowledge of the range of available immune therapies and a deeper understanding of their
action should beneﬁt therapeutic decision-making. This review discusses the agents used in
neuroimmunology and their mechanisms of action. First-line treatments typically include
corticosteroids, intravenous immunoglobulin, and plasmapheresis, while for severe disease
second-line “induction” agents such as rituximab or cyclophosphamide are used. Steroid-
sparing agents such as mycophenolate, azathioprine, or methotrexate are often used in
potentially relapsing or corticosteroid-dependent diseases. Lessons from adult neuroimmu-
nology and rheumatology could be translated into pediatric autoimmune central nervous
system disease in the future, including the potential utility of monoclonal antibodies targeting
lymphocytes, adhesion molecules for lymphocytic migration, cytokines or their receptors, or
complement. Finally, many agents used in other ﬁelds have multiple mechanisms of action,
including immunomodulation, with potential usefulness in neuroimmunology, such as anti-
biotics, psychotropic drugs, probiotics, gut health, and ketogenic diet. All currently accepted
and future potential agents have adverse effects, which can be severe; therefore, a “risk-
versus-beneﬁt” determination should guide therapeutic decision-making.
Semin Pediatr Neurol ]:]]]-]]] C 2017 Elsevier Inc. All rights reserved.
Introduction
There is increasing interest in immune-mediated brain disease.
The recent descriptions of autoantibody biomarkers associated
with encephalitis and demyelination has put “neuroimmunol-
ogy” on the map, and as a “treatable group of conditions”, they
should be high on the differential list of any child with a new
presentation or change in neurological function. Immune-
mediated brain conditions can be separated according to
syndrome such as autoimmune encephalitis, autoimmune
demyelination, or autoimmune neuropsychiatric syndrome.
Unfortunately, other than autoantibody biomarkers, our ability
to deﬁne dominant immunopathologic processes in individual
patients is limited, and so it is often necessary to consider that
multiple immuneprocesses (ie, T cell, B cell, autoantibody, and
innate immunity) are operating in individual patients. Indeed,
even in immune disorders with pathogenic autoantibodies
such as aquaporin-4 (AQP4) antibody–associated neuromye-
litis optica, there is strong evidence of the role of B cells, T cells,
eosinophils, neutrophils, cytokines, chemokines, as well as
http://dx.doi.org/10.1016/j.spen.2017.08.002 1
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autoantibodies.1 Therefore, these disorders are often immuno-
logically complex; and hence, the approach may need to be
ﬂexible. Indeed, there are many anecdotal experiences of
patients with autoimmune central nervous system (CNS)
diseases who do not respond to steroids (glucocorticoids
[GCs]), but who do respond to intravenous immunoglobulin
(IVIG), and likewise patients who do not respond to cyclo-
phosphamide (CPA) who then respond to rituximab (RTX).
Until there are improved molecular techniques to deﬁne the
immune system in individual patients, it will be necessary to be
ﬂexible in therapeutic choices.
This review therefore is intended to help the clinician
appreciate the mechanisms of actions of drugs, and to facilitate
link the likely dominant pathologic process, the possible
immune mechanism, and the mechanisms of drug action
(described below and in Table 1). In conditions where there is
clear evidence that there is an “autoaggressive” process, and a
potentially poor prognosis, then immune suppression is
warranted. In other syndromes, such as pediatric acute-onset
neuropsychiatric syndromes, where the exact immune mech-
anism is unclear but an immune dysregulation process seems
likely, then immunemodulation (±immune suppression)may
be indicated if the disease is impairing.
This review therefore discusses agents that are generally
considered “ﬁrst line” such as GCs, IVIG, and therapeutic
apheresis (TA) in the treatment of suspected or conﬁrmed
autoimmune or inﬂammatory brain disease. Secondly, we will
describe immune suppressants, such as RTX and CPA that are
used as “second-line induction or rescue” agents in inﬂamma-
tory or autoimmune CNS disease. We will also refer to
mycophenolate mofetil (MMF) and azathioprine (AZA),
which are typically used in GC responsive conditions as
“steroid sparers”, or early in the disease course when it is
considered likely to be immune responsive with high risk of
relapse (such as AQP4 antibody–associated neuromyelitis
optica spectrum disorders). We will also discuss agents that
are used for immune suppression effective in immune-
mediated brain disease, such as tacrolimus, and other agents
such as the protease inhibitor bortezomib and compounds that
modulate signaling (ruxolitinib and other Janus kinase [JAK]
inhibitors). In addition, we will brieﬂy review “disease modify-
ing therapies” used in multiple sclerosis.
We will consider new emerging monoclonal therapies that
have been developed for the rheumatology or immunology
market that target speciﬁc lymphocytes (ocrelizumab [OCR],
ofatumumab, and alemtuzumab), complement (eculizumab),
cytokines or cytokine receptors (tocilizumab, daclizumab and
the tumor necrosis factor α [TNF-α] inhibitors inﬂiximab, and
adalimumab) or affect lymphocyte adhesion across vessel walls
(natalizumab). Other nonmonoclonal compounds that target
cytokineswill also be reviewed, such as anakinra (anti-IL1) and
etanercept (TNF-α inhibitor). All of these agents have potential
for use in neuroinﬂammatory disorders although improved
understanding of the underlying immunopathogenesis is
essential to make clearer “therapeutic decisions”. We will also
discuss commonly used licensed drugs that have immune
modulatory properties, but their use in immune-mediate brain
disease is not well established, which include antibiotics such
as minocycline and other macrolides, nonsteroidal anti-
inﬂammatories, psychotropic drugs, and also “naturopathic”
agents such as curcumin. These agents lack an evidence base
for effect in neuroinﬂammation, but so do all of the “conven-
tional therapies” described earlier. And ﬁnally, it is likely that
the role of gut health, gut immunity, and the microbiome will
become an increasing focus in immune dysregulation disor-
ders in general.
A General Approach to
Therapeutic Decision-Making
Until we have a better understanding of autoimmune and
inﬂammatory CNS disease, it will be necessary to use broad
immune suppressive or immune modulatory agents such as
GCs or IVIG. For this reason, there is often a “common
approach” to the ﬁrst- and second-line treatment of these
conditions, regardless of the speciﬁc syndrome. However, in
the future, with improved understanding of the pathophysi-
ology of disease, it can be hoped that there will be “targeted”
therapies that could be more effective, and hopefully safer (see
examples of option in “future therapies” below). The other
unaddressed issue surrounds the fact thatmost therapies target
peripheral immune cells or proteins, rather than the immune
system in the brain. The role of the blood-brain barrier, and the
relative importance of therapies gaining access to the CNS are
important yet unanswered issues.
“First-Line Agents” for Classic
Neuroinﬂammation
Glucocorticoids
GCs belong to the class of corticosteroids, which are steroid
hormones produced in the adrenal cortex under the regulation
of the hypothalamic-pituitary-adrenal axis. Beside GCs, cortico-
steroids include mineralocorticoids and androgens. GCs act via
the nearly ubiquitous glucocorticoid receptor, andplay a central
role in numerous physiological functions, including homeo-
stasis, inﬂammation, behavior, metabolism and immune func-
tion; GCs also have anti-inﬂammatory, immunosuppressive,
antiproliferative, and vasoconstrictive properties.2 Intravenous
or oralGCs represent themainstay of acute treatment in the vast
majority of autoimmune and immune-mediated neurological
conditions,3-7 in view of their potent and wide actions on the
immune system (Table 1).8 High-dose intravenous methyl-
prednisolone pulses (30/mg/kg) are generally given once daily
for 3-5 days in acute diseases, sometimes followed by oral
prednisone taper over weeks-months.3-7 An alternative
approach, rather than oral prednisolone taper, is to use “pulses”
of GCs, such as monthly (3 days) intravenous methylpredni-
solone or 3-4 weekly (3 days) of oral dexamethasone.9
Although most inﬂammatory disorders are treated with meth-
ylprednisolone/dexamethasone or prednisolone, adrenocorti-
cotropic hormone has a role in moderate-severe opsoclonus
myoclonus ataxia syndrome.9 It is possible that the type of GCs
M. Nosadini et al.2
Table 1 Summary of the Key Modes of Action and Principal Effects of the Main Immune Therapies in Neurologic Diseases
Immune Therapy Key Mechanisms of Action in Neurologic Diseases Targets and Effects
Glucocorticoids (GCs) Genomic modes of action Thymocytes and B cells are sensitive to GC-induced cell death
GCs produce a decrease in T-cell activity by targeting dendritic
cell,8 downregulating the expression of MHC class II and of
other co-stimulatory molecules and proinﬂammatory
cytokines, and interfering with T cell receptor signaling
GCs promote the expression of anti-inﬂammatory cytokines
Pharmacological treatment withGCs is associatedwith reduced
immunoglobulin concentrations, exception made for IgE
Corticosteroids Binding of the liganded GC receptor (GR) to positive
(transactivation) or negative (transrepression) GC-response
elements (GREs) within the DNA
Liganded GR tethering and blocking of transcription factors,
without contacting DNA
Binding of the liganded GR to composite elements (DNA
sequencescontainingboth aGREanda responseelement for a
distinct transcription factor)
Non-genomic modes of action
GC intercalation into plasma membranes
GC binding-mediated dissociation of heatshock proteins and
other co-factors from the GR
Interaction of the liganded GR with cytoplasmic signaling
complexes and the mithocondria8
A uniﬁed model for GC-mediated regulation of the immune system
Besides immunosuppressive properties of GCs, there are also data
supporting an immune-enhancing role of GCs: basal levels of GR
signaling would sensitize cells to harmful stimuli, promoting the
induction of an inﬂammatory response upon tissue insult; during
the inﬂammatory state, however, stress-induced (or
pharmacological) concentrations of GCs would restrain the
immune response, thereby shortening the duration of the immune
response8
Intravenous immunoglobulin (IVIG) F(ab′)2-dependent mechanisms: Antibody binding-mediated effects with neutralization of cytokines,
complement, immune cell receptors, and pathogenic circulating
autoantibodies
Blockade of cell-cell interactions that are mediated by cell-
surface receptors
Neutralization of cytokines, complement, immune cell receptors
and pathogenic circulating autoantibodies10
Preparation of polyclonal human
immunoglobulins made from a pool of
healthy donors
Fc-dependent mechanisms:
Competitive blockade of immune complement binding to low-
afﬁnity FcγRs
Modulation of activating and inhibitory FcγR expression on
innate immune effector cells and B cells
Increased autoantibody clearance by FcRn saturation10
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Table 1 (continued )
Immune Therapy Key Mechanisms of Action in Neurologic Diseases Targets and Effects
Therapeutic apheresis (TA) Therapeutic plasma exchange (TPE): blood is passed through a
medical device separating plasma from other components of
blood
Removal of antibodies and immune complexes
Possible role on the removal of cytokines, soluble cytokine
receptors, and soluble adhesion molecule, although the
evidence on this is mixed19Therapeutic plasma exchange and
immunoadsorption
Immunoadsorption (IA): plasma of the patient, after separation from
the blood, is passed through a device with columns lined with
immobilized antibodies or selective antigens, binding selected
proteins and removing them from plasma18
Rituximab (RTX) B lymphocyte destructionmediated by binding to cell surfaceCD20
located on the B lymphocytes, through 3 main mechanisms23:
B cell depletion23
Transient, dose-dependent T-cell inactivation: decreased
inﬂammatory cytokine production, proliferation capacity and
expression of T-cell activation markers24
Chimeric B cell-depleting monoclonal anti-
CD20 antibody Antibody-dependent cellular cytotoxicity: Following binding to
cells, antibodies recruit innate immune effector cells that
express receptors for the Fc portion of the antibodies (FcγRs),
which in turn trigger phagocytosis and cause release of
cytotoxic substances
Complement-dependent cytotoxicity: The classical pathway of
thecomplement system is activatedbyantibodybinding. TheFc
portion of IgG binds to the complement C1q component, which
triggers a proteolytic cascade to generate themembrane attack
complex, which is responsible for eliminating target cells.
Induction of direct cell death: Blocking of various survival
signaling pathways; Downregulation of anti-apoptotic Bcl-2
proteins; Activation of the Fas-mediated pathway through
upregulation of Fas receptor; Caspase-dependent and
independent mechanism
Transient, dose-dependent decrease in T-cell inﬂammatory and
proliferation capacity in response to ‘‘foreign’’ stimuli (both by
depriving B-cell antigen-presenting cells and through its direct
effect on T cells)24
Cyclophosphamide (CPA) Irreversible alkylation of DNA bases, with formation of DNA
crosslinks resulting in impaired essential DNA processes such as
DNA replication and/or transcription, eventually leading to cell
apoptosis30,31
Autoimmune effector cells (T cells, B cells, and NK cells) are
exquisitely sensitive to high-dose CPA, since aldehyde
dehydrogenase (ALDH), the enzyme responsible for detoxiﬁcation
of CPA, is poorly expressed in lymphocytes30
Alkylating agent (prodrug of phoshoramide
mustard)
M
.
N
o
s
a
d
in
i
e
t
a
l.
4
Mycophenolate mofetil (MMF) Inhibition of inosine monophosphate dehydrogenase (IMPDH), the
rate-limiting enzyme in de novo synthesis of guanosine
nucleotides34
Antiproliferative effects on T and B lymphocytes, monocytes,
ﬁbroblasts, endothelial, mesangial and vascular smooth cells
Induction of apoptosis in lymphocytes, monocytes
Induction of necrosis in lymphocytes
Reduction of cytokine production by T lymphocytes, dendritic
cells and endothelial cells
Reduction of immunoglobulin production by B lymphocytes
Reduction of chemotaxis to inﬂammation sites inmonocytes and
lymphocytes
Inhibition of cell-cell interaction and endothelial adhesion in
monocytes, dendritic cells, neutrophils and ﬁbroblasts
Other: inhibition of mast cell degranulation, of nitric oxide
production by endothelial cells; suppression of ﬁbroblast
ability to migrate, adhere and heal wounds; inhibition of
extracellular matrix production in human mesangial cells33
Prodrug ofmycophenolic acid (MPA), which
acts as an inhibitor of inosine
monophosphate dehydrogenase (IMPDH)
Azathioprine (AZA) Mercaptopurine metabolites are incorporated into replicating DNA,
halting replication, as well as blocking the pathway for purine
synthesis. Cytostatic and immunosuppressive action35
Interference with T and B cell proliferation
Synthetic purine analog derived from
6-mercaptopurine
Methotrexate (MTX) Inhibition of purine and pyrimidine synthesis (main antitumoral
effect)
Reduction of antigen-dependent T-cell proliferation, inhibition of
T cell activation and suppression of intercellular adhesion
molecule expression by T cells; increased CD95 sensitivity of
activated T cells
Selective downregulation of B cells
Antimetabolite, folic acid antagonist Inhibition of dihydrofolate reductase
(DHFR) decreases tetrahydrofolate (THF) levels, which results in
attenuated DNA/protein/lipid methylation
Inhibition of thymidylate synthase (TS) interference with DNA
synthesis
Inhibitionof 5-aminoimidazole-4-carboxamide ribonucleotide
(AICAR) transformylase blocks de novo purine synthesis
Suppression of transmethylation reactions with accumulation of
polyamines
Promotion of adenosine release with adenosine-mediated
suppression of inﬂammation (main anti-inﬂammatory effect)
The released adenosine diminishes stimulated neutrophil
adhesion
By increasing intracellular AICAR accumulation, MTX increases
adenosine concentration and diminishes leukocyte
accumulation in inﬂammatory exudates35
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that produces maximal effect is disease and patient dependent,
but there is little data to comment on this further.
Intravenous Immunoglobulin
IVIG is a preparation containing polyclonal human G isotype
immunoglobulins (IgG) made from a pool of plasma of
thousands of healthy blood donors.10,11 Plasma is obtained
either by separation of whole blood or by plasmapheresis, and
immunoglobulin is then extracted from other plasmatic
proteins via fractionation.
While low-dose IVIG (~0.4 g/kg) is used as a replacement
therapy in immune deﬁciencies, high doses of IVIG (1-2 g/kg)
have anti-inﬂammatory and immunomodulatory actions, and
have been used in autoimmune disorders for about forty
years.10 The extensive use of IVIG in clinical practice as an
immunomodulatory agent is notmirrored by a comprehensive
knowledge of the modes of action of IVIG. In view of the
heterogeneity of autoimmune and immune-mediated condi-
tions that respond to IVIG, it is indeed generally believed that
IVIG modes of action may be manifold10 (Table 1). High-dose
IVIG is usually given in acute diseases (2 g/kg over 1-5 days),12
while lower doses (0.4-1 g/kg in 1 day) are given in chronic
treatments. However, it is sometimes observed that lower
doses (0.4-1 g/kg) fail to produce immune modulation in
severe disease, when higher doses (2 g/kg) should be consid-
ered, if agreeable to local guidelines. IVIG is an expensive
treatment subject to increasing demand, and guidelines
regulating IVIG use according to the evidence base have been
created in different countries, to ensure its availability for
patients who are most likely to beneﬁt from the therapy.12-17
Therapeutic Apheresis
TA techniques most used in pediatric neurology include
therapeutic plasma exchange (TPE) and immunoadsorption
(IA) (Table 1). TPE is a procedure in which blood of the patient
is passed through a medical device separating plasma from
other components of blood.18 Centrifugation- or, less fre-
quently, ﬁltration-based devices can be used for TPE.19 When
the plasma is removed, substances with a certain molecular
weight or higher areﬁltrated, and compensation for protein loss
is achieved through a replacement solution such as colloid
(ie, albumin and/or plasma) or a combination of crystalloid/
colloid solution. In IA, plasma of the patient, after separation
from the blood, is passed through a device with columns lined
with immobilized antibodies or selective antigens, binding
selected proteins and removing them from plasma. In contrast
to TPE, IA permits a more targeted removal of plasma proteins,
allowing those unbound to return to the circulation.20
Most commonly the objective of TA is to remove suspected
antibodies implicated in the pathogenesis of autoimmune
disease, although TPE also works by removing from the
circulation large-molecular-weight molecules other than
immunoglobulins, such as immune complexes and comple-
ments. In acute disease, 5-7 exchanges are usually carried out
over 10-14 days. Guidelines on the use of TA have been issued
by the American Society for Apheresis every 7 years from 1986
to 2007, and subsequently every 3 years, most recently in
2010, 2013 and lastly in 2016 (Table 2).18,21
“Second-Line Induction Agents”
for Severe Disease
Rituximab
RTX is a chimeric B cell-depleting monoclonal anticluster of
differentiation 20 (CD20) antibody, initially developed to treat
lymphoma, comprised of both mouse and human portions
(Table 1). CD20 is a B-cell surface differentiationmarker found
on pre-B and mature B lymphocytes, which is lost as B cells
differentiate into plasma cells (plasmablasts and plasmocytes)
and is not found on other cell types or free in circulation. CD20
is involved in calcium transportation across cell membrane.
The binding of RTX to cell surface CD20 located on the B
lymphocytes results in destruction of the lymphocyte by
different potentialmechanisms, including antibody-dependent
cytotoxicity or complement-dependent cytotoxicity, stimula-
tion of apoptosis, or growth arrest.22,23 Beside B-cell depletion,
there are data suggesting that RTXmay also induce substantial
reversible T-cell depletion, mainly of CD4þ cells.24,25 Indeed,
part of the rapid responses to RTX seen in some patients may
be related to direct B cell effects or B cell-T cell interaction
effects, rather than “autoantibodies” per se.
RTX treatment regimens vary, although most frequent dose
is 375 mg/m2 weekly for 4 weeks. RTX treatment monitoring
is via CD19 count, which should be done monthly after RTX
administration,26,27 as CD19 repopulation over the threshold
of 10 × 106 cells/L has been associated to increased risk for
relapses in severe autoimmune CNS disease such as AQP4
antibody–positive neuromyelitis optica.26,28 CD20 is
expressed during the midstages of ontogeny and virtually
disappears at the plasma cell stage; CD19 expression mirrors
CD20 expression and can, therefore, serve as a surrogate
marker in patients with circulating RTX.29
Cyclophosphamide
CPA is an alkylating agent activated by cytochromes (P450) in
the liver, whose active metabolite is phoshoramide mustard
(Table 1). Alkylating agents are electrophilic entities that react
with nucleophilic moieties of DNA or proteins resulting in the
covalent transfer of an alkyl group. CPA cytotoxic effects derive
from the ability of phoshoramide mustard to alkylate DNA
bases, forming DNA crosslinks both between and within DNA
strands (interstrand and intrastrand crosslinkages). This is
irreversible and results in impaired essential DNA processes
such as DNA replication or transcription, eventually leading to
cell apoptosis.30 The effects of CPA are cell cycle independent;
however, aswith all alkylating agents, rapidly proliferating cells
are most sensitive.31 Early hematopoietic stem cells are spared
from CPA cytotoxicity because of their high levels of aldehyde
dehydrogenase, an enzyme that confers resistance to the drug
by detoxifying the active metabolite of CPA. Conversely,
committed immune effector cells (T cells, B cells, and NK
cells) are exquisitely sensitive to high-dose CPA because of
M. Nosadini et al.6
Table 2 Neurologic Indications for Therapeutic Apheresis According to the Guidelines on the Use of Therapeutic Apheresis of the American Society for Apheresis18
Disease TA
Modality
Indication Category,
Grade*
Rationale for TA andMechanism of Action
Acute disseminated encephalomyelitis
(ADEM)
TPE Steroid refractory II, 2C Removal of presumed pathogenic autoantibodies
(potential candidate target of autoantibodies: myelin
oligodendrocyte glycoprotein)
Acute inﬂammatory demyelinating
polyradiculoneuropathy (Guillain-Barre syndrome)
TPE Primary treatment I, 1A Removal of autoantibodies damaging the peripheral
nerve myelin (molecular mimicry?), and possibly of
circulating immune complexes and of complement18
After IVIG (2 g/kg) III, 2C
Chronic focal encephalitis (Rasmussen encephalitis) TPE – III, 2C Removal of presumed pathogenic autoantibodies to neural
molecules, that may be produced in the CNS after cytotoxic
T cell-mediated neuronal damage
Dermatomyositis/polymyositis TPE IV, 2B Removal of autoantibodies such as ANA, anti-Ro, anti-La,
and Sm, anti-ribonucleoprotein, or myositis-speciﬁc, that are
commonly present, although not speciﬁc to the disease
ECP IV, 2C
Hashimoto encephalopathy: steroid-responsive encephalopathy
associated with autoimmune thyroiditis†
TPE – II, 2C Removal of presumed pathogenic autoantibodies (anti-thyroid
antibodies)
Multiple sclerosis TPE Acute CNS
inﬂammatory
demyelinating
II, 1B Removal of presumedpathogenic autoantibodies, and/or immune
complexes or modulating immune response18
IA Acute CNS
inﬂammatory
demyelinating
III, 2C
TPE Chronic progressive III, 2B
Myasthenia gravis TPE Moderate-severe I, 1C Removal of autoantibodies (anti-AChR, anti-Musk)
TPE Pre-thymectomy I, 1C
Neuromyelitis optica spectrum disorders TPE Acute II, 1B Removal of anti-aquaporin 4 autoantibodies
TPE Maintenance III, 2C
N-methyl-D-aspartate receptor (NMDAR)
antibody encephalitis†
TPE – I, 1C Removal of anti-NMDAR autoantibodies
Paraneoplastic neurological syndromes TPE – III, 2C Removal of autoantibodies (anti-Hu, anti-
CV2/CRMP5, anti-Yo, anti-Tr, and anti-amphiphisin)IA – III, 2C
Paraproteinemic demyelinating
polyneuropahties/chronic acquired demyelinating
polyneuropathies
TPE Anti-MAG
neuropathy
III, 1C Removal of anti-MAG antibodies
TPE Multifocal Motor
Neuropathy
IV, 1C
TPE IgG/IgA I, 1B
TPE IgM I, 1C
TPE Multiple myeloma III, 2C
IA IgG/IgA/IgM III, 2C
Pediatric autoimmune neuropsychiatric disorders ssociated with
streptococcal infections (PANDAS); Sydenham chorea
TPE PANDAS
exacerbation
II, 1B Removal of (possible pathogenetic) autoantibodies
(antineuronal, antibasal ganglia)
TPE Sydenham chorea,
severe
III, 2B
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Table 2 (continued )
Disease TA
Modality
Indication Category,
Grade*
Rationale for TA andMechanism of Action
Progressive multifocal leukoencephalopathy
associated with natalizumab†
TPE – I, 1C Removal of natalizumab, decrease in receptor
saturation, restoration of leukocyte transmigration
Stiff-person syndrome TPE – III, 2C Removal of autoantibodies (anti-GAD)
Voltage-gated potassium channel (VGKC) antibodies TPE – II, 2C Removal of anti-VGKC autoantibodies
Category18 Description
I Disorders for which apheresis is accepted as ﬁrst-line therapy, either as a primary
standalone treatment or in conjunction with other treatments
II Disorders for which apheresis is accepted as second-line therapy, either as a
standalone treatment or in conjunction with other treatments
III Optimum role of apheresis therapy is not established. Decision making should be
individualized
IV Disorders in which published evidence demonstrates or suggests apheresis to be
ineffective or harmful. IRB approval is desirable if apheresis treatment is undertaken
in these circumstances
Recommendation18 Description Methodological quality of supporting evidence
Grade 1A Strong recommendation, high-
quality evidence
RCTs without important limitations or overwhelming
evidence from observational studies
Grade 1B Strong recommendation,
moderate-quality evidence
RCTs with important limitations (inconsistent results,
methodological ﬂaws, indirect, or imprecise) or
exceptionally strong evidence from observational studies
Grade 1C Strong recommendation, low-
quality or very low-quality
evidence
Observational studies or case series
Grade 2A Weak recommendation, high-
quality evidence
RCTs without important limitations or overwhelming
evidence from observational studies
Grade 2B Weak recommendation,
moderate-quality evidence
RCTs with important limitations (inconsistent results,
methodological ﬂaws, indirect, or imprecise) or
exceptionally strong evidence from observational studies
Grade 2C Weak recommendation, low-
quality or very low-quality
evidence
Observational studies or case series
ECP: extracorporeal photophoresis. (Modiﬁed with permission from Schwartz et al.18)
⁎See bottom part of Table 2 for category and grade. (Adapted with permission from the Guidelines on the use of therapeutic apheresis of the American Society for Apheresis.18)
†Hashimoto encephalopathy, N-methyl-d-aspartate receptor antibody encephalitis, and progressivemultifocal leukoencephalopathy associatedwith natalizumabwere the newneurologic diseases included
in the last Guidelines on the use of therapeutic apheresis of the American Society for Apheresis.18
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their relatively low levels of aldehyde dehydrogenase.32 CPA
dose regimenusually is 750 mg/m2 intravenously everymonth
for 6 months.
Maintenance Therapy: Steroid-
Sparing Drugs
Mycophenolate Mofetil
MMF is a prodrug of mycophenolic acid (MPA). MPA is a
fermentation product of Penicillium brevicompactum and other
analogue fungi, and acts as an inhibitor of inosine mono-
phosphate dehydrogenase (IMPDH).33 IMPDH is the rate-
limiting enzyme in de novo synthesis of guanosine nucleotides,
converting inosinemonophosphate, produced from adenosine
monophosphate by adenosine deaminase, in guanosine
monophosphate.34
MPA effects on B and T lymphocytes represent the principal
mechanism by which MMF exerts immunosuppressive
action.34 This is due to the fact that lymphocytes are more
dependent on the synthesis of guanosine nucleotides than
other cell types, and IMPDH is required for lymphocytic clonal
expansion; moreover, MPA selectively targets the type II
isoform of IMPDH, which is expressed in activated lympho-
cytes, rather than the type I (expressed in most cell types).
Therefore, MPA has a more potent cytostatic effect on
lymphocytes than other cells.34 A vast repertoire of cells are
targeted by MPA action, and its main effects include anti-
proliferative and proapoptitic effects, inhibition of chemotaxis,
endothelial adhesion, and cell-cell interactions (Table 1).
Azathioprine
AZA is a synthetic purine analog derived from 6-mercapto-
purine (Table 1). The AZA molecule contains the following 2
moieties: 6-mercaptopurine and an imidazole derivative. The
immunosuppressive action of AZA depends on the synergistic
cooperation of relatively weak cytostatic effect of low doses of
6-mercaptopurine and the chemosensitizing effect induced by
highly reactive imidazole derivatives.35 The active metabolites
of AZA act by disrupting the function of endogenous purines.
Mercaptopurine metabolites are incorporated into DNA, halt-
ing replication, as well as blocking the pathway for purine
synthesis. AZA thus most strongly affects proliferating cells,
such as the T cells and B cells of the immune system.
Methotrexate
Methotrexate (MTX) is an antimetabolite that interferes with
the actions of folate in cellular synthesis.36 MTX antagonizes
the enzyme dihydrofolate reductase, resulting in the arrest of
the synthesis of tetrahydrofolate and therefore preventing the
synthesis of purines and pyrimidines. Themajor effect of MTX
is therefore onmore rapidly dividing cell systems, typically the
gut lining and bone marrow, and this is the main antitumoral
action ofMTX.36On the contrary, anti-inﬂammatory actions of
MTX are thought to be exerted throughmultiple mechanisms,
especially by increase in extracellular adenosine release
(Table 1).37
Tacrolimus (FK-506)
Tacrolimus is an immune suppressive agent, a macrolide
calcineurin inhibitor that acts by inhibiting the production of
interleukin (IL)-2.38 It is commonly used in organ transplant
patients and in some autoimmune diseases, such as ulcerative
colitis. Among neurologic conditions, tacrolimus has been
shown to be of beneﬁt in Rasmussen encephalitis39 and
neuromyelitis optica.40 Calcineurin inhibitor cyclophospha-
mide is another immune suppressant, although concerns
about serious adverse events, such as impaired fertility and
late development of malignancy, are of greater concern in
children than in adults.41,42
Other Agents
Bortezomib
Bortezomib is a protease inhibitor, developed for cancer
treatment, which inhibits proinﬂammatory cytokine cascades
and reduces plasma cell production and therefore autoanti-
body production, and has been recently used in adults with
anti-N-methyl-D-aspartate encephalitis who were refractory to
conventional treatment.43,44
Oral Agents That Modulate Cell Signaling
JAK is a key enzyme involved in cell signaling and agents
targeting JAK (such as ruxolitinib and tofacitinib) have anti-
inﬂammatory properties by reducing cytokine production.
These agents are used to treat myeloﬁbrosis, and have
emerging roles in the treatment of rheumatoid arthritis, ulcer-
ative colitis and other autoimmune diseases, and may have a
role in genetic autoinﬂammatory disorders.45,46
Future Utility of Monoclonal
Antibodies
Monoclonal antibodies that have theoretical use in pediatric
autoimmune CNS disease have been developed for oncology
(ie, RTX), rheumatology (ie, etanercept), or the treatment of
adult neurological disease (ie, natalizumab in multiple scle-
rosis). With improved understanding of pathophysiology and
biomarkers, some of these agents could theoretically be used in
the future in pediatric autoimmune CNS disease. A few
examples demonstrating the potential current and future utility
of monoclonal antibodies are described, and listed in
Table 3.27,47-62
Monoclonal Antibodies That Target
Lymphocytes
Ocrelizumab (OCR) is a humanized monoclonal anti-CD20
antibody that has the same therapeutic target as RTX,51 which
has shown efﬁcacy inmultiple sclerosis.47,49,51Ofatumumab is
Pediatric autoimmune CNS disease 9
Table 3 Monoclonal Antibodies Used in Neurology (Selected Agents)
Monoclonal
Antibody
H/h/C Target andMechanism of Action Main Uses in Central Nervous System
Autoimmune and Immune-Mediated Conditions
Monoclonal antibodies targeting lymphocytes
Alemtuzumab h Target: CD52 (expressed on the cell surface of lymphocytes and at lower levels
on monocytes, macrophages, eosinophils, and natural killer [NK] cells)
FDA-approved for MS
Mechanism: Targeting of the CD52 molecule, which is present on the cell
surface of lymphocytes and at lower levels on monocytes, macrophages,
eosinophils, and natural killer (NK) cells. The exact physiologic function of
CD52 is largely unknown but is thought to be involved in T cell activation, cell
migration, and induction of regulatory T cells. By binding to CD52 on the cell
surface, alemtuzumab causes long-lasting depletion of lymphocytes and
monocytes mediated by antibody-dependent cell-mediated cytotoxicity,
complement-dependent cytotoxicity, and apoptosis53
EMA-approved for MS patients who have had an
inadequate response to ≥2 drugs indicated for the
treatment of MS50-53
Rituximab C Target: CD20 (expressed on pre-B and mature B lymphocytes) MS, NMO spectrum disorders, anti-N-methyl-D-aspartate
receptor encephalitis, opsoclonus myoclonus ataxia
syndrome, NPSLE9,26,49
Mechanism: B lymphocyte destruction and transient decrease in T-cell
inﬂammatory and proliferation capacity in response to ‘‘foreign’’ stimuli
(Table 1)
Ocrelizumab h Target: CD20, same epitope as rituximab (expressed on pre-B and mature B
lymphocytes)
Under consideration for approval forMSby theFDAand the
EMA47,50-53
Mechanism: Depletion of CD20 expressing B-cells through antibody-
dependent cell-mediated phagocytosis and cytotoxicity, as well as
complement-mediated cytolysis50
Ofatumumab H Target: CD20, different epitopeas rituximabandocrelizumab (expressedonpre-
B and mature B lymphocytes)
Relapsing-remitting MS. Safer choice than natalizumab in
JC-virus positive patients51,52
Mechanism: pronounced complement-mediated cytotoxicity in vitro
Monoclonal antibodies targeting complement
Eculizumab h Target: complement protein C5 NMO spectrum disorders48
Mechanism: Targeting of the cleavage of C5, preventing the release of C5a and
activation of the terminal complement pathway
Monoclonal antibodies targeting lymphocyte adhesion
Natalizumab h Target: α4 integrin (a component of the very late antigen (VLA)-4 present on
lymphocytes)
FDA-approved for relapsing
MS
Mechanism: Inhibition of lymphocyte migration across the blood-brain barrier
by blocking a4 integrin, a component of the very late antigen (VLA)-4 present
on lymphocytes, and thereby inhibiting interaction between VLA-4 and the
ligand vascular cell adhesion molecule (VCAM) on endothelial cells53
EMA-approved as a second-line treatment in patients with
highly active relapsing-remittingMS inwhom the disease
remains active despite appropriate treatment with ≥1
other DMT or as ﬁrst treatment in patients with severe
disease53
Monoclonal antibodies targeting cytokines or cytokine receptors
Tocilizumab h Target: IL-6 receptor Autoimmune encephalitis refractory to rituximab,59NMO60
Mechanism: Binding to the IL-6 binding site of human IL-6 receptor and
competitively inhibits IL-6 signaling. Tocilizumab ameliorates inﬂammatory
manifestations and normalizes acute phase protein levels58
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a human monoclonal anti-CD20 antibody that binds to an
epitope distinct from that of OCR or RTX, and appears to be
effective in multiple sclerosis.50,51
Alemtuzumab was developed for blood cancer indications
and targets CD52, a mature lymphocyte antigen, consisting of
a glycoprotein expressed on the surface of different leukocyte
populations, including T lymphocytes, B lymphocytes, and
natural killer cells.51 Alemtuzumab is highly effective at
reducing relapse in multiple sclerosis, but has a high rate of
adverse events, including thyroid autoimmune disease.53
Monoclonal Antibodies That Target
Complement
Eculizumab is amonoclonal antibody that targets complement
protein C5. Antibody-mediated complement cytotoxicity is
evident in the pathology of neuromyelitis optica, and an open-
label pilot study of eculizumab in patients with severe neuro-
myelitis optica showed a reduction in relapse rate.48
Monoclonal Antibodies That Target
Lymphocyte Adhesion Across Vessel Walls
Natalizumab is a humanized monoclonal antibody that
targets α-4 integrin, an essential adhesion molecule expressed
on the surface of lymphocytes, involved in lymphocyte
trafﬁcking in to the CNS. Natalizumab is highly effective in
the treatment of multiple sclerosis.54 The major adverse event
is the risk of progressive multifocal leukoencephalopathy due
to John Cunningham virus, but there is now John Cunning-
ham serological screening that can provide relative risk
analysis.
Monoclonal Antibodies and Other Biologics
That Target Cytokines or Cytokine Receptors
Anakinra is an IL-1 receptor antagonist therefore blocking
action of IL-1, and is used to treat rheumatoid arthritis and
neonatal-onset multisystem inﬂammatory disease, a genetic
autoinﬂammatory disorder associated with alteration in IL-1 β
cytokine.55 Recent reports show that the potential effect of
anakinra is the treatment of febrile infection-related epilepsy
syndrome, associated with reduction in proinﬂammatory
cytokines.56 Tocilizumab is a monoclonal antibody that targets
IL-6 receptor and inhibits binding of IL-6 to IL-6 receptor. IL-6
is a pleitropic cytokine central to many proinﬂammatory
pathways used to treat rheumatoid arthritis,57 and has recently
been shown to be useful as rescue treatment in RTX non-
responsive adults with autoimmune encephalitis, and neuro-
myelitis optica.58,59Daclizumab is a monoclonal antibody that
selectively binds to the IL-2 receptorα-chain. It has been found
useful as a second-line treatment for multiple sclerosis.60,61
TNF-α inhibitors include inﬂiximab and adalimumab, used
in Crohn disease, rheumatoid arthritis and other rheumato-
logical conditions.62 These monoclonal antibodies target
the cytokine TNF-α, blocking its proinﬂammatory action.
The use of inﬂiximab has been reported in neurosarcoidosis63
and, more rarely, in limbic encephalitis,64 while recentlyD
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adalimumab has shown good efﬁcacy in terms of seizure
reduction in Rasmussen encephalitis.65 Etanercept, another
TNF-α inhibitor, is a circulating dimeric fusion protein
composed of the extracellular portion of human soluble
TNF-α receptor fused with the Fc portion of human immu-
noglobulin G1. Opportunistic infections and tuberculosis can
be reactivated with the use of TNF-α inhibitors, and tuber-
culosis should be screened for before prescribing it. There may
also be increased risk of malignancies.66
Disease Modifying Drugs for
Multiple Sclerosis
Interferon-β and glatiramer acetate are ﬁrst-line immunomo-
dulatory disease modifying therapies used for the treatment of
multiple sclerosis in children.67 These therapies have been
developed based on animal models of multiple sclerosis.
Interferon acts through speciﬁc receptors to regulate signaling
cascades, and its effect is mediated through the inhibition of
autoreactive T cells and proinﬂammatory cytokines, reduction
of lymphocyte migration, and induction of anti-inﬂammatory
mediators. Glatiramer acetate acts by inhibiting speciﬁc effector
T lymphocytes and inﬂuencing antigen-presenting cells and
suppressor T lymphocytes.68
Fingolimod is a second-line drug, which modulates the
sphingosine-1-phosphate receptor and sequesters lympho-
cytes in lymph nodes, preventing them from contributing to
the immune pathology. Teriﬂunomide is an oral de novo
inhibitor of the dihydroorotate dehydrogenase enzyme
involved in pyrimidine synthesis. Teriﬂunomide exerts anti-
inﬂammatory effects, possibly through reduction of activated
lymphocytes in the CNS.68 There is paucity of data on the use
of ﬁngolimod and teriﬂunomide in pediatricmultiple sclerosis,
although results of studies are awaited. Alemtuzumab, natali-
zumab and other monoclonal antibodies mainly used in
multiple sclerosis are described earlier.
Other ImmuneModulation
Agents
Many drugs used in everyday medical practice have immune
modulatory effects that are underappreciated or unrecognized.
Some of these agents could be useful in the treatment of
immune dysregulation syndromes.
Many antibiotics have proven anti-inﬂammatory or immune
modulatory properties, and are used as prophylaxis for chronic
inﬂammatory lung disease, such as cystic ﬁbrosis and chronic
dermatitis.69 The anti-inﬂammatory and immune modulatory
properties of macrolides such as erythromycin and azithromy-
cin are manifold, and other antibiotics also likely have similar
properties.70 It is possible that these anti-inﬂammatory proper-
ties are the cause of effect in infection provoked neuropsychi-
atric syndromes,71 rather than antimicrobial actions, although
this hypothesis is unproven.
Nonsteroidal anti-inﬂammatory drugs (NSAIDs) have, as
the name suggests, anti-inﬂammatory properties andmay have
adjunctive roles in chronic inﬂammation, if tolerated.72 Other
immunomodulatory agents used in rheumatology include
hydroxychloroquine, sulfasalazine, and leﬂunamide,73 and
have theoretical utility in immune brain disease.
Many drugs used in psychiatry such as the serotonin
reuptake inhibitors SSRIs74 and neuroleptics75 have anti-
inﬂammatory properties observed for decades. The anti-
inﬂammatory mechanism of action of these psychotropic
drugs is likely complex, but it is interesting that dopamine
receptors and serotonin receptors exist on the cell surface of
lymphocytes, and have cell signaling properties.76,77 Serotonin
reuptake inhibitor and neuroleptics also have potential anti-
inﬂammatory effects onmicroglia, the resident immune cells of
the CNS.74
The role of the gut-immune-brain interaction,78 and the
role of the microbiome in multiple sclerosis and other
autoimmune diseases is an area of active interest.79 Pro-
biotics, and other gut health management will likely be an
emerging area of attention in chronic autoimmune CNS
conditions.80 The utility of fecal transplantation, used in
the treatment of gastrointestinal diseases, has recently
been hypothesized and investigated in autoimmune neu-
ropsychiatric disorders.81 Along these lines, the ketogenic
diet has anti-inﬂammatory properties, among other mech-
anisms of action, and requires further attention in febrile
infection-related epilepsy syndrome and other immune
brain disease.82 Naturopathic agents and foods also have
active ingredients with anti-inﬂammatory properties such
as curcumin.83 Vitamin D is recognized as a major factor
related to autoimmune diseases and its deﬁciency repre-
sents a risk factor for these conditions.84 Because of the
high prevalence of vitamin D insufﬁciency or deﬁciency in
patients with multiple sclerosis, type 1 diabetes mellitus
and systemic lupus erythematosus, vitamin D supplemen-
tation has been considered a prospective candidate for the
treatment of such autoimmune diseases.85
Another area of interest and potential beneﬁt is the
therapeutic use of helminths. Parasitic helminths have been
shown to have the ability to alter or suppress the host’s
immune responses, which could be beneﬁcial to the host by
helping control excessive inﬂammatory responses.86 Animal
models and preclinical trials have suggested a beneﬁcial effect
of helminth infections on inﬂammatory bowel conditions,
multiple sclerosis,87 asthma and atopy.
Extracellular vesicles (EVs) represent a newborn area of
investigation in neuroimmunology. EVs are membrane-sur-
rounded structures released by most cell types. From the
therapeutic perspective, the most promising cellular sources of
EVs are mesenchymal stem cells, which are easy to obtain and
maintain.88 Mesenchymal stem cells-EVs have been demon-
strated to have immunosuppressive effects on B lymphocytes,
and immunomodulatory actions on B and T cells in vitro.89
Therefore, EVs are currently being investigated as a novel
therapeutic approach for treating brain inﬂammatory-related
diseases of CNS such as Parkinson disease, Alzheimer disease,
multiple sclerosis, amyotrophic lateral sclerosis, meningitis,
brain, spinal cord, and peripheral nerve injury and brain
tumors.88
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Safety
Although some of the monoclonal antibodies provide great
excitement as “targeted” immune therapies, it is important to
remind clinicians that agents developed for speciﬁc indications
may not work in other diseases, or even be detrimental. For
example, diseasemodifying therapies used inmultiple sclerosis
can make neuromyelitis optica worse. And drugs developed
for adults with rheumatological disease may have different
effects and adverse effects in children with brain disease. All
immune suppressive drugs run a risk of infusion related
adverse events, immune suppressive side effects such as
infection, viral reactivation, and increased risk of neoplasia,
as well as drug speciﬁc adverse events. Therefore, a “risk versus
beneﬁt” determination must be considered in all therapeutic
decision making.90
Clinical Implications
A more comprehensive knowledge of the range of available
immune therapies and a deeper understanding of their modes
of action should help the clinician in therapeutic decision-
making, according to the prevalent pathophysiological mech-
anism. Although some immune treatments are widely used
and their efﬁcacy and safety proﬁle in pediatric neurology is
relatively well understood, a plethora of new treatments are
currently being investigated and represent an exciting future
horizon in the ﬁeld of pediatric neuroimmunology. The
relative rarity of many of these conditions emphasize the need
for multicenter cohorts in order to obtain reliable data on the
real effectiveness and tolerability of these new compounds.
Only with improved biological understanding of disease, and
reproducible biomarkers examining immunogenetic, proteo-
mic, transcriptomic, microbiomic factors, will we be able to
truly translate the potential promise of these drugs into clinical
practice. Until then, careful consideration and “risk versus
beneﬁt” therapeutic decisions based on the disease severity and
natural history will be essential, but the clinician should not be
“disempowered by complexity” as “empiric” trials of immune
therapy in seronegative immune CNS syndromes can reduce
disability or be life-saving.
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We have reviewed the literature of immune therapy in autoimmune encephalitis associated
with antibodies to cell surface antigens including N-methyl-D-aspartate receptor (NMDAR),
leucine-rich, glioma-inactivated protein-1 (LGI1), contactin-associated protein-2 (Caspr2), the
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), γ-aminobutyric
acid-A receptor (GABAAR), γ-aminobutyric acid-B receptor (GABABR), Glycine R and other
rarer antigens. Most studies are retrospective cohorts, and there are no randomised controlled
trials. Most clinicians use first-line therapy (steroids, intravenous immunoglobulin, plasma
exchange), and if severe or refractory, second-line therapy (rituximab, cyclophosphamide).
When present, tumours should be removed. There are common therapeutic themes emerging.
Firstly, patients given immune therapy do better and relapse less than patients given no
treatment. Secondly, patients given early treatment do better. And thirdly, when patients
fail first-line therapy, second-line therapy improves outcomes and reduces relapses. Given the
retrospective uncontrolled data, the literature has inherent bias, including severity and report-
ing bias.
KEYWORDS: Autoimmune encephalitis ● antibodies to neuronal cell surface antigens ● immune therapy ● treatment ●
limbic encephalitis ● NMDAR ● LGI1 ● Caspr2 ● AMPAR
Autoantibodies against neuronal antigens were
first recognized in patients with acquired neu-
rological syndromes and tumors distant to the
nervous system. These paraneoplastic syn-
dromes include limbic encephalitis, brainstem
encephalitis, cerebellar ataxia and peripheral
neuropathy, among others, and are often asso-
ciated with onconeuronal antibodies, which
target intracellular antigens, including Hu,
Yo, Ri, Ma2, CV2/CRMP5, amphiphysin and
glutamic acid decarboxylase (GAD). These
onconeuronal antibodies cannot access the
antigen under physiological circumstances,
and neuronal tissues from these patients show
prevalent infiltration by T lymphocytes.
Moreover, experimental studies after immuni-
zation with the antigen Hu did not cause neu-
rological disease in mice, and response to
immune therapy is poor in these paraneoplastic
disorders.[1–4] Therefore, onconeuronal auto-
antibodies are considered biomarkers for the
presence of tumors rather than pathogenic
mediators of neurological disease [5] and
should motivate the search for an associated
malignancy.
More recently, autoantibodies targeting neu-
ronal cell surface proteins have been identified in
cases of encephalitis that were previously unex-
plained. The first of this novel class was identified
in 2007 and targeted the N-methyl-D-aspartate
receptor (NMDAR).[6] Subsequently, antibo-
dies were identified against the glycine receptor
(GlyR),[7] the α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor (AMPAR),[8]
the leucine-rich, glioma-inactivated protein-1
(LGI1), the contactin-associated protein-2
(Caspr2),[9,10] the γ-aminobutyric acid-A
receptor (GABAAR) and γ-aminobutyric acid-B
receptor (GABABR),[11,12] the metabotropic
glutamate receptor 5 (mGluR5),[13] the dopa-
mine-2 receptor (D2R),[14] the dipeptidyl-
peptidase-like protein-6 (DPPX),[15] and the
IgLON5.[16] The presence of tumor varies,
with some antibodies commonly associated with
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tumors, whereas in other antibody-associated syndromes tumors
are rare or absent.[17] Disease onset can be at any age and is often
more acute or subacute than in classic paraneoplastic syndromes,
which tend to be more insidious [5], although the clinical distinc-
tion between onconeuronal and cell surface antibody syndromes
may be challenging at presentation, especially in patients with
limbic encephalitis. Similarly, significant overlap between different
types of encephalitis with neuronal surface antibodies exists at
onset,[17] as behavioral and psychiatric changes, seizures, memory
deficits and sleep disturbances may be common features. The two
most frequent clinical syndromes are anti-NMDAR encephalitis, a
multiphasic disease with behavioral and psychiatric changes, move-
ment disorders, seizures, hyporesponsive state and dysautonomia,
[6] and limbic encephalitis, characterized by confusion, agitation,
memory loss and seizures, which can be associated with various
antibodies, including anti-LGI1, anti-AMPAR and anti-
GABABR. In view of the relative rarity of these conditions, and
as the discovery of these neuronal surface antibodies is quite recent,
the spectrum of the clinical syndromes and the best treatment
approach is yet to be defined. These cell surface antibody syn-
dromes have in common the presence of serum and cerebrospinal
fluid (CSF) autoantibodies, predominantly IgG, which bind to the
extracellular domain of cell surface antigens that are important to
neuronal function. Three antibody assays were initially used to
define the presence of neuronal surface antibodies in patients’
serum and CSF: demonstration of antibody binding to fixed
brain sections, to the surface of cultured live neurons, and to the
surface of human embryonic kidney (HEK293) cells transfected
with specific antigens.[18,19] This approach has been simplified,
and cell-based assays using HEK293 cells currently represent the
commonly available technique used for diagnosis, although assays
involving all three techniques improve the diagnostic specificity
and are commonly used in novel antibody discovery, and CSF is
generally considered more specific than serum.[4,20] Unlike the
onconeuronal antibodies, the neuronal cell surface autoantibodies
can reach their target protein in the absence of cell damage and
influence the antigen function or cause antigen internalization, and
therefore, are potentially pathogenic.[4,21] Most importantly,
autoimmune encephalitis associated with neuronal surface antibo-
dies are generally more likely to respond to immune therapy,
resulting in good recovery in up to 70–80% of cases.[20,22] No
randomized controlled trials in autoimmune encephalitis have
been published, and available evidence is mostly based on retro-
spective data. The treatment of these conditions is similar to other
autoimmune disorders of the central nervous system (CNS). First-
line immune therapies generally consist of corticosteroids (intrave-
nous and oral), sometimes with intravenous immunoglobulin
(IVIG) and/or plasma exchange (PE). Second-line treatments are
usually administered when the first-line therapies fail to produce
adequate benefit, or when the disease is known to be severe or
relapsing, and typically include rituximab, cyclophosphamide,
azathioprine, mycophenolate mofetil or others.
We conducted a systematic review on immune therapy in
autoimmune encephalitis with neuronal surface antibodies to
appreciate the use and type of immune treatment, its efficacy
and the available evidence on the possible benefit of early and
aggressive treatment.
The autoimmune encephalitis syndromes are presented in turn
and defined by the autoantibody. The literature search was con-
ducted in September 2015, and the search strategy varied accord-
ing to each syndrome and is stated in the text, with only larger
cohorts described in the more common syndromes. The reporting
of different findings and outcomes is variable, and the number of
patients with available data is reported in the text and tables.
Similarly, the reported outcome measures are variable, with mod-
ified Rankin scale (mRS) (Box 1) [23] or qualitative descriptions
of outcome used in most instances.
Anti-NMDAR antibodies
Epidemiology and clinical features
Encephalitis associated with autoantibodies against the
NMDAR was first described in 2007 in women with ovarian
teratoma [6] and has subsequently been reported also in chil-
dren and in both genders. The proportion of paraneoplastic
cases varies according to the age and appears to be considerably
lower in pediatric series (2.2–7.7%) [24–27] than in series
including adults (20.4–59.2%).[18,28,29] The frequency of
anti-NMDAR encephalitis surpassed that of individual viral
etiologies in the California Encephalitis Project.[30] The dis-
order is characterized by a multistage course that progresses
from behavioral or psychiatric disturbances, memory deficits,
seizures and language disintegration into a state of unrespon-
siveness with catatonic features, movement disorders and auto-
nomic instability.[31] The disease course is often prolonged up
to several months, and while a proportion of patients recover
fully, in sporadic reports even without immune therapy,[32]
Box 1. Modified Rankin scale description.[23]
Modified Rankin
scale score
Description
0 No symptoms at all
1 No significant disability despite symptoms:
able to carry out all usual duties and
activities
2 Slight disability: unable to carry out all
previous activities but able to look after
own affairs without assistance
3 Moderate disability: requiring some help,
but able to walk without assistance
4 Moderately severe disability: unable to walk
without assistance, and unable to attend to
own bodily needs without assistance
5 Severe disability: bedridden, incontinent,
and requiring constant nursing care and
attention
6 Dead
Modified Rankin scale is a neurological disability score often used to describe
outcome in the articles included in this review.
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many have behavioral, cognitive or neurological sequelae of
varying severity. Immune therapy appears to yield a more favor-
able outcome,[28] but although treatment strategies have been
suggested in adults,[31] to date there is no established therapeu-
tic algorithm.
We searched for articles with >30 cases each and treatment
details on patients with anti-NMDAR encephalitis, and the
authors included in this review eight papers published between
2008 and 2015 (Table 1).[18,24–29,33] One of the articles is a
prospective population-based study,[26] while all the others are
retrospective noncontrolled series. The articles report a total of
905 patients (726/905, 80.2% females), 577 of which were
described in one large case series by Titulaer and colleagues.
[29] The age at disease onset ranged between 0.7 and 85 years,
although most cases were children, adolescents and young adults
(427/905, 47% ≤18 years).
Treatment
Most patients received immune therapy (766/829, 92.4%).
According to available data, steroids were administered in
83.3% (634/761) of patients, IVIG in 66% (502/761) and PE
in 31.1% (244/761). In the large case series by Titulaer et al.,
steroids and IVIG were often given together (202/462, 44%)
[29]. Second-line immune therapies were administered in about
a third of cases with available information (229/684, 33.5%):
rituximab in 23.5% (195/828), cyclophosphamide in 14.5%
(120/828) and other immune therapies in 8.9% (74/828)
(azathioprine, mycophenolate mofetil, methotrexate or tacroli-
mus). Management of anti-NMDAR encephalitis is challenging,
and symptomatic treatment often focuses on sedation and
improving sleep–wake cycle, and patients appear to have a
high rate of adverse events to neuroleptics.[34]
Immune therapy versus no immune therapy
Results in the reviewed articles suggest that the use of immune
therapy is associated with a better outcome. In particular, within
the non-paraneoplastic group in the cohort described by Irani
and colleagues, those patients administered no immune therapy
did significantly worse than those who were treated
(p < 0.0001).[28] In the large case series by Titulaer,[29] 29%
of the 29 patients who received no surgery and no immune
therapy had a poor outcome (mRS 3–6) as opposed to 21.3% of
the total cohort (n = 501). Moreover, the use of immune
therapy in the initial episode of encephalitis was associated
with a lower frequency of relapses (p = 0.038).[29]
Timing of immune therapy
Several observations in the reviewed articles also suggest that
early commencement of immune therapy favors a better neuro-
logical outcome. In particular, improvement of mRS score was
associated with early (<40 days) administration of immune
therapies in non-paraneoplastic patients (p < 0.0001).[28]
Similarly, early treatment was a predictor of good outcome
(mRS 0–2) (p < 0.0001) in the cohort described by Titulaer.
[29] In children with anti-NMDAR encephalitis treated with T
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Table 1. Summary of the literature review on the treatment of anti-NMDAR encephalitis (only cohorts >30 patients were included).
[18,24–29,33] (continued).
Dalmau [18] Florance [33] Irani [28] Titulaer [29] Dale [24] Hacohen [25] Wright [26] Zekeridou [27]
Tumor 58/98
(59.2%)
8/32 (25%) 9/44 (20.4%) 220/577
(38.1%)
3/39 (7.7%) 1/46 (2.2%) 1/31 (3.2%) 1/36 (2.8%)
Immune therapy† 92/100 (92%) 30/31 (96.8%) 35/44 (79.5%) 462/501
(92.2%)
39/39 (100%)§ 41/46 (89.1%) 31/31 (100%) 36/36 (100%)
First-line n.a. 30/31 (96.8%) n.a. 462/501
(92.2%)
n.a. 41/46 (89.1%) 31/31 (100%) 36/36 (100%)
Steroids 76/100 (76%) n.a. 33/44 (75%) 421/501 (84%) 37/39 (94.9%) 36/46 (78.3%) 31/31 (100%) n.a.
IVIG 62/100 (62%) n.a. 15/44 (34.1%) 346/501
(69.1%)
34/39 (87.2%) 23/46 (50%) 22/31 (71%) n.a.
Plasma exchange 34/100 (34%) n.a. 13/44 (29.5%) 163/501
(32.5%)
11/39 (28.2%) 14/46 (30.4%) 9/31 (29%) n.a.
Second-line n.a. 7/31 (22.6%) n.a. 134/501
(26.7%)
39/39 (100%) 10/46 (21.7%) 10/31 (32.2%) 29/36 (80.5%)
Rituximab 10/100 (10%) 6/31 (19.3%) 2/44 (4.5%) 101/501
(20.1%)
39/39 (100%) 5/46 (10.9%) 6/31 (19.3%) 26/36 (80.5%)
Cyclophosphamide 9/100 (9%) 5/31 (16.1%) 4/44 (9.1%) 81/501 (16.2%) 8/39 (20.5%) 2/46 (4.3%) 6/31 (19.3%) 5/36 (13.9%)
Other: 1/100 (AZA)
(1%)
0/31 (0%) 1/44 (2.3%) AZA
1/44 (2.3%) MMF
23/44 (52.3%)
combination of the
above
31/501 (6.2%)
AZA, MMF,
methotrexate or
tacrolimus
4/39 (10.2%)
MMF or AZA
5/46 (10.9%)
MMF
1/46 (2.2%) AZA
1/31 (3.2%)
MMF
1/36 (2.8%) MMF
5/36 (13.9%) AZA
Median length of
follow-up (range)
17 months
(1–194)
4.5 months
(2–14.5)
16 months (3.6–121) 24 months (4–
186)
1.3 years (0.4–
4.5) (post
rituximab)
30 months (6–60) 12 months in
all patients
12 and 24 months
in 35/36 and 31/
36 patients,
respectively
No. of patients
who relapsed
15/100 (15%) n.a. 10/44 (22.7%) 45/501 (9%) n.a. 15/46 (32.6%) 7/31 (22.6%) 3/36 (8.3%)
Outcome mRS 0: 47/
100 (76%)
mRS 1–2: 28/
100 (28%)
mRS 3–5: 18/
100 (18%)
mRS 6: 7/100
(7%)
Full recovery:
9/31 (29%)
Substantial
improvement:
14/31 (45.2%)
Limited
improvement:
8/31 (25.8%)
n.a. mRS 0–2: 394/
501 (78.6%)
mRS 3–5: 77/
501 (15.4%)
mRS 6: 30/501
(6%)
mRS 0: 7/39
(17.9%)
mRS 1–5: 30/39
(76.9%)
mRS 6: 2/39
(5.1%)
Full recovery: 15/
46 (32.6%)
mRS 1–5: 31/46
(67.4%)
Full recovery:
19/30 (63.3%)
Partial recovery:
10/30 (32.2%)
No recovery: 1/
30 (3.2%)
In the first 24
months:
mRS 0: 20/36
(55.5%)
mRS 1–2: 10/36
(27.8%)
mRS 3–5: 5/36
(13.9%)
mRS 6: 1/36
(2.8%)
†At first episode.
‡Data on treatment and outcome available only in 501/577 patients with follow-up ≥4 months [29].
§The immune therapy listed refers only to the medications received before rituximab [24].
AZA: Azathioprine; F: Females; IVIG: Intravenous immunoglobulin; M: Males; MMF: Mycophenolate mofetil; mRS: Modified Rankin scale; n.a.: Not available; NMDAR: N-methyl-D-aspartate receptor.
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rituximab, patients who received rituximab early (≤0.1 year) did
better than patients treated late (>0.1 year) (mRS 0–2: 92% vs.
57.1%).[24] Similarly, in a recent collation of 80 pediatric
patients from 34 published articles, the median time from
symptom onset to initiation of treatment was shorter in children
who recovered completely compared to those who had not
recovered completely at follow-up (15 vs. 21 days)
(p = 0.014).[35] In a recent French series in the pediatric age
group, the authors observed that treatment delay has tended to
become shorter over time (2007–2012) [27], inferring that there
seems to be improved recognition of the disease, that allows for
expedited diagnosis and commencement of appropriate therapy.
In paraneoplastic patients, limited data also suggest a better
outcome in patients with early tumor removal.[18]
Second-line immune therapy
The use of second-line immune therapies also appears to be
beneficial. In the article by Titulaer, of 221 patients who did not
improve with first-line treatment, the patients who received
second-line immune therapy (125/221, 57%) had a better out-
come (mRS 0–2) than those who did not (p = 0.012) [29]. In
the same paper, the introduction of second-line therapy in 15
patients who had multiple attacks reduced the likelihood of
further relapses (p = 0.024). On the other hand, in the French
series by Zekeridou [27], the authors observed that despite a
high rate of use of second-line immune therapy (80.6%, 29/36,
mostly rituximab) the outcome in their cohort was very similar
to the outcome reported in other series with lower rate of
second-line treatment. In this same series, first-line treatment
only, rather than second-line therapy, was associated with good
outcome in univariate analysis (p = 0.01). Though this was not
confirmed in multivariate analysis, and this finding may be
influenced by a “severity bias,” as second-line therapy is more
commonly used in patients with severe disease. In a recent small
series of three children with anti-NMDAR encephalitis who did
not respond to first- and second-line (rituximab, azathioprine)
treatments, the authors suggest that intrathecal treatment with
methotrexate and methylprednisolone may be a useful add-on
therapy in refractory disease.[36]
Outcome
Relapses occurred in 11.2% of patients (85/758), and 5.1%
patients died (40/783). A considerable reduction in relapse
rate occurred over time, from 15% in a cohort reported in
2008 [18] to 9% in 2013 [29]. Similarly, the rate of severe
deficits or death at follow-up (mRS 3–6) dropped from 25% to
21.3% in these series, possibly due to earlier and more aggressive
therapy with increased disease recognition over this time.
The variable measures used for outcome at follow-up and the
heterogeneous follow-up duration (range 1–186 months)
(Table 1) partly hamper the comparison of outcome between
different series, especially in view of the fact that patients con-
tinue to improve for up to 18 months after symptom onset [29].
In the largest study by Titulaer and colleagues, at a median
follow-up of 24 months (range 4–186), 78.6% (394/501)
patients had an mRS of 0–2, 15.4% (77/501) an mRS of 3–5
and 6% (30/501) died [29].
Anti-LGI1 antibodies
Epidemiology and clinical features
In 2010, two independent groups demonstrated that LGI1 and
Caspr2 represent the major targets of voltage-gated potassium
channel (VGKC) antibodies.[9,10,37] Limbic encephalitis is the
predominant clinical syndrome associated with anti-LGI1 anti-
bodies, often in association with hyponatremia. Morvan’s syn-
drome and acquired neuromyotonia have also been described,
sometimes with overlapping phenotypes.[10] Detection of anti-
LGI1 antibodies has also been reported in patients with exclu-
sive or predominant seizure presentation.[38,39] A distinctive
type of seizure, faciobrachial dystonic seizures (FBDS), has been
described in association with anti-LGI1 antibodies, and it com-
monly precedes the onset of limbic encephalitis, representing an
important diagnostic clue.[39,40] Other reported atypical man-
ifestations associated with anti-LGI1 antibodies include progres-
sive encephalomyelitis with rigidity and myoclonus (PERM),
[41] isolated chorea,[42] hemianesthesia [43] and neurocardiac
prodromes.[44,45] The association with tumor is rare, and it
has been reported respectively in 0% and 11% of patients in the
two largest case series (lung tumor, thyroid tumor, renal cell
tumor, ovarian teratoma, thymoma).[9,10]
Eight articles published between 2010 and 2014 reporting ≥4
patients with anti-LGI1 encephalitis were included in this
review (Table 2).[9,10,38,39,46–49] One of the papers is a
prospective series,[39] whereas all the others are retrospective.
The articles report a total of 168 patients, predominantly males
(107/168, 63.7%), all adults (age range 28–92 years). While the
clinical phenotype of the patients is of limbic encephalitis in
most of the articles, seizures are the predominant feature in two
papers. Cognitive impairment, confusion, memory problems
and/or psychiatric issues are also common.[38,39] Additional
antibodies were detected in 4% (4/99) of patients with available
information (anti-Caspr2, anti-contactin-2).
Treatment
97.2% (103/106) of the patients with available information received
immune therapy at the first episode of disease. First-line treatments
were administered in 97.1% (102/105): steroids in 89.5% (94/105),
IVIG in 50% (53/106) and PE in 14.1% (15/106). Second-line
therapies were used in a limited proportion of cases (28/105,
26.7%): rituximab in 11.4% (12/105), cyclophosphamide in
1.9% (2/105), mycophenolate mofetil in 9.5% (10/105), azathiopr-
ine in 7.6% (8/105) and tacrolimus in 1.9% (2/105).
Immune therapy versus no immune therapy
Inadequate data are available on the outcome of the 2.8%
(3/106) patients who did not receive immune therapy.
However, in the prospective series of 10 patients with FBDS,
[39] >20% reduction in FBDS was noted within the first month
of immune therapy in nine cases who were refractory to anti-
epileptic agents for a median of 30 days (range 11–200)
www.tandfonline.com 1395
Immune therapy in autoimmune encephalitis Review
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 Sy
dn
ey
 L
ibr
ary
] a
t 2
0:1
8 1
8 A
pr
il 2
01
6 
Table 2. Summary of the literature review on the treatment of anti-LGI1 encephalitis (only cohorts ≥4 patients were included)
[9,10,38,39,46–49].
Lai [9] Irani [10] Quek [38] Irani [39] Shin [46] Irani [47] Malter [48] Wegner [49]
Study design Retrospective Retrospective Retrospective Prospective Retrospective Retrospective Retrospective Retrospective
No. of patients 57 55 14 9 14 6 9 4
Clinical description
(no. of females)
57/57: LE
(seizures in
42/57,
hyponatremia
in 28/47)
(F: 20/57,
35.1%)
49/55: LE
2/55: Morvan’s
syndrome
1/55:
neuromyotonia
1/55: epilepsy
2/55:
undefined
diagnosis
(F: 18/55,
32.7%)
10/14:
predominant
seizure
presentation,
with cognitive,
psychiatric,
personality or
other changes
4/14: exclusive
seizure
presentation
(F: 6/14, 42.8%)
9/9: faciobrachial
dystonic seizures
(cognitive impairment
in 8/10)
(F: 5/10, 50%)†
14/14: suspected
autoimmune
encephalitis (seizures in
14/14, memory
impairment, confusion
and/or abnormal
behavior in 12/14)
(F: 6/14, 42.8%)
6/6: LGI1-
associated
encephalopathy
(F: 4/6, 66.7%)
9/9: LE
(seizures in
9/9, memory
deficits in 8/
9)
(F: 3/9,
33.3%)
4/4: LE
(psychiatric
symptoms in
1/4, cognitive
deficits in 4/4/,
focal seizures
in 4/4)
(F: 0/4, 0%)
Median age at
onset (range)
60 years
(30–80)
Adults (median
and range n.a.)
60.5 years
(39–74)
68 years (28–92)‡ 60.5 years (41–78) 65 years
(48–73)
55 years
(32–67)
68 years
(interquartile
range
61–72.7)
Tumor 6/53 (11.3%):
–1/53: lung
–2/53: thyroid
–1/53: renal
cell
–1/53 ovarian
teratoma
–1/53:
thymoma
0/55 (0%) n.a. 1/10 (1%)
–1/10: multiple
endocrine neoplasia
type 1
1/14 (7.1%)
–1/14: renal cell
carcinoma
n.a. 0/9 (0%) 0/4 (0%)
Additional
antibody
1/55 (1.8%)
–1/55: Caspr2
n.a. 1/14 (7.1%) (type
of antibody n.a.)
2/9 (22.2%)
–1/9: Caspr2
–1/9: contactin-2
0/12 (0%) n.a. 0/9 (0%) n.a.
Immune therapy† 48/50 (96%) n.a. 14/14 (100%) 9/9 (100%) 13/14 (92.8%) 6/6 (100%) 9/9 (100%) 4/4 (100%)
First-line 48/50 (96%) 13/13 (100%) 9/9 (100%) 13/14 (92.8%) 6/6 (100%) 9/9 (100%) 4/4 (100%)
Steroids 42/50 (84%) 12/13 (92.3%) 9/9 (100%) 13/14 (92.8%) 5/6 (80%) 9/9 (100%) 4/4 (100%)
Intravenous
immunoglobulin
31/50 (62%) 4/13 (30.8%) 4/10 (40%) 8/14 (57.1%) 4/6 (66.7%) 0/9 (0%) 2/4 (50%)
PE 3/50 (6%) 3/13 (23.1%) 1/10 (10%) 1/14 (7.1%) 3/6 (50%) 0/9 (0%) 4/4 (100%)
Second-line 6/50 (12%) 11/13 (84.6%) 0/9 (0%) 5/14 (35.7%) 6/6 (100%) 0/9 (0%) 1/4 (25%)
Rituximab 3/50 (6%) 0/13 (0%) 0/9 (0%) 3/14 (21.4%) 6/6 (100%) 0/9 (0%) 0/4 (0%)
(continued)
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Table 2. Summary of the literature review on the treatment of anti-LGI1 encephalitis (only cohorts ≥4 patients were included)
[9,10,38,39,46–49]. (continued).
Lai [9] Irani [10] Quek [38] Irani [39] Shin [46] Irani [47] Malter [48] Wegner [49]
Cyclophosphamide 0/50 (0%) 0/13 (0%) 0/9 (0%) 1/14 (7.1%) 0/6 (100%) 0/9 (0%) 1/4 (25%)
Other: 2/50 (4%)
AZA
9/13 (69.2%)
mycophenolate
mofetil
4/13 (30.8%)
AZA
0/9 (0%) 2/14 (14.3%) AZA
2/14 (14.3%)
Tacrolimus
1/6 (16.7%)
mycophenolate
mofetil
0/9 (0%) 0/4 (0%)
Median length of
follow-up (range)
18 months
after initial
immune
therapy (2–60)
(data available
in 33/57)
>36 months 7.5 months
(2–48) (data
available in 12/
14)
17.7 months (6–29.7) 4.5 months (1–24)
(data available in 12/14)
34.2 months
(17.9–92.1)
39.8 months
(12.4–71.8)
23 months
(20–37)
No. of patients
who relapsed
6/33 (18.2%) n.a. 3/14 (21.4%) 4/10 (40%)‡ 2/13 (15.4%) 1/6 (16.7%) 0/9 (0%) 0/4 (0%)
Outcome Full recovery:
12/50 (24%)
Mild disability:
27/50 (54%)
Moderate
disability: 8/50
(16%)
Death: 3/50
(6%)
mRS were
significantly
reduced after
treatments
(p < 0.0001).
Death: 1/55
(1.8%)
(unrelated to
the clinical
syndrome)
Seizure freedom:
11/13 (84.6%)
Seizure
improvement: 2/
13 (15.4%)
All returned to their
baseline, although
typically without
complete
normalization of
formal
neuropsychology
testing scores
mRS 0: 6/12 (50%)
mRS 1: 3/12 (25%)
mRS 2: 2/12 (16.7%)
mRS 5: 1/12 (8.3%)
mRS 1: 3/6
(50%)
mRS 2: 3/6
(50%)
Seizure free:
8/9 (88.9%)
Memory
deficits: 6/8
(75%)
● –3/8 (37.5%):
figural +
verbal
● –2/8 (25%):
figural
● –1/8 (12.5%):
verbal
mRS 0: 2/4
(50%)
mRS 1: 1/4
(25%)
mRS 3: 1/4
(25%)
†At first episode.
‡Including one patient negative for LGI1, Caspr2 and contactin-2 (voltage-gated potassium channel-complex antibodies 377 pM) [39].
AZA: Azathioprine; Caspr2: Contactin-associated protein-2; F: Females; LE: Limbic encephalitis; LGI1: Leucine-rich, glioma-inactivated protein-1; mRS: Modified Rankin scale; n.a.: Not available; PE: Plasma exchange.
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(p = 0.006). The addition of corticosteroids was associated with
cessation of FBDS within 1 week in 30% (3/10) of patients, and
within 2 months in 60% (6/10). Moreover, the eight cases who
initially received antiepileptic drugs or no treatment all devel-
oped cognitive impairment, whereas the two who received early
immune therapy did not develop cognitive impairment
(p = 0.02). As regards the type of immune therapy, Shin and
colleagues observed that the subgroup of patients initially trea-
ted with concurrent steroids and IVIG had a better outcome
and higher rate of complete recovery (mRS 0) than the sub-
group who initially received only steroids (p = 0.042).[46]
Timing of immune therapy
Time to return to an mRS of 1 significantly correlated with time
to administration of immune therapy (p = 0.03) (but not time
to antiepileptic drug administration, p = 0.10) in the series by
Irani.[39] In the paper by Shin and coworkers, good outcome
(mRS ≤1) was reported in the patients who started immune
therapy early (≤1 month) (p = 0.058).[46] By contrast, Malter
and colleagues found no correlation between time to immune
therapy, and seizure and memory outcomes.[48]
Second-line immune therapy
Data on the benefit of second-line immune therapy are limited.
In a recent series of six patients with anti-LGI1 antibody-asso-
ciated encephalopathy,[47] rituximab produced clear benefit in
both mRS and FBDS frequency in one patient after failed
readministration of steroids, and this effect was reproduced at
relapse. Possible improvement with rituximab was observed in
two additional patients after steroids and IVIG (respectively in
verbal memory, and in cognitive function and emotional labi-
lity). In the remaining three patients, rituximab appeared to
have no or marginal clinical benefit in reducing seizure fre-
quency or the mRS score. In contrast, the most consistent
reductions in seizure frequency were associated with steroids or
IVIG, and mRS improvement appeared to be most consistently
associated with corticosteroids. Among the 13 cases reported by
Shin et al. [46], two patients had three relapses, both of whom
were initially treated with corticosteroids only; the addition of
rituximab and tacrolimus led to a cessation of any further
relapse in one of the two patients. Another recent article reports
that rituximab was associated with long-term remission of all
symptoms in two patients with anti-LGI1 encephalitis after
inefficacy of first-line treatments (15 and 56 months follow-
up, respectively).[50]
Patients who received second-line immune treatments had a
higher relapse rate than patients treated with first-line only (6/
23, 26.1% vs. 6/32, 18.7%), and lower rates of good outcome
(mRS 0 or seizure freedom: 10/23, 43.5% vs. 26/30, 86.7%),
although this may be related to “severity bias.”[38,39,46–49]
Outcome
The natural history of anti-LGI1 encephalitis is variable, with
spontaneous complete recovery possible without immune
therapy,[51] although death has also been described.[9] Length
of follow-up ranged between 2 and 92.1 months in the cohorts
(Table 2). Rate of good outcome (full recovery or mRS 0) was
27.8% (20/72) in the studies using neurological status as an
outcome measure.[9,46,49] 86.4% (19/22) patients were
seizure-free in the studies using seizure status as the main out-
come measure [38,48]. Relapses occurred in 18% patients (16/
89), and death in 2.5% (4/158) patients.
Anti-Caspr2 antibodies
Epidemiology and clinical features
Caspr2 is a cell adhesion molecule that clusters VGKCs (Kv1.1/
1.2) at the juxtaparanodes of the nodes of Ranvier in both the
peripheral and the CNS. In one of the two original series that led
to its identification as one of the major targets of anti-VGKC
antibodies,[10] over a third of anti-Caspr2 patients had limbic
encephalitis (7/19, 36.8%); however, seizures were less common
than in cases with positive anti-LGI1 antibodies. Neuromyotonia,
neuropathic pain, insomnia, dysautonomia and weight loss were
more frequent in patients with anti-Caspr2 antibodies.
Subsequent series have confirmed the association of anti-Caspr2
antibodies with both central and peripheral neurological manifes-
tations, including encephalopathy, seizures, limbic encephalitis,
[52–54] cerebellar ataxia,[55,56] Morvan’s syndrome [9,57,58]
and peripheral nerve hyperexcitability [9,59]. The association
with tumor has been reported in up to 52.4% of cases, especially
thymoma [10,57,60]. Additional antibodies have been described
in up to 85.7% of patients (anti-VGKC, anti-LGI1, anti-MUSK,
anti-AchR, etc.).[57,59]
Six articles reporting ≥5 patients with anti-Caspr2 antibodies,
published between 2010 and 2015, were included in this review
(Table 3).[10,53–55,57,59] A total of 71 patients are described
in these papers (31/86, 36% females), with age at onset ranging
between 8 and 77 years (1/67, 1.5% children).
Treatment
The majority of patients with adequate information received
immune therapy (37/40, 92.5%), and first-line treatments
were administered in 85.7% (18/21): steroids in 61.9% (13/
21), IVIG in 38.1% (8/21) and PE in 14.3% (3/21). Second-
line therapies were administered in 28.6% (6/21): rituximab in
14.3% (3/21), cyclophosphamide in 4.8% (1/21), mycopheno-
late mofetil and cyclosporine in 9.5% (2/21) each.
Immune therapy versus no immune therapy
In a recent series, all four patients who received immune therapy
had good recovery (mRS 0–1), whereas the only patient not
treated had a poor outcome (mRS 4) [54]. In the series by
Lancaster et al. [59], the two patients who did not receive
immune therapy had a worse outcome (full recovery: 0/2, 0%;
severe sequelae: 1/2, 50%) than the patients who did receive
immune therapy (full recovery: 2/8, 25%; severe sequelae: 1/8,
12.5%). In the series by Irani et al., all patients received
immune therapy, but mRS was significantly reduced post-
treatment only in the patients without tumor, whereas four of
the six patients with tumor died [10].
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Table 3. Summary of the literature review on the treatment of anti-Caspr2 autoimmunity (only cohorts ≥5 patients were included).
[10,53–55,57,59]
Irani [10] Lancaster [59] Becker [55] Irani [57] Pinatel [53] Sunwoo [54]
Study design Retrospective Retrospective Retrospective Retrospective Retrospective Retrospective
No. of patients 19 8 12‡ 21 7 5
Clinical
description
(no. of females)
7/19: LE
3/19: Morvan’s syndrome
7/19: neuromyotonia
2/19: epilepsy only
(F: 3/19, 15.8%)
5/8: encephalopathy or seizures
+ neuropathy or peripheral
nerve hyperexcitability (3 also
had myasthenia gravis, bulbar
weakness, or symptoms that
initially suggested motor
neuron disease)
2/8: encephalopathy or seizures
1/8: isolated peripheral nerve
hyperexcitability
(F: 1/8, 12.5%)
9/12: cerebellar
ataxia
3/12: controls
(F: 8/9, 88.9%)
21/21:
Morvan’s
syndrome
(F: n.a.)
7/7: LE
(F: 0/7, 0%)
2/5: isolated seizures
1/5: encephalopathy and
seizures
1/5: encephalopathy,
behavioral changes,
insomnia, seizures
1/5: encephalopathy,
dysarthria, insomnia, PNS
symptoms
(F: 2/5, 40%)
Median age at
onset (range)
Range 44–77 years (median n.
a.)
60.5 years (46–77) 58 years (35–76)
(data available in 9/
13)
Adults (median
and range n.
a.)
64 years (60–73) 43.5 years (8–65) (1 child)
Tumor 6/19 (31.6%):
–5/19: thymomas
–1/19: endometrial
adenocarcinoma
1/8 (12.5%):
–1/8: History of low-grade
bladder cancer
0/9 (0%) 11/21 (52.4%)
–10/21:
thymomas
–1/21: small
cell lung
cancer
3/7 (42.8%):
–2/7: prostate
cancer
–1/7: thyroid
cancer
0/5 (0%)
Additional
antibody
n.a. 6/7 (85.7%):
–4/7: VGKC
–1/7: VGKC, MUSK, AchR
–1/7: VGKC, AchR, GAD
2/6 (33.3%):
–1/6: ANA
–1/6: thyroid
antibody, VGKC
complex
15/21
(71.4%):
–15/21: LGI1
0/7 (0%) 0/5 (0%)
Immune
therapy†
19/19 (100%) 6/8 (75%) 1/1 (100%) n.a. 7/7 (100%) 4/5 (80%)
First-line n.a. 6/8 (75%) 1/1 (100%) 7/7 (100%) 4/5 (80%)
Steroids 5/8 (62.5%) 0/1 (0%) 4/7 (57.1%) 4/5 (80%)
Intravenous
immunoglobulin
2/8 (25%) 1/1 (100%) 2/7 (28.6%) 3/5 (60%)
Plasma exchange 2/8 (25%) 0/1 (0%) 1/7 (14.3%) 0/5 (0%)
Second-line n.a. 3/8 (37.5%) 1/1 (100%) 1/7 (14.3%) 1/5 (20%)
Rituximab 3/8 (37.5%) 0/1 (0%) 0/7 (0%) 0/5 (0%)
Cyclosporine 1/8 (12.5%) 0/1 (0%) 0/7 (0%) 0/5 (0%)
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Second-line immune therapy
In the combined cohorts, patients who did not receive second-
line immune therapy had a worse outcome than those who did
(mRS ≥3: 3/9, 33.3% vs. 1/7, 14.3%). Two case reports in
2013 described beneficial effect with B-cell-depleting therapies
(rituximab and tocilizumab) in one patient with Morvan’s syn-
drome and one with epilepsy, dysarthria and paroxysmal kinesi-
genic dyskinesia, respectively.[58,61]
Outcome
The follow-up data are limited. In general, relapse appears
uncommon, and full recovery occurred in about one-fourth of
patients, whereas 12.1% died (4/33 with adequate information).
Anti-AMPAR antibodies
Epidemiology and clinical features
Autoantibodies against the GluA1 or GluA2 subunits of AMPAR
were first described in 2009 [8]. AMPAR is an ionotropic gluta-
mate receptor important for synaptic plasticity, memory and learn-
ing.[62]While the initial clinical description in the first 10 patients
with anti-AMPAR encephalitis was of limbic encephalitis,[8], sub-
sequent identification of new cases led to a phenotype expansion to
include multifocal/diffuse encephalopathy, hyponatremia, limbic
encephalitis preceded by motor deficits or a predominantly psy-
chiatric syndrome.[63] The disorder is paraneoplastic in 63–70%
of cases,[8,63] and it has been described in association with small
cell lung cancer, thymoma, breast and ovarian cancer. However,
the condition is rare and further clinical descriptions will help
define the spectrum of disease.
A literature search for all articles reporting patients with anti-
AMPAR encephalitis led to the identification of eight articles
published between 2009 and 2015, reporting a total of 43
patients (Table 4) (32/43, 74.4% females), all adults (age
range 23–87 years).[8,63–69] All articles are retrospective; four
reported an individual patient,[64,66,68,69] two were small
series describing 4 and 3 patients, respectively,[65,67] and
only two were larger cohorts reporting 10 and 22 patients,
respectively.[8,63] Most of the cases with available information
were positive for anti-GluA2 antibodies (19/37, 51.3%), or for
both anti-GluA1 and anti-GluA2 antibodies (11/37, 29.7%),
whereas a minority for anti-GluA1 antibodies only (7/37,
18.9%). In the 20 cases with available paired CSF and serum
samples, antibodies were found in the CSF in all cases (20/20)
and in serum in 75% (15/20) [63–66]. 25.6% of patients had
other antibodies (10/39), and in the largest series the authors
observed that these additional autoantibodies often dictated the
clinical phenotype, and that in the patients with cancer and
onconeuronal or tumor-related antibodies the median survival
was significantly shorter than those patients with cancer but
without additional onconeuronal antibodies (p = 0.009) [63].
Treatment
Most of the patients received immune therapy during the first
episode of disease (40/42, 95.2%). Steroids were administered
in 80.9% patients (34/42), IVIG in 52.4% (22/42) and PE inT
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Table 4. Summary of the literature review on the treatment of anti-AMPAR encephalitis (all available cohorts were included).[8,63–69]
Lai [8] Bataller [64] Graus [65] Wei [66] Höftberger [63] Dogan
Onugoren [67]
Elamin [68] Li [69]
Study design Retrospective Retrospective Retrospective Retrospective Retrospective Retrospective Retrospective Retrospective
No. of patients 10 1 4 1 22‡ 3 1 1
Clinical description
(no. of females)
10/10: LE
(F: 9/10, 90%)
1/1: LE
(F: 1/1, 100%)
2/4: LE
2/4: other
encephalitis with
psychosis
(F: 4/4, 100%)
1/1:
encephalitis
(F: 1/1,
100%)
12/22: LE
8/22: limbic dysfunction with
multifocal/diffuse
encephalopathy
1/22: LE preceded by motor
deficits
1/22: psychosis
(F: 14/22, 63.6%)
3/3: LE
(F: 1/3, 33.3%)
1/1:
encephalitis
(F: 1/1,
100%)
1/1:
encephalitis
(F: 1/1,
100%)
Median age at
onset (range)
60 years (38–87) 67 years 59 years
(51–71)
30 years 62 years (23–81) 61 years (61–62) 73 years 47 years
Tumor 7/10 (70%):
–2/10: breast
cancer
–1/10: thymic
carcinoma
–1/10: thymoma
–1/10: malignant
thymoma
–1/10: non-SCLC
–1/10: SCLC
1/1 (100%):
–1/1:
adenocarcinoma
3/4 (75%)
–2/3: SCLC
–1/3: malignant
thymoma
0/1 (0%) 14/22
–5/22: SCLC
–4/22: thymoma
–2/22: breast cancer
–2/22: ovarian teratoma
–1/22: lung cancer
1/3 (33.3%)
–1/3: ovarian
adenocarcinoma
0/1 (0%) 1/1 (100%):
–1/1:
thymoma
Additional
antibody
3/10 (30%):
–1/3: GAD
–1/3: CV2/
CRMP5
–1/3: SOX1,
VGCC
0/1 (0%) n.a. 0/1 (0%) 7/22 (31.8%):
–2/22 CRMP5
–1/22 amphiphysin
–1/22 SOX1
–2/22 NMDAR
–1/22 SOX1, GABABR
0/3 (0%) 0/1 (0%) 0/1 (0%)
Immune therapy† 9/10 (90%) 1/1 (100%) 4/4 (100%) 1/1 (100%) 20/21 (95.2%) 3/3 (100%) 1/1 (100%) 1/1 (100%)
First-line 9/10 (90%) 1/1 (100%) 4/4 (100%) 1/1 (100%) 20/21 (95.2%) 3/3 (100%) 1/1 (100%) 1/1 (100%)
Steroids 9/10 (90%) 0/1 (0%) 4/4 (100%) 0/1 (0%) 17/21 (80.9%) 3/3 (100%) 0/1 (0%) 1/1 (100%)
Intravenous
immunoglobulin
5/10 (50%) 1/1 (100%) 0/4 (0%) 1/1 (100%) 12/21 (57.1%) 2/3 (66.7%) 1/1 (100%) 0/1 (0%)
PE 2/10 (20%) 0/1 (0%) 0/4 (0%) 0/1 (0%) 6/21 (28.6%) 2/3 (66.7%) 0/1 (0%) 0/1 (0%)
Second-line 1/10 (10%) 1/1 (100%) 0/4 (0%) 1/1 (100%) 5/21 (23.8%) 0/3 (0%) 0/1 (0%) 0/1 (0%)
Rituximab 0/10 (0%) 0/1 (0%) 0/4 (0%) 1/1 (100%) 5/21 (23.8%) 0/3 (0%) 0/1 (0%) 0/1 (0%)
Cyclophosphamide 1/10 (10%) 1/1 (100%) 0/4 (0%) 0/1 (0%) 1/21 (4.8%) 0/3 (0%) 0/1 (0%) 0/1 (0%)
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Table 4. Summary of the literature review on the treatment of anti-AMPAR encephalitis (all available cohorts were included).[8,63–69]
(continued).
Lai [8] Bataller [64] Graus [65] Wei [66] Höftberger [63] Dogan
Onugoren [67]
Elamin [68] Li [69]
Other 0/10 (0%) 0/1 (0%) 0/4 (0%) 1/1 (100%)
AZA
0/21 (0%) 0/3 (0%) 0/1 (0%) 0/1 (0%)
Median length of
follow-up (range)
15.5 months
(0.5–120)
12 months n.a. 119 days 72 weeks (5–266) (data
available in 21/22 patients)
6 months (5–14) n.a. 10 months
No. of patients
who relapsed
5/10 (50%) 0/1 (0%) 0/4 (0%) 0/1 (0%) 1/21 (4.8%) 3/3 (100%) 1/1 (100%) 0/1 (0%)
Outcome Returned to
baseline: 2/10
(20%)
Residual deficits:
5/10 (50%)
Death: 3/10
(30%)
Residual deficits:
1/1 (100%)
mRS 0–5: 4/4
(100%)
Residual
deficits: 1/1
(100%)
mRS 0: 1/21 (4.8%)
mRS 1: 4/21 (19%)
mRS 2: 5/21 (23.8%)
mRS 3: 4/21(19%)
mRS 4: 1/21 (4.8%)
mRS 5: 1/21 (4.8%)
mRS 6: 5/21 (23.8%)
Full recovery: 1/3
(33.3%)
Partial recovery:
1/3 (33.3%)
Limited recovery:
1/3 (33.3%)
n.a. Partial
recovery: 1/1
(100%)
Memory deficits 4/10 (40%) 1/1 (100%) n.a. 1/1 (100%) n.a. 1/3 1/1 (100%)
Psychiatric
problems
3/10 (30%)
(behavior mood)
0/1 (0%) n.a. 1/1 (100%)
(behavior
mood)
3/3 (psychiatric,
mood)
0/1 (0%)
Speech problems 1/10 (10%) 0/1 (0%) n.a. 1/1 (100%) 0/3 1/1 (100%)
Other 1/10 (10%)
(muscle spasms
and rigidity)
0/1 (0%) n.a. 0/1 (0%) 0/3 0/1 (0%)
†At first episode.
‡Data on treatment ad outcome available in 21/22 patients [63].
AZA: Azathioprine; F: Females; LE: Limbic encephalitis; mRS: Modified Rankin scale; n.a.: Not available; PE: Plasma exchange; SCLC: Small cell lung cancer; SOX1; Sry-like high mobility group box 1; CRMP5: Collapsin
response-mediator protein 5; VGCC: Voltage-gated calcium channels; NMDAR: N-methyl-D-aspartate receptor; GABABR: γ-aminobutyric acid-B receptor.
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23.8% (10/42). Second-line immune therapies were adminis-
tered in 19% (8/42) of patients: rituximab in 14.3% (5/42),
cyclophosphamide in 7.1% (3/42) and azathioprine in 2.4%
(1/42).
Immune therapy versus no immune therapy
Only two patients in the total cohort did not receive immune
therapy. These were two women with tumor and onconeuronal
or tumor-related antibodies, and both died (one due to limbic
encephalitis, one due to cancer) [8,63].
Timing of immune therapy
Data on the timing of immune therapy are insufficient to
establish a relationship with outcome. In the largest series of
22 patients [63], the median time from symptom onset until
diagnosis was relatively long (6.5 weeks, interquartile range
4–18.3 weeks), possibly due to the fact that the disease is still
incompletely characterized and recognized.[70]
Second-line immune therapy
The eight patients with anti-AMPAR encephalitis who received
second-line treatments during the first episode had lower rates
of relapses and death (0/8, 0% and 0/8, 0%, respectively) than
the 34 patients who did not receive second-line immune thera-
pies (10/34, 29.4% and 8/33, 24.2%, respectively).
Outcome
Length of follow-up ranged between 0.5 and 120 months.
10.8% of patients had a full recovery (mRS 0) (4/37), whereas
most cases recovered partially (25/37, 67.6%). Most frequent
sequelae were memory deficits (8/16, 50%), psychiatric issues
(behavior/mood) (7/16, 43.7%), speech problems (3/16,
18.7%) or muscle spasms and rigidity (1/16, 6.2%). Relapses
occurred in 23.8% of patients (10/42), and death in 21.6%
(8/37) (related to cancer in five, to cardiorespiratory arrest in
one, to myocardial infarction in one and to status epilepticus
after a relapse of limbic encephalitis in one).
Anti-GABAAR antibodies
Autoantibodies targeting the GABAAR, the primary ligand-gated
fast-acting inhibitory brain receptor,[71] were first identified in
2014 in 18 patients.[12] While six of these had high-titer CSF
and serum anti-GABAAR antibodies and a relatively homoge-
neous presentation with encephalitis and refractory seizures, the
remaining 12 patients, with low-titer antibodies present only in
the serum, had variable symptomatology including stiff-person
syndrome and opsoclonus myoclonus ataxia syndrome. The clin-
ical heterogeneity was further confirmed in a later series, in which
clinical syndromes in the 15 cases with available information
included isolated seizures, isolated psychiatric disturbances, iso-
lated cognitive impairment, limbic encephalitis and other symp-
toms.[72] The diversity of these clinical presentations raises
questions about the pathogenic role of these antibodies,[73]
particularly at lower titers. The detection of tumors is rare,
ranging between 11.1% and 21.4%.[12,72] Other autoantibodies
have been identified in up to 66.7% of cases, most frequently
anti-GAD, anti-thyroid peroxidase, anti-GABABR, anti-ANA,
anti-VGKC, anti-NMDAR and others,[12,72] once again raising
questions of antibody-specific pathogenicity.
Only 66 cases have been identified so far, 45 of which are
described in one recent series (clinical and treatment data only
available in 15/45 of these) (Table 5).[12,72,74,75] Age at onset
ranged between 2 and 74 years (16/66, 24.2% <20 years), and
genders were similarly represented (31/66, 47% females).
Only 54.5% (18/33) of patients with adequate information
received immune therapy. This treatment rate was particularly
low in the recent retrospective series by Pettingill et al. (4/15,
26.7%), possibly due to the heterogeneity of the clinical phe-
notypes, which was only rarely suggestive of autoimmune ence-
phalitis to the treating clinician.[72] First-line immune therapies
were administered in 54.5% (18/33): steroids in 42.4% (14/33),
IVIG in 27.3% (9/33) and PE in 18.2% (6/33). Second-line
therapies were used in 18.2% (6/33) of cases: rituximab in
12.1% (4/33), cyclophosphamide in 6.1% (2/33), and
azathioprine and cyclosporine in 3% (1/33) each.
The patients receiving immune therapy had better outcomes
than those who did not receive immune therapy (mRS 0: 2/18,
11.1% vs. 0/12, 0%), though there was a higher rate of relapse
(3/18, 16.7% vs. 1/12, 8.3%). The patients receiving immune
therapy were more likely to die (4/18, 22.2% vs. 1/12, 8.3%),
possibly related to severity bias. The patients treated with sec-
ond-line therapy had lower relapse rates than those who did not
receive second-line therapy (0/6, 0% vs. 4/24, 16.7%), and
better outcomes (mRS 0: 1/6, 16.7% vs. 1/24, 4.2%), despite
similar death rates (1/6, 16.7% vs. 4/24, 16.7%).
In the total cohort, relapses occurred in 13.3% (4/30) of patients.
At last follow-up, ranging between 1 and 192 months, only 6.7%
(2/30) patients had a full recovery, and 10% (3/30) died.
Anti-GABABR antibodies
Epidemiology and clinical features
In 2010, GABABR was identified as the target antigen in a subset
of patients with limbic encephalitis [11]. In a subsequent series,
anti-GABABR antibodies were detected in 14.3% of patients
with limbic encephalitis (10/70).[76] Cerebellar ataxia and
other clinical syndromes (including PERM, opsoclonus myoclo-
nus ataxia syndrome and epilepsy) have also been described in
association with anti-GABABR antibodies, although uncom-
monly.[11,76–78] GABABRs have an inhibitory function and
are widely expressed in the brain and spinal cord with the highest
levels in the hippocampus, thalamus and cerebellum.[79]
Clinical, MRI and electroencephalographic data suggest that the
brain regions most affected are the hippocampi and temporal
lobes, explaining the relative similarity of anti-GABABR ence-
phalitis to other types of limbic encephalitis [11]. Tumors have
been detected in up to 80% of patients,[76,77,80] typically
SCLC. In the majority of cases, other coexisting autoantibodies
have been identified, mostly against intracellular antigens.[78]
Six articles published between 2010 and 2015, with ≥5
patients with positive anti-GABABR antibodies, were included
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Table 5. Summary of the literature review on the treatment of anti-GABAAR encephalitis (all available
cohorts were included).[12,72,74,75]
Petit-Pedrol [12] Ohkawa [74] Pettingill [72] Simabukuro [75]
Study design Retrospective Retrospective Retrospective Retrospective
No. of patients 18 2 45‡ 1
Clinical description
(no. of females)
6/18 with high titer (>1:160)
cerebrospinal fluid and serum
anti-GABAAR antibody:
encephalitis and refractory
seizures or status epilepticus
12/18 with low-titer serum only
(≤1:160) anti-GABAAR
antibody: 6 Encephalitis with
seizures, 4 stiff-person
syndrome (1 with seizures), and
2 opsoclonus myoclonus ataxia
syndrome
(F: 6/18, 33.3%)
2/2: encephalitis
with cognitive
impairment and
multifocal brain
MRI abnormalities
(F: 1/2, 50%)
15/15: variable symptomatology
(7/15 seizures, 7/15 memory
impairment, 4/15 confusion or
disorientation, 5/15 psychiatric
features, 2/15 hallucinations, 4/
15 anxiety)
(F: 23/45, 50%)
1/1: LE
(F: 1/1, 100%)
Median age at onset
(range)
24.5 years (2–74) (7 children) 52.2 years (46–59) 51 years (2–73) (8/45 were
<20 years old)
45 years
Tumor 2/18 (11.1%):
–1/18: Hodgkin’s lymphoma
–1/18: Previous history of
ovarian cancer
2/2 (100%):
2/2: Invasive
thymoma
3/14 (21.4%):
–1/14: dysembryoplastic
neuroepithelial tumors
–1/14: Prostatic cancer
–1/14: Non-Hodgkin’s
lymphoma
1/1 (100%):
–1/1: Thymoma
Additional antibody 12/18 (66.7%):
–4/18: GAD
–1/18: TPO, thyroglobulin
–1/18: TPO
–1/18: GABABR
–1/18: GABABR, GAD, TPO,
thyroglobulin
–1/18: GAD, TPO, thyroglobulin
–1/18: NMDAR
–1/18: ANA, anti-endomysial
IgA
–1/18: ANA
2/2 (100%):
–1/2: AchR, VGKC,
LGI1, DCC
–1/2: VGKC,
Caspr2, DCC
3/15 (20%):
–2/15: VGKC complex
–1/15: NMDAR, Caspr2, VGKC
complex
1/1 (100%):
–1/1: LGI1
Immune therapy† 12/15 (80%) 1/2 (50%) 4/15 (26.7%) 1/1 (100%)
First-line 12/15 (80%) 1/2 (50%) 4/15 (26.7%) 1/1 (100%)
Steroids 10/15 (66.7%) 1/2 (50%) 2/15 (13.3%) 1/1 (100%)
Intravenous
immunoglobulin
7/15 (46.7%) 1/2 (50%) 1/15 (6.7%) 0/1 (0%)
Plasma exchange 3/15 (20%) 0/2 (0%) 2/15 (13.3%) 1/1 (100%)
Second-line 5/15 (33.3%) 0/2 (0%) 1/15 (6.7%) 0/1 (0%)
Rituximab 4/15 (26.7%) 0/2 (0%) 0/15 (0%) 0/1 (0%)
Cyclosporine 2/15 (13.3%) 0/2 (0%) 0/15 (0%) 0/1 (0%)
Other: 1/15 (6.7%) cyclosporine 0/2 (0%) 1/15 (6.7%) azathioprine 0/1 (0%)
Median length of follow-
up (range)
24 months (1–192) (d.a. in
9/18)
8 months (d.a. in
1/2 patients)
18 months (2–20) (d.a. in 9/45) Not available
No. of patients who
relapsed
1/15 (6.7%) 1/2 (50%) 1/12 (8.3%) 1/1 (100%)
(continued )
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in this review (Table 6).[11,67,76–78,80] All are retrospective
noncontrolled studies, reporting a total of 79 patients (35/79,
44.3% females), with age at onset between 16 and 85 years (3/
79, 3.8% ≤18 years).
Treatment
Most of the patients received immune therapy (53/67, 79.1%).
First-line treatments were administered in 79.1% (53/67): ster-
oids in 64.2% (43/67), IVIG in 43.3% (29/67) and PE in
19.4% (13/67). Only a minority of patients received second-
line immune therapies (9/67, 13.4%): rituximab was used in
6% (4/67), cyclophosphamide in 4.5% (3/67), mycophenolate
mofetil in 3% (2/67) and azathioprine in 1.5% (1/67).
Immune therapy versus no immune therapy
In the first series by Lancaster et al. [11], most of the patients
who received immune therapy had full or substantial improve-
ment (10/13, 76.9%) as opposed to none of the patients who
did not receive immune therapy (0/3, 0%) (p = 0.005); more-
over, 23.1% (3/13) of those who received immune therapy
eventually died as opposed to all of those who were not treated
(3/3, 100%). In the cohort reported by Boronat et al. [76], after
excluding one nonassessable patient, 90% (9/10) of patients
who received immune therapy and cancer treatment (when
appropriate) showed neurological improvement as opposed to
none of the four patients who did not receive immune therapy
or whose tumor treatment was not completed (p = 0.005). In
the combined cohorts, patients who received immune therapy at
the first episode had better outcomes than those who did not
(mRS 0–1: 23/51, 45.1% vs. 1/13, 7.7%), and lower rates of
death (12/51, 23.5% vs. 8/11, 76.9%), despite higher rates of
relapses (2/36, 5.5% vs. 0/9, 0%).
Second-line immune therapy
In the series by Kim et al., where the majority of patients
recovered only partially (mRS 2 in 3/5, 60%) [80], the authors
comment that the relatively partial response to treatment in
anti-GABABR encephalitis might be attributed to insufficient
immune therapy, including second-line treatments. In
concordance with this, in the combined cohorts in this review,
the patients who received second-line treatments had a margin-
ally more favorable outcome than those who did not have
second-line treatment (mRS 0–1: 3/9, 33.3% vs. 17/55,
30.9%). In addition, patients who received second-line treat-
ment had lower rates of relapses (0/5, 0% vs. 2/41, 4.9%) and
of death (1/9, 11.1% vs. 21/55, 38.2%).
Outcome
Relapses occurred in a very limited proportion of patients (2/53,
3.8%). At last follow-up (range 0–72 months), 25.3% (18/71)
of patients had a complete recovery and 33.8% (24/71) had
died.
Anti-GlyR antibodies
First described in 2008 [7], anti-GlyR antibodies have been
reported in a broad range of clinical syndromes, including
PERM,[7,81,82] stiff-person syndrome,[83–85] epilepsy,
[86,87] limbic encephalitis,[82,88] cerebellar ataxia,[89,90]
transverse myelitis,[91] optic neuritis,[92] neuromyelitis optica
[93] and multiple sclerosis [84,92]. The association with tumor
(thymoma, lymphoma, lung tumor) is rare (0–9%) and has
been reported mostly with PERM and stiff-person syndrome,
[82,83] in which coexisting anti-GAD antibodies have also been
frequently described [82–84] and, more rarely, anti-NMDAR
antibodies.[94] Additional antibodies detected in the other clin-
ical phenotypes include anti-VGKC (epilepsy) [82,86] and anti-
bodies against myelin oligodendrocyte glycoprotein and
aquaporin-4 (optic neuritis).[92]
Seven articles published between 2013 and 2015 with ≥5
patients, all retrospective, were included in this review
(Table 7).[82–84,86,87,90,92] The papers report a total of
112 patients with anti-GlyR antibodies (47/95, 49.5% females),
55 of which derive from two separate cohorts described in one
large series.[82] Age at onset ranged between 3 and 75 years
(13/89, 14.6% children).
77.3% (58/75) of patients in the combined cohort received
immune therapy. First-line agents were administered in 79.4%
(54/68) of patients with available data: steroids in 66.2% (45/
Table 5. Summary of the literature review on the treatment of anti-GABAAR encephalitis (all available
cohorts were included).[12,72,74,75] (continued).
Petit-Pedrol [12] Ohkawa [74] Pettingill [72] Simabukuro [75]
Outcome Full recovery: 2/15 (13.3%)
Substantial/marked
improvement: 4/15 (26.7%)
Neurological sequelae: 6/15
(40%)
Death: 3/15 (20%)
Neurological
sequelae: 2/2
(100%)
Improvement: 8/12 (66.7%)
Steady decline: 1/12 (8.3%)
Huntington disease confirmed:
1/12 (8.3%)
Death: 2/12 (16.7%)
Close to baseline:
1/1 (100%)
†At first episode.
‡Clinical and treatment data available only in 15/45 [72].
d.a.: Data available; F: Females; GABAAR: γ-aminobutyric acid-A receptor; GAD: Glutamic acid decarboxylase; TPO: Thyroid peroxidase; VGKC: Voltage-gated potassium
channels; NMDAR: N-methyl-D-aspartate receptor; ANA: Antinuclear antibodies; AchR: Acetilcholine receptor; LGI1: Leucine-rich, glioma-inactivated protein 1; Caspr2:
Contactin-associated protein-2; MRI: Magnetic resonance imaging.
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Table 6. Summary of the literature review on the treatment of anti-GABABR encephalitis (only cohorts ≥5 patients included).[11,67,76–
78,80]
Lancaster [11] Boronat‡ [76] Jeffery [77] Höftberger [78] Kim [80] Dogan
Onugoren [67]
Study design Retrospective Retrospective Retrospective Retrospective Retrospective Retrospective
No. of patients 17 10 17 20 5 10
Clinical description
(no. of females)
15/17: LE
2/17: controls (1:
progressive cerebellar
ataxia; 1: progressive
encephalomyelitis with
rigidity and myoclonus)
(F: 9/17, 52.9%)
9/10: LE (6: SCLC
without onconeural ab;
1: SCLC with Hu-ab; 2:
no tumor, no onconeural
ab)
1/10: cerebellar ataxia
(F: 2/10, 20%)
10/17: LE
1/17: rapidly progressive
encephalomyelopathy
1/17: cerebellar ataxia
5/17: other syndromes
(3: CSN; 2: PNS)
(F: 11/17, 64.7%)
17/20: LE
1/20: ataxia
1/20: status
epilepticus
1/20: opsoclonus
myoclonus ataxia
syndrome
(F: 8/20, 40%)
5/5: LE
(F: 3/5, 60%)
10/10: LE
(F: 2/10, 20%)
Median age at onset
(range)
62 years (24–75) 59 years (47–70) 63 years (16–85)
(2 children, age 16 and
18 years)
61.5 years (16–77)
(1 child, age 16 years)
63 years
(58–71)
69.5 years (51–75)
Tumor 7/17 (41.2%):
–5/17: SCLC
–1/17: neuroendocrine
lung tumor
-1/17: mediastinal
adenopathy
8/10 (80%):
–7/10: SCLC
–1/10: carcinoid of
thymus
13/17 (76.5%):
–9/17: SCLC
–1/17: SCLC and breast
–1/17: lung mass
–1/17: multiple myeloma
–1/17: rectal carcinoma
10/20 (50%):
–10/20: SCLC
4/5 (80%):
–4/5: SCLC
5/10 (50%):
–4/10: SCLC
–1/10: lung cancer
Additional antibody 9/17 (52.9%):
–3/17: VGCC
–2/17: GAD
–1/17: TPO, GAD
–1/17: TPO,
thyroglobulin
–1/17: GAD, TPO, SOX1
–1/17: GAD, TPO,
thyroglobulin
6/10 (60%):
–2/10: GAD
–1/10: SOX1, VGKC
–1/10: GAD, SOX1
–1/10: Hu
–1/10: BRSK2
16/16 (100%):
–10/16: VGCC
–1/16: AGNA /SOX1,
VGCC, VGKC
–1/16: VGCC, VGKC,
CRMP5
–1/16: Hu
–1/16: Hu, ANNA3
–1/16: ANNA3, GAD
–1/16: CRMP5
7/20 (35%):
–3/20: SOX1
–1/20: Ri
–1/20: Amphiphysin
–1/20: GAD
–1/20: NMDAR
2/5 (40%):
–2/5: Hu
4/10 (40%):
–3/10: SOX1
–1/10: Hu
Immune therapy† 13/17 (76.5%) 8/10 (80%) 5/6 (83.3%) 15/19 (78.9%) 4/5 (80%) 8/10 (80%)
First-line 13/17 (76.5%) 8/10 (80%) 5/6 (83.3%) 15/19 (78.9%) 4/5 (80%) 8/10 (80%)
Steroids 11/17 (64.7%) 7/10 (70%) 2/6 (33.3%) 14/19 (73.7%) 3/5 (60%) 6/10 (60%)
Intravenous
immunoglobulin
6/17 (35.3%) 7/10 (70%) 1/6 (16.7%) 7/19 (36.8%) 4/5 (80%) 4/10 (50%)
Plasma exchange 2/17 (11.8%) 0/10 (0%) 4/6 (66.7%) 5/19 (26.3%) 0/5 (0%) 2/10 (20%)
Second-line 1/17 (5.9%) 0/10 (0%) 1/6 (16.7%) 4/19 (21%) 0/5 (0%) 3/10 (30%)
Rituximab 0/17 (0%) 0/10 (0%) 0/6 (0%) 2/19 (10.5%) 0/5 (0%) 2/10 (20%)
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Table 6. Summary of the literature review on the treatment of anti-GABABR encephalitis (only cohorts ≥5 patients included).[11,67,76–
78,80] (continued).
Lancaster [11] Boronat‡ [76] Jeffery [77] Höftberger [78] Kim [80] Dogan
Onugoren [67]
Cyclophosphamide 0/17 (0%) 0/10 (0%) 1/6 (16.7%) 1/19 (5.3%) 0/5 (0%) 1/10 (10%)
Other: 1/17 (5.9%)
mycophenolate mofetil
0/10 (0%) 0/6 (0%) 1/19 (5.3%)
mycophenolate
mofetil
0/5 (0%) 1/10 (10%) AZA
Median length of follow-up
(range)
9 months (0–72) n.a. 1 months (0–34) 7 months (0.75–45) 3 months
(1–12)
3 months (1–12)
No. of patients who
relapsed
1/17 (5.9%) 1/10 (10%) 0/12 (0%) n.a. 0/5 (0%) 0/9 (0%)
Outcome Full recovery: 4/16 (25%)
Substantial
improvement: 4/16
(25%)
Partial improvement: 2/
16 (12.5%)
Death: 6/16 (37.5%)
Complete recovery: 3/9
(33.3%)
Partial improvement: 1/9
(11.1%)
No response: 1/9
(11.1%)
Death: 4/9 (44.4%)
Complete resolution: 2/
12 (16.7%)
Neurological sequelae of
varying severity: 7/12
(58.3%)
Death: 3/12 (25%)
Complete response:
6/20 (30%)
Partial response: 6/20
(30%)
Death: 8/20 (40%)
mRS 1: 2/5
(40%)
mRS 2: 3/5
(60%)
Complete remission: 1/
9 (11.1%)
Partial improvement: 3/
9 (33.3%)
No improvement: 2/9
(22.2%)
Death: 3/9 (33.3%)
†At first episode.
‡One patient of this series was excluded as it was included in the initial series by Lancaster et al. [11].
ab: Antibody; AGNA: Anti-glial nuclear antibody; GABABR: γ-aminobutyric acid-B receptor; GAD: Glutamic acid decarboxylase; LE: Limbic encephalitis; mRS: Modified Rankin scale; SCLC: Small cell lung cancer; SOX1; Sry-
like high mobility group box 1; TPO: Thyroid peroxidase; VGCC: Voltage-gated calcium channels; VGKC: Voltage-gated potassium channel; NMDAR: N-methyl-D-aspartate receptor; CRMP5: Collapsin response-mediator
protein 5.
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Table 7. Summary of the literature review on the treatment of anti-GlyR autoimmunity (only cohorts ≥5 patients were included).[82–
84,86,87,90,92]
McKeon [83] Brenner
[86]
Alexopoulos
[84]
Ekizoglu [87] Carvajal-Gonzalez
[82]
Carvajal-
Gonzalez
[82]§
Gresa-
Arribas
[90]
Martinez-
Hernandez [92]
Study design Retrospective Retrospective Retrospective Retrospective Retrospective Retrospective Retrospective Retrospective
No. of patients 11 12 11 5 45 10 6 12
Clinical
description
(no. of females)
5/11: variant SPS‡
4/11: classic SPS
1/11: PERM
1/11: control with optic
atrophy
(F: 6/11, 54.5%)
12/12:
epilepsy
(F: 6/12,
50%)
9/11: SPS with
high titer
(>20,000 units)
of anti-GAD ab
1/11: SPS with
low anti-GAD
titer (<50 U/ml)
1/11:
relapsing-
remitting
multiple
sclerosis, GAD-
negative
(F: n.a.)
4/5: focal
epilepsy of
unknown origin
1/5: mesial
temporal lobe
epilepsy with
hippocampal
sclerosis
(F: 3/5, 60%)
33/45: PERM
5/45: limbic
encephalitis or
epileptic
encephalopathy
2/45: SPS
2/45: brainstem
features
2/45: demyelinating
optic neuropathies
1/45: unclear
diagnosis
(F: 21/45, 46.7%)
5/10: PERM
4/10: SPS
1/10:
acquired
hyperekplexia
(F: 6/10,
60%)
4/6:
cerebellar
ataxia
2/6: epilepsy
(F: n.a.)
7/12: isolated ON
(final diagnosis:
recurrent isolated ON
in 4, monophasic
isolated ON in 1,
neuromyelitis optica
in 1, multiple sclerosis
in 1)
5/12: multiple
sclerosis
(F: 5/7, 71.4%)
Median age at
onset (range)
43 years (5–69)
(2 children)
47 years
(27–73)
n.a. 16 years (3–17)
(5 children)
50 years (1–75)
(4 children)
42 years (19–
54) (d.a. in
9/10)
n.a. 27 years (11–38)
(2 children) (d.a. in
7/12)
Tumor 1/11 (9.1%):
–1/11: Hodgkin’s
lymphoma
0/12 (0%) 0/11 (0%) 0/5 (0%) 4/45 (8.9%)
–3/45: thymoma
–1/45: lymphoma
5/45 (11.1%) had
previous tumors,
treated
1/10 (10%):
–1/10:
previous
breast cancer
0/6 (0%) 0/12 (0%)
Additional
antibody
6/11 (54.5%)
–6/11: GAD
1/12 (8.3%)
–1/12: VGKC
10/11 (90.9%)
–10/11: GAD
(9 high titer, 1
low titer)
0/5 (0%) 13/28 (46.4%):
–4/28: GAD
–3/28 VGKC
-complex
–3/28: NMDAR
–6/45: thyroid ab
4/9 (44.4%):
–4/9: GAD
6/6 (100%):
–6/6: GAD
4/12 (33.3%):
–3/12: MOG
–1/12: AQP4 (all
patients with ON)
Immune
therapy†
7/10 (70%) n.a. n.a. 2/5 (40%) 37/44 (84.1%) 9/9 (100%) n.a. 3/7 (42.8%)
First-line 7/10 (70%) 1/5 (20%) 37/44 (84.1%) 9/9 (100%) n.a.
Steroids 5/10 (50%) 1/5 (20%) 31/44 (70.4%) 8/9 (88.9%) n.a.
Intravenous
immunoglobulin
3/10 (30%) 1/5 (20%) 20/44 (45.4%) 5/9 (55.5%) n.a.
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Table 7. Summary of the literature review on the treatment of anti-GlyR autoimmunity (only cohorts ≥5 patients were included).[82–
84,86,87,90,92] (continued).
McKeon [83] Brenner
[86]
Alexopoulos
[84]
Ekizoglu [87] Carvajal-Gonzalez
[82]
Carvajal-
Gonzalez
[82]§
Gresa-
Arribas
[90]
Martinez-
Hernandez [92]
Plasma
exchange
1/10 (10%) 0/5 (0%) 17/44 (38.6%) 2/9 (22.2%) n.a.
Second-line 2/10 (20%) 1/5 (20%) 11/44 (25%) 0/9 (0%) 3/7 (42.8%)
Rituximab 0/10 (0%) n.a. 2/44 (4.5%) 0/9 (0%) 1/7 (14.3%)
Cyclosporine 0/10 (0%) n.a. 4/44 (9.1%) 0/9 (0%) 0/7 (0%)
Other 2/10 (20%) AZA n.a. 4/44 (9.1%) AZA
3/44 (6.8%)
mycophenolate
mofetil
1/44 (2.3%)
Cyclosporine
0/9 (0%) 1/7 (14.3%) AZA
1/7 (14.3%)
methotrexate
1/7 (14.3%)
Glatiramer ac.
Median length
of follow-up
(range)
12 months (0–60) n.a. n.a. n.a. 3 years (2–7), since
first ab detection
n.a. n.a. 41 months (24–133)
(data available in 7/
12)
No. of patients
who relapsed
n.a. n.a. n.a. n.a. 6/43 (13.9%) n.a. n.a. 6/7 (data available in
7/12)
Outcome No symptoms/signs: 1/10
(10%)
Near normal: 2/10 (20%)
Substantial–considerable
improvement: 3/10
(30%)
Mild–moderate
improvement: 2/10
(20%)
Worsening after initial
improvement: 1/10
(10%)
improvement of visual
acuity: 1/10 (10%)
n.a. n.a. Good response
to AED (no IT):
3/5 (60%)
Poor response
to AED, good
response to IT:
1/5 (20%)
Poor response
to AED,
response to IT
n.a.: 1/5 (20%)
mRS 0: 7/44 (15.9%)
mRS 1: 19/44
(43.2%)
mRS 2: 8/44 (18.2%)
mRS 3: 4/44 (9.1%)
mRS 4: 1/44 (2.3%)
mRS 5: 1/44 (2.3%)
mRS 6: 4/45 (8.9%)
Good or very
good
response to
IT: 3/8
(37.5%)
Partial or
moderate
response to
IT: 2/8 (25%)
Poor
response to
IT: 3/8
(37.5%)
n.a. EDSS 0: 5/7 (71.4%)
EDSS 2: 1/7 (14.3%)
EDSS 2.5: 1/7
(14.3%)
†At first episode.
‡Patients were classified as having classic SPS if lower extremity and lumbar stiffness and spasms were present, and variant SPS if symptoms were restricted to either axial or extremity muscles or upper body muscles.
Patients with hyperekplexia had isolated exaggerated startle in response to tactile or auditory stimuli [83]
§Refers to the second cohort of patients described in the paper, available in the supplemental material [82].
ab: Antibody; AED: Antiepileptic drugs; AZA: Azathioprine; EDSS: Kurtzke Expanded Disability Status scale; F: Females; GAD: Glutamic acid decarboxylase; IT: Immune therapy; mRS: Modified Rankin scale; n.a.: Not
available; ON: Optic neuritis; PERM: Progressive encephalopathy with rigidity and myoclonus; SPS: Stiff-person syndrome; VGKC: Voltage gated potassium channel; NMDAR: N-methyl-D-aspartate receptor; MOG: Myelin
oligodendrocyte glycoprotein; AQP4: Aquaporin-4.
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68), IVIG in 42.6% (29/68) and PE in 29.4% (20/68). In the
largest published series,[82] approaches to first-line immune
therapy were variable but typically started with intravenous
methylprednisolone followed by high-dose prednisolone, and
sometimes by PE, IVIG or both. In the combined cohort
from the seven articles, second-line immune therapies were
used at the first disease event in 22.7% (17/75): rituximab in
4.3% (3/70), cyclophosphamide in 5.7% (4/70), azathioprine in
10% (7/70), mycophenolate mofetil in 4.3% (3/70), methotrex-
ate in 1.4% (1/70), cyclosporine in 1.4% (1/70) and glatiramer
acetate in 1.4% (1/70).
According to available data, the patients who received
immune therapy had higher rate of good recovery than those
who were not treated (mRS 0–1: 25/44, 56.8% vs. 3/10, 30%)
and a slightly lower mortality rate (3/44, 6.8% vs. 1/10, 10%).
However, in the patients who received second-line treatment as
compared to the patients who did not, there were similar rates
of good recovery (mRS 0–1: 4/16, 25% vs. 11/45, 24.4%) and
of death (1/16, 6.2% vs. 3/45, 6.7%). Data on the timing of
immune therapy are insufficient for comparison.
Follow-up ranged between 0 and 133 months, and relapses
occurred in 24% of patients (12/50). 5.3% (4/75) patients died,
and 21.3% (13/61) had a good outcome (mRS 0).
Anti-DPPX antibodies
Encephalitis associated with antibodies against DPPX, a reg-
ulatory subunit of neuronal Kv4.2 potassium channels, was
first described in 2013 in four patients [15]. Since then, 27
additional cases with positive anti-DPPX antibodies have
been reported, 20 of which are described in one series
(Table 8).[95–98] Anti-DPPX encephalitis is typically char-
acterized by prodromal diarrhea and weight loss, followed by
encephalopathy (with delirium, psychosis, depression, sei-
zures, brainstem disorders), sleep disturbances, central hyper-
excitability (myoclonus, exaggerated startle, diffuse rigidity,
hyperreflexia) and dysautonomia (involving the gastrointest-
inal tract, bladder, cardiac conduction system and thermo-
regulation).[96] PERM has also been described in three
patients with anti-DPPX antibodies.[95] Most cases are
non-paraneoplastic, and tumor was detected in only two
patients (B-cell neoplasms) in the largest series of 20 cases
(10%).[96] In the same cohort, additional antibodies were
detected in five patients (25%).
All five available articles reporting cases with positive anti-
DPPX antibodies were included in this review (Table 8).[15,95–
98] In the 31 patients reported (11/31, 35.5% females), age at
onset ranged between 13 and 76 years (1/13, 7.7% children).
64.3% (18/28) of patients received immune therapy during the
first episode of disease. First-line treatments were used in 64.3%
(18/28): steroids in 64.3% (18/28), IVIG in 28.6% (8/28) and
PE in 21.4% (6/28). 35.7% (10/28) of patients received second-
line therapies: 21.4% (6/28) received rituximab, 10.7% (3/28)
cyclophosphamide, 10.7% (3/28) azathioprine and 3.6% (1/28)
mycophenolate mofetil.
According to available data, diagnosis was often delayed,
resulting in long time to initiation of immune therapy (median
16 months, range 5–96).[15,95,97]
Patients who did not receive immune therapy at the first
episode had worse outcomes than patients who did receive
immune therapy (mRS 0–1: 0/9, 0% vs. 7/18, 38.9%) and
higher rates of death (2/9, 22.2% vs. 1/18, 5.5%) despite
lower rates of relapses (1/10, 10% vs 7/18, 38.9%). Similarly,
patients who received second-line treatments at the first episode
had better outcomes than patients who did not receive second-
line therapies (mRS 0–1: 4/10, 40% vs. 3/17, 17.6%) and lower
rates of death (0/10, 0% vs. 3/17, 17.6%) despite similar rates
of relapses (3/10, 30% vs. 5/17, 29.4%).
Length of follow-up ranged between 0 and 18 years. Relapses
occurred in 28.6% (8/28) of cases, 26.9% (7/26) of patients had
complete remission or mild disability (mRS 0–1) and 11.5% (3/
26) died.
Anti-IgLON5 antibodies
In 2014, an atypical sleep disorder with abnormal sleep move-
ments and behavior, and obstructive sleep apnea, was described
in eight patients, whose serum or CSF showed an identical
pattern of reactivity to the neuropil of rat brain.[16]
Immunohistochemical studies identified an antibody against
an unknown neuronal cell surface protein, and antigen charac-
terization allowed the identification of IgLON5, a neuronal cell
adhesion molecule. The sleep disorder in these patients was
characterized by obstructive sleep apnea, stridor and abnormal
sleep architecture. The sleep disorder was the initial and main
complaint in four patients, who also had bulbar involvement
and dysautonomia; two of these also developed movement dis-
orders. In two other patients, the sleep disturbance was preceded
by gait instability, and followed by dysarthria, dysphagia, ataxia
and chorea. The remaining two patients had a rapid evolution
with sleep disorder and disequilibrium, dysarthria, dysphagia,
vocal cord paresis and central hypoventilation. Neuropathology
in two patients showed neuronal loss and extensive deposits of
hyperphosphorylated tau mainly involving the tegmentum of
the brainstem and hypothalamus. In the same series, anti-
IgLON5 antibodies were also found in a control with progres-
sive supranuclear palsy [16]. Subsequently, two additional
patients have been reported.[99,100] All the patients tested
carried the HLA-DRB1*1001 and HLA-DQB1*0501 alleles,
whereas none had tumor or coexisting antibodies.
All anti-IgLON5 patients were adults (range 52–76 years) (7/
10, 70% females).[16,99,100] The majority of patients received
immune therapy (9/10, 90%), even though most presented late.
[16] First-line treatments were used in 90% (9/10) (steroids in
7/10, 70%; IVIG in 4/10, 40%) and second-line therapies in
70% (7/10) (rituximab in 3/10, 30%; cyclophosphamide in 4/
10, 40%). In the series by Sabater, only one patient showed
some improvement after immune therapy, but died suddenly
thereafter.[16] Relapses were rare (1/10, 10%). Despite the
extensive use of immune therapy, at last follow-up (range 0.8–
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Table 8. Summary of the literature review on the treatment of anti-DPPX encephalitis (all available
cohorts were included).[15,95–98]
Boronat [15] Balint [95] Tobin [96] Piepgras [97] Stoeck [98]
Study design Retrospective Retrospective Retrospective-prospective Retrospective Retrospective
No. of patients 4 3 20 3 1
Clinical description
(no, of females)
4/4: encephalitis
(rapidly progressive
encephalopathy with
agitation, delusions,
hallucinations,
myoclonic jerks and
diarrhea)
(F: 2/4, 50%)
3/3: progressive
encephalopathy
with rigidity and
myoclonus
(F: 0/3, 0%)
20/20: encephalopathy (with
cortical, cerebellar or brainstem
manifestations), myelopathy,
weight loss, autonomic dysfunction
(F: 8/20, 40%)
3/3: encephalitis
(initial diarrhea
followed by
neuropsychiatric
symptoms)
(F: 0/3, 0%)
1/1:
eEncephalitis
(night sweats,
diarrhea,
ataxia, tremor,
memory
deficits, and
panic attacks)
(F: 1/1, 100%)
Median age at
onset (range)
59.5 years (45–76) 26 years (15–27)
(1 child)
53 years (13–75) (N° of children
not available)
68 years (50–68) 40 years
Tumor 0/4 (0%) 0/3 (0%) 2/20 (10%):
1/20: gastrointestinal follicular
lymphoma
1/20: chronic lymphocytic leukemia
0/1 (0%) 0/1 (0%)
Additional
antibody
0/4 (0%) 0/3 (0%) 5/20 (25%):
–1/20: GAD
1/20: GAD, ANA
1/20: dsDNA, APL -IgM, ANA
1/20: Gastric parietal cell
1/20: Thyroglobulin
0/1 (0%) 0/1 (0%)
Immune therapy† 3/3 (100%) 2/3 (66.7%) 11/20 (55%) 1/1 (100%) 1/1 (100%)
First-line 3/3 (100%) 2/3 (66.7%) 11/20 (55%) 1/1 (100%) 1/1 (100%)
Steroids 3/3 (100%) 2/3 (66.7%) 11/20 (55%) 1/1 (100%) 1/1 (100%)
Intravenous
immunoglobulin
1/3 (33.3%) 1/3 (33.3%) 5/20 (25) 1/1 (100%) 0/1 (0%)
Plasma exchange 0/3 (0%) 1/3 (33.3%) 5/20 (25%) 0/1 (0%) 0/1 (0%)
Second-line 1/3 (33.3%) 0/3 (0%) 8/20 (40%) 0/1 (0%) 1/1 (100%)
Rituximab 1/3 (33.3%) 0/3 (0%) 5/20 (25%) 0/1 (0%) 0/1 (0%)
Cyclophosphamide 0/3 (0%) 0/3 (0%) 3/20 (15%) 0/1 (0%) 0/1 (0%)
Other 0/3 (0%) 0/3 (0%) 2/20 (10%) AZA
1/20 (5%) mycophenolate mofetil
0/1 (0%) 1/1 (100%)
AZA
Median length of
follow-up (range)
49 months (21–68)
(data available in 3/4)
8 years (5–18) 6 months (0–68) 27 months (data
available in 1/3)
3 years
No. of patients
who relapsed
3/3 (100%) 3/3 (100%) 2/20 (10%) 0/1 (0%) 0/1 (0%)
Outcome mRS 1: 1/3 (33.3%)
mRS 2: 1/3 (33.3%)
mRS 3: 1/3 (33.3%)
mRS 3: 2/3
(66.7%)
mRS 6: 1/3
(33.3%)
Complete remission or mild
disability: 4/18 (22.2%)
Partial response to immune
therapy: 5/18 (27.8%)
Unchanged: 6/18 (33.3%)
Progressive worsening: 1/18
(5.6%)
Death: 2/18 (11.1%)
Almost complete
return to
premorbid level
of functioning:
1/1 (100%)
Marked
improvement:
1/1 (100%)
†At first episode.
AZA: Azathioprine; ANA: Antinuclear antibodies; APL: Antiphospholipid; GAD: Glutamic acid decarboxylase.
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13 years), 70% of patients died (7/10) and the remaining 30%
(3/10) had unchanged clinical picture.
Anti-D2R antibodies
Basal ganglia encephalitis is dominated by movement and psy-
chiatric disorders, and is similar to encephalitis lethargica,
described in epidemic form in the early 20th century.[101–
103] In 2012, antibodies to D2R were identified in 12 of 17
patients with basal ganglia encephalitis with negative anti-
NMDAR antibodies.[14] In this cohort, the clinical syndrome
was dominated by movement disorders (dystonia, parkinsonism,
chorea, oculogyric crises), psychiatric disturbances (agitation,
emotional lability, anxiety, psychotic symptoms), sleep distur-
bances, lethargy, drowsiness, brainstem dysfunction, seizures
and ataxia.[14] Anti-D2R antibodies were subsequently detected
in two patients who relapsed with encephalopathy and chorea
after herpes simplex encephalitis.[104] None of the patients
reported so far had tumor, and additional antibodies have
been detected rarely (anti-NMDAR antibodies, 1/14, 7.1%).
[104] In non-encephalopathic patients, anti-D2R antibodies
have been identified in Sydenham’s chorea, and occasional
patients with Tourette syndrome [14] and isolated psycho-
sis.[105]
A total of 14 patients with anti-D2R antibodies-positive
basal ganglia encephalitis have been described (8/14, 57.1%
females),[14,104] all in pediatric age (range 10 months to
15 years). First-line immune therapies were administered in
57.1% (8/14) of patients (steroids in 8/14, 57.1%; IVIG in 3/
14, 21.4%) and second-line treatments in none. In the origi-
nal series by Dale et al., although the cohort was treated
empirically, the most recent patients were treated aggressively
and early with immune therapy and made a complete recov-
ery.[14] However, two of the five patients that were not
treated had a full recovery, suggesting that the autoimmune
process can be spontaneously reversible. In the combined
cohorts, relapses occurred in 21.4% (3/14) of patients. At
last follow-up (range 1–14 years), 35.7% (5/14) of patients
had a full recovery, and the rest were left with neurological
sequelae (movement disorder, cognitive impairment, beha-
vioral or psychiatric disturbances).
Anti-mGluR5 antibodies
In 1982, Carr described a neuropsychiatric disorder with mem-
ory loss, depression, personality changes and hallucinations in
his daughter, who was subsequently diagnosed with Hodgkin’s
lymphoma.[106] He called this Ophelia syndrome and
described resolution of the neurological symptoms with tumor
treatment. Subsequently, further cases of Ophelia syndrome
were reported (Hodgkin’s lymphoma and limbic encephalitis),
[107–109] and in 2011 anti-mGluR5 antibodies were detected
in two patients.[13] mGluR5 is expressed primarily in the
hippocampus and amygdala and plays a role in behavioral
learning and memory,[110] which could explain the neurologi-
cal symptoms in these patients.[111] While a subsequent report
confirmed the association of anti-mGluR5 antibodies and
Ophelia syndrome,[111] another paper expanded the phenotype
with identification of these antibodies in a patient with limbic
encephalitis and prosopagnosia, without tumor.[112] Hodgkin’s
lymphoma has been identified in 75% (3/4) of the anti-
mGluR5 patients described.[13,111,112] No additional antibo-
dies have been detected.
The age at onset in the four anti-mGluR5 patients reported
ranged between 15 and 46 years (median 32.5) (2/4, 50%
females).[13,111,112] Seventy-five percent (3/4) of patients
received immune therapy. First-line treatments were adminis-
tered in 75% (3/4) (steroids in 3/4, 75%, PE in 1/4, 25%)
and second-line therapies in 25% (1/4) (rituximab). Both the
patients reported by Lancaster et al. [13] had prompt and
successful tumor treatment and, although only one received
immune therapy, both had a full recovery. Similarly, Carr’s
daughter had a full recovery in the absence of immune ther-
apy.[106] However, poor outcome with death in Ophelia
syndrome has been reported in other cases, with [113] or
without [109] immune therapy (antibody status unknown).
In a recent case report, the profound improvement of neu-
ropsychiatric abnormalities, prosopagnosia and anterograde
amnesia with steroids, PE and rituximab suggested a beneficial
role of immune therapy.[112] In the combined cohorts of
anti-mGluR5-positive patients, there were no relapses and, at
last follow-up (range 17 months to 4 years), 75% (3/4) of
patients recovered fully and 25% (1/4) had only partially
recovered.
Summary
In the last decade, the progressive identification of a growing
number of antibodies to neuronal surface antigens has defined
encephalitic syndromes whose etiology was previously
unknown. The relatively good response to immune therapy in
these patients has led to a paradigm shift in their clinical
management.[114] In the absence of randomized controlled
trials on the treatment of autoimmune encephalitis with anti-
bodies to neuronal surface antigens, the authors conducted a
literature review to define and summarize the available evidence
of immune therapy in these disorders. The main results of this
review show that immune therapy, especially first-line therapy,
is used in most cases, and the available data have demonstrated
the following trends (Table 9):
1) The use of immune therapy rather than no therapy is
more commonly associated with a better outcome
[10,11,14,25,28,29,39,54,59,76,78,95,96,112] and a
lower rate of relapses.[29,39]
2) Early commencement of immune therapy is more
commonly associated with a better outcome.
[14,24,25,28,29,35,39,46,95,96]
3) The use of second-line immune therapies is more commonly
associated with a better outcome [29,95,96,112] and a lower
rate of relapses,[29,46] although this is particularly influ-
enced by severity bias, as sicker patients are more likely to
receive second-line therapy.
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Table 9. Summary of the literature review on the evidence on the efficacy of immune therapy in autoimmune encephalitis, as reported in
the original papers (immune therapy vs. no immune therapy, early vs. late commencement of immune therapy and second-line immune
therapy vs. no second-line immune therapy).
N-Methyl-
D-aspartate
receptor
Leucine-
rich, glioma-
inactivated
protein-1
Contactin-
associated
protein-2
α-Amino-3-
hydroxy-5-
methyl-4-
isoxazo
lepropionic
acid
receptor
γ-
Aminobutyric
acid-A
receptor
γ-
Aminobutyric
acid-B
receptor
Glycine
receptor
Dipeptidyl-
peptidase-
like
protein-6
IgLON5 Dopamine-
2 receptor
Metabotropic
glutamate
receptor 5
Beneficial use of
IT vs. no IT
On
outcome
Irani† [28]
Titulaer [29]
Hacohen
[25]
Irani †‡ [10]
Irani † [39]
Irani, † [10]
Lancaster,
[59]
Sunwoo,
[54]
– – Lancaster † [11]
Boronat † [76]
Höftberger [78]
– Balint [95]
Tobin [96]
– Dale [14] Prüss [112]
On
relapses
Titulaer †
[29]
Irani [39] – – – – – – – – –
Beneficial effect
of early vs. late
commencement
of IT
On
outcome
Irani † [28]
Titulaer †
[29]
Hacohen
[25]
Dale † [24]
Byrne † [35]
Irani †§ [39]
Shin [46]
– – – – – Balint [95]
Tobin [96]
– Dale [14] –
On
relapses
– – – – – – – – – – –
Beneficial use of
second-line IT vs.
no second-line IT
On
outcome
Titulaer †
[29]
– – – – – – Balint [95]
Tobin [96]
– – Prüss [112]
On
relapses
Titulaer† [29] Shin [46] – – – – – – – – –
Results in one study in anti-leucine-rich, glioma-inactivated protein-1 encephalitis [48] and in anti-N-methyl-D-aspartate receptor encephalitis [27] suggested no beneficial effect of early commencement of immune therapy
and of use of second-line therapy, respectively.
†With statistical significance.
‡Faciobrachial dystonic seizures were controlled more effectively with IT than antiepileptic drugs (p = 0.006) [39].
§Time to return to a modified Rankin scale 1 was significantly correlated with time to immune therapy administration [39].
IT: Immune therapy.
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Figure 1. Proposed management and treatment algorithm in autoimmune encephalitis. Oncological searches and tumor
treatment, when appropriate, should be done in all patients.
* Oral steroid taper duration should be variable according to severity of clinical syndrome, speed of recovery, risk of relapse and need for
second-line therapy.AZA: Azathioprine; CSF: Cerebrospinal fluid; CYC: Cyclophosphamide; EEG: Electroencephalography; IVIG:
Intravenous immunoglobulin; IVMP: Intravenous methylprednisolone; MMF: Mycophenolate mofetil; RTX: Rituximab.
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In our literature review, the rate of treatment varied con-
siderably between different disorders. Use of immune therapy
was over 92% in anti-NMDAR, anti-LGI1, anti-Caspr2, anti-
AMPAR and anti-IgLON5 encephalitis, whereas it dropped
down to 53.1% and 57.1% in anti-GABAAR and anti-D2R
encephalitis, respectively. This variability in the frequency of
treatment is likely influenced by a number of clinical variables.
Some of these entities are now well known by treating clin-
icians (i.e., anti-NMDAR encephalitis), and testing is com-
monly requested, whereas some of the rarer entities are not
commonly recognized, or the presentation is often nonspecific
or has a broad differential diagnosis. Especially in the syn-
dromes that have been more extensively described, immune
therapy is often started based on clinical suspicion whilst
awaiting confirmation of autoantibody status. Figure 1 shows
the proposed management and treatment algorithm for auto-
immune encephalitis.[115] Despite extensive testing, a signifi-
cant proportion of encephalitis remains antibody-negative and,
while this may be in some cases ascribed to the limitations of
the test, future challenges include identification of novel anti-
bodies in patients who are apparently seronegative.[116] A
negative test should also raise the possibility of another (non-
autoimmune) diagnosis.
Although the majority of encephalitis with neuronal surface
antibodies are treatment-responsive, anti-IgLON5 encephalitis
appears to be different from the other autoimmune encephali-
tides, with poor response to immune therapy and high mortality
rate.[16]
The main limitations intrinsic to the data reported to date (and
therefore this review) are the limited number of patients, and the
retrospective and nonstandardized nature of data and outcome
measures. Severity and reporting bias are likely to be present in
the reported literature. It is also possible that some patients are re-
described in different publications. Given the rarity of these dis-
orders, only multicenter collaboratives could conduct randomized
controlled trials in autoimmune encephalitis. There is already
enough evidence to render a randomized controlled trial of immune
therapy against control (null treatment) to be unethical; however, a
randomized controlled trial of first-line therapy versus first- and
second-line therapy at onset would be a potentially viable option.
Expert commentary
The recent identification of autoantibodies to neuronal cell surface
antigens in encephalitis with previously unknown etiology has led
to an increased awareness and treatment of autoimmune encepha-
litis. There are no randomized controlled trials on the treatment of
autoimmune encephalitis; available data are mostly based on retro-
spective studies and, in some cases, on a restricted number of
patients. With these limitations, there are trends suggesting a
beneficial role of immune therapy on outcome and relapse rate
as compared to symptomatic treatment only or no treatment.
Furthermore, patients appear to have a better outcome when
treated early in the course of the disease. The addition of sec-
ond-line immune therapy also appears to yield a better outcome
and decrease relapses. These data demonstrate the importance of
prompt disease recognition, followed by early and aggressive
immune treatment to improve outcomes.
Five-year view
While some autoimmune encephalitis syndromes with antibo-
dies to neuronal cell surface antigens are relatively well known
(i.e., anti-NMDAR encephalitis), in other cases the recent
identification and the rarity of these disorders result in an
incomplete clinical characterization of the syndromes and
late or missed diagnoses—this represents an obstacle to a
prompt diagnosis and early commencement of appropriate
therapy, which has been shown to favor a better outcome.
The same limitations have resulted in the lack of quality data
on treatment to date. In this context, large prospective multi-
center cohorts may play a pivotal role in expanding our
knowledge of the phenotype of some of these entities, and
allowing for quicker disease recognition and reduction in
treatment delay. Despite obvious ethical limitations in treat-
ment trials, multicenter collaboratives may also allow for the
creation of randomized controlled trials of immune therapy,
which would provide important data to guide the manage-
ment of these disorders. Finally, a proportion of encephalitis
with suspected autoimmune etiology remains antibody-nega-
tive to date, and future challenges include identification of
novel antibodies in these cases. Patients with suspected auto-
immune encephalitis who are antibody-negative can be given
an empiric therapeutic trial, whilst maintaining vigilance for
an alternate diagnosis.
Financial & competing interests disclosure
Dr SS Mohammad has received a postgraduate scholarship from the
National Health and Medical Research Council (Australia). Dr S
Ramanathan has received a postgraduate scholarship from the National
Health and Medical Research Council (Australia) and the Petre
Foundation (Australia). Dr F Brilot has received research funding from
the National Health and Medical Research Council, MS Research
Australia, Star Scientific Foundation, Pfizer Neuroscience, Tourette
Syndrome Association and the University of Sydney. Dr RC Dale has
received research funding from the National Health and Medical
Research Council, MS Research Australia, Star Scientific Foundation,
Pfizer Neuroscience, Tourette Syndrome Association, University of
Sydney, and the Petre Foundation. R Dale has received honoraria from
Biogen-Idec and Bristol-Myers Squibb as an invited speaker.
The authors have no other relevant affiliations or financial involvement
with any organization or entity with a financial interest in or financial
conflict with the subject matter or materials discussed in the manuscript
apart from those disclosed.
www.tandfonline.com 1415
Immune therapy in autoimmune encephalitis Review
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 Sy
dn
ey
 L
ibr
ary
] a
t 2
0:1
8 1
8 A
pr
il 2
01
6 
References
Papers of special note have been highlighted as:
•• of considerable interest
1. Dalmau J, Furneaux HM, Rosenblum
MK, et al. Detection of the anti-Hu
antibody in specific regions of the nervous
system and tumor from patients with
paraneoplastic encephalomyelitis/sensory
neuronopathy. Neurology.
1991;41:1757–1764.
2. Voltz R, Dalmau J, Posner JB, et al. T-cell
receptor analysis in anti-Hu associated
paraneoplastic encephalomyelitis.
Neurology. 1998;51:1146–1150.
3. Sillevis Smitt PA, Manley GT, Posner JB.
Immunization with the paraneoplastic
encephalomyelitis antigen HuD does not
cause neurologic disease in mice.
Neurology. 1995;45:1873–1878.
4. Lancaster E, Dalmau J. Neuronal autoan-
tigens–pathogenesis, associated disorders
and antibody testing. Nat Rev Neurol.
2012;8:380–390.
5. Irani SR, Gelfand JM, Al-Diwani A, et al.
Cell-surface central nervous system auto-
antibodies: clinical relevance and
emerging paradigms. Ann Neurol.
2014;76:168–184.
6. Dalmau J, Tüzün E, Wu HY, et al.
Paraneoplastic anti-N-methyl-D-aspartate
receptor encephalitis associated with
ovarian teratoma. Ann Neurol.
2007;61:25–36.
•• The first description of anti-N-methyl-
d-aspartate receptor antibodies.
7. Hutchinson M, Waters P, McHugh J,
et al. Progressive encephalomyelitis, rigid-
ity, and myoclonus: a novel glycine
receptor antibody. Neurology.
2008;71:1291–1292.
8. Lai M, Hughes EG, Peng X, et al. AMPA
receptor antibodies in limbic encephalitis
alter synaptic receptor location. Ann
Neurol. 2009;65:424–434.
9. Lai M, Huijbers MG, Lancaster E, et al.
Investigation of LGI1 as the antigen in
limbic encephalitis previously attributed
to potassium channels: a case series.
Lancet Neurol. 2010;9:776–785.
10. Irani SR, Alexander S, Waters P, et al.
Antibodies to Kv1 potassium channel-
complex proteins leucine-rich, glioma
inactivated 1 protein and contactin-
associated protein-2 in limbic encephalitis,
Morvan’s syndrome and acquired neuro-
myotonia. Brain. 2010;133:2734–2748.
11. Lancaster E, Lai M, Peng X, et al.
Antibodies to the GABA(B) receptor in
limbic encephalitis with seizures: case ser-
ies and characterisation of the antigen.
Lancet Neurol. 2010;9:67–76.
•• Results of this study show a statistically
significant association between good
outcome and use of immune therapy.
12. Petit-Pedrol M, Armangue T, Peng X,
et al. Encephalitis with refractory sei-
zures, status epilepticus, and antibodies to
the GABAA receptor: a case series, char-
acterisation of the antigen, and analysis of
the effects of antibodies. Lancet Neurol.
2014;13:276–286.
13. Lancaster E, Martinez-Hernandez E,
Titulaer MJ, et al. Antibodies to metabo-
tropic glutamate receptor 5 in the
Ophelia syndrome. Neurology.
2011;77:1698–1701.
14. Dale RC, Merheb V, Pillai S, et al.
Antibodies to surface dopamine-2 recep-
tor in autoimmune movement and
Key issues
● Antibodies against neuronal cell surface antigens have been recently identified in encephalitis with previously unknown etiology.
● The antigens targeted by these autoantibodies include N-methyl-D-aspartate receptor, leucine-rich, glioma-inactivated protein-1,
contactin-associated protein-2, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, γ-aminobutyric acid-A receptor, γ-
aminobutyric acid-B receptor, glycine receptor, dipeptidyl-peptidase-like protein-6, IgLON5, dopamine-2 receptor and metabotropic
glutamate receptor 5.
● The most frequent autoimmune encephalitis with antibodies to neuronal cell surface antigens are anti-N-methyl-D-aspartate receptor
encephalitis and limbic encephalitis, which can be associated with a diversity of antibodies.
● Compared to classic paraneoplastic disorders with antibodies to intracellular antigens, in autoimmune encephalitis with antibodies to
neuronal cell surface antigens, the association with tumor is variable and sometimes absent, the antibodies are considered pathogenic
and generally there is good response to immune therapy.
● In view of the rarity of autoimmune encephalitis with antibodies to neuronal cell surface antigens and their recent description, there are
no randomized controlled trials on treatment, and data are mostly based on retrospective studies.
● According to available data, there are common therapeutic themes emerging: patients given immune therapy do better and relapse less
than patients given no treatment; patients given early treatment do better; and lastly, second-line therapy improves outcomes and
reduces relapses.
● When other diagnoses have been excluded and there is a reasonable clinical suspicion of autoimmune encephalitis, immune therapy is
often started whilst waiting for results of antibody testing.
● In view of the possible high morbidity in the acute phase, management of autoimmune encephalitis with antibodies to neuronal cell
surface antigens is challenging. Symptomatic treatment may be beneficial in addition to immune therapy, especially to address sleep
disturbances, agitation, psychiatric issues and seizures.
● Despite the inconsistent association with tumor in autoimmune encephalitis with antibodies to neuronal cell surface antigens,
oncological investigations should be performed in all cases as treatment of associated malignancies in these cases is shown to be
beneficial.
1416 Expert Rev. Neurother. 15(12), (2015)
Review Nosadini et al.
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 Sy
dn
ey
 L
ibr
ary
] a
t 2
0:1
8 1
8 A
pr
il 2
01
6 
psychiatric disorders. Brain.
2012;135:3453–3468.
15. Boronat A, Gelfand JM, Gresa-Arribas N,
et al. Encephalitis and antibodies to
dipeptidyl-peptidase-like protein-6, a
subunit of Kv4.2 potassium channels.
Ann Neurol. 2013;73:120–128.
16. Sabater L, Gaig C, Gelpi E, et al. A novel
non-rapid-eye movement and rapid-eye-
movement parasomnia with sleep breath-
ing disorder associated with antibodies to
IgLON5: a case series, characterisation of
the antigen, and post-mortem study.
Lancet Neurol. 2014;13:575–586.
17. Leypoldt F, Armangue T, Dalmau J.
Autoimmune encephalopathies. Ann N
Y Acad Sci. 2015;1338:94–114.
18. Dalmau J, Gleichman AJ, Hughes EG,
et al. Anti-NMDA-receptor encephalitis:
case series and analysis of the effects of
antibodies. Lancet Neurol. 2008;7:1091–
1098.
19. Hughes EG, Peng X, Gleichman AJ, et al.
Cellular and synaptic mechanisms of anti-
NMDA receptor encephalitis. J Neurosci.
2010;30:5866–5875.
20. Zuliani L, Graus F, Giometto B, et al.
Central nervous system neuronal surface
antibody associated syndromes: review
and guidelines for recognition. J Neurol
Neurosurg Psychiatry. 2012;83:638–645.
21. Vincent A, Bien CG, Irani SR, et al.
Autoantibodies associated with diseases
of the CNS: new developments and
future challenges. Lancet Neurol.
2011;10:759–772.
22. Lancaster E, Martinez-Hernandez E,
Dalmau J. Encephalitis and antibodies to
synaptic and neuronal cell surface pro-
teins. Neurology. 2011;77:179–189.
23. van Swieten JC, Koudstaal PJ, Visser
MC, et al. Interobserver agreement for
the assessment of handicap in stroke
patients. Stroke. 1988;19:604–607.
24. Dale RC, Brilot F, Duffy LV, et al.
Utility and safety of rituximab in pedia-
tric autoimmune and inflammatory CNS
disease. Neurology. 2014;83:142–150.
•• Results of this study show a statistically
significant association between good
outcome and early commencement of
rituximab.
25. Hacohen Y, Absoud M, Hemingway C,
et al. NMDA receptor antibodies asso-
ciated with distinct white matter syn-
dromes. Neurol Neuroimmunol
Neuroinflamm. 2014;1:e2.
26. Wright S, Hacohen Y, Jacobson L, et al.
N-methyl-D-aspartate receptor antibody-
mediated neurological disease: results of a
UK-based surveillance study in children.
Arch Dis Child. 2015;100:521–526.
27. Zekeridou A, Karantoni E, Viaccoz A,
et al. Treatment and outcome of children
and adolescents with N-methyl-D-aspar-
tate receptor encephalitis. J Neurol.
2015;262:1859–1866.
28. Irani SR, Bera K, Waters P, et al. N-
methyl-D-aspartate antibody encephalitis:
temporal progression of clinical and para-
clinical observations in a predominantly
non-paraneoplastic disorder of both sexes.
Brain. 2010;133:1655–1667.
•• Results of this study show a statistically
significant association between good
outcome and use of immune therapy,
especially when started early in the
course of the disease.
29. Titulaer MJ, McCracken L, Gabilondo I,
et al. Treatment and prognostic factors for
long-term outcome in patients with anti-
NMDA receptor encephalitis: an observa-
tional cohort study. Lancet Neurol.
2013;12:157–165.
•• The largest case series of patients with
anti-N-methyl-d-aspartate receptor
encephalitis, providing important data
on treatment. Results of this study show
that good outcome was significantly
associated with early commencement of
immune therapy and use second-line
immune therapy. Relapse rate was sig-
nificantly decreased in patients treated
with immune therapy compared to
those not treated and in patients who
received second-line therapies.
30. Gable MS, Sheriff H, Dalmau J, et al.
The frequency of autoimmune
N-Methyl-D-Aspartate receptor encepha-
litis surpasses that of individual viral
etiologies in young individuals enrolled in
the California encephalitis project. Clin
Infect Dis. 2012;54:899–904.
31. Dalmau J, Lancaster E, Martinez-
Hernandez E, et al. Clinical experience
and laboratory investigations in patients
with anti-NMDAR encephalitis. Lancet
Neurol. 2011;10:63–74.
32. Evoli A, Spinelli P, Frisullo G, et al.
Spontaneous recovery from anti-
NMDAR encephalitis. J Neurol.
2012;259:1964–1966.
33. Florance NR, Davis RL, Lam C, et al.
Anti-N-methyl-D-aspartate receptor
(NMDAR) encephalitis in children
and adolescents. Ann Neurol.
2009;66:11–18.
34. Mohammad SS, Jones H, Hong M, et al.
Symptomatic treatment of children with
anti-NMDAR encephalitis. Dev Med
Child Neurol. 2015 Aug 28.
DOI:10.1111/dmcn.12882. [Epub ahead
of print].
35. Byrne S, Walsh C, Hacohen Y, et al.
Earlier treatment of NMDAR antibody
encephalitis in children results in a better
outcome. Neurol Neuroimmunol
Neuroinflamm. 2015;2:e130.
•• Results of this study show a statistically
significant association between good
outcome and early commencement of
immune therapy.
36. Tatencloux S, Chretien P, Rogemond V,
et al. Intrathecal treatment of anti-N-
Methyl-D-aspartate receptor encephalitis
in children. Dev Med Child Neurol.
2015;57:95–99.
37. Vincent A, Buckley C, Schott JM, et al.
Potassium channel antibody-associated
encephalopathy: a potentially immu-
notherapy-responsive form of limbic
encephalitis. Brain. 2004;127:701–712.
38. Quek AM, Britton JW, McKeon A, et al.
Autoimmune epilepsy: clinical character-
istics and response to immunotherapy.
Arch Neurol. 2012;69:582–593.
39. Irani SR, Stagg CJ, Schott JM, et al.
Faciobrachial dystonic seizures: the influ-
ence of immunotherapy on seizure control
and prevention of cognitive impairment
in a broadening phenotype. Brain.
2013;136:3151–3162.
•• Results of this prospective study show a
statistically significant association
between good outcome (seizure reduc-
tion and good cognitive outcome) and
use of immune therapy, and between
time to recover and time to commence-
ment of immune therapy.
40. Irani SR, Michell AW, Lang B, et al.
Faciobrachial dystonic seizures precede
Lgi1 antibody limbic encephalitis. Ann
Neurol. 2011;69:892–900.
41. Shugaiv E, Leite MI, Şehitoğlu E, et al.
Progressive encephalomyelitis with rigid-
ity and myoclonus: a syndrome with
diverse clinical features and antibody
responses. Eur Neurol. 2013;69:257–262.
42. Ramdhani RA, Frucht SJ. Isolated chorea
associated with LGI1 antibody. Tremor
Other HyperkinetMov (N Y). 2014;4:1–2.
43. Gong J, Zhang Y, Wang F, et al.
Frequent hemianesthesia as initial symp-
tom of limbic encephalitis associated with
LGI1 antibodies. Neurol Sci.
2015;36:1953–1955.
www.tandfonline.com 1417
Immune therapy in autoimmune encephalitis Review
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 Sy
dn
ey
 L
ibr
ary
] a
t 2
0:1
8 1
8 A
pr
il 2
01
6 
44. Naasan G, Irani SR, Bettcher BM, et al.
Episodic bradycardia as neurocardiac
prodrome to voltage-gated potassium
channel complex/leucine-rich, glioma
inactivated 1 antibody encephalitis.
JAMA Neurol. 2014;71:1300–1304.
45. Nilsson AC, Blaabjerg M. More evidence
of a neurocardiac prodrome in anti-LGI1
encephalitis. J Neurol Sci. 2015;357:310–
311.
46. Shin YW, Lee ST, Shin JW, et al.
VGKC-complex/LGI1-antibody encepha-
litis: clinical manifestations and response
to immunotherapy. J Neuroimmunol.
2013;265:75–81.
47. Malter MP, Frisch C, Schoene-Bake JC,
et al. Outcome of limbic encephalitis with
VGKC-complex antibodies: relation to
antigenic specificity. J Neurol.
2014;261:1695–1705.
48. Irani SR, Gelfand JM, Bettcher BM, et al.
Effect of rituximab in patients with leu-
cine-rich, glioma-inactivated 1 antibody-
associated encephalopathy. JAMA
Neurol. 2014;71:896–900.
49. Wegner F, Wilke F, Raab P, et al. Anti-
leucine rich glioma inactivated 1 protein
and anti-N-methyl-D-aspartate receptor
encephalitis show distinct patterns of
brain glucose metabolism in 18F-fluoro-
2-deoxy-d-glucose positron emission
tomography. BMC Neurol. 2014;14:136.
50. Brown JW, Martin PJ, Thorpe JW, et al.
Long-term remission with rituximab in
refractory leucine-rich glioma inactivated
1 antibody encephalitis. J
Neuroimmunol. 2014;271:66–68.
51. Szots M, Marton A, Kover F, et al.
Natural course of LGI1 encephalitis: 3-5
years of follow-up without immunother-
apy. J Neurol Sci. 2014;343:198–202.
52. Suleiman J, Wright S, Gill D, et al.
Autoantibodies to neuronal antigens in
children with new-onset seizures classified
according to the revised ILAE organiza-
tion of seizures and epilepsies. Epilepsia.
2013;54:2091–2100.
53. Pinatel D, Hivert B, Boucraut J, et al.
Inhibitory axons are targeted in hippo-
campal cell culture by anti-Caspr2 auto-
antibodies associated with limbic
encephalitis. Front Cell Neurosci.
2015;9:265.
54. Sunwoo JS, Lee ST, Byun JI, et al.
Clinical manifestations of patients with
CASPR2 antibodies. J Neuroimmunol.
2015;281:17–22.
55. Becker EB, Zuliani L, Pettingill R, et al.
Contactin-associated protein-2 antibodies
in non-paraneoplastic cerebellar ataxia. J
Neurol Neurosurg Psychiatry.
2012;83:437–440.
56. Huda S, Wong SH, Pettingill P, et al. An
11-year retrospective experience of anti-
bodies against the voltage-gated potas-
sium channel (VGKC) complex from a
tertiary neurological centre. J Neurol.
2015;262:418–424.
57. Irani SR, Pettingill P, Kleopa KA, et al.
Morvan syndrome: clinical and serological
observations in 29 cases. Ann Neurol.
2012;72:241–255.
58. Ong E, Viaccoz A, Ducray F, et al.
Dramatic improvement after rituximab
in a patient with paraneoplastic treat-
ment-refractory Morvan syndrome asso-
ciated with anti-CASPR2 antibodies. Eur
J Neurol. 2013;20:e96–7.
59. Lancaster E, Huijbers MG, Bar V, et al.
Investigations of caspr2, an autoantigen of
encephalitis and neuromyotonia. Ann
Neurol. 2011;69:303–311.
60. Vincent A, Irani SR. Caspr2 antibodies in
patients with thymomas. J Thorac Oncol.
2010;5:S277–S280.
61. Krogias C, Hoepner R, Müller A, et al.
Successful treatment of anti-Caspr2 syn-
drome by interleukin 6 receptor blockade
through tocilizumab. JAMA Neurol.
2013;70:1056–1059.
62. Bassani S, Valnegri P, Beretta F, et al.
The GLUR2 subunit of AMPA recep-
tors: synaptic role. Neuroscience.
2009;158:55–61.
63. Höftberger R, Van Sonderen A, Leypoldt
F, et al. Encephalitis and AMPA receptor
antibodies: novel findings in a case series
of 22 patients. Neurology.
2015;84:2403–2412.
64. Bataller L, Galiano R, García-Escrig M,
et al. Reversible paraneoplastic limbic
encephalitis associated with antibodies to
the AMPA receptor. Neurology.
2010;74:265–267.
65. Graus F, Boronat A, Xifró X, et al. The
expanding clinical profile of anti-AMPA
receptor encephalitis. Neurology.
2010;74:857–859.
66. Wei YC, Liu CH, Lin JJ, et al. Rapid
progression and brain atrophy in anti-
AMPA receptor encephalitis. J
Neuroimmunol. 2013;261:129–133.
67. Dogan Onugoren M, Deuretzbacher D,
Haensch CA, et al. Limbic encephalitis
due to GABAB and AMPA receptor
antibodies: a case series. J Neurol
Neurosurg Psychiatry.
2015;86:965–972.
68. Elamin M, Lonergan R, Killeen RP, et al.
Posterior cortical and white matter changes
on MRI in anti-AMPA receptor antibody
encephalitis. Neurol Neuroimmunol
Neuroinflamm. 2015;2:e118.
69. Li X, Mao YT, Wu JJ, et al. Anti-AMPA
receptor encephalitis associated with thy-
momatous myasthenia gravis. J
Neuroimmunol. 2015;281:35–37.
70. Panzer JA, Dale RC. Anti-AMPA recep-
tor encephalitis: the family of glutama-
tergic autoencephalitides further expands.
Neurology. 2015;84:2390–2391.
71. Tretter V, Moss SJ. GABA(A) receptor
dynamics and constructing GABAergic
synapses. Front Mol Neurosci. 2008;1:1–
13.
72. Pettingill P, Kramer HB, Coebergh JA,
et al. Antibodies to GABAA receptor α1
and γ2 subunits: clinical and serologic
characterization. Neurology.
2015;84:1233–1241.
73. Steiner I, Rüegg S. Neurology. Another
autoimmune encephalitis? Not yet.
Neurology. 2015;84:1192–1193.
74. Ohkawa T, Satake S, Yokoi N, et al.
Identification and characterization of
GABA(A) receptor autoantibodies in
autoimmune encephalitis. J Neurosci.
2014;34:8151–8163.
75. Simabukuro MM, Petit-Pedrol M, Castro
LH, et al. GABAA receptor and LGI1
antibody encephalitis in a patient with
thymoma. Neurol Neuroimmunol
Neuroinflamm. 2015;2:e73.
76. Boronat A, Sabater L, Saiz A, et al. GABA
(B) receptor antibodies in limbic ence-
phalitis and anti-GAD-associated neuro-
logic disorders. Neurology.
2011;76:795–800.
•• Results of this study show a statistically
significant association between good
outcome and use of immune therapy.
77. Jeffery OJ, Lennon VA, Pittock SJ, et al.
GABAB receptor autoantibody frequency
in service serologic evaluation. Neurology.
2013;81:882–887.
78. Höftberger R, Titulaer MJ, Sabater L,
et al. Encephalitis and GABAB receptor
antibodies: novel findings in a new case
series of 20 patients. Neurology.
2013;81:1500–1506.
79. Bettler B, Kaupmann K, Mosbacher J,
et al. Molecular structure and physiologi-
cal functions of GABA(B) receptors.
Physiol Rev. 2004;84:835–867.
80. Kim TJ, Lee ST, Shin JW, et al. Clinical
manifestations and outcomes of the
treatment of patients with GABAB
1418 Expert Rev. Neurother. 15(12), (2015)
Review Nosadini et al.
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 Sy
dn
ey
 L
ibr
ary
] a
t 2
0:1
8 1
8 A
pr
il 2
01
6 
encephalitis. J Neuroimmunol.
2014;270:45–50.
81. Bourke D, Roxburgh R, Vincent A, et al.
Hypoventilation in glycine-receptor anti-
body related progressive encephalomyeli-
tis, rigidity and myoclonus. J Clin
Neurosci. 2014;21:876–878.
82. Carvajal-González A, Leite MI, Waters P,
et al. Glycine receptor antibodies in
PERM and related syndromes: character-
istics, clinical features and outcomes.
Brain. 2014;137:2178–2192.
83. McKeon A, Martinez-Hernandez E,
Lancaster E, et al. Glycine receptor auto-
immune spectrum with stiff-man syn-
drome phenotype. JAMA Neurol.
2013;70:44–50.
84. Alexopoulos H, Akrivou S, Dalakas MC.
Glycine receptor antibodies in stiff-person
syndrome and other GAD-positive CNS
disorders. Neurology. 2013;81:1962–
1964.
85. Clardy SL, Lennon VA, Dalmau J, et al.
Childhood onset of stiff-man syndrome.
JAMA Neurol. 2013;70:1531–1536.
86. Brenner T, Sills GJ, Hart Y, et al.
Prevalence of neurologic autoantibodies
in cohorts of patients with new and
established epilepsy. Epilepsia.
2013;54:1028–1035.
87. Ekizoglu E, Tuzun E, Woodhall M, et al.
Investigation of neuronal autoantibodies
in two different focal epilepsy syndromes.
Epilepsia. 2014;55:414–422.
88. Zuliani L, Ferlazzo E, Andrigo C, et al.
Glycine receptor antibodies in 2 cases of
new, adult-onset epilepsy. Neurol
Neuroimmunol Neuroinflamm. 2014;1:
e16.
89. Ariño H, Gresa-Arribas N, Blanco Y,
et al. Cerebellar ataxia and glutamic acid
decarboxylase antibodies: immunologic
profile and long-term effect of immu-
notherapy. JAMA Neurol.
2014;71:1009–1016.
90. Gresa-Arribas N, Ariño H, Martínez-
Hernández E, et al. Antibodies to inhibi-
tory synaptic proteins in neurological
syndromes associated with glutamic acid
decarboxylase autoimmunity. PLoS One.
2015;10:e0121364.
91. Hacohen Y, Absoud M, Woodhall M,
et al. Autoantibody biomarkers in child-
hood-acquired demyelinating syndromes:
results from a national surveillance
cohort. J Neurol Neurosurg Psychiatry.
2014;85:456–461.
92. Martinez-Hernandez E, Sepulveda M,
Rostásy K, et al. Antibodies to aquaporin
4, myelin-oligodendrocyte glycoprotein,
and the glycine receptor α1 subunit in
patients with isolated optic neuritis.
JAMA Neurol. 2015;72:187–193.
93. Woodhall M, Çoban A, Waters P, et al.
Glycine receptor and myelin oligoden-
drocyte glycoprotein antibodies in
Turkish patients with neuromyelitis
optica. J Neurol Sci. 2013;335:221–223.
94. Turner MR, Irani SR, Leite MI, et al.
Progressive encephalomyelitis with rigid-
ity and myoclonus: glycine and NMDA
receptor antibodies. Neurology.
2011;77:439–443.
95. Balint B, Jarius S, Nagel S, et al.
Progressive encephalomyelitis with rigid-
ity and myoclonus: a new variant with
DPPX antibodies. Neurology.
2014;82:1521–1528.
96. Tobin WO, Lennon VA, Komorowski L,
et al. DPPX potassium channel antibody:
frequency, clinical accompaniments, and
outcomes in 20 patients. Neurology.
2014;83:1797–1803.
97. Stoeck K, Carstens PO, Jarius S, et al.
Prednisolone and azathioprine are effective
in DPPX antibody-positive autoimmune
encephalitis. Neurol Neuroimmunol
Neuroinflamm. 2015;2:e86.
98. Piepgras J, Höltje M, Michel K, et al.
Anti-DPPX encephalitis: pathogenic
effects of antibodies on gut and brain
neurons. Neurology. 2015;85:890–897.
99. Högl B, Heidbreder A, Santamaria J,
et al. IgLON5 autoimmunity and abnor-
mal behaviours during sleep. Lancet.
2015;385:1590.
100. Simabukuro MM, Sabater L, Adoni T,
et al. Sleep disorder, chorea, and demen-
tia associated with IgLON5 antibodies.
Neurol Neuroimmunol Neuroinflamm.
2015;2:e136.
101. Von Economo C. Encephalitis lethargica.
Its sequelae and treatment. Newman KO,
Translator. London: Oxford University
Press; 1931.
102. Dale RC, Church AJ, Surtees RA, et al.
Encephalitis lethargica syndrome: 20 new
cases and evidence of basal ganglia auto-
immunity. Brain. 2004;127:21–33.
103. Dale RC, Brilot F. Autoimmune basal
ganglia disorders. J Child Neurol.
2012;27:1470–1481.
104. Mohammad SS, Sinclair K, Pillai S, et al.
Herpes simplex encephalitis relapse with
chorea is associated with autoantibodies
to N-Methyl-D-aspartate receptor or
dopamine-2 receptor. Mov Disord.
2014;29:117–122.
105. Pathmanandavel K, Starling J, Merheb V,
et al. Antibodies to surface dopamine-2
receptor and N-methyl-D-aspartate
receptor in the first episode of acute psy-
chosis in children. Biol Psychiatry.
2015;77:537–547.
106. Carr I. The Ophelia syndrome: memory
loss in Hodgkin’s disease. Lancet.
1982;1:844–845.
107. Pfliegler G, Pósán E, Glaub D, et al.
Hodgkin’s disease and memory loss:
another case of the Ophelia syndrome. Br
J Haematol. 1990;74:232.
108. Shinohara T, Kojima H, Nakamura N,
et al. Pathology of pure hippocampal
sclerosis in a patient with dementia and
Hodgkin’s disease: the Ophelia syndrome.
Neuropathology. 2005;25:353–360.
109. Olmos D, Rueda A, Jurado JM, et al.
Presentation of Hodgkin’s lymphoma
with Ophelia syndrome. J Clin Oncol.
2007;25:1802–1803.
110. Lu YM, Jia Z, Janus C, et al. Mice lacking
metabotropic glutamate receptor 5 show
impaired learning and reduced CA1 long-
term potentiation (LTP) but normal CA3
LTP. J Neurosci. 1997;17:5196–5205.
111. Mat A, Adler H, Merwick A, et al.
Ophelia syndrome with metabotropic
glutamate receptor 5 antibodies in CSF.
Neurology. 2013;80:1349–1350.
112. Prüss H, Rothkirch M, Kopp U, et al.
Limbic encephalitis with mGluR5 anti-
bodies and immunotherapy-responsive
prosopagnosia. Neurology.
2014;83:1384–1386.
113. Juneja M, Kaur S, Mishra D, et al.
Ophelia syndrome: hodgkin lymphoma
with limbic encephalitis. Indian Pediatr.
2015;52:335–336.
114. Lim M, Hacohen Y, Vincent A.
Autoimmune encephalopathies. Pediatr
Clin North Am. 2015 Jun;62(3):667–
685. DOI:10.1016/j.pcl.2015.03.011.
Epub 2015 Apr 7. Review.
115. Granerod J, Cunningham R, Zuckerman
M, et al. Causality in acute encephalitis:
defining aetiologies. Epidemiol Infect.
2010;138:783–800.
116. Paul NL, Kleinig TJ. Therapy of paraneo-
plastic disorders of the CNS. Expert Rev
Neurother. 2015;15:187–193.
www.tandfonline.com 1419
Immune therapy in autoimmune encephalitis Review
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 Sy
dn
ey
 L
ibr
ary
] a
t 2
0:1
8 1
8 A
pr
il 2
01
6 
 71 
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Background: Given the rarity of this condition, especially in children, there is a paucity of
large reported paediatric case series of anti-N-methyl-d-aspartate receptor encephalitis.
Methods: To contribute to define the features of this condition, we describe retrospectively a
new nationwide case series of 20 children (50% females), referred by 13 Italian centres.
Results:Mean age at onset was 8 years (range 3e17). Prodromal symptoms were reported in
31.6%; onset was with neurological symptoms in 70%, and with behavioural/psychiatric
disturbances in 30%. Most patients developed a severe clinical picture (90%), and 41%
experienced medical complications; children 12e18 years old seemed to be more severe
and symptomatic than younger patients. All children received first-line immune therapy;
second-line treatment was administered to 45%. Relapses occurred in 15%. At last follow-
up (mean 23.9 months, range 5e82), 85% patients had mRS 0e1; this rate was higher among
older patients, and in those receiving first immune therapy within 1 month.
Conclusions: Our case series confirms a symptomatologic core of paediatric anti-N-methyl-
d-aspartate receptor encephalitis, even though displaying some distinctive features that
may be explained by a specific genetic background or by the limited number of patients.
The growing incidence of this condition, the relative age-dependent variability of its
manifestations, the availability of immunotherapy and the possible better outcome with
early treatment impose a high index of clinical suspicion be maintained. In the absence of
data suggesting other specific etiologies, paediatricians should consider this diagnosis for
children presenting with neurological and/or behavioural or psychiatric disturbances,
regardless of age and gender.
© 2015 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights
reserved.
1. Introduction
Since its description as a paraneoplastic syndrome in women
with ovarian teratoma,1 anti-N-methyl-D-aspartate receptor
encephalitis has been increasingly recognized also in children
with or without associated tumours. However, despite
numerous case reports in the literature, only few large case
series are available in paediatric age.2e8
In order to contribute to a further definition of the
peculiar features of this condition in children and therefore
to improve awareness and early diagnosis among paedia-
tricians, we add a new paediatric nationwide case series to
the literature. The description and the comparison of such
case series may represent the basis for the future devel-
opment of specific therapeutic recommendations in pae-
diatric age.
2. Methods
In February 2014 the paediatric neurologic units in Italy were
contacted and invited to participate to a national working
group on paediatric anti-N-methyl-D-aspartate receptor en-
cephalitis (Italian Working Group on Paediatric Anti-N-
methyl-D-aspartate Receptor Encephalitis) and to search
retrospectively for paediatric cases. The first working meeting
was held in Padua, Italy, on 10thMarch 2014; on such occasion
the inclusion and exclusion criteria and the questionnaire for
data collection were discussed and shared.
2.1. Inclusion and exclusion criteria
Patients with anti-N-methyl-D-aspartate receptor encephalitis
in paediatric age (18 years) referred by any of the centres
participating to the ItalianWorkingGrouponPaediatricAnti-N-
methyl-D-aspartate Receptor Encephalitis until July 2014, with
diagnosis confirmed by positive anti-N-methyl-D-aspartate re-
ceptor antibodies on serum and/or cerebrospinal fluid (CSF).
Exclusion criteria were age >18 years, negative anti-N-methyl-
D-aspartate receptor antibodies, or antibodies not tested.
2.2. Patient recruitment and data collection
Upon identification of eligible cases, a comprehensive set of
clinical and investigative data, organized in a structured
questionnaire, was collected for each patient. Data collection
was carried out in one of the three following ways: at the
meeting held in Padua, Italy, on 10th March 2014; through a
telephonic interview to the treating physician conducted by
the main investigators (MN, SS, AS); or through a question-
naire filled out by the treating physicians. Data were reviewed
by the principal investigators (SS, AS, MN) and the treating
physicians were subsequently contacted for clarification and/
or completion of missing data.
2.3. Operational definitions
We defined as acute phase of disease the nadir of severity of
the illness. Based on the disease manifestations reported in
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the literature, we categorized symptoms into eight major
groups: behavioural and/or psychiatric disturbances; psy-
chomotor agitation;movement disorder; speech disturbances;
seizures; changes in vigilance, hyporeactivity and/or cata-
tonia; autonomic instability; sleepewake cycle
disturbances.3e5
Concerning disease severity, we defined “severe” the pa-
tients who were bedridden in the acute phase of disease, had
at least 7 of the major symptoms described above and at least
1 among need for paediatric intensive care unit and/or length
of hospitalization 3 weeks or longer. Conversely, we defined
“mild” the cases who did not meet the preceding criteria.
We defined encephalopathy as in the recent consensus
definition for ADEM9 as an alteration in consciousness (e.g.
stupor, lethargy) or behavioural change unexplained by fever,
systemic illness or postictal symptoms. First-line immune
therapy was defined as the employ of corticosteroids, intra-
venous immunoglobulin (IVIG) and/or plasma exchange;
second-line immunotherapy included cyclophosphamide
and/or rituximab.
The modified Rankin Scale (mRS) was used to assess
outcome at the last follow-up based on the treating physi-
cians' and the principal investigators' judgement (nearly
coincident, despite the limitations imposed by the retrospec-
tive assessment).
Similarly to other paediatric case series in the literature,3,5
and taking into account the possible difference between
children and adolescents suggested by other authors,3 we
subdivided children by age groups (<12 years and 12e18
years), in order to allow comparison between disease features
in these subsets of patients (Table 1). We also analysed data
with respect to the youngest group of patients (<5 years of
age).
3. Results
3.1. Demographics
Twenty paediatric patients with anti-N-methyl-D-aspartate
receptor encephalitis were enrolled in the present study; data
are shown in Table 1. Patients were referred by 13 different
centres in Italy, and they resided in 14 different Italian prov-
inces. Onsetwas betweenMay 2007 andNovember 2013.Mean
age at onset was 8 years (age range 3 years and 1 monthe17
years and 9 months); most patients were <12 years old (75%,
15/20), while only a fourth were 12e17 years (25%, 5/20).
Genders were equally represented in our population (50%, 10/
20males), with a slight preponderance of female gender in the
younger age group as compared to the older patients. Most
patients were Caucasian (60%, 12/20), 15% (3/20) were Asiatic,
10% (2/20) African, 5% (1/20) Hispanic and 10% (2/20) were of
mixed ethnic origin.
3.2. Family and personal history
Family history for autoimmune and immune-mediated dis-
eases was reported in 18.7% (3/16); personal history was un-
remarkable in 76.5% (13/17), while in 2 cases (11.8%, 2/17)
dysgraphia and dyslexia were reported respectively.
3.3. Initial symptoms
Prodromal flu-like symptoms were reported in 31.6% (6/19)
patients. In most patients disease onset was characterized by
a neurologic manifestation (seizures, movement disorder,
changes in vigilance, autonomic or sleepewake cycle distur-
bances) (70%, 14/20) (in 2 of these 14 cases with neurological
onset, psychiatric disturbances associated shortly thereafter),
whereas in 30% (6/20) the first symptom was behavioural or
psychiatric disturbance (in addition to psychiatric symptoms,
4 of these 6 patients had neurological symptoms shortly
thereafter) (Fig. 1). With the limitations imposed by the
restricted number of patients, the rate of neurological pre-
sentationwas higher among older patients as compared to the
younger ones (80% versus 66.7%). Among patients with
neurological onset, seizures were the most common mani-
festation (Table 1), followed by movement disorder and
changes in vigilance. Among patients with seizures as the first
symptom of disease, genders were similarly distributed, with
a slight preponderance of females (66.7%, 4/6).
3.4. Symptoms in the acute phase of disease
In the acute phase of disease, all of the patients were
encephalopathic and 90% (18/20) developed a severe clinical
picture. A milder phenotype was observed in two of our chil-
dren: in particular, they were not bedridden, had no auto-
nomic instability and did not require admission to the
paediatric intensive care unit. Both these two patients
belonged to the youngest age group (<5 years).
Themean number of major symptomswas 7.3 (range 4e8).
During the course of their illness, all patients developed
behavioural changes and/or psychiatric disturbances, speech
disturbances, and movement disorder (100%, 20/20 each).
Psychomotor agitation and changes in consciousness and
vigilance were reported in 95% (19/20) each, autonomic
instability in 90% (18/20), seizures in 85% (17/20), and
sleepewake cycle disturbances in 82.3% (14/17). Movement
disorders included mostly limb dyskinesias, dystonias, chor-
eoathetosis, oro-facial dyskinesias, and freezing; most com-
mon dysautonomias were hyperthermia, cardiac rhythm
disturbances, hypo/hyperventilation, blood pressure dysre-
gulation. During the acute phase of their illness, 47.4% (9/19)
patients were admitted to the intensive care unit, 36.8% (7/19)
underwent intubation, and 41.2% (7/17) experienced medical
complications; all these rates were higher in the older age
group, especially when compared to the patients < 5 years
(Table 1). Medical complications included weight loss,
muscular abscess, pyelonephritis, rhabdomyolysis, paralytic
ileus, colelitiasis, normocytic anaemia, macrocytic anaemia,
pneumonia, malignant hyperthermia, syndrome of inappro-
priate antidiuretic hormone secretion, fracture of radial bone,
deep venous thrombosis, and vaginal candidiasis.
3.5. Tumour
Oncologic searches were negative in all patients at first
episode (20/20), but ovarian teratoma was detected in 1 girl
belonging to the older age group at disease relapse, about 18
months from onset; in this patient, oncologic markers,
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Table 1e Clinical features, diagnostic tests, treatment and outcome of the 20 childrenwith anti-N-methyl-D-aspartate encephalitis. Legend: EEG: electroencephalography;
IVIG: intravenous immunoglobulin; MRI: magnetic resonance imaging; n.a.: not available; OT: ovarian teratoma; PICU: paediatric intensive care unit; ≈: about.
Age <5 years <12 years 12e18 years All patients
Number of patients 9/20 (45%) 15/20 (75%) 5/20 (25%) 20
Proportion of females 4/9 (44.4%) 8/15 (53.3%) 2/5 (40%) 10/20 (50%)
Mean age at onset (range) 4 years (3.1e4.9) 6.1 years (3.1e11.9) 13.7 years (12e17.7) 8 years (3.1e17.7)
Ethnic origin
Caucasic 4/9 (44.4%) 9/15 (60%) 3/5 (60%) 12/20 (60%)
Asiatic 1/9 (11.1%) 2/15 (13.3%) 1/5 (20%) 3/20 (15%)
African 1/9 (11.1%) 1/15 (6.7%) 1/5 (20%) 2/20 (10%)
Hispanic 1/9 (11.1%) 1/15 (6.7%) 0/5 (0%) 1/20 (5%)
Mixed 2/9 (22.2%) 2/15 (13.3%) 0/5 (0%) 2/20 (10%)
Referring center
Northern Italy 5/9 (55.6%) 11/15 (73.3%) 3/5 (60%) 14/20 (70%)
Central Italy 1/9 (11.1%) 1/15 (6.7%) 1/5 (20%) 2/20 (10%)
Southern Italy 3/9 (33.3%) 3/15 (20%) 1/5 (20%) 4/20 (20%)
Positive family history for
autoimmune and
immune-mediated
conditions
1/7 (14.3%) 2/12 (16.7%) 1/4 (25%) 3/16 (18.7%) (1/2 Hashimoto's thyroiditis; 1/2 multiple sclerosis; 1/2 n.a.)
Positive personal medical
history
0/8 (0%) 0/13 (0%) 2/4 (50%) 2/17 (11.8%) (1/2 dysgraphia; 1/2 dyslexia)
Prodromal symptoms 3/9 (33.3%) 5/15 (33.3%) 1/4 (25%) 6/19 (31.6%)
Type of onset
Neurologic 7/9 (77.8%) 10/15 (66.7%) 4/5 (80%) 14/20 (70%)
Seizures - 3/9 (33.3%) 4/10 (40%) 2/4 (50%) 6/14 (42.8%)
Movement disorder 2/9 (22/2%) 4/10 (40%) 0/4 (0%) 4/14 (28.6%)
Changes in vigilance 1/9 (11.1%) 1/10 (10%) 1/4 (25%) 2/14 (14.3%)
Autonomic instability 0/9 (0%) 0/10 (0%) 1/4 (25%) 1/14 (7.1%)
Sleep-wake cycle
disturbances
1/9 (11.1%) 1/10 (10%) 0/4 (0%) 1/14 (7.1%)
Behavioural/Psychiatric
(unusual behaviour,
aggressiveness,
irritability, confusion,
hallucinations)
2/9 (22.2%) 5/15 (33.3%) 1/5 (20%) 6/20 (30%)
Severity of phenotype in the acute phase
Severe 7/9 (77.8%) 13/15 (86.7%) 5/5 (100%) 18/20 (90%)
Mild 2/9 (22.2%) 2/15 (13.3%) 0/5 (0%) 2/20 (10%)
Symptoms in the acute phase
Mean number of major
symptoms (range)
7 (4e8) 7.3 (4e8) 7.6 (7e8) 7.3 (4e8)
Movement disorder 9/9 (100%) 15/15 (100%) 5/5 (100%) 20/20 (100%)
Behavioural/Psychiatric
disturbances
9/9 (100%) 15/15 (100%) 5/5 (100%) 20/20 (100%)
Speech disturbances 9/9 (100%) 15/15 (100%) 5/5 (100%) 20/20 (100%)
Psychomotor agitation 8/9 (88.9%) 14/15 (93.3%) 5/5 (100%) 19/20 (95%)
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Changes in vigilance,
hyporeactivity
8/9 (88.9%) 14/15 (93.3%) 5/5 (100%) 19/20 (95%)
Autonomic instability 7/9 (77.8%) 13/15 (86.7%) 5/5 (100%) 18/20 (90%)
Seizures 7/9 (77.8%) 12/15 (80%) 5/5 (100%) 17/20 (85%)
Sleep-wake cycle
disturbances
6/9 (66.7%) 12/15 (80%) 3/3 (100%) 15/18 (83.3%)
Associated tumour 0/9 (0%) 0/15 (0%) 1/5 (20%) 1/20 (5%) (OT)
PICU 2/8 (25%) 6/14 (42.8%) 3/5 (60%) 9/19 (47.4%)
Orotracheal intubation 2/8 (25%) 4/14 (28.6%) 3/5 (60%) 7/19 (36.8%)
Medical complications 1/8 (12.5%) 4/12 (33.3%) 3/5 (60%) 7/17 (41.2%)
Abnormal MRI 6/9 (66.7%) 7/15 (46.7%) 3/5 (40%) 9/20 (45%)
Abnormal EEG 8/8 (100%) 14/14 (100%) 5/5 (100%) 19/19 (100%). Recorded seizures in 6/19 (31.6%)
Cerebrospinal fluid
Pleocytosis 2/7 (28.6%) 6/13 (46.1%) 3/3 (100%) 9/16 (56.2%)
Oligoclonal bands 5/7 (71.4%) 8/13 (61.5%) 3/4 (75%) 11/17 (64.7%)
Time from onset to first immune therapy
<30 days 5/7 (71.4%) 9/13 (69.2%) 2/3 (66.7%) 11/16 (68.7%)
30 days 2/7 (28.6%) 4/13 (30.8%) 1/3 (33.3%) 5/16 (31.2%)
Immune therapy 15/15 (100%) 5/5 (100%) 20/120 (100%)
1 treatment 0/9 (0%) 1/15 (6.7%) 1/5 (20%) 2/20 (10%) (IVIG)
2treatments 9/9 (100%) 14/15 (93.3%) 4/5 (80%) 18/20 (90%)
First-line immune therapy 9/9 (100%) 13/13 (100%) 5/5 (100%) 18/18 (100%)
Corticosteroids 9/9 (100%) 14/15 (93.3%) 4/5 (80%) 18/20 (90%)
IVIG 9/9 (100%) 13/15 (86.7%) 4/5 (80%) 17/20 (85%)
Plasma exchange 2/9 (22.2%) 5/15 (33.3%) 2/5 (40%) 7/20 (35%)
Second-line immune
therapy
4/9 (44.4%) 7/15 (46.7%) 2/5 (40%) 9/20 (45%)
Cyclophosphamide 3/9 (33.3%) 6/15 (40%) 1/5 (20%) 7/20 (35%)
Rituximab 2/9 (22/2%) 2/15 (13.3%) 1/5 (20%) 3/20 (15%)
Other treatments
Antiepileptic drugs 8/9 (88.9%) 14/15 (93.3%) 5/5 (100%) 19/20 (95%)
Antipsychotic drugs 3/6 (50%) 7/10 (70%) 3/3 (100%) 10/13 (76.9%)
Mean length of
hospitalization (range)
(data available in 18/20)
7.9 weeks (1e20 11.4 weeks (1e32) 8.6 weeks (3e13) 10.7 weeks (1e32)
Length of
hospitalization < 4
weeks
4/8 (50%) 4/14 (28.6%) 1/4 (25%) 5/18 (27.8%)
Destination at discharge
Home 8/9 (88.9%) 12/14 (85.7%) 3/4 (75%) 15/18 (27.8%)
Rehabilitation 1/9 (11.1%) 2/14 (14.3%) 1/4 (25%) 3/18 (16.7%)
Relapses 1/9 (11.1%) 2/15 (13.3%) 1/5 (20%) 3/20 (15%)
Time from disease onset
to relapse
3 years 3 years and 4 years 1.5 years 2.8 years (range 1.5e4 years)
Presenting symptom at
relapse
Movement disorder 1/2 Movement disorder
1/2 Headache, seizures,
behavioural disturbances
1/1 Behavioral disturbances 1/3 Movement disorder
1/3 Headache, seizures, behavioural disturbances
1/3 Behavioral disturbances
(continued on next page)
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abdominal ultrasounds andmagnetic resonancewere initially
negative, but pelvic ultrasound detected teratoma at follow-
up.
3.6. Investigations
Anti-N-methyl-D-aspartate receptor antibodies were tested on
CSF in 13/20 cases (positive in 100% 13/13); in the remaining 7
cases, they were tested on serum (positive in 100%, 7/7). Brain
magnetic resonance imaging was normal in 55.5% (11/20)
cases. Electroencephalographic (EEG) tracing was abnormal in
all patients (19/19), but epileptic seizures were captured only
in a minority of cases (31.6%, 6/19). In all the cases with
available information, slowing of EEG was reported (11/11),
whereas epileptic spikes were detected in half (7/14). CSF
pleocytosis was reported in 56.2% (9/16); intrathecal oligoclo-
nal bands were present in 64.7% (11/17).
3.7. Treatment
All of our patients received an immune treatment. First im-
mune therapy was administered within 29 days of symptom
onset in 68.7% (11/16), while in the remaining 31.2% (5/16) it
was administered after the 30th day. Mean time from disease
onset to first immune treatment was 23.7 days (range 5e60;
data available in 16/20 patients).
Treatment strategies varied greatly; 90% of patients (18/20)
received at least two treatments, while in 10% cases (2/20)
patients were only treated with IVIG. In 45% of cases (9/20),
after first-line immune therapy patients received a second-
line immune therapy. Treatment involved corticosteroids in
90% (18/20) (intravenous methylprednisolone in most cases),
IVIG in 85% (17/20), plasma exchange in 35% (7/20), cyclo-
phosphamide in 35% (7/20), rituximab in 15% (3/20). In 15% (3/
20) mycophenolate mofetil was also administered. Antiepi-
leptic treatment was administered to 95% (19/20) patients,
treatment for psychiatric disturbances or psychomotor
agitation to 76.9% (10/13).
3.8. Outcome
None of the patients died. Mean length of hospitalization was
10.7 weeks (range 1e32 weeks) (data available in 18/20); length
of hospitalization was slightly shorter in the older age group.
Most patients were discharged home (83.3%, 15/18), while
16.7% (3/18) were transferred to a rehabilitation unit. Mean
duration of follow-up was 23.9 months (range 5e82 months)
(data available in 19/20).
3.9. Relapses
Relapse of disease occurred in 3 cases (15%), at about 1.5, 3 and
4 years from disease onset respectively. Two of these cases
were younger than 12 years (1 male, 1 female), 1 was older (1
female). All 3 cases had a severe disease course during the first
episode, and had a substantial recovery before the following
episode. During the first episode none of these patients
received second-line treatments: 2 were treated with corti-
costeroids and IVIG, 1 only with IVIG. In 2 of the 3 cases, the
clinical picture at relapse was milder than at presentation.
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3.10. Neurological outcome at last follow-up
At last follow-up, mean mRS score was 0.9 (median 1, range
0e5). Of the 3 patients who had a multiphasic disease course
with relapses, 2 had anmRS score of 1 and 1 had anmRS score
of 0. Rate of good recovery (mRS 0e1) was higher among older
patients (12e18 years), especially when compared to the very
young age group (<5 years).
Rate of mRS 0 or 1 at last follow-up was higher among the
11 patients in whom first immune therapy was administered
within 29 days from disease onset (90.9%, 10/11) than in the 5
cases in whom it was administered after 29 days from disease
onset (60%, 3/5) (Table 2). At last follow-up, ongoing epilepsy
was reported in 5.5% (1/15) patients, and ongoing antiepileptic
treatment in 40% (6/15). Electroencephalographic normaliza-
tion occurred in 55.5% (9/18).
4. Discussion
We described the first Italian case series of paediatric anti-N-
methyl-D-aspartate receptor encephalitis. Large case series of
children with anti-N-methyl-D-aspartate receptor encephali-
tis are rare in the literature (Table 3). Among these, are those
described by Florance in 2009 (n ¼ 32)3, by Titulaer in 2013
(n ¼ 212)5, by Dale in 2014 (n ¼ 39)6, and by Armangue in 2013
(n ¼ 20)4; the latter is particularly comparable to ours as
regards the number and the ethnic origin of the subjects.
Among smaller case series are those reported in 2009 by Dale
(n ¼ 10)2 and later by Hacohen (n ¼ 13).7,8
Our case series is mostly confirmatory of data previously
reported in the literature, though some differences can be
observed. The significance of these latter is possibly
strengthened by the overall concordance of our findings with
previously published cohorts, supporting the general reli-
ability of our data. With regards to demographic features, the
prevalence of female gender described in paediatric and adult
literature4e6,10 is not observed in our population; this finding
may possibly be incidental, considered the limited sample
size. Of note, family history for autoimmune and immune-
mediated diseases was reported in nearly 19% of cases. Posi-
tive family history is reported in other autoimmune diseases
and, while in the case of anti-N-methyl-D-aspartate receptor
encephalitis available data are not yet sufficient to confirm
this finding, this remains an area of interest requiring further
work.
Prodromal symptoms are reported in over 85% of adult
cases,1 and in 48%e100% of children3,4,11 in the literature. The
lower rate of prodromal symptoms in our population (less
than one third of cases) is possibly due to underreporting, in
consideration of the retrospective nature of our work. As
regards disease onset, the first symptoms were psychiatric or
behavioural in one third of cases, and neurologic in over two
thirds, most frequently seizures and movement disorder,
followed by changes in vigilance, autonomic instability and
sleepewake cycle disturbances. The rate of neurological pre-
sentation is similar to that reported by Armangue and co-
workers,4 whereas in the ten cases described by Dale and
colleagues2 neurologic and psychiatric presentation were
equally distributed, and “pure” neurological presentation
dropped to 12.5% in the cases reported by Florance.3 Data in
the literature suggest an increase of the rate of psychiatric
presentation with age,3,4 peaking to 77% in adult series,1 but
our population does not reflect this trend. In contrast to recent
data in the literature,12 we did not observe male prevalence
among our cases presenting with seizures. It is noteworthy
that the seizures reported at disease presentation occurred
before the first access to the hospital and were witnessed by
non-medical personnel; therefore, considered the variety of
movement disorders and of paroxysmal non epileptic mani-
festations in these patients, the epileptic nature of the events
reported as “seizures” by care-givers should not be taken for
granted.13 Similarly, during the course of the disease only in a
subset of patients EEG tracing allowed to capture an epileptic
seizure. In accordance to our findings, electroencephalo-
graphic detection of unequivocal ictal activity is relatively rare
in the literature.12,14e21
Similarly to the cases described by Armangue,4most of our
patients developed a severe clinical picture in the acute phase
of disease, being bedridden and displaying a variable combi-
nation of other severe symptoms. As an additional indicator of
the potential severity of anti-N-methyl-D-aspartate receptor
encephalitis, medical complications and the use of symp-
tomatic therapies were common in our cohort. Medical com-
plications are a relevant aspect of anti-N-methyl-D-aspartate
receptor encephalitis, since they can severely affect the
overall recovery process and the length of hospitalization.
Therefore, future guidelines for the management of this dis-
ease should include the optimal management of medical
complications.
During disease course, movement disorder, behavioural or
psychiatric disturbances and speech problems were observed
in all our cases; besides, over 90% had psychomotor agitation,
changes in vigilance, hyporeactivity, catatonia and autonomic
instability, and over 80% had seizures and sleepewake cycle
disturbances. In the older age group (12e18 years) all patients
had all the symptoms and none had the mild form of the
disease according to our categorization, possibly suggesting a
more severe and symptomatic phenotype in older patients as
Fig. 1 e Disease onset divided by neurological symptoms
(seizures, movement disorder, changes in vigilance,
autonomic or sleepewake cycle disturbances) or
psychiatric symptoms (psychiatric or behavioral changes)
in the patients < 12 years, in the patients 12e18 years and
in all patients.
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compared to younger children, and in particular to the
youngest group (<5 years). Accordingly, more patients in the
older age group as compared to younger patients, and espe-
cially to patients <5 years, had medical complications, were
admitted to the paediatric intensive care unit and underwent
orotracheal intubation. In possible accordance with our find-
ings, in the case series by Titulaer and colleagues more pa-
tients in the older age group had autonomic instability and
central hypoventilations as compared to cases younger than
12 years,5 and a lower severity of autonomic manifestations
and central hypoventilation in children as compared to adults
is reported also by Florance and colleagues.3 Though, definite
conclusions on the different severity of disease in the two age
groups can't be drawn due to the limited number of cases in
our population.
Tumour (ovarian teratoma) was found in one girl belonging
to the older age group (5% of all patients), only after the patient
presented a clinical relapse; similar rates of tumour detection
are reported by Dale et al. (7.7%)6 and by Titulaer et al., even
though in this latter case in patients younger than 12 years
(6%)5; our rate of tumour detection is considerably lower than
those reported by Armangue (18%) and Florance (25%),3,4
despite a longer follow-up.
All of our patients received immune therapy. Mean time
fromdisease onset to first immune therapywas about 23 days,
similarly to data reported by Titulaer and colleagues (21
days).5 First immune therapy was administered within the
29th day from disease onset in about two thirds of cases, and
in a higher proportion of patients as compared to what re-
ported in the case series by Armangue and coworkers4; this
may be possibly ascribed to the ever-growing knowledge of
this condition, likely responsible for its earlier detection than
in the past. In the case series reported by Armangue,4 a higher
rate of early treatment (<30 days) in children < 12 years is
reported as compared to children aged 12e18 years (66.67%
versus 45.45%); this difference is only minimal in our popu-
lation. Relapses occurred in 15% of our children; of note, the
three patients that relapsed received only first-line immune
therapy. In the case series described by Titulaer and co-
workers,5 a relapse-decreasing effect of second-line
immunotherapy was observed in patients without tumour
and in patients who had already relapsed. Accordingly, a
higher relapse rate occurred in cohorts in which a lower rate
of second-line immune therapy was used.2,3,8 All the three
cases that relapsed in our cohort had completely normalized
before relapsing. Therefore, these data suggest that clinical
normalization does not guarantee an absolutely reduced risk
of relapse, and that possibly the length of treatment should
not rely solely on the clinical normalization, even though
reliable biological markers of the disease are lacking at the
moment.
At last follow-up, 85% of patients had a good recovery (mRS
0e1), similarly to the rate of full recovery andmild disability in
the case series by Armangue and colleagues (85%),4 with
similar length of follow-up; all the 3 patients who had relapses
had a substantial recovery at last follow-up. Of utmost
importance among our findings, rate of low mRS (0e1) at
follow-up was higher among patients in whom the first im-
mune therapy was started within 1 month from disease onset
(Table 2). Supporting our results, early immune therapy has
been reported to yield better outcomes in other case series in
the literature.5,6,22 These data suggest the importance of an
early recognition of this disorder in order to allow for early
immune therapy and therefore possibly for a better outcome.
4.1. Limitations
The restricted number of patients is among the main limita-
tions of our study, hampering statistical analysis, especially
among subgroups of cases. The multicenter nature of our
work, although allowing for the collection of a larger number
of cases than if limited to a single centre, is responsible for the
incompleteness or heterogeneity of information in some
subsets of data.
4.2. Conclusions
The characteristics of the Italian population of children with
anti-N-methyl-D-aspartate receptor encephalitis are mostly
confirmatory of data in the literature, though some distinctive
Table 2 eNeurological outcome at last follow-up in relation to the timing of initiation of first immune therapy from disease
onset.
Neurological outcome at last follow-up in relation to the timing of initiation of first immune therapy from disease onset
In the 11/16 in whom first immune therapy was started < 30 days from disease onset
(mean length of follow-up, available in 10/11: 24.8 months; range 5e71)
mRS 0e1
10/11 (90.9%) (mean length of follow-up available in 9/10: 25.7 months; range: 5e71
months)
mRS 2-3
0/11 (0%)
mRS 4e6
1/11 (9.1%) (length of follow-up: 17 months)
In the 5/16 in whom first immune therapy was started ≥ 30 days from disease onset
(mean length of follow-up: 27.2 months; range 6e82)
mRS 0e1
3/5 (60%) (mean length of follow-up: 16 months; range: 15e18 months)
mRS 2e3
2/5 (40%) (mean length of follow-up: 44 months; range: 6e82 months)
mRS 4e6
0/5 (0%)
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Table 3 eMajor findings from some of the main pediatric case series in the literature of patients with anti-N-methyl-D-aspartate receptor encephalitis (case series with
≥10 patients were included). Legend: AZA: azathioprine; CS: corticosteroids; CSF: cerebrospinal fluid; CYC: cyclophosphamide; EEG: electroencephalography; IVIG:
intravenous immunoglobulines; MMF: mycophenolate mofetil; MRI: magnetic resonance imaging; N: number; Neurol.: neurological; n.a.: not available; OCB: oligoclonal
bands; PE: plasma exchange; PICU: pediatric intensive care unit; prodr.: prodromal; RTX: rituximab.
Articles (notes) Florance et al.,
20093
Dale et al., 20092 Armangue et al., 20134 Titulaer et al., 20135
(data in
adultsþ children, unless
otherwise specified)
Dale et al., 201420 Hacohen et al., 20148
(NMDAR ab positive
patients, different
clinical syndromes)
N of cases (<18
years)
32 10 20 211 (þ367 adults) 39 46
Females 26/32 (81%) 8/10 (80%) 14/20 (70%) 468/577 (81%) 29/39 (74%) 32/46 (69%)
Age at onset Median 14 years
(range 1.9e18)
Median 7 years (range
1.3e13)
Median 13 years (range
0.7e18)
Median 21 years (range
1e85)
Median 8.7 years (range
1.6e17 years)
Median 10.5 years (range
1e18)
Prodr. symptoms 15/31 (48%) n.a. 11/20 (55%) n.a. n.a. n.a.
Onset type
Neurol. 4/32 (12.5%) 5/10 (50%) 12/20 (60%) Neurol. in most children
<12 years;
n.a. 43/46 (93%)
Psychiatric 28/32 (87.5%) 5/10 (50%) 8/20 (40%) behavioral in most adults. n.a. 3/46 (7%)
Disease severity n.a. n.a. PCPC maximum: median 4
(range 4e6) - 495/570 (87%): maximum
mRS 5
- 498/571 (87%) patients
developed 4 of the 8
categories of symptoms
- 435/567 (77%) ICU
Median worst mRS: 5 n.a.
Tumour 8/32 (27%) 0/10 (0%) 2/20 (10%) 220/577 (38%) 3/39 (8%) 1/46 (2%)
Abnormal EEG 25/25 (100%) n.a. 18/20 (90%) 432/482 (90%) n.a.
Abnormal MRI 10/32 (31%) 3/10 (30%) 9/20 (45%) 180/540 (33%) n.a. 19/46 (41%)
CSF
Pleocytosis 27/31 (87%) 4/10 (40%) 14/20 (70%) Abnormal CSF in 418/532
(79%)
n.a. n.a.
OCB 5/6 (83%) 9/9 (100%) n.a. n.a. OCB: 14/32 (44%)
Time from onset to
first immune
therapy
n.a. n.a. n.a. Median 21 days (range 2
e730)
Disease duration
before RTX: median 0.1
years (range 0.05e5.1)
n.a.
Immune therapy 1st-line: 30/32 (97%)
2nd-line: 7/32 (22%)
n.a. 1st-line: 20/20 (100%)
2nd-line: 7/20 (35%)
1st-line: 462/501 (92%)
2nd-line: 134/501 (27%)
2nd-line: 39/39 9100%) 1st-line: 41/46 (89%)
2nd-line: 12/46 (26%)
CYC: 5/32 (16%)
RTX: 6/32 (19%)
CS: 20/20 (100%)
IVIG: 15/20 (75%)
PE: 1/20 (5%)
CYC: 3/20 (15%)
RTX: 7/20 (35%)
CS: 421/501 (84%)
IVIG: 346/501 (69%)
PE: 163/501 (33%)
CYC: 81/501 (16%)
RTX: 101/501 (20%)
CS: 37/39 (95%)
IVIG: 34/39 (87%)
PE: 11/39 (28%)
CYC: 8/39 (20%)
RTX: 39/39 (100%)
MMF/AZA: 4/39 (10%)
CS: 36/46 (78%)
IVIG: 25/46 (54%)
PE: 14/46 (30%)
CYC: 2/46 (4%)
RTX: 5/46 (11%)
MMF: 7/46 (15%)
AZA: 1/46 (2%)
Length of admission n.a. Mean 13.6 weeks (range
6e35)
Mean 56 days (range 13
e336)
n.a. n.a. n.a.
(continued on next page)
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features can be observed. The limited number of patientsmay
be implicated in these differences, especially in the older age
group; a different genetic background in the population can't
be ruled out, either. The growing incidence of this condition,
the availability of therapeutic interventions, the possibility of
a better outcome with early treatment and with second-line
immune therapies, and the relative age-dependent vari-
ability of clinical manifestations impose a high clinical sus-
picion towards this disease be maintained. In the absence of
clinical-anamnestic data or physical and neuroradiologic
findings suggesting other specific etiologies, paediatricians
should always consider this diagnosis when a child of any age
and gender presents with a combination of one or more
neurological deficits (especially dyskinetic movement disor-
der, paroxysmal episodes of uncertain aetiology and classifi-
cation, speech disturbances) and one or more behavioural or
psychiatric disturbances (including subtle behavioural
changes, apathy, withdrawal, disinhibition, agitation).
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ABBREVIATIONS
HSE Herpes simplex encephalitis
HSV Herpes simplex virus
mRS Modified Rankin Scale
NMDAR N-methyl-D-aspartate receptor
PCR Polymerase chain reaction
AIM To conduct a systematic literature review on patients with biphasic disease with herpes
simplex virus (HSV) encephalitis followed by anti-N-methyl-D-aspartate receptor (NMDAR)
encephalitis.
METHOD We conducted a case report and systematic literature review (up to 10 December
2016), focused on differences between herpes simplex encephalitis (HSE) and anti-NMDAR
encephalitis phases, age-related characteristics of HSV-induced anti-NMDAR encephalitis, and
therapy. For statistical analyses, McNemar’s test, Fisher’s test, and Wilcoxon rank sum test
were used (two-tailed significance level set at 5%).
RESULTS Forty-three patients with biphasic disease were identified (31 children). Latency
between HSE and anti-NMDAR encephalitis was significantly shorter in children than adults
(median 24 vs 40.5d; p=0.006). Compared with HSE, anti-NMDAR encephalitis was
characterized by significantly higher frequency of movement disorder (2.5% vs 75%
respectively; p<0.001), and significantly lower rate of seizures (70% vs 30% respectively;
p=0.001). Compared with adults, during anti-NMDAR encephalitis children had significantly
more movement disorders (86.7% children vs 40% adults; p=0.006), fewer psychiatric
symptoms (41.9% children vs 90.0% adults; p=0.025), and a slightly higher median modified
Rankin Scale score (5 in children vs 4 in adults; p=0.015). During anti-NMDAR encephalitis,
84.6 per cent of patients received aciclovir (for ≤7d in 22.7%; long-term antivirals in 18.0%
only), and 92.7 per cent immune therapy, but none had recurrence of HSE clinically or using
cerebrospinal fluid HSV polymerase chain reaction (median follow-up 7mo).
INTERPRETATION Our review suggests that movement disorder may help differentiate
clinically an episode of HSV-induced anti-NMDAR encephalitis from HSE relapse. Compared
with adults, children have shorter latency between HSE and anti-NMDAR encephalitis and,
during anti-NMDAR encephalitis, more movement disorder, fewer psychiatric symptoms, and
slightly more severe disease. According to our results, immune therapy given for HSV-
induced anti-NMDAR encephalitis does not predispose patients to HSE recurrence.
Herpes simplex encephalitis (HSE) is one of the most
common causes of severe sporadic encephalitis. Herpes
simplex virus (HSV) 1 is usually the responsible pathogen
in adults and children, whereas HSV2 is mostly detected
in neonates.1 Symptoms in the early stages in adults and
children include fever, headache, fatigue, vomiting, sei-
zures, confusion, somnolence, decreased consciousness,
and focal neurological signs.2–4 HSE is characterized by
unfavourable outcome with severe neurological sequelae
or death in about 35% of patients.5 While HSE is usually
a monophasic disease, relapses have been reported in
7.1% to 12.5% of adult patients,3 and in 14.3% to
26.7% of children.2,6,7 In some cases, the association of
relapses with a low initial dose of aciclovir,6 the good
response to a second course of aciclovir,2 or the detection
of positive HSV-polymerase chain reaction (PCR) in cere-
brospinal fluid (CSF) have suggested incomplete viral
inactivation or new viral replication.4 However, in other
cases, the negativity of HSV PCR in CSF at relapse, the
absence of new necrotic haemorrhagic lesions on brain
magnetic resonance imaging (MRI), the poor response to
aciclovir, and the efficacy of immune therapy have
© 2017 Mac Keith Press DOI: 10.1111/dmcn.13448 1
suggested that an immune-mediated mechanism may be
responsible.8
Anti-N-methyl-D-aspartate receptor (anti-NMDAR)
encephalitis is a condition characterized by multistage pro-
gression with psychiatric and behavioural symptoms, move-
ment disorder, seizures, speech disturbances, decreased
consciousness, and dysautonomias. After its description, it
has been suggested that anti-NMDAR antibodies may be
implicated in the immune-mediated relapses after HSE,9
and cases of anti-NMDAR encephalitis after HSE have been
subsequently described both in adult and paediatric age.
We report the case of a 7-year-old female who recently
presented to our hospital with anti-NMDAR encephalitis
following an episode of HSE. As correct and early recogni-
tion of this condition is crucial for the commencement of
appropriate therapy, this case prompted us to perform a
systematic review of the literature on patients with biphasic
disease with HSE followed by anti-NMDAR encephalitis
(HSV-induced anti-NMDAR encephalitis) and on the rela-
tionship between central nervous system (CNS) HSV
infection and anti-NMDAR antibodies.
METHOD
Case report and literature review
We illustrate a new case of biphasic disease with HSE fol-
lowed by HSV-induced anti-NMDAR encephalitis, and we
present the results of a systematic literature review on the
relationship between CNS HSV infection and the develop-
ment of anti-NMDAR antibodies. A literature search was
first done by one of the researchers (FC), and then carried
out again by another researcher (MN), independently, in
order to ensure inclusion of all relevant papers. The litera-
ture review was carried out in PubMed only (up to 10
December 2016), using the following search terms:
‘NMDAR’ OR ‘anti-NMDAR’ OR ‘anti-NMDAR
encephalitis’ OR ‘NMDA receptor encephalitis’ OR ‘N-
Methyl-D-Aspartate’ OR ‘Anti-N-Methyl-D-Aspartate
Receptor’ OR ‘Anti-N-Methyl-D-Aspartate Receptor
encephalitis’. The available results were searched manually
for ‘herpes’, ‘HSV’, and ‘herpetic’.
Inclusion criteria
Patients with biphasic disease with HSE followed by HSV-
induced anti-NMDAR encephalitis were included in the
literature review. We also included, separately, patients
with HSE with detection of anti-NMDAR antibodies (in
the absence of a clinical episode of anti-NMDAR
encephalitis), and patients with anti-NMDAR encephalitis
with concomitant positive HSV markers (in the absence of
a preceding clinical or radiological episode of HSE). Both
full-text and abstract-only articles were included.
Data extraction and collection
In the selected articles, a comprehensive data set was col-
lected via a form designed for the present study. The form
was created by one of the authors (MN) after reading the
relevant literature, to capture core features and relevant
data on published patients with biphasic disease with HSE
followed by HSV-induced anti-NMDAR encephalitis. The
form consisted of an Excel spreadsheet (Microsoft, Red-
mond, WA, USA), where each column captured a different
piece of information and data relative to each patient was
recorded in a different line. When data were inadequate or
insufficient for a definite piece of information, we recorded
it as ‘not available’. Data of the individual patients were
then pooled and analysed via the spreadsheet. A Microsoft
Word document transposition of the form is provided as
Appendix S1 (online supporting information).
Data extraction was first done by one of the researchers
(FC), and then verified by another researcher (MN), who
checked for accuracy and completeness of collected data.
Other authors were involved in data analysis, interpreta-
tion, and supervision of the project. Data collection
focused on symptoms during HSE and anti-NMDAR
encephalitis, CSF data, evidence of CNS HSV infection,
antibody status, antiviral and immune therapy, and
outcome. Similar to other major published case series of
anti-NMDAR encephalitis,10,11 we categorized the main
symptoms of disease as encephalopathy (defined as altered
level of consciousness persisting for >24h and including
lethargy, irritability, or a change in personality and beha-
viour);12 psychiatric/behavioural changes or agitation;
movement disorder; speech disturbances; cognitive deterio-
ration; seizures; autonomic disturbances; and sleep–wake
cycle disturbances. We defined first-line immune therapy
as corticosteroids, intravenous immunoglobulin and
plasmapheresis, and second-line immune therapy as ritux-
imab, cyclophosphamide, mycophenolate mofetil, azathio-
prine, and others. With regard to severity of disease and
outcome, based on the clinical description available in the
case reports, modified Rankin Scale (mRS) score was retro-
spectively assigned in different phases:13 at nadir of the
episode of HSE; at recovery (before onset of anti-NMDAR
encephalitis); at nadir of the episode of anti-NMDAR
encephalitis; and at last available follow-up. mRS scores
were assigned independently by two of the main investiga-
tors (MN and FC) and then compared. Discordant ratings
were resolved by consensus. For paediatric patients, the
Pediatric Cerebral Performance Category scale, as done by
Armangue et al.,14 was also applied (MN) in addition to
the mRS scoring. Comparison of percentages and median
values were used in most cases as main summary measures.
The literature review was subject to publication bias and
selective reporting within studies.
Statistical methods
Comparison of symptoms between the HSE and the anti-
NMDAR encephalitis phases was done with McNemar’s
What this paper adds
• Movement disorder is characteristic of anti-N-methyl-D-aspartate receptor
(NMDAR) encephalitis but not of herpes simplex virus (HSV) encephalitis.
• Despite immune therapy for HSV-induced anti-NMDAR encephalitis, none of
the patients had recurrence of HSV encephalitis.
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test (the analysis was carried out only for symptoms com-
parable between HSE and anti-NMDAR encephalitis).
The frequency of symptoms at anti-NMDAR encephalitis
was compared with Fisher’s exact test between adults and
children. The Wilcoxon rank sum test was used for the
comparison between children and adults with regard to
median mRS score and median time between onset of
HSE and of anti-NMDAR encephalitis. The significance
level was set at 5% (two-tailed). Data were entered into an
Excel spreadsheet and analysed with SAS 9.4 (SAS Institute
Inc., Cary, NC, USA) for Windows.
RESULTS
Case report
A previously well 7-year-old female presented to the paedi-
atric emergency department at the University Hospital of
Padua (Italy) with a prolonged febrile generalized convul-
sive seizure followed by vomiting. The patient was lethar-
gic, irritable, confused, and disoriented in space and time,
and had a 3-day history of headache and fever. An elec-
troencephalography showed significant bilateral slowing,
more marked on the right side, with bilateral temporo-
occipital epileptic discharges and subclinical focal temporal
seizures (Fig. S1a, b; online supporting information). Brain
MRI demonstrated diffusion restriction in temporal,
mesial, and insular areas, prevalent on the right hemisphere
(Fig. 1a–c), and a lumbar puncture showed 152/lL white
cells (mostly mononuclear), no red cells, glucose 2.7mmol/
L, normal lactate and proteins, and negative anti-NMDAR
antibodies. mRS score in the acute phase was 5.
Antiepileptic drugs and empirical intravenous aciclovir
(60mg/kg/day) were started, and continued after confirma-
tion of positive HSV PCR in CSF. At discharge after 21
days of antiviral treatment, the patient had regained nor-
mal consciousness and had no motor deficits, although she
was not independent in activities of daily living and had
residual cognitive deficits with slowed cognition, move-
ments, and speech; inability to read; and prosopagnosia
(mRS score 3).
Eight days after discharge (31d after onset of HSE), the
patient returned to the emergency department with a 2-
day history of lethargy, irritability, confusion, echolalia,
nonsense talk, obsessions, sleep–wake cycle disturbances,
drooling, dyskinesias, and stereotypies. Treatment with
intravenous aciclovir was resumed. Electroencephalography
showed poor organization of background activity, espe-
cially on the right hemisphere, bilateral frontotemporal
slow waves, and epileptiform discharges (Fig. S1c). Brain
MRI showed evolution of the previous lesions, in the
absence of new areas of cytotoxic oedema (Fig. 1d, e), and
the lumbar puncture disclosed negative HSV PCR and
positive anti-NMDAR antibodies. mRS score in the acute
phase of the relapse was 5. The patient received five
plasma exchanges (started 9d after onset of anti-NMDAR
encephalitis) and high-dose intravenous methylpred-
nisolone (30mg/kg/day for 5d, started 22d after onset of
anti-NMDAR encephalitis) followed by oral prednisolone
(1mg/kg/day for 2mo, tapered in 1mo, total 3mo), with
significant improvement. She was discharged on oral pred-
nisone, carbamazepine, and olanzapine after 34 days of the
relapse admission. At the 16-month follow-up from the
onset of HSE, the patient had mild residual persistent
prosopagnosia, mild mood disorder, and obsessive–compul-
sive behaviours (mRS score 2). She was back in mainstream
school (with support), and she had normal sleep–wake
cycle, no motor deficits, no seizures, and remained on car-
bamazepine.
Literature review
Biphasic illness: HSE followed by HSV-induced anti-
NMDAR encephalitis
Our literature search led to the identification of 20 articles,
published between 2013 and 2016, reporting a total of 42
patients who experienced biphasic disease with HSE fol-
lowed by HSV-induced anti-NMDAR encephalitis.14–33
The full text of all articles was available. With the addition
of our case, a total of 43 patients with biphasic disease with
HSE followed by HSV-induced anti-NMDAR encephalitis
were identified (31 children). Data on these patients are
detailed in Table SI (online supporting information), and
the main results are highlighted in the following sections.
Main clinical differences between the HSE and the anti-
NMDAR encephalitis phases
Compared with the HSE phase, the anti-NMDAR
encephalitis phase was characterized by a significantly
lower rate of seizures (n=28/40 [70%] in HSE vs n=12/40
[30%] in anti-NMDAR encephalitis; p=0.001), and by a
significantly higher frequency of movement disorder (n=1/
40 [3%] in HSE vs n=30/40 [75%] in anti-NMDAR
encephalitis; p<0.001). During anti-NMDAR encephalitis,
the most frequent type of movement disorder (according
to the terminology reported in the original papers) was
choreoathetosis (n=22/30; 73%), followed by dyskinesias
(n=16/30; 53%), ballismus or hemiballismus (n=7/30;
23%), dystonia (n=5/30; 17%), athetosis (n=3/30; 10%),
and stereotypies, posturing, intentional tremor, and myo-
clonus (n=1/30; 3% each). Movement disorder was gener-
alized in 48% (n=12/25), and the orofacial region was
involved in 69% (18/26).
Main differences between children and adults during the
anti-NMDAR encephalitis phase
The median time between onset of HSE and onset of
anti-NMDAR encephalitis was significantly shorter in
children (median 24d) than in adults (median 40.5d)
(p=0.006). During anti-NMDAR encephalitis, movement
disorder occurred significantly more often in children
than in adults (n=26/30 [87%] in children vs n=4/10
[40%] in adults; p=0.006), whereas psychiatric symptoms
were reported more frequently in adults than in children
(n=9/10 [90%] in adults vs n=13/31 [42%] in children;
p=0.025). No statistically significant differences between
children and adults were detected as regards cognitive
Review 3
deterioration, seizures, sleep–wake cycle disturbances,
dysautonomias, and speech problems. The severity of dis-
ease measured with mRS score was slightly higher in chil-
dren than in adults at nadir of anti-NMDAR encephalitis
(median 5 vs 4; p=0.015) (no statistically significant differ-
ence between children and adults was observed between
median mRS at nadir of HSE, at recovery after HSE, or
at last follow-up).
(a) (d)
(e)
(b)
(c)
Figure 1: Brain magnetic resonance imaging (MRI) in our paediatric patient with biphasic disease with herpes simplex encephalitis (HSE) followed by
herpes simplex virus (HSV)-induced anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. (a–c) Brain MRI 4 days after onset of HSE. (a) T2-
weighted axial and coronal images; (b) diffusion-weighted images, axial; (c) apparent diffusion coefficient images, axial. The brain MRI at day 4 from
onset of HSE demonstrated diffusion restriction in cortical–subcortical regions in the right temporal lobe, in the right insula, and the right parieto-occipi-
tal region. T2-weighted images also showed cortical thickening of the right temporomesial lobe with increased intensity of right parieto-occipital areas.
A smaller area of increased intensity was shown in left temporoparietal cortex. (d, e) Brain MRI 4 days after onset of anti-NMDAR encephalitis (33
days from onset of HSE). (d) T2-weighted axial and coronal images; (e) diffusion-weighted images and apparent diffusion coefficient axial images. The
brain MRI at day 4 from onset of anti-NMDAR encephalitis showed high signal in right temporal subcortical white matter, atrophic evolution of the
known right parietal–insular–temporal lesion, ex vacuo dilatation of the temporal horn of the right ventricle, and small atrophic–degenerative cortical–
subcortical areas in the left inferior and mesial temporal gyri. No cytotoxic oedema and no enhancement after gadolinium were observed.
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Treatment during HSE and anti-NMDAR encephalitis
phases, and disease recurrences
In total, 98% (n=40/41) of the patients with available
information received aciclovir during the episode of HSE,
and only 5% received additional intravenous immunoglob-
ulin and/or corticosteroids (n=2/43).22,33
At the onset of anti-NMDAR encephalitis, 85% (33/39)
of the patients were still on aciclovir from the previous
episode of HSE or were started on a new empirical course.
In these patients, duration of antiviral treatment from anti-
NMDAR encephalitis was less than or equal to 7 days in
23% (n=5/22) and greater than or equal to 14 days in the
remaining 77% (n=17/22) (data available for n=22/33);
only four patients (n=4/22; 18%) received a prolonged
course with oral valaciclovir/aciclovir (for 122d, 152d,
153d, and 243d respectively).20,24,31 During the episode of
anti-NMDAR encephalitis, first- and second-line immune
therapies were administered in 93% (n=38/41) and 53%
(n=21/40) of patients respectively.
None of the patients who received immune therapy for
HSV-induced anti-NMDAR encephalitis were reported to
have new viral replication with recurrence of HSE at a
median follow-up of 7 months (mean 15.9, range 1.2–160;
data available for 39 patients).
Patients with HSE and detection of anti-NMDAR
antibodies, and patients with anti-NMDAR encephalitis
with concomitant positive HSV markers
HSE with detection of anti-NMDAR antibodies (in the absence
of a clinical episode of anti-NMDAR encephalitis). The detec-
tion of anti-NMDAR antibodies during or after an episode
of HSE, in the absence of a clinical episode of anti-
NMDAR encephalitis, was reported in 25 adult patients
described in one retrospective and one prospective series
(both had available full text; top part of Table SII, online
supporting information).9,34 All these patients had HSE
confirmed by positive CSF HSV PCR, and positive anti-
NMDAR antibodies in CSF and/or serum (n=25/25;
100%). In the prospective series by Westman et al.,34 anti-
bodies were detectable only after 3 months in 10 of 12
positive cases. The rate of detection of anti-NMDAR anti-
bodies (IgG type) in patients with HSE was 9% and 25%
respectively, in the two studies.9,34 In the prospective series
by Westman et al.,34 the development of anti-NMDAR
autoantibodies was associated with significantly impaired
recovery of neurocognitive performance. On the contrary,
Pr€uss et al.9 were unable to detect significant clinical dif-
ferences between the antibody-positive and antibody-nega-
tive patient groups.
Anti-NMDAR encephalitis with concomitant positive HSV
markers (in the absence of clinical or radiological evidence of
HSE). The detection of positive HSV PCR in CSF dur-
ing an episode of anti-NMDAR encephalitis was reported
in six patients, described in five articles (all had full text
available).35–39 Data on these patients are limited (bottom
part of Table SII). These patients had clinical anti-
NMDAR encephalitis (confirmed by anti-NMDAR
antibodies in serum and/or CSF in six of six patients
[100%]), with detection of positive CSF HSV PCR (n=6/6;
100%) concomitantly or before detection of autoantibodies
(in the absence of clinical or radiological evidence of
HSE). In two of these patients the initial positive CSF
HSV PCR was negative on subsequent testing, prompting
the authors to consider it a spurious result.35,37 Interest-
ingly, in one patient with anti-NMDAR encephalitis con-
firmed by positive anti-NMDAR antibodies in CSF, the
detection of HSV in CSF by PCR discouraged the use of
immune therapy, and the patient received only antiviral
treatment with improvement in psychiatric symptoms but
persistence of mild memory impairment.39
DISCUSSION
We present a comprehensive and up-to-date systematic lit-
erature review on the relationship between HSV and anti-
NMDAR antibodies, and we describe a new illustrative
paediatric case with HSE followed by HSV-induced anti-
NMDAR encephalitis.
Clinical features of HSV-induced anti-NMDAR
encephalitis
We were able to identify 43 patients with biphasic disease
with HSE followed by HSV-induced anti-NMDAR
encephalitis. Our review confirms that the appearance of
movement disorder is one of the main symptoms differen-
tiating HSV-induced anti-NMDAR encephalitis from the
preceding episode of HSE (Table SI).20 Choreoathetosis
and dyskinesias were the most frequent types of movement
disorder, and the orofacial region was often involved. In
this respect, other case reports and series published before
the description of anti-NMDAR encephalitis have pointed
to movement disorder, especially choreoathetosis, as a key
feature of relapses post-HSE, often reporting negativity of
viral testing.4,40–44 With regard to the overall clinical man-
ifestations during HSV-induced anti-NMDAR encephalitis,
our literature review shows that the clinical picture is simi-
lar to that of anti-NMDAR encephalitis not preceded by
HSE, including the known age-specific features of the dis-
ease. Indeed, psychiatric symptoms were more frequent in
adults in our literature cohort, whereas neurological mani-
festations, such as movement disorder, were more repre-
sented in children (Table SI), similarly to what was
previously reported in patients with anti-NMDAR
encephalitis not preceded by HSE.11,45,46 Although it
should be taken into account that under-reporting of psy-
chiatry and cognitive features in young children is possible,
we also observed a slightly more severe disease in children
than in adults, and a shorter latency between HSE and
autoimmune encephalitis in children.
Therapeutic decision-making in relapses after HSE
In case of recurrence of symptoms after HSE, high clinical
suspicion should be maintained towards both the possibili-
ties of a viral and an autoimmune relapse, and antiviral
therapy should be started promptly. Subsequently, in the
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absence of microbiological and neuroradiological findings
consistent with a viral reactivation, early commencement of
immune therapy should also be considered. Indeed, in view
of the known pathogenicity of anti-NMDAR antibodies,47
immune therapy may be associated with a good response,
especially if administered early.10,11,19,48–51 An algorithm
for clinical and therapeutic approach in relapses after HSE
is proposed in Figure 2.
Pathogenic hypotheses
The results of our literature review on patients with bipha-
sic disease with HSE followed by HSV-induced anti-
NMDAR encephalitis support the hypothesis that CNS
HSV infection may trigger an autoimmune response in the
CNS, resulting in the production of anti-NMDAR anti-
bodies and in a fully-fledged autoimmune clinical syn-
drome.9 Indeed, an independent co-occurrence of viral and
autoimmune encephalitis is unlikely given the relative rar-
ity of both conditions. The mechanisms underlying the
synthesis of anti-NMDAR antibodies following HSV
infection remain unknown. As hypothesized by other
authors, the virus-induced neuronal destruction may expose
neuronal antigens to the systemic immunity, initiating a
primary autoimmune response.9 Other possibilities may
involve non-specific B-cell activation and/or molecular
mimicry due to shared epitopes between HSV and
NMDAR, as seen in other neurological diseases such as
multiple sclerosis, acute disseminated encephalomyelitis,
Guillain–Barre syndrome, and Sydenham chorea.52–55 The
possibility of a common genetic predisposition between the
two entities may also contribute.29
Different to the biphasic disease described above (HSE
followed by HSV-induced anti-NMDAR encephalitis;
Table SII, top part), in patients with HSE with con-
comitant detection of anti-NMDAR antibodies (in the
absence of a clinical episode of anti-NMDAR encephali-
tis) the pathogenic role of antibodies remains unclear.9,34
In particular, whether some of the clinical manifestations
observed in these cases during HSE may be due to an
additional effect of anti-NMDAR antibodies is not
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Figure 2: Proposed algorithm for clinical and therapeutic approach in relapses after HSE. In case of recurrence of symptoms after HSE, both a viral
and an autoimmune relapse should be suspected, and aciclovir should be promptly started at presentation. The subsequent treatment approach should
be guided by a combination of clinical, radiological, and laboratory data. In particular, the presence of movement disorder should raise the suspicion of
an autoimmune relapse, as this symptom is very uncommon in HSE, whereas it is characteristic of anti-NMDAR encephalitis. However, the detection of
new necrotic–haemorrhagic MRI lesions is more suggestive of an episode of new viral replication, even although extension of previous lesions is possi-
ble in autoimmune relapses. While CSF data may be regarded as the most decisive in differentiating between viral and autoimmune relapses after HSE
(in particular, CSF HSV PCR and anti-NMDAR antibodies), the availability of these data is generally delayed by a few days after presentation, hence the
relevance of identifying other clinical–radiological features differentiating viral and autoimmune relapses. When an autoimmune relapse is suspected
based on the abovementioned data, immune therapy should be started, and when viral searches are confirmed as negative aciclovir may be discontin-
ued.
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known. In this setting, the anti-NMDAR antibodies may
be just a ‘silent marker’ of a postinfective autoimmune
response without a specific contributory or causal role.
Interestingly, no significant clinical differences were
observed between the anti-NMDAR seropositive and
seronegative subgroups of HSE patients reported by
Pr€uss et al.,9 questioning whether the anti-NMDAR anti-
bodies in these patients are therefore contributing to the
disease.9 On the contrary, the development of anti-
NMDAR autoantibodies was associated with significantly
impaired recovery of neurocognitive performance in
another prospective series.34
In the group of patients with clinical anti-NMDAR
encephalitis and concomitant detection of HSV in the CSF
by PCR (in the absence of a clinical or radiological episode
of HSE),35–39 data are very limited (Table SII, bottom
part). With regard to the (sometimes transient) detection
of positive HSV PCR of CSF, a laboratory error was
hypothesized by the authors in one-third of these patients
(false positive);35,37 although definite conclusions cannot be
drawn, it cannot be excluded that a previous subclinical
CNS HSV infection may have triggered anti-NMDAR
encephalitis.
Supporting these findings, an interesting recent work
focused on the frequency of coexisting herpes viruses
and autoantibodies in patients with encephalitis (herpes
or autoimmune) in clinical laboratory service, disclosing
that autoantibodies and herpes virus DNA frequently
coexist in encephalitic CSF.56 In this study, as well as in
other case reports, other types of herpes viruses beside
HSV have been found in association with anti-NMDAR
antibodies, including Epstein–Barr virus, human her-
pesvirus 6 and 7, and varicella zoster virus.56–60 How-
ever, other autoantibodies to neuronal surface antigens,
in particular anti-dopamine-2 receptor,20 anti-c-aminobu-
tyric acid A receptor antibodies and antibodies against
unknown neuronal cell surface proteins,27 have also been
detected in patients with immune-mediated encephalitis
(with negative CSF HSV PCR) occurring after HSE,16,27
suggesting that other antibodies may also be produced in
this syndrome. In these cases, similarly to what is sug-
gested for anti-NMDAR antibodies, it may be hypothe-
sized more broadly that autoantibody production is
triggered by herpes viruses infection, but further study
for novel autoantibodies is required.
Insights into the use of immune therapy in HSE
The hypothesis that CNS HSV infection may trigger an
autoimmune response sheds more light on the pathogen-
esis of HSE itself, supporting the observation that the
cerebral insult in HSE results not only from neuronal
cell death secondary to direct viral invasion, but also
from secondary inflammatory changes and cerebral
oedema due to the immune response to the virus.
Therefore, in view of their anti-inflammatory action, cor-
ticosteroids could have an important role also in the
management of the acute phase of HSE.61 So far,
corticosteroid use has been limited by concerns that their
immunosuppressive actions could increase viral replica-
tion and spread. However, experimental animal models
of HSE have shown that the addition of corticosteroids
to aciclovir treatment does not increase viral replication
and dissemination.61,62 In this respect, it is noteworthy
that in our literature cohort none of the patients treated
with immune therapy for HSV-induced anti-NMDAR
encephalitis (or for HSE) was reported to have recur-
rence of HSE, despite only very few receiving long-term
antiviral therapy.20,24,31 Moreover, the beneficial effect of
adjunctive steroids in HSE has been anecdotally
described both in paediatric and adult age,63–66 and in
an experimental study on a mouse model of HSE, the
severity of long-term MRI anti-N-methyl-D-aspartate
receptor (NMDAR) abnormalities was significantly
reduced with add-on corticosteroids during acute HSE.62
The optimal timing for adjunctive steroid therapy has
not yet been established,65 and while in some cases a
beneficial effect has been reported after early simultane-
ous administration of aciclovir and steroids,64 in other
cases steroid administration was delayed by a few days
to weeks, with good results.65 Delayed but not early glu-
cocorticoid treatment was associated with neuroprotec-
tion and survival in a study on experimental HSE in
mice.67 Clinical trials in this field are under way.68
Limitations
The small number of patients and the retrospective nature
represent the main limitations of our work. Moreover, dis-
ease severity scoring was likely subject to significant intrin-
sic biases, mostly relative to the availability and
heterogeneity of information in the original papers, and
the fact that the scoring was done retrospectively and by
two researchers only. It is possible that the overall out-
come may also be influenced by a reporting bias, due to
unwillingness to report fatal outcomes. While the study of
the outcome according to the administration of adjunctive
immune therapy during HSE would be of great clinical
interest, this could not be evaluated because only a few of
the patients received immune therapy during HSE. Simi-
larly, owing to the small numbers, a comparison between
the outcome of patients with a clinical episode of anti-
NMDAR encephalitis who did or did not receive immune
therapy was not possible. Also, the study of the timing of
appearance of anti-NMDAR antibodies after HSE could
not be defined, in view of the different timing of antibody
testing. The statistical analysis in our work was limited by
the small number of patients and by the heterogeneity of
data availability in the original papers; individual data for
each patient were especially limited in case series compared
with reports.19
CONCLUSION
The development of HSV-induced anti-NMDAR
encephalitis, along with the detection of anti-NMDAR
antibodies during HSE and of HSV in CSF with PCR
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during anti-NMDAR encephalitis, supports the likelihood
that CNS HSV infection may trigger a secondary autoim-
mune response, resulting in the production of anti-
NMDAR antibodies. Moreover, the hypothesis of an
autoimmune response triggered by a CNS HSV infection
supports the possibility that the pathogenesis and the neu-
ronal damage of HSE involves not only a direct viral
insult, but also a secondary autoimmune process, possibly
providing arguments in favour of the rationale for the
debated use of immune therapy in the acute phase of HSE.
Interestingly, our review shows that despite the use of
immune therapy for HSV-induced anti-NMDAR
encephalitis, none of the patients experienced recurrence of
HSE. Finally, while remaining vigilant for the possibility
of new viral replication, high clinical suspicion toward an
autoimmune aetiology should be maintained in case of
relapses of HSE, in view of the different treatment and the
good response to immune therapy. The identification of
early predictors of autoimmune relapse post-HSE would
allow early intervention and, possibly, prevention of sec-
ondary autoimmunity, and it remains among future chal-
lenges.69
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SUPPORTING INFORMATION
The following additional material may be found online:
Appendix S1: Form used for data collection for the literature
review on patients with herpes simplex encephalitis followed by
herpes simplex virus-induced anti-N-methyl-D-aspartate receptor
encephalitis (Word document transposition of the Excel spread-
sheet form).
Figure S1: Electroencephalography (EEG) tracings in a pae-
diatric patient with biphasic disease with herpes simplex encepha-
litis (HSE) followed by herpes simplex virus (HSV)-induced anti-
N-methyl-D-aspartate receptor (NMDAR) encephalitis. (a, b)
EEG tracing 4 days from onset of HSE, showing significant bilat-
eral slowing, more marked on the right side, with (a) bilateral
temporo-occipital periodic epileptiform discharges and (b) subcli-
nical focal temporal right seizures. (c) EEG tracing 4 days after
onset of anti-NMDAR encephalitis (33 days from onset of HSE),
showing slowed and poorly organized electrical activity, especially
in the right hemisphere, with significant slow activity and epilepti-
form discharges in the frontotemporal areas bilaterally; no delta
brush patterns nor seizures were recorded.
Table SI: Main results of our literature review: demographics,
clinical data, laboratory investigations, treatment, and outcome of
the paediatric and adult patients identified with biphasic disease
with herpes simplex encephalitis (HSE) followed by herpes sim-
plex virus (HSV)-induced anti-N-methyl-D-aspartate encephalitis,
including our paediatric case (total 43 patients)
Table SII: Main results of our literature review on patients
with herpes simplex encephalitis (HSE) with detection of anti-N-
methyl-D-aspartate (anti-NMDAR) antibodies (in the absence of
a clinical episode of anti-NMDAR encephalitis), and on patients
with anti-NMDAR encephalitis and concomitant detection of
positive polymerase chain reaction for herpes simplex virus in cer-
ebrospinal fluid (in the absence of a preceding clinical or radio-
logical episode of HSE)
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Supplementary material 
 
Supplementary Figure 1 
 
Figure S1: Electroencephalography (EEG) tracings in a paediatric patient with biphasic disease with 
herpes simplex encephalitis (HSE) followed by herpes simplex virus (HSV)-induced anti-N-methyl-D-
aspartate receptor (NMDAR) encephalitis. (a, b) EEG tracing 4 days from onset of HSE, showing 
significant bilateral slowing, more marked on the right side, with (a) bilateral temporo-occipital periodic 
epileptiform discharges and (b) subclinical focal temporal right seizures. (c) EEG tracing 4 days after 
onset of anti-NMDAR encephalitis (33 days from onset of HSE), showing slowed and poorly organized 
electrical activity, especially in the right hemisphere, with significant slow activity and epileptiform 
discharges in the frontotemporal areas bilaterally; no delta brush patterns nor seizures were recorded. 
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Supplementary Table 1 
Results of the literature review on reported patients with HSE with detection of anti-NMDAR antibodies (in the absence of a clinical episode of anti-
NMDAR encephalitis) 
Articles reporting patients with HSE with detection of anti-NMDAR 
antibodies (in the absence of an episode of anti-NMDAR encephalitis) 
29,30 
Number of patients 25 
Demographics  
Gender 14/25 (56%) females 
Median age at HSE 53 y (mean 53, range 24-79) [data in 13/13] 
Clinical data during HSE*  
Fever 25/25 (100%) 
Seizures 8/25 (32%) 
Encephalopathy/Drowsiness/Decreased consciousness 11/13 (84.6%) 
Headache 18/25 (72%) 
Speech difficulties 2/13 (15.4%) 
Irritability or behavioural change 4/13 (30.8%) 
Vomiting 6/13 (46.1%) 
Memory impairment 8/13 (61.5%) 
Feeding difficulties/Oro-motor dysfunction 1/13 (15.4%) 
Diarrhoea 0/13 (0%) 
Movement disorder 0/13 (0%) 
Laboratory investigations during HSE  
CSF pleocytosis (>4 WBC/ml)  25/25 (100%) (median 237, mean  390.3, range 132-1288, data in 13/13) 
CSF proteinorrachia (>45 g/L) 13/13 (100%) (median 121, mean  140.5, range 47-346, data in 13/13) 
CSF oligoclonal bands 6/12 (50%) 
Evidence of HSV infection  25/25 (100%): HSV-PCR in CSF in 25/25 
Data on anti-NMDAR antibodies  
Rate of detection of anti-NMDAR antibodies (IgG) in HSE reported in the original 
articles 
4/44 (9%)9 – 12/49 (24.5%)30 
Positive anti-NMDAR antibodies in serum and/or CSF 25/25 (100%) 
Timing of detection of anti-NMDAR antibodies ≥3 m after HSE in 10/1230 
Treatment  
Acyclovir 25/25 (100%); 7/25 received valaciclovir follow-up therapy for 3 months 
Immune therapy 4/25 (16%) (adjunctive corticosteroids) 
Disease severity and outcome  
Median mRS at nadir of HSE 3 (mean 3.3, range 3-6) [data in 12/25] 
Median mRS at last follow-up n.a. 
Median length of follow-up from onset of HSE n.a. 
Results of the literature review on reported patients with anti-NMDAR encephalitis and concomitant detection of positive HSV-PCR in CSF (in the 
absence of a preceding clinical or radiological episode of HSE) 
Articles reporting patients with anti-NMDAR encephalitis with detection of 
positive HSV-PCR in CSF (in the absence of a preceding episode of HSE) 
534-38 
Number of patients 6~ 
Demographics  
Gender 1/3 (33.3%) females 
Median age at anti-NMDAR encephalitis 29 y (mean 25.3, range 4-43) [data in 3/6] 
Clinical data during anti-NMDAR encephalitis  
Encephalopathy  2/2 (100%) 
Movement disorder 2/2 (100%) 
Psychiatric symptoms or behavioural changes 2/2 (100%) 
Cognitive deterioration 2/2 (100%) 
Seizures 1/2 (50%) 
Sleep-wake cycle disturbances 1/2 (50%) 
Autonomic disturbances 0/2 (0%) 
Speech disturbances 1/2 (50%) 
Tumour 0/6 (0%) 
Laboratory investigations during anti-NMDAR encephalitis  
CSF pleocytosis (>4 WBC/ml) 2/3 (66.7%) (median 12, mean 58, range 4-158) 
CSF proteinorrachia (>45 g/L) 1/2 (50%) (median 57.5, mean 57.5, range 17-98) 
CSF oligoclonal bands n.a. 
Evidence of HSV infection (CSF and/or serum) 6/6 (100%): HSV-PCR in CSF in 6/6 
Positive anti-NMDAR antibodies in serum and/or CSF 6/6 (100%): 4/5 serum, 2/2 CSF  
Treatment  
Acyclovir 5/5 (100%) 
Immune therapy 4/5 (80%) 
First-line immune therapy 4/5 (80%) 
Corticosteroids 3/5 (60%) 
Intravenous immunoglobulin 3/5 (60%) 
Plasma exchange 3/5 (60%) 
Second-line immune therapy 0/5 (0%) 
Time from first symptoms of anti-NMDAR encephalitis to first immune therapy 7 d [data in 1/6] 
Disease severity and outcome  
Median mRS at nadir of anti-NMDAR encephalitis 4.5, (mean 4.5, range 4-5) [data in 2/6] 
Median mRS at last follow-up 0 (mean 1.3, range 0-4) [data in 3/6] 
Median length of follow-up from onset of anti-NMDAR encephalitis 5 m (mean 5.8, range 2.5-10) [data in 3/6] 
 
Supplementary Table 1. Top part: Demographics and clinical data on the literature review on paediatric 
and adult patients with HSE with detection of anti-NMDAR antibodies (in the absence of a clinical 
episode of anti-NMDAR encephalitis). Bottom part: Demographics and clinical data on the literature 
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review on paediatric and adult patients with anti-NMDAR encephalitis and concomitant detection of 
positive HSV-PCR in CSF (in the absence of a preceding clinical or radiological episode of HSE). 
Legend: anti-NMDAR encephalitis: anti-N-methyl-D-aspartate receptor encephalitis; CSF: 
cerebrospinal fluid; d: days; HSE: herpes simplex encephalitis; mRS: modified Rankin Scale; HSV: 
herpes simplex virus; m: months; n.a.: not available; m: months; OCB: oligoclonal bands; WBC: white 
blood cells; y: years. 
*One patient had headache, fever, memory impairment, confusion, somnolence, status epilepticus; he 
developed hemorrhagic necrosis, massive swelling, herniation, and died.9 
§Of the 8 patients with positive anti-NMDAR antibodies in serum reported by Prüss and colleagues, 3/8 
had positive IgA and/or IgM with negative IgG, and 5/8 had positive IgG inconstantly associated with 
positive IgA and/or IgM.9 Of the 11 patients with positive anti-NMDAR antibodies in CSF, 6/11 had 
positive IgA and/or IgM with negative IgG, and 5/11 had positive IgG inconstantly associated with 
positive IgA and/or IgM.9 
~ The two patients described by Hacohen et al, 2013,35 despite the limited availability of information, 
were considered to have positivity of HSV-PCR in CSF during anti-NMDAR encephalitis in view of the 
fact that they became progressively worse despite adequate antiviral therapy, were found to have 
NMDAR antibodies when reinvestigated, and showed a definite response to intensive immunotherapy 
with steroids, IVIG and plasma exchange. 
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Supplementary information: form for data collection 
Form used for data collection for the literature review on patients with HSE followed by HSV-induced anti-NMDAR encephalitis (word document 
transposition of the Excel spreadsheet form) 
 
 Article and patient 
data 
First disease phase: HSE Second disease phase: anti-NMDARE Outcome 
# Article 
referen
ce 
Patien
t age 
Sex Clinical 
manifestatio
ns of HSE* 
mRS 
at 
nadir 
of 
HSE 
mRS at 
recovery 
from HSE 
(and before 
onset of 
anti-
NMDARE
)  
CSF 
data: 
WBC, 
RBC, 
proteins, 
OCB, 
HSV-
PCR, 
anti-
NMDA
R ab 
Serum 
data: 
HSV-
PCR, 
HSV 
serology, 
anti-
NMDAR 
ab (if 
done) 
Antivira
l 
treatme
nt: type, 
dose and 
duration 
Adjunctiv
e immune 
therapy 
Time from 
onset of 
HSE to 
onset of 
anti-
NMDARE 
Clinical 
manifestatio
ns of anti-
NMDARE**  
Tumour mRS at 
nadir of 
anti-
NMDARE 
CSF 
data: 
WBC, 
RBC, 
proteins, 
OCB, 
HSV-
PCR, 
anti-
NMDAR 
ab 
Serum 
data: 
HSV-PCR, 
HSV 
serology, 
anti-
NMDAR 
ab 
Antivira
l 
treatme
nt: type, 
dose and 
duration
^ 
Immune 
therapy 
(time from 
onset of 
anti-
NMDARE 
to first 
immune 
therapy; 
type of 
immune 
therapy) 
Recurrences 
(recurrences 
of HSE? 
recurrences 
of anti-
NMDARE?) 
mRS 
at last 
follow
-up   
Time 
from 
onset 
of 
HSE 
to last 
follow
-up 
1                      
2                      
3                      
4                      
5                      
6                      
7                      
etc                      
 
Legend: ab: antibodies; anti-NMDARE: anti-N-methyl-D-aspartate receptor encephalitis; CSF: cerebrospinal fluid; HSE: herpes simplex encephalitis; HSV: herpes 
simplex virus; mRS: modified Rankin Scale (mRS was scored by the authors based on the case description); OCB: oligoclonal bands; PCR: polymerase chain 
reaction; RBC: red blood cells; WBC: white blood cells. 
#Patient number 
*Clinical manifestations of HSE: in particular: Fever? Seizures? Encephalopathy / Decreased consciousness / Drowsiness? Headache? Speech difficulties? Irritability 
/ Behavioural changes? Vomiting? Memory disturbances? Feeding difficulties / Oro-motor dysfunction? Diarrhoea? Movement disorder? Other? 
**Clinical manifestations of anti-NMDAR encephalitis: in particular: Encephalopathy? Movement disorder (and type of movement disorder)? Psychiatric symptoms 
or behavioural changes / Agitation? Cognitive deterioration? Seizures? Sleep-wake cycle disturbances? Autonomic disturbances? Speech disturbances? Other? 
^Antiviral treatment: other information collected was: Was the antiviral treatment still ongoing from the episode of HSE? In case antiviral treatment was no more 
ongoing, or in case it had not been given for the preceding episode of HSE, was it started empirically at the time of anti-NMDAR encephalitis? 
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3.3 Modes of use, efficacy and tolerability of individual immune therapeutic agents in 
different clinical situations in paediatric neurology 
 
 
3.3.1 Intravenous immunoglobulin in acute Sydenham's chorea 
 
Published in Journal of Paediatrics and Child Health 
 
Mohammad SS, Nosadini M, Grattan-Smith P, Dale RC.  
Intravenous immunoglobulin in acute Sydenham's chorea: A systematic review.  
J Paediatr Child Health 2015;51:1235-8.  
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Intravenous immunoglobulin in acute Sydenham’s chorea:
A systematic review
Shekeeb S Mohammad,1 Margherita Nosadini,1,3 Padraic Grattan-Smith2 and Russell C Dale1,2
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Abstract: Sydenham’s chorea (SC) is a major manifestation seen in 25% of patients with acute rheumatic fever. SC is the prototypic autoim-
mune neurological disorder, which has a less appreciated associated risk of psychiatric morbidity. We undertook a systematic review to examine
whether the use of intravenous immunoglobulin affects clinical recovery and morbidity.
Key words: behavioural; developmental; general paediatrics; immunology; neurology.
Clinical Scenario
A 13-year-old girl of Polynesian background presented with
asymmetric generalised chorea and emotional lability over a
1-week period. She had a high erythrocyte sedimentation rate
(ESR) of 45 mm/h, tested negative for antinuclear and anti
double-stranded DNA antibodies and had a pan-systolic
murmur that was confirmed to be due to mitral regurgitation on
echocardiography. A diagnosis of acute rheumatic fever (ARF)
with Sydenham’s chorea (SC) as a major feature was made, as
per the revised Jones criteria.1 She was given 2 g/kg of intra-
venous immunoglobulin (IVIg) in the acute phase and moni-
tored with serial Unified SC Rating Scale (USCRS) scores,2,3
which normalised over a 3-month period (45/108 at onset,
18/108 at 3-week follow-up and 2/108 at 3-month follow-up).
The USCRS contains six behaviour items, seven activities of
daily living (ADL) items and 14 motor items; the total score
ranges from 0 to 108, with 108 indicating maximum severity.
This scale was tested on 84 Brazilian patients and validated by
strong interrater reliability across most domains except for some
behavioural domains.3 At 6-month follow-up, there was no
chorea and her behaviour and functioning were normal.
SC is one of the major criteria for diagnosis of ARF and is seen
in ∼25% of cases.4 The incomplete resolution of chorea in some
cases,5 risk of antipsychotic-related parkinsonism6 and psychi-
atric morbidity7,8 associated with SC has long been highlighted
by detailed follow-up studies, but is still not widely appreciated.
SC is the prototypic autoimmune movement and
neuropsychiatric disorder, triggered after streptococcal infec-
tion. The autoimmune basis of SC is supported by the recent
finding of antibodies to cell surface dopamine-2 receptors.9,10
The fact that SC predominantly affects young people such as our
index case raises the important question whether residual mor-
bidity can be prevented with the use of immune therapies in the
acute phase. We undertook a systematic review on the evidence
for use of IVIg in acute SC.
Structured Clinical Question
Does the use of IVIg in acute SC
a. Reduce the duration of acute chorea and neurocognitive
symptoms?
b. Prevent development of long-term neurological and psychi-
atric complications?
(P) Population = children with acute SC
(I) Intervention = IVIg
(C) Comparator = supportive therapy or placebo
(O) Outcome = duration of chorea and/or long-term neuro-
logical or psychiatric problems
Search strategy
We searched Medline from 1946 to the third week of December
2014 and Excerpta Medica dataBASE – EMBASE for the key
words: ((Sydenham* AND chorea) OR (rheumatic chorea))
AND (IVIg OR immunoglobulin). We also reviewed all refer-
ences in the relevant search results to ensure that any studies
were not missed. We limited the search results to randomised
controlled trials (RCTs), uncontrolled trials, cohort studies and
case series (>2 patients). We found only two studies (Table 1)
that met our search criteria. We did not include comparator or
outcome parameters in our search because of the limited
number of eligible studies.
Selected studies and critical appraisal
We summarise and appraise both selected RCTs (Table 1) in our
discussion using the Critical Appraisal Skills Programme tool
Correspondence: Dr Shekeeb S Mohammad, Clinical School, The Chi-
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Table 1 Immune therapy using IVIg in SC – comparison of two randomised controlled trials
Author, year Study population Study design and
Level of evidence
Intervention Measures of outcome Follow-up Results Relapses in
IVIg-treated
patients
Limitations
Garvey et al.,
200511
18 children with
acute SC
(4/18 randomised
to IVIg, 6/18 to
Prednisone,
8/18 to PEX)
RCT
Level II
(IVIg vs. Steroids
vs PEX)
Prednisone 1 mg/kg for 10
days, 10-day taper
IVIg 1 g/kg on 2 days
PEX ﬁve to six courses
1. Severity scale
a. Functionality
b. Severity of chorea
12 months Prednisone group (n = 6):
29% reduction in mean
chorea score
IVIg group (n = 4): 72%
reduction in mean
chorea score
PEX group (n = 8): 50%
reduction in mean
chorea score
2/4 (50%) No placebo
No blinding on follow-up
No behaviour domains in
rating scale
Small number of cases
Smaller and shorter
prednisone dose
Walker et al.,
201212
20 children with
acute SC
(10/20 randomised
to IVIg)
RCT
Level II
(IVIg vs.
symptomatic
treatment)
Symptomatic treatment
(haloperidol)
versus
Symptomatic treatment
(haloperidol) + IVIg
1. Severity scale
a. Behaviour
b. Functionality
c. Motor function
2. SPECT ﬁndings
3. Duration of symptomatic
treatment
6 months In the symptomatic
treatment + IVIg group,
as compared with the
symptomatic treatment
only:
(i) improved clinical score
at 1, 3 and 6 months (P
< 0.05); and (ii) shorter
symptomatic treatment
(P < 0.05)
1/10 (10%) No placebo
Non-validated rating scale
Small number of cases
SPECT results not analysed
IVIg, intravenous immunoglobulin; PEX, plasma exchange; RCT, randomised controlled trial; SC, Sydenham’s chorea; SPECT, single photon emission CT.
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based on the Journal of the American Medical Association
guidelines.13 A simplified version of the checklist can be accessed
at: http://www.casp-uk.net/#!casp-tools-checklists/c18f8.
The first study is an RCT by Garvey and colleagues11 who
examined whether IVIg or plasma exchange (PEX) are superior
to prednisone in decreasing the severity of SC. The study did not
compare the effect of immune therapy to placebo or sympto-
matic treatment only. Eighteen patients were included in the
study, from a cohort of 38 children with acute SC seen in a
tertiary hospital over an 8-year period. The diagnosis of SC was
clinical after excluding other causes of chorea. Patients with
severe heart failure, previous SC (2/38), mild chorea (15/38),
mental retardation and another neurological or psychiatric dis-
order were excluded. Of the 18 patients included in the study,
four were randomised to IVIg (1 g/kg for 2 days), eight to PEX
(single-volume PEX cycles, five to six exchanges) and six to
prednisone (1 mg/kg/day for 10 days followed by a taper over
the next 10 days). The three treatment groups were comparable
in age and gender distribution. Prior to immune therapy, 14/18
children were on symptomatic treatment (valproate in 9/18,
haloperidol in 8/18, others in 5/18). The symptomatic medica-
tions were not altered during immune therapy, except in two
patients. In the IVIg group, the mean time from diagnosis to
initiation of immune treatment was 10 weeks (median 7.8,
range 5.4–19.0). The investigators used a 6-point chorea rating
scale, which evaluated chorea severity and functional ability to
carry out ADL at 1, 2, 3, 6 and 12 months following treatment.
The scale did not include measures of behavioural and emo-
tional symptoms, which are commonly seen in SC and are often
the major cause of morbidity.3 During intervention and follow-
up, the investigators were not blinded to the immune therapy.
In the IVIg group, the mean severity score decreased from 13.6
(median 13.5, range 11–16.6) at baseline, to 3.75 (median 4,
range 2–5) at 1 month and then 1.75 (median 2, range 0–3) at
12 months after immune therapy. Although the IVIg group
showed a quicker improvement in chorea, no statistically sig-
nificant difference was found in the change of severity scores
between the groups at 1- or 12-month follow-up. 2/4 patients in
the IVIg group relapsed within 1 year, compared with 2/8 in the
PEX group, and none in the prednisone group. Serious side
effects in the IVIg group occurred in 1/4 (hepatitis C infection).
Minor side effects in the IVIg group included mild nausea (n = 2)
and vomiting and headache during the infusion (n = 1).
The more recent South African study by Walker and col-
leagues12 compared the outcome of 10 children with SC treated
with symptomatic management (haloperidol 0.025–0.05 mg/
kg/day) to that of 10 children who received additional IVIg.
None of the patients in the study received other immune treat-
ments, and the study did not have a placebo arm. The investi-
gators enrolled 20/23 children with SC seen in a tertiary
hospital over a 6-year period. Exclusion criteria included chil-
dren with mild chorea, heart failure, IgA deficiency, known
allergy to IVIg, age >14 years or weight >50 kg. Data on the
interval between diagnosis and initiation of immune therapy
was not provided. The investigators used a locally derived sever-
ity scale at 1, 3 and 6 months, scoring of single photon emission
CT (SPECT) scans at baseline and 1 month, and duration of
symptomatic therapy with haloperidol as outcome measures.
The severity score included domains of behaviour, functional
abilities to perform daily tasks and rating of motor function
including severity of chorea. In contrast to the first study from
Garvey et al.11 the scale included neurological as well as psychi-
atric symptoms; hence, making it more suited for complete
evaluation of SC patients, although this scale has not been
formally validated. The baseline chorea rating was not blinded,
but follow-up clinical rating and rating of the SPECT scans were
done by the principle investigator as well as by a blinded
observer with good inter-investigator agreement. At baseline,
there was no statistical difference in the clinical severity score
between the two treatment groups (IVIg group: mean 11.8,
standard deviation (SD) 2.04; symptomatic treatment group:
mean 10.6, SD 2.41). At 1-month follow-up, those treated with
IVIg had significantly better scores (IVIg group: mean 3.7; symp-
tomatic treatment: mean 7.4; P = 0.006). At 3 and 6 months, the
clinical scores in the IVIg group were better than the sympto-
matic group, but the statistical significance was not maintained.
The SPECT scan findings could not be analysed due to limited
numbers (only 14/20 patients had SPECT scan at baseline, and
only 12/14 had 1-month scan). The mean time on haloperidol
was 51 days (median 46) in the IVIg group. This was signifi-
cantly shorter than in the symptomatic treatment only group
who received a mean 136.7 days of haloperidol (median 180) (P
= 0.015). At 6-month follow-up, 1/20 patients in the IVIg group
and 2/20 in the symptomatic treatment group had relapsed with
chorea. At 6-month follow-up, no patients in the IVIg group had
ongoing problems, whereas six patients in the symptomatic
group had ongoing problems of learning difficulties, attention-
deficit/hyperactivity disorder, behaviour and mood problems,
and/or persisting chorea or tics. No side effects of treatment
occurred in the IVIg group, whereas in the symptomatic, group
five patients had drowsiness, two had slurring of speech, one
had headache and one had drooling and dizziness.
How can the research be done better?
SC is a relatively uncommon disorder particularly in resource
rich countries. This makes it difficult to conduct an RCT span-
ning many years. The trial by Garvey et al.11 did not include a
placebo arm. This is obviously difficult because of ethical and
logistical issues with sham PEX or intravenous infusion.
However, sham or placebo could be incorporated for IVIg and
for oral steroids in a future study. As many patients with SC
currently do not receive any active pharmacological interven-
tion, introduction of a placebo arm should be ethically justifi-
able, but these would be milder patients. Symptomatic
treatment with anticonvulsants like carbamazepine and
valproate as well as neuroleptics is known to decrease manifest
chorea. A stringent clinical trial could have more control over
the type, dose and duration of symptomatic medications used to
minimise confounding effects. A further issue is that the dose of
steroid used in this study was of lower dose, and of shorter
duration than in other autoimmune brain conditions. Likewise,
intravenous methylprednisolone is more rapidly effective than
oral prednisolone and could have been more effective. These
factors could have led to a false impression of the steroid group
responding more slowly than the IVIg and PEX groups. The
study was also weakened by the lack of blinding on follow-up.
The major morbidity from SC, apart from concomitant
IVIg in Sydenham choreaSS Mohammad et al.
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rheumatic heart disease, is long-term neuropsychiatric
sequelae. Both of the trials reviewed here did not have long
enough follow-up to capture the burden of these sequelae and
compare them between the treatment groups. The trials used
scoring systems focussed on motor ability. Although the scale
used by Walker et al.12 used measures of behaviour, it is not clear
whether specific components of the scoring system improved
more significantly than others on follow-up. Future trials
require longer follow-up using a validated scale such as the
USCRS or a similar validated scale with better performance on
the psychiatric domains. The time from diagnosis to immune
therapy was not standardised in the first study and not detailed
in the second. Early immune therapy may work better than
later immune therapy as demonstrated by other immune-
mediated neurological disorders like anti-N-methyl D-aspartate
receptor (NMDAR) encephalitis.14 A future trial should prospec-
tively define the time frame within which immune therapy
could be initiated, and could also compare early versus later
immune therapy to examine whether this makes a difference to
outcome.
How would I apply the information to patients?
The studies reviewed here demonstrate a short-term benefit in
symptomatic improvement from SC with use of IVIg. However,
they do not clarify an optimum timing and duration for use of
IVIg, and do not provide data on the effect on long-term neu-
rological and psychiatric complications. IVIg is attractive com-
pared with steroids and PEX in view of a better side effect profile
and being less invasive than PEX. The experience of IVIg con-
tamination with hepatitis C in the Garvey et al. study highlights
that IVIg is not risk-free and should be used with consideration.
The recognition of long-term neuropsychiatric morbidity in
SC, and the possibility of improving outcome with early
immune therapy holds promise. However, the ‘partially resolv-
ing’ nature of SC should preclude the use of more potent and
toxic immune suppressing agents such as rituximab. In our
opinion use of a single 2 g/kg dose of IVIg in children with
moderate-severe SC associated with significant impairment is
reasonable in view of the risk of long-term psychiatric
morbidity. We would also remind clinicians that SC is a
neuropsychiatric disorder and it is important to screen both
adults and children for behavioural and psychiatric problems in
the acute phase and on follow-up.
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ABBREVIATIONS
IVIG Intravenous immunoglobulin
mRS Modified Rankin Scale
NMDAR N-methyl-D-aspartate receptor
PNS Peripheral nervous system
AIM Intravenous immunoglobulin (IVIG) is an expensive therapy used in immunodeficiency
and autoimmune disorders. Increasing demands and consequent shortages result in a need
for usage to conform to guidelines.
METHOD We retrospectively evaluated IVIG use for neuroimmunological indications and
adherence to existing guidelines in a major Australian paediatric hospital between 2000 and
2014.
RESULTS One-hundred and ninety-six children (96 male, 100 female; mean age at disease
onset 6y 5mo [range 3mo–15y 10mo], mean age at first IVIG dose 7y 2mo [range 3mo–16y
5mo]) received IVIG for neuroimmunological indications during the study period (28.1% had
Guillain–Barre syndrome), representing 15.5% of all hospital indications. In total, 1669 IVIG
courses were administered (total 57 221g, median 78g/patient, range 12–5748g). The highest
median numbers of courses were in chronic inflammatory demyelinating polyneuropathies,
opsoclonus-myoclonus ataxia syndrome, suspected immune-mediated epilepsies, and
Rasmussen’s encephalitis. Adverse reactions occurred in 25.5% of patients, but these were
mostly minor. Outcome at follow-up was best in anti-N-methyl-D-aspartate receptor (anti-
NMDAR) encephalitis, Guillain–Barre syndrome, and myasthenia gravis, and worst in
Rasmussen’s encephalitis and epilepsies. The total cost of IVIG was US$2 595 907 (median
$3538/patient, range $544–260 766). Of patients receiving IVIG, 45.4% to 57.1% were given the
therapy for ‘weak’ indications or indications ‘not listed’ in international guidelines. Some
entities commonly treated with IVIG in current practice, such as anti-NMDAR encephalitis and
transverse myelitis, are not listed in most guidelines.
INTERPRETATION Our study demonstrates that IVIG is generally well tolerated but expensive,
and discloses discrepancies between guidelines and clinical practice in paediatric neurology,
suggesting both the need for greater adherence to current recommendations, and for
recommendations to be updated to accommodate emerging indications.
Intravenous immunoglobulin (IVIG) is a fractionated
blood product made from pooled human plasma, that has
been used in the treatment of immune deficiencies and
autoimmune disorders for almost four decades.1 Supple-
mentation of the immune system with IVIG broadens the
spectrum of a recipient’s immune response and attenuates
autoimmune reactivity,1 although the precise mechanisms
of anti-inflammatory and immunoregulatory action are not
completely understood, and are thought to be diverse
according to the underlying pathophysiology.1–3
The demand for IVIG has increased over the years, result-
ing in high cost to health providers and IVIG shortages.2
Guidelines regulating IVIG use according to the evidence
base have been created in different countries, to ensure its
availability for patients who are most likely to benefit from
the therapy.4–9 However, recommendations vary across dif-
ferent guidelines. In Australia, the use of IVIG is regulated
by the National Blood Authority of Australia Criteria. Based
on the available evidence, these identify conditions for which
the role of IVIG is ‘established’, ‘emerging’, ‘supported in
exceptional circumstances only’, or ‘not supported’.9 The
United Kingdom guidelines use a similar descriptive classifi-
cation for the use of IVIG: ‘highest priority’, ‘appropriate’,
‘limited/little/no evidence’, ‘not recommended’.7 In other
guidelines, such as those from North America and Europe,
recommendations are based on levels of evidence categor-
ized as ‘A (established effective)’, ‘B (probably effective)’, ‘C
(possible effective)’, and ‘U (inadequate data)’.4,6,8
To review the current clinical practice regarding the use
of IVIG in paediatric neurology, we carried out a
© 2016 Mac Keith Press DOI: 10.1111/dmcn.13159 1
retrospective study in a large paediatric neurology centre
in Sydney, Australia, focusing on the clinical indications
for IVIG administration, adherence to guidelines, cost, tol-
erability, and long-term outcome.
METHOD
Patient identification
The study was conducted at the Children’s Hospital at
Westmead, New South Wales, Australia, approved as service
improvement (activity number: 4695). A list of all patients
who received IVIG at the Children’s Hospital at Westmead
between January 2000 and June 2014 was provided by the
hospital pharmacy and the blood bank (independent sources
distributing all IVIG at the hospital). A total of 1264 chil-
dren was treated with IVIG for any paediatric indication in
the study period. To identify the patients who received IVIG
for neurological indications only, the clinical files of the
1264 total patients were reviewed in the hospital informatic
database (PowerChart; Cerner Corporation PTY Ltd.,
North Sydney, NSW, Australia). Seven patients were
excluded because of insufficient clinical information, and
1038 because of IVIG administration for non-neurological
indications (Fig. 1). Of the non-neurological indications, the
most common were Kawasaki disease (312 of 1264, 24.7%)
and acute lymphoblastic leukaemia (128 of 1264, 10.1%). A
total of 219 children who received IVIG for neurological
indications was identified (219 of 1264, 17.3%). Of these, 23
did not have a neuroimmunological disorder, and were
excluded (Fig. 1). Therefore, 196 children received IVIG for
neuroimmunological indications at the Children’s Hospital
at Westmead during the study period, and were included in
our study (196 of 1264 of all patients, 15.5%).
Data collection
Data were collected via retrospective chart review of the
hospital informatic database. The clinical diagnosis in the
discharge letter was verified by correlating with the diag-
nostic investigations performed, and with the diagnosis at
follow-up. The clinical indications for IVIG administration
were grouped into central nervous system (CNS) and
peripheral nervous system (PNS) indications (Fig. 1). The
indications for which IVIG was dispensed were reviewed
in light of the most recent available international guideli-
nes on IVIG use.4–7,9 Data collected on IVIG use included
type, dose, number of courses, total quantity administered,
and side effects. To calculate the cost of IVIG, we used
the mean price of all IVIG products used at the Children’s
Hospital at Westmead as of July 2015 in Australian dollars
(AUD), and then converted this to American dollars
(USD) (currency conversion as of December 2015: 1
AUD=0.73 USD). Other immune therapies received
besides IVIG were also recorded and categorized as first-
line (corticosteroids, plasma exchange) and second-line
(mycophenolate mofetil, cyclophosphamide, rituximab, aza-
thioprine, methotrexate, and other).
With regard to the severity of disease, modified Rankin
Scale (mRS) score10 was assigned retrospectively by the
main investigators (RCD, MN) based on the clinical data
in the acute phase before receiving IVIG. Outcome was
assessed retrospectively at the last follow-up available in
the informatic database, and scored via mRS and via type
of ongoing impairments (subdivided into: none, cognitive/
learning, behavioural, motor, visual, epilepsy, and other).
Scores of 0 to 2 were interpreted as a good outcome, as in
previous studies.11 For some patients, the available follow-
up in the informatics database was ≤12 months from the
first IVIG administration (and the patients were lost to fol-
low-up). In these cases, we conducted telephone interviews
to the patients (if current age ≥18y) or to their family (if
current age <18y), to extend the length of follow-up (total
43 interviews). This was done after approval from the local
ethics committee (LNR/15/SCHN/218) and after obtain-
ing informed consent from the family. After extending fol-
low-up, only 23 patients had follow-up ≤12 months (23 of
196, 11.7%).
RESULTS
Demographics
There were similar distributions of male (96 of 196, 49%)
and female (100 of 196, 51%) patients in our cohort. Mean
age at disease onset was 6 years 5 months (median 5y 1mo,
range 3mo–15y 10mo). Mean age at first IVIG dose was
7 years 2 months (median 6y 3mo, range 3mo–16y 5mo).
An increasing number of patients was started on IVIG for
neuroimmunological indications during the study period:
48 between 2000 and 2004, 57 between 2005 and 2009,
and 91 between 2010 and 2014 (Fig. 2).
Clinical indications for IVIG administration
The clinical indications for IVIG administration in our
cohort are detailed in Figure 1. Central neuroimmunologi-
cal disorders (113 of 196, 57.7%) were slightly more com-
mon than peripheral neuroimmunological disorders (83/
196, 42.3%). Over time, there was a relative rise in the
proportion of patients who received IVIG for central, as
opposed to peripheral, indications (Fig. 2). The most com-
mon central indications were encephalitis (47 of 196,
24%), followed by inflammatory demyelinating CNS disor-
ders (29 of 196, 14.8%), and epilepsy (11 of 196, 5.6%).
Among peripheral indications, the most common indica-
tions were demyelinating neuropathies (64 of 196, 32.6%),
followed by disorders of the neuromuscular junction (12 of
196, 6.1%). The most common individual indication was
Guillain–Barre syndrome (55 of 196, 28.1% of the whole
cohort).
What this paper adds
• Intravenous immunoglobulin (IVIG) is an expensive but relatively well toler-
ated treatment commmonly used in paediatric neurology.
• Some indications for IVIG administration seem to respond poorly to treat-
ment.
• Other conditions commonly treated with IVIG are not listed in most guide-
lines.
• Greater adherence to current recommendations is required, and recommen-
dations need to be updated.
2 Developmental Medicine & Child Neurology 2016
Severity of disease
In the patients with available information (190 of 196,
96.9%), the mean mRS before receiving IVIG was 3.7
(median 4, range 2–5). The mRS scores before IVIG
initiation and on last follow-up according to category of
clinical indication are shown in Figure 3. Of the patients
in the cohort, 31.2% were admitted to the intensive care
unit (60 of 192).
- Acute lymphoblastic leukaemia (n=128)
- Neuroblastoma (n=45)
- Acute myeloid leukaemia (n=42)
- Common variable immune deficiency (n=40)
- Idiopathic thrombocytopenic purpura (n=29)
- Hypo/Agammaglobulinaemia (n=20)
- Stevens-Johnson syndrome (n=16)
- Severe combined immune deficiency (n=13)
- Other (n=393)
- Kawasaki disease (n=312)
7 patients 1264 patients
196 patients
23 patients
1257 patients
219 patients
neurological
indications only
with adequate data
Excluded
Excluded
Excluded
Study
population
received IVIG at CHW
for any indication
(2000 – 2014)
inadequate data
1038 patients
non-neurological indications
non-neuroimmunological indications
- Metabolic/Neurodegenerative (n=10):
Metachromatic leukodystrophy (n=4), X-linked
adrenoleukodystrophy (n=3), Undiagnosed
degenerative disease of the CNS (n=2),
Cerebellar leukodystrophy (n=1)
- Other genetic (n=3): SMARD (n=1), Rett
syndrome (n=1), Refractory epilepsy (n=1)
- Peripheral non-inflammatory neuropathies
(n=4): Dejerine-Sottas disease (n=1), Distal
hereditary motor neuropathy (n=1), Chronic
active axonal neuropathy (n=1), Congenital
progressive hypomyelinating neuropathy (n=1) 
- Other (n=6): Leber hereditary optic neuropathy
(n=2), PRES (n=1), Baclofen poisoning (n=1),
Botulism (n=1), Hirayama disease (n=1)  
neuroimmunological indications
Indication categories
Encephalitis (n=47)a
Inflammatory demyelinating CNS
diseases (n=29)
Autoimmune CNS syndromes (n=10)
Postinfectious movement disorders (n=6)
Paediatric acute neuropsych. syndromes
(n=3)
Genetic auto-inflammation (n=2)
CNS involvement in systemic
inflammatory diseases (n=2)
Undiagnosed complex autoimmune
disorders (n=3)c
Demyelinating neuropathies (n=64)
Disorders of the neuromuscular junction
(n=12)
Inflammatory myopathies (n=7)
Epilepsies (n=11)
CNS INDICATIONS (n=113, 57.7%)
Infectious and infection-associated encephalitis (n=11): Enterovirus (n=7), Mycoplasma (n=1), HSV (n=1), Acute
Monophasic inflammatory demyelinating CNS diseases (n=22): Transverse myelitis (n=21), Optic neuritis (n=1)
Relapsing inflammatory demyelinating CNS diseases (n=7): Multiple sclerosis (n=4), Neuromyelitis optica with
anti-AQP4 or anti-MOG antibodies (n=3)b
Epilepsies (n=11): FIRES (n=3), Lennox-Gastaut (n=2), Landau-Kleffner (n=1), Other (n=5)
Opsoclonus-myoclonus ataxia syndrome (n=9)
ROHHAD syndrome (n=1)
Sydenham chorea (n=4)
Other (n=2): Acute cerebellar ataxia (n=1), Complex movement disorder (n=1)
Paediatric acute neuropsych. syndromes (n=3): PANDAS/Tourette syndrome (n=2), PANS (n=1)
Genetic auto-inflammation (n=2): Aicardi–Goutières syndrome (n=1), Suspected autoinflammatory
neurodegenerative brain disorder (n=1)
Neuropsych. systemic lupus erythematosus (n=2)
Undiagnosed complex autoimmune disorders (n=3)
Acute demyelinating neuropathies (n=55): Guillain-Barré syndrome (n=55)
Chronic demyelinating neuropathies (n=9): Chronic inflammatory demyelinating polyneuropathy (n=7),
Mononeuritis (n=2)
Myasthenia gravis (n=12)
Inflammatory myopathies (n=7): Dermatomyositis (n=6), Orbital myositis (n=1)
necrotizing encephalopathy (n=1), Influenza (n=1)
Anti-NMDAR encephalitis (n=8)
Acute disseminated encephalomyelitis (n=7)
Rasmussen’s encephalitis (n=5)
Other autoimmune or immune-mediated encephalitis (n=16): Basal ganglia (n=4), anti-VGKC (n=1), Suspected
autoimmune encephalitis (n=11)
Indication groups: Specifications
PNS INDICATIONS (n=83, 42.3%)
Figure 1: Cohort selection. From the total 1264 children who received IVIG at the Childrens Hospital at Westmead between January 2000 and June
2014, only the 196 patients who received IVIG for neuroimmunological indications were included in our cohort (study population). The central nervous
system (CNS) and peripheral nervous system (PNS) indications for IVIG administration in our cohort are shown. Of these, only the indication groups
with at least five patients were used for the major analyses in the text and in Figure 3. aClassification of encephalitis adapted from Pillai et al.37 bThe
diagnosis of neuromyelitis optica was made according to the revised Wingerchuk criteria,38and met also the latest criteria for neuromyelitisoptica spec-
trum disorder.39 cDetails on the patients in the group of undiagnosed complex autoimmune disorders are provided in the online supporting information.
AQP4, aquaporin-4; CHW, the Childrens Hospital at Westmead, New South Wales, Australia; CNS, central nervous system; FIRES, febrile infection-
related epilepsy syndrome; HSV, herpes simplex virus; IVIG, intravenous immunoglobulin; MOG, myelin oligodendrocyte glycoprotein; neuropsych, neu-
ropsychiatric; NMDAR, N-methyl-D-aspartate receptor; PANDAS, paediatric autoimmune neuropsychiatric disorder associated with group A streptococci;
PANS, paediatric acute-onset neuropsychiatric syndrome; PNS, peripheral nervous system; PRES, posterior reversible encephalopathy syndrome; ROH-
HAD, rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation; SMARD, spinal muscular atrophy with respira-
tory distress; VGKC, voltage-gated potassium channel.
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Other immune therapies
Data on other immune therapies are detailed in Table SI
(online supporting information). The IVIG was the only
immune therapy given in 25.5% of patients from the total
cohort (50 of 196). The sole use of IVIG varied according
to the clinical indication, and was highest in Guillain–Barre
syndrome (41 of 55, 74.5%). Immune therapies other than
IVIG were given in 74.5% of patients (146 of 196), most
commonly corticosteroids (144 of 196, 73.5%; oral pred-
nisone 121 of 196, 61.7%, and intravenous methylpred-
nisolone 84 of 196, 42.8%). Plasma exchange was used in a
limited number of cases (4 of 196, 2%). Second-line
immune therapies were administered in 26.7% of patients
(39 of 146), and included mycophenolate mofetil (16 of
146, 10.9%), rituximab (12 of 146, 8.2%), cyclophos-
phamide (7 of 146, 4.8%), azathioprine (7 of 146, 4.8%),
and others (Table SI).
Immunoglobulin measurement before IVIG administration
Before commencement of IVIG treatment, IgG, IgA, and
IgM were measured in 37.2% of patients (73 of 196), and
some minor reductions in baseline immunoglobulin values
were noted (IgG [2 of 73, 2.7%], IgA [2 of 73, 2.7%], and
IgM [4 of 73, 5.5%]).
Number of courses and quantity of IVIG administered
A total of 1669 IVIG courses (mean 8.5 courses per
patient, median 1, range 1–150) was administered in the
196 patients during the total cohort treatment time
of 144.2 years (mean 1.7y, median 0.5, range 0.02–10.5)
(with exclusion of the IVIG courses administered for
Guillain–Barre syndrome: total 1603 IVIG courses, mean
11.4, median 2, range 1–150). The corresponding total
quantity of IVIG was 57 221g in the whole cohort (mean
291.9g per patient, median 78, range 12–5748). Data on
IVIG courses and quantity by clinical diagnosis are
detailed in Table I and Figure S1 (online supporting infor-
mation). In the indication groups with at least five patients,
chronic demyelinating neuropathies were the indication
with highest median number of IVIG courses per patient,
followed by opsoclonus-myoclonus ataxia syndrome,
epilepsies, and Rasmussen’s encephalitis; the highest med-
ian quantity of IVIG per patient was administered in
chronic demyelinating polyneuropathies, opsoclonus-myo-
clonus ataxia syndrome, myasthenia gravis, Rasmussen’s
encephalitis, epilepsies, and relapsing inflammatory
demyelinating diseases (Table I).
Dose of IVIG and days of treatment
High dose IVIG (2g/kg given over 2–5d) was given for
408 courses in 177 patients, typically as the first course. In
chronic therapy, lower doses were given per course: 1.2 to
1.8g/kg (116 courses in eight patients), 1g/kg (254 courses
in 27 patients), and 0.2 to 0.8g/kg (891 courses in 25
patients).
Type of IVIG and cost
Intragam (CSL Pharma) accounted for over half of the total
quantity of IVIG (32 100g/57 221g, 56.1%). Other types of
IVIG used were Octagam (Octapharma) (11 610g/57 221g,
20.3%), Flebogamma (Grifols) (7587g/57 221g, 13.2%),
Sandoglobulin (CSL Pharma) (5474g/57 221g, 9.6%),
28
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Figure 2: Number of patients started on intravenous immunoglobulin (IVIG), divided by year of IVIG initiation (year 2014 is up to June), and by central
and peripheral indications. The number of children commenced on IVIG every year increased over the study period, mostly because of an increase of
IVIG administration for central indications, while peripheral indications were relatively stable over time.
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Figure 3: Modified Rankin Scale (mRS) in the acute phase of disease, before IVIG administration, in the total population and according to indication
group (only the indications with at least five patients are represented, see Fig. 1). The change in mRS 0 to 2 is presented at IVIG administration, and at
final follow-up. CNS, central nervous system; infl. demyel., inflammatory demyelinating; IVIG, intravenous immunoglobulin; neuropsych., neuropsychiatric;
NMDAR, N-methyl-D-aspartate receptor; PNS, peripheral nervous system.
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Intraglobin F (Paviour Pharma) (325g/57 221g, 0.6%), and
Kiovig (Baxter) (125g/57 221g, 0.2%). Based on a mean of
the IVIG prices as at July 2015 in AUD (mean 620 AUD/
10g=453.7 USD/10g), the total cost for IVIG in the whole
cohort in the study period 2000 to 2014 was 2 595 907
USD (mean 13 244 USD per patient, median 3538, range
544–260 766). The IVIG cost per patient according to
clinical indication group, reflecting the IVIG quantity
administered per patient, is detailed in Table I. In the
indication groups with at least five patients, the highest
median costs per patient were in chronic demyelinating
neuropathies, opsoclonus-myoclonus ataxia syndrome,
myasthenia gravis, Rasmussen’s encephalitis, epilepsies, and
relapsing inflammatory demyelinating diseases. The lowest
median costs per patient were in infectious and infection-
associated encephalitis, acute disseminated encephalomyeli-
tis, monophasic inflammatory demyelinating CNS diseases,
Guillain–Barre syndrome, other autoimmune or immune-
mediated encephalitis, and anti-N-methyl-D-aspartate recep-
tor (anti-NMDAR) encephalitis.
IVIG tolerability
Adverse reactions or infusion reactions to IVIG of any
severity were reported in 25.5% of the total cohort (50 of
196). Severe or medically significant (but not life-threaten-
ing) adverse events (grade 3), according to the National
Institutes of Health Common Terminology Criteria for
Adverse Events,12 occurred in 2% of the total patients (4 of
Table I: Number of IVIG courses and quantity of IVIG (g) administered by clinical indication
Indications for IVIG administration
Number of IVIG courses Quantity of IVIG (g) Cost per patient
(USD)
Total Mean Median Range Total Mean Median Range Mean (median)
CNS indications (n=113)
Encephalitis (n=47)
Infectious and infection-associated
encephalitis (n=11)
14 1.3 1 1–3 530 48.2 24 12–246 2186 (1089)
Anti-NMDAR encephalitis (n=8) 51 6.4 3.5 1–23 1626.5 203.3 68 30–1020 9223 (3085)
Acute disseminated encephalomyelitis
(n=7)
9 1.3 1 1–3 454 64.8 30 24–200 2940 (1361)
Rasmussen’s encephalitis (n=5) 28 5.6 6 2–11 1147 229.4 220 54–420 10 407 (9981)
Other autoimmune or immune-mediated
encephalitis (n=16)
111 6.9 1 1–56 3316 207.2 60 18–1661 9400 (2722)
Inflammatory demyelinating CNS diseases (n=29)
Monophasic inflammatory demyelinating
CNS diseases (n=22)
23 1 1 1–2 1367 62.1 36 12–275 2817 (1633)
Relapsing inflammatory demyelinating
CNS diseases (n=7)
119 17 4 1–79 3022 431.7 180 90–1846 19 584 (8166)
Epilepsies (n=11)
Epilepsies (n=11) 416 37.9 11 1–150 6748 613.4 180 48–2298 27 828 (8166)
Autoimmune CNS syndromes (n=10)
Opsoclonus-myoclonus ataxia syndrome
(n=9)
236 26.2 13 3–147 5237 581.9 260 60–2592 26 399 (11 795)
ROHHAD syndrome (n=1) 17 17 17 N/A 1200 1200 1200 N/A 54 440 (54 440)
Postinfectious movement disorders (n=6)
Sydenham chorea (n=4) 8 2 1 1–5 482 120.5 90 40–262 5467 (4083)
Other (n=2) 4 2 2 1–3 129 64.5 64.5 24–105 2926 (2926)
Paediatric acute neuropsychiatric syndromes (n=3)
Paediatric acute neuropsychiatric
syndromes (n=3)
20 6.7 5 3–12 1917 639 321 150–1446 28 989 (14 562)
Genetic autoinflammation (n=2)
Genetic autoinflammation (n=2) 8 4 4 3–5 260 130 130 60–200 5898 (5898)
CNS involvement in systemic inflammatory diseases (n=2)
Neuropsych. systemic lupus
erythematosus (n=2)
15 7.5 7.5 3–12 1707 853.5 853.5 267–1440 38 720 (38 720)
Undiagnosed complex autoimmune disorders (n=3)
Undiagnosed complex autoimmune
disorders (n=3)
21 7 10 1–10 2078 692.7 1010 48–1020 31 425 (45 820)
PNS indications (n=83)
Demyelinating neuropathies (n=64)
Acute demyelinating neuropathy
(Guillain–Barre syndrome) (n=55)
66 1.2 1 1–4 4081.5 74.2 45 12–407 3366 (2041)
Chronic demyelinating neuropathies
(n=9)
285 31.7 24 3–90 12504 1389.3 900 50–5748 63 028 (40 830)
Disorders of the neuromuscular junction (n=12)
Myasthenia gravis (n=12) 100 8.3 2.5 1–29 4886 407.2 227.5 24–1299 18 473 (10 321)
Inflammatory myopathies (n=7)
Inflammatory myopathies (n=7) 117 16.7 3 1–88 4529 647 141 75–3500 29 352 (6397)
CNS, central nervous system; IVIG, intravenous immunoglobulin; N/A, not applicable; NMDAR, N-methyl-D-aspartate receptor; PNS, periph-
eral nervous system; ROHHAD, rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation; USD,
US dollars.
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196), whereas no life-threatening consequences (grade 4) or
deaths related to adverse events (grade 5) occurred. Grade 3
adverse events included aseptic meningitis (defined as the
presence of at least three of the following: fever, headache,
altered mental status, stiff neck, photophobia) in 1.5% of
cases (3 of 196), and by aseptic meningitis and hypotension
requiring intervention in 0.5% of cases (1 of 196).
In the remaining 23.5% of patients (46 of 196), adverse
events were mild or moderate (grade 1–2).12 The most
commonly reported adverse reactions were headache (12 of
196, 6.1%), vomiting, or nausea (11 of 196, 5.6%), local
skin reactions or problems at the site of cannula insertion
(9 of 196, 4.6%), fever (9 of 196, 4.6%), and hypotension
not requiring intervention (3 of 196, 1.5%). Rarer adverse
reactions were bradycardia (3 of 196, 1.5%), rash (3 of
196, 1.5%), hypertension, tachycardia, shortness of breath,
flushing (each 2 of 196, 1%), pallor, abdominal pain,
drowsiness, derangement of liver function tests, evidence
of hepatitis B immunity (passive transfer of immunoglobu-
lin, not infection), haemolytic reaction with fever and
lethargy, increased respiratory rate, and intermittent
apnoea, and sweatiness during infusion (each 1 of 196,
0.5%). Of the patients who received multiple IVIG
courses, side effects most commonly occurred during the
first course only (14 of 24, 58.3%).
Outcome
Data on outcome at last follow-up are detailed in Table II
(and its extended legend provided in Appendix S1, online
supplementary information), Table SII (online supplemen-
tary information), and Figure 3. The mean length of fol-
low-up in the total cohort was 52 months (median 36,
range 0.25–186). Of the patients, 173 of 196 (88.3%) had
follow-up of more than 12 months. In the indication
groups with at least five cases, patients with epilepsy and
inflammatory myopathies had the longest follow-up peri-
ods, whereas patients with anti-NMDAR encephalitis and
myasthenia gravis had the shortest follow-up (Table II). At
last available follow-up, mean mRS in the total cohort was
1.8 (median 2, range 0–6). Of the patients, 20.4% (40 of
196) had mRS 0 (no symptoms at all), 20.9% (41 of 196)
had mRS 1 (no significant disability despite symptoms),
25% (49 of 196) had mRS 2 (slight disability), 25% (49 of
196) had mRS 3 (moderate disability), 6.6% (13 of 196)
had mRS 4 (moderately severe disability), 0.5% (1 of 196)
had mRS 5 (severe disability), and 1.5% (3 of 196) of
patients had died (mRS 6: one with febrile infection-
related epilepsy syndrome, one with Lennox-Gastaut
syndrome, one with dermatomyositis) (Table SII). At last
follow-up, 20.4% (40 of 196) of patients reported ongoing
cognitive or learning problems, 9.2% (18 of 196) beha-
vioural problems, 46.9% (92 of 196) motor problems,
3.6% (7 of 196) visual impairment, 12.7% (25 of 196)
epilepsy, and 37.2% (73 of 196) other problems.
In the indication groups with at least five cases, patients
with anti-NMDAR encephalitis, Guillain–Barre syndrome,
and myasthenia gravis had the lowest mean and median
mRS at last follow-up, the highest proportion of good
outcome (mRS 0–2), and the greatest change to mRS 0 to
2 from the acute phase to the last follow-up (see Fig. 3,
Table II, and Appendix S1). By contrast, patients with
Rasmussen’s encephalitis and epilepsy had the highest
mean and median mRS at follow-up, the lowest propor-
tions of good outcome (mRS 0–2), and the smallest
change to mRS 0 to 2 between the acute phase and the
follow-up (Fig. 3).
Clinical indications for IVIG administration in our cohort:
comparison with existing guidelines on the use of IVIG
Table III presents the role of IVIG according to different
guidelines, in each of the clinical indications for which IVIG
were administered in our cohort. With reference to the
guidelines including both CNS and PNS indications,4–7,9
the proportion of patients in our cohort who received
IVIG for indications not strongly recommended or not
listed in the guidelines ranged between 45.4% and 57.1%.
Table SIII (online supporting information) gives details
with regard to the Australian criteria for the clinical use of
IVIG.9
DISCUSSION
To review the clinical practice regarding the use of IVIG
in paediatric neurology, we carried out a retrospective
study at the Children’s Hospital at Westmead, Sydney, for
the period 2000 to 2014. Kawasaki disease was the clinical
indication for which IVIG was most commonly adminis-
tered, outnumbering all neurological indications, which
represented about one-sixth of all patients given IVIG in
our institution.
Neurological indications for IVIG treatment were simi-
larly distributed between CNS and PNS indications in our
cohort, but the increase in use of IVIG for neurological
disorders over the study period is mostly a result of the
rise in CNS indications. This is at least partly because the
description of some of these disorders, including anti-
NMDAR encephalitis, is relatively recent. The understand-
ing of the immunological basis for anti-NMDAR
encephalitis and other cell surface autoimmune encephalitis
has likely resulted in an increased willingness to use
immune therapy in patients with encephalitis.
These observations may also partly explain why about
half of the patients in our cohort (45.4–57.1%) received
IVIG for indications not strongly recommended or not
listed in the most recent available international guidelines
for the use of IVIG. Besides, some of these disorders are
very rare, such as rapid-onset obesity with hypothalamic
dysfunction, hypoventilation, and autonomic dysregulation
syndrome, and the evidence on the efficacy of immune
therapy is limited. Others, such as transverse myelitis, are
more common, but quality evidence on the efficacy of
IVIG is lacking; a randomized controlled trial is currently
under way.13 Given that transverse myelitis can have a
poor prognosis, with less than 50% making a full recov-
ery,14 it is understandable that clinicians are more likely to
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treat these patients more aggressively with multiple
immune therapies including IVIG. Furthermore, some of
the indication categories in our cohort are poorly defined
entities (such as ‘suspected autoimmune encephalitis’ and
‘undiagnosed complex autoimmune disorders’), and these
are therefore not dealt with in the available guidelines, as
expected. It is likely that future revisions of the existing
recommendations will include some of these currently
unlisted diagnostic entities, or accommodate for the uncer-
tainty in some of the disorders in which an autoimmune
mechanism is suspected but unproven.
In general, the available evidence for the benefit of IVIG
in neurological conditions is limited, and Cochrane reviews
are available only for Guillain–Barre syndrome,15 chronic
inflammatory demyelinating polyneuropathy,16 myasthenia
gravis,17 dermatomyositis,18 and multiple sclerosis.19 A
Cochrane review on the use of IVIG in childhood
encephalitis, the second most common indication category
for IVIG administration in our cohort, is under way.20
Given the increasing description of autoantibody-
associated encephalitis syndromes and the emerging evi-
dence of improved outcomes with early immune therapy, it
seems fair to consider IVIG treatment for these.21
In our cohort, the proportion of patients who received
IVIG for indications not strongly recommended or not
listed in the current available guidelines was higher than in
previous studies.22–24 In an audit on the use of IVIG in
clinical practice in adults, conducted in Sydney about
12 years ago,23 25.5% of patients received IVIG for indica-
tions not strongly recommended in the existing criteria at
the time.25 Similarly, 30% of patients in a more recent
French study in adults also received IVIG ‘off-label’.24,26
Table II: Length of follow-up and neurological outcome by clinical indication
Indications for IVIG administration
Mean length of
follow-up in months
(median, range)
Mean mRS
at follow-up
(median, range)
Proportion of patients with
complete recovery and good
outcome
mRS 0,
complete
recovery (%)
mRS 0–2,
good
outcome (%)
CNS indications (n=113)
Encephalitis (n=47)
Infectious and infection-associated encephalitis (n=11) 48.3 (32, 13–160) 2.3 (3, 0–4) 3/11 (27.3) 4/11 (36.4)
Anti-NMDAR encephalitis (n=8) 36 (23.5, 10–98) 0.9 (0, 0–3) 5/8 (62.5) 7/8 (87.5)
Acute disseminated encephalomyelitis (n=7) 54 (51, 27–99) 2 (2, 1–3) 0/7 (0) 5/7 (71.4)
Rasmussen’s encephalitis (n=5) 80.4 (83, 8–164) 3 (3, 3) 0/5 (0) 0/5 (0)
Other autoimmune or immune-mediated encephalitis (n=16) 39.1 (33, 14–117) 2.1 (2, 0–4) 1/16 (6.2) 11/16 (68.7)
Inflammatory demyelinating CNS diseases (n=29)
Monophasic inflammatory demyelinating CNS diseases
(n=22)
45.9 (30.5, 0.5–169) 2 (2, 0–4) 5/22 (22.7) 12/22 (54.5)
Relapsing inflammatory demyelinating CNS diseases (n=7) 59.4 (36, 7–139) 1.4 (1, 0–4) 2/7 (28.6) 6/7 (85.7)
Epilepsies (n=11)
Epilepsies (n=11) 89.4 (94, 25–151) 3.3 (3, 1–6) 0/11 (0) 3/11 (27.3)
Autoimmune CNS syndromes (n=10)
Opsoclonus-myoclonus ataxia syndrome (n=9) 64.9 (40, 10–181) 2.1 (2, 1–3) 0/9 (0) 7/9 (77.8)
ROHHAD syndrome (n=1) 18 4 0/1 (0) 0/1 (0)
Postinfectious movement disorders (n=6)
Sydenham chorea (n=4) 10.1 (11.5, 0.25–17) 1.5 (1.5, 1–2) 0/4 (0) 4/4 (100)
Other (n=2) 43 (43, 38–48) 2 (2, 1–3) 0/2 (0) 1/2 (50)
Paediatric acute neuropsychiatric syndromes (n=3)
Paediatric acute neuropsychiatric syndromes (n=3) 33.7 (29, 13–59) 2.3 (3, 1–3) 0/3 (0) 1/3 (33.3)
Genetic autoinflammation (n=2)
Genetic autoinflammation (n=2) 12.5 (12.5, 6–19) 4.5 (4.5 (4–5) 0/2 (0) 0/2 (0)
CNS involvement in systemic inflammatory diseases (n=2)
Neuropsych. systemic lupus erythematosus (n=2) 44.5 (44.5, 29–60) 2.5 (2.5 (2–3) 0/2 (0) 1/2 (50)
Undiagnosed complex autoimmune disorders (n=3)
Undiagnosed complex autoimmune disorders (n=3) 20 (18, 17–25) 2.3 (3, 1–3) 0/3 (0) 1/3 (33.3)
PNS indications (n=83)
Demyelinating neuropathies (n=64)
Acute demyelinating neuropathy (Guillain–Barre syndrome)
(n=55)
55.7 (44, 0.25–186) 1.2 (1, 0–4) 20/55 (36.4) 44/55 (80)
Chronic demyelinating neuropathies (n=9) 49 (32, 15–110) 2 (2, 1–3) 0/9 (0) 7/9 (77.8)
Disorders of the neuromuscular junction (n=12)
Myasthenia gravis (n=12) 37.7 (30, 4.5–123) 1.25 (1, 0–3) 3/12 (25) 11/12 (91.7)
Inflammatory myopathies (n=7)
Inflammatory myopathies (n=7) 84.3 (85, 1.5–175) 2.1 (2, 0–6) 1/7 (14.3) 6/7 (85.7)
In the indication groups with at least five cases, the greatest change to mRS 0–2 from the acute phase to the last follow-up occurred in
patients with anti-NMDAR encephalitis, Guillain–Barre syndrome, and myasthenia gravis (see also Fig. 3). By contrast, Rasmussen’s
encephalitis and epilepsy had the lowest proportions of patients with good outcome (mRS 0–2) and the smallest change to mRS 0–2
between the acute phase and the follow-up. See Appendix S1 for an extended version of Table II legend. CNS, central nervous system;
IVIG, intravenous immunoglobulin; mRS, modified Rankin Scale; NMDAR, N-methyl-D-aspartate receptor; PNS, peripheral nervous system;
ROHHAD, rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation.
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Table III: Indications for IVIG administration in our cohort: role for IVIG according to different guidelines
Role for IVIG in different guidelines including
CNS and PNS indications 2012, NBA 2011, Wimperis 2008, Elovaaraa 2007, Feasbyb 2006, Orangec
Committee issuing the guidelines (Country) (see legend
for details on the recommendations in each guideline)
National Blood
Authority Australia
(NBA) (Australia)
Department of
Health (UK)
EFNS task force on the
use of intravenous
immunoglobulin in
treatment of neurological
diseases (Europe)
IVIG Hematology and
Neurology Expert Panels
(Canada)
Primary
Immunodeficiency
Committee of the
American Academy of
Allergy, Asthma And
Immunology (USA)
Recommendations for the use of IVIG (subdivided into stronger and weaker by the authors)
Stronger recommendation categories Established
Emerging
Highest priority
Appropriate
Established effective (LoE
A)
Probably effective (LoE B)
Recommended (based on
LoE 1a to 6)
Definitely beneficial
Probably beneficial
Might provide benefit
(A, B)
Weaker recommendation categories/Not
recommended
Exceptional
circumstances
only
Not supported
Limited/little/no
evidence
Not recommended
Possibly effective (LoE C)
Good practice point
(class IV evidence)
Not recommended (based
on LoE 1a to 6)
Might provide benefit
(C, D)
Indications for IVIG administration in our cohort: role for IVIG according to different guidelines
Central indications (n=113)
Encephalitis (n=47)
Infectious/infection-associated encephalitis (n=11):
Enterovirus (n=7), Mycoplasma (n=1), HSV (n=1),
Influenza (n=1), Acute necrotizing encephalopathy
(n=1)
– – – – –
Anti-NMDAR encephalitis (n=8) – Limited evidence – – –
Acute disseminated encephalomyelitis (n=7) Emerging Limited evidence Good practice point (class
IV)
Recommended (LoE 4) Might provide benefit
(III C)
Rasmussen’s encephalitis (n=5) Exceptional Appropriate Good practice point (class
IV)
Recommended Might provide benefit
(IIb B)
Basal ganglia (n=4) – – – – –
Anti-VGKC encephalitis (n=1) Exceptional Limited evidence – – –
Other suspected autoimmune encephalitis (n=11) – Limited evidence – – –
Inflammatory demyelinating diseases (n=29)
Transverse myelitis (n=21) – – – – –
Optic neuritis (n=1) Not supported – – – –
Multiple sclerosis (n=4) Emerging Not recommended Probably effective (LoE B) Recommended (LoE 1a) –
Neuromyelitis optica (n=3) Exceptional – Good practice point (class
IV)
– –
Epilepsies (n=11)
FIRES (n=3), Lennox-Gastaut (n=2), Landau-Kleffner
(n=1), Other (n=5)
Exceptional Limited evidence Good practice point (class
IV)
Not recommended (LoE
1b)
Might provide benefit
(Ia A)
Autoimmune CNS syndromes (n=10)
Opsoclonus-myoclonus ataxia syndrome (n=9) Emerging Limited evidence – Recommended (LoE 4) Might provide benefit
(III C)
ROHHAD syndrome (n=1) – – – – –
Postinfectious movement disorders (n=6)
Sydenham chorea (n=4) – – – – –
Other (n=2) – – – – –
Paediatric acute neuropsychiatric syndromes (n=3)
PANDAS/Tourette syndrome (n=2) Exceptional Little/No evidence – Recommended (LoE 1b) Might provide benefit
(IIb B)
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Table III: Continued
Role for IVIG in different guidelines including
CNS and PNS indications 2012, NBA 2011, Wimperis 2008, Elovaaraa 2007, Feasbyb 2006, Orangec
PANS (n=1) Not supported – – – –
Genetic autoinflammation (n=2)
Aicardi–Goutieres syndrome (n=1), Suspected
autoinflammatory neurodegen. brain disorder (n=1)
– – – – –
CNS involvement in systemic inflammatory diseases (n=2)
Neuropsychiatric systemic lupus erythematosus
(n=2)
Not supported Little/no evidence – – Might provide benefit
(III D)
Undiagnosed complex autoimmune disorders (n=3)
Undiagnosed complex autoimmune disorders (n=3) – – – – –
Peripheral indications (n=83)
Demyelyinating neuropathies (n=64)
Acute demyelinating neuropathy (Guillain–Barre
syndrome) (n=55)
Established Highest priority Established effective
(LoE A)
Recommended (LoE 1a) Definitely beneficial (Ia A)
Chronic inflammatory demyelinating
polyneuropathy (n=7)
Established Highest priority Established effective
(LoE A)
Recommended (LoE 1a) Definitely beneficial (Ia A)
Mononeuritis (n=2) – – – – –
Disorders of the neuromuscular junction (n=12)
Myasthenia gravis (n=12) Established Appropriate Established effective
(LoE A)
Recommended (LoE 1b) Probably beneficial
(Ib-IIa B)
Inflammatory myopathies (n=7)
Dermatomyositis (n=6) Established Appropriate Probably effective (LoE B) Recommended (LoE 1b) Probably beneficial (IIa B)
Orbital myositis (n=1) – – – – –
Total quantity of IVIG (g) given for weaker
indications, or not recommended/not listed
41.4% (23 682.5g/
57 221g)
53% (30 349g/
57 221g)
48.8% (27 928.5g/57 221g) 36.4% (20 858.5g/57 221g) 38.4% (22 004.5g/57 221g)
Total patients who received IVIG for weaker
indications, or not recommended/not listed
49% (96/196) 56.6% (111/196) 57.1% (112/196) 45.4% (89/196) 50% (98/196)
See Appendix S1 for an extended version of Table III legend. a–c EFNS, European Federation of Neurological Societies; FIRES, febrile infection-related epilepsy syndrome; HSV, herpes sim-
plex virus; IVIG, intravenous immunoglobulin; LoE, level of evidence; NMDAR, N-methyl-D-aspartate receptor; PANDAS, paediatric autoimmune neuropsychiatric disorder associated with
group A streptococci; PANS, paediatric acute-onset neuropsychiatric syndrome; PNS, peripheral nervous system; ROHHAD, rapid-onset obesity with hypothalamic dysfunction, hypoventila-
tion, and autonomic dysregulation; VGKC, voltage-gated potassium channel.
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In these studies,23,24 the most common neurological indi-
cations for IVIG included chronic inflammatory demyeli-
nating polyneuropathy, myasthenia gravis, multifocal
motor neuropathy, and dermatomyositis, reflecting the dif-
ferent age in the study population (adult only) compared
with ours.
The dose of IVIG used in our cohort was variable, but
generally 2g/kg was used in acute diseases that required
only one course (i.e. Guillain–Barre syndrome), whereas
smaller doses and a high number of courses were used in
chronic diseases, such as chronic inflammatory demyelinat-
ing polyneuropathy. Adverse reactions to IVIG occurred in
25.5% of patients in our cohort, but serious events were
rare. It is possible that the actual rate of non-serious
adverse reactions is higher because of under-reporting
given the retrospective design of this study, especially in
the case of patients who were discharged soon after receiv-
ing IVIG. Most of the patients were very impaired before
receiving IVIG (mRS 3–5 in 94.7%), and most were given
other immune therapies, with the exception of patients
with Guillain–Barre syndrome in whom most received
IVIG monotherapy. The length of follow-up was relatively
long in our population, and generally there was a good
recovery, with mRS 0 to 2 in 66.8% of cases, although
three patients did die. The improvement at last follow-up
was most marked in the patients with anti-NMDAR
encephalitis, Guillain–Barre syndrome, and myasthenia
gravis. It is significant that some of these entities, such as
anti-NMDAR encephalitis, are not specifically mentioned
in most of the existing guidelines for the use of IVIG, even
though their description predates the publication date of
the guideline.
The least marked improvement at follow-up was
observed in patients with Rasmussen’s encephalitis and epi-
lepsy (Fig. 3), questioning the role of IVIG in these condi-
tions. It is the personal experience of the authors that
some patients with Rasmussen’s encephalitis and epilepsy
do benefit from IVIG and other immune therapies,
whereas other patients get no apparent benefit. Even
though some evidence for a role of IVIG in epilepsy is
available,27 according to two Cochrane reviews no reliable
conclusions can be drawn regarding the efficacy of IVIG in
epilepsy.28,29 Recently, the efficacy of immune therapy over
antiepileptic drugs has been reported in specific types of
seizures with autoimmune aetiology, such as faciobrachial
dystonic seizures,30 and in patients with positive neuronal
surface antibodies with exclusive or prevalent seizure pre-
sentations.31 Therefore, IVIG likely does have a role in
some types of immune-mediated epilepsy, although our
data suggest the benefits are equivocal outside of proven
autoimmune encephalitis with seizures. Even though IVIG
does seem to have a role in adult-onset Rasmussen’s
encephalitis,32,33 the results of our study support other data
in the literature suggesting limited efficacy of IVIG in pae-
diatric Rasmussen’s encephalitis.34,35 It is noteworthy that
the subgroups receiving less benefit (Rasmussen’s
encephalitis, epilepsies) received a large amount of IVIG at
a high financial cost. Therefore when using IVIG for less
accepted indications, clinicians should try to define clear
outcome targets, and be willing to stop IVIG if those tar-
gets are not met; this is not easy to achieve in patients with
refractory syndromes when families describe modest
benefits.
A very limited number of patients in our cohort were
treated with plasma exchange. The use of plasma exchange
in children may present unique challenges and higher com-
plication rates compared with adults, especially in patients
who are poorly cooperative or have autonomic instability.36
In addition, the use of plasma exchange is at least partly
subject to the experience and expertise of individual cen-
tres, and our centre has generally used IVIG rather than
plasma exchange. We have only recently started using
plasma exchange in neurological patients.
The long study period, large cohort, long follow-up, and
comparison with different guidelines are among the
strengths of this study. Its limitations are primarily a result
of its retrospective nature, including the retrospective
assignment of mRS disability score and the detection of
side effects to IVIG. In addition, the natural history of dif-
ferent clinical conditions and the use of other immune
therapies as well as IVIG will have influenced the clinical
outcomes at last follow-up, and make the efficacy of IVIG
difficult to define with confidence in our study. We
decided to exclude the 23 patients initially treated with
IVIG for suspected neuroimmunological conditions who
were subsequently found to have other disease mechanisms
(Fig. 1), because the natural disease history in these
patients may be different.
In summary, IVIG represents an expensive resource, and
demand has increased worldwide in recent years. Updated
guidelines for the clinical use of IVIG are essential to
rationalize the use of IVIG in an evidence-based fashion,
ensuring availability for the conditions for which IVIG use
is clearly beneficial, and limiting unnecessary expenses.
Our study captures the recent clinical practice as regards
the use of IVIG in a large paediatric neurology centre, fur-
ther highlighting an imbalance between generally accepted
clinical practice (e.g. use of IVIG for transverse myelitis
and anti-NMDAR encephalitis), and clinical guidelines that
are usually generated based on randomized controlled trial
evidence. Furthermore, future studies to prove efficacy of
IVIG, such as IVIG versus placebo, are likely to be consid-
ered unethical for most of these conditions, whereas ‘head-
to-head’ studies comparing IVIG with other first-line
agents may require large numbers to generate statistical
significance.
APPENDIX: MEMBERS OF THE IVIG IN NEUROLOGY
STUDY GROUP
In addition to the authors listed at the top of this article,
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Hospital at Westmead, University of Sydney;
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Hospital at Westmead, University of Sydney;
Juliana Teo, Department of Haematology, the Chil-
dren’s Hospital at Westmead, University of Sydney;
Esther M. Tantsis, Neuroimmunology group, Institute
for Neuroscience and Muscle Research, Kids Research
Institute, Children’s Hospital at Westmead, University of
Sydney;
Sudarshini Ramanathan, Neuroimmunology group,
Institute for Neuroscience and Muscle Research, Kids
Research Institute, Children’s Hospital at Westmead,
University of Sydney, and Department of Neurology,
Westmead Hospital, Sydney;
Richard Webster, T.Y. Nelson Department of Neurol-
ogy and Neurosurgery, the Children’s Hospital at West-
mead, University of Sydney, Australia.
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SUPPORTING INFORMATION
The following additional material may be found online:
Figure S1: Number of IVIG courses per patient (mean, med-
ian range) by clinical indication group (only the indications with
at least five patients are represented, see Fig. 1).
Table SI: First-line and second-line immune therapies admin-
istered beside IVIG according to indication group.
Table SII: Detailed data on outcome at last follow-up by clini-
cal indications.
Table SIII: Role for IVIG in the clinical indications of our
cohort according to the National Blood Authority Australia, Cri-
teria for the clinical use of intravenous immunoglobulin in Aus-
tralia, 2nd edition, July 2012.
Appendix S1: Patients with undiagnosed complex autoimmune
disorders; extended legends to Tables II and III.
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Supplementary material 
 
Supplementary Figure 1 
 
 
 
 
Figure S1: Number of IVIG courses per patient (mean, median range) by clinical indication group (only 
the indications with at least five patients are represented, see Fig. 1). 
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Supplementary Table 1 
 
 
Indication groups  Other first-line immune therapies Second-line immune therapies 
CNS INDICATIONS (n=113) Total Before/ 
With 
IVIG 
After 
IVIG 
Steroids PE Total Before/ 
With 
IVIG 
After  
IVIG 
RTX CYC Other second-line 
immune therapies 
Encephalitis (n=47)            
Infectious and infection-associated 
encephalitis (n=11) 
10/11  
(90.9%) 
8/11  
(72.7%) 
2/11 
(18.2%) 
10/11 
(90.9%) 
- - - - - - - 
Anti-NMDAR encephalitis (n=8) 8/8  
(100%) 
8/8 
(100%) 
- 8/8 
(100%) 
- 4/8  
(50%) 
- 
 
4/8 
(50%) 
3/8 
(37.5%) 
- 1/8 (12.5) MMF 
Acute disseminated 
encephalomyelitis (n=7) 
7/7 
(100%) 
7/7 
(100%) 
- 7/7 
(100%) 
- 1/7  
(14.3%) 
- 
 
1/7 
(14.3%) 
- 
 
- 
 
1/7 (14.3%) MMF 
Rasmussen’s encephalitis (n=5) 5/5 
(100%) 
4/5 
(80%) 
1/5 
(20%) 
5/5 
(100%) 
- - - - - - - 
Other autoimmune or immune-
mediated encephalitis (n=16) 
16/16 
(100%) 
14/16 
(87.5%) 
2/16 
(12.5%) 
16/16 
(100%) 
- 4/16  
(25%) 
- 4/16 
(25%) 
2/16 
(12.5%) 
1/16 
(6.25%) 
1/16 (6.25%) MMF 
Inflammatory demyelinating CNS 
diseases (n=29) 
           
Monophasic inflammatory 
demyelinating CNS diseases 
(n=22) 
20/22 
(90.9%) 
 
20/22 
(90.9%) 
 
- 20/22 
(90.9%) 
0/22 
(0%) 
- - - - - - 
Relapsing inflammatory 
demyelinating CNS diseases (n=7) 
7/7 
(100%) 
 
7/7 
(100%) 
 
- 7/7 
(100%) 
1/7 
(14.3%) 
4/7  
(57.1%) 
 
1/7 
(14.3%) 
 
3/7 
(42.8%) 
- - 3/7 (42.8%) IFN, 
1/7 (14.3%) each 
MMF, AZA, Mitox 
Epilepsies (n=11)            
Epilepsies (n=11) 
 
10/11 
(90.9%) 
8/11 
(72.7%) 
2/11 
(18.2%) 
10/11 
(90.9%) 
- 2/11  
(18.2%) 
- 2/11 
(18.2%) 
2/11 
(18.2%) 
- - 
Autoimmune CNS syndromes (n=10)            
Opsoclonus myoclonus ataxia 
syndrome (n=9) 
8/9 
(88.9%) 
8/9 
(88.9%) 
- 8/9 
(88.9%) 
- 5/9  
(55.5%) 
- 5/9  
(55.5%) 
3/9 
(33.3%) 
3/9 
(33.3%) 
- 
ROHHAD syndrome (n=1) 1/1 
(100%) 
1/1 
(100%) 
- 1/1 
(100%) 
- 1/1  
(100%) 
- 1/1 
(100%) 
1/1 
(100%) 
1/1 
(100%) 
- 
Postinfectious movement disorders 
(n=6) 
           
Sydenham chorea (n=4) 4/4 
(100%) 
3/4 
(75%) 
1/4 
(25%) 
4/4 
(100%) 
- - - - - - - 
Other (n=2) 2/2 
(100%) 
2/2 
(100%) 
- 2/2 
(100%) 
- - - - - - - 
Paediatric acute neuropsych. 
syndromes (n=3) 
           
Paediatric acute neuropsych. 
syndromes (n=3) 
2/3 
(66.7%) 
1/3 
(33.3%) 
1/3,  
(33.3%) 
2/3 
(66.7%) 
- - - - - - - 
Genetic auto-inflammation (n=2)            
Genetic auto-inflammation (n=2) 2/2 
(100%) 
2/2 
(100%) 
- 2/2 
(100%) 
- 1/2 
(50%) 
1/2 
(50%) 
- 1/2 
(50%) 
1/2 
(50%) 
1/2 (50%) MMF 
CNS involvement in systemic 
inflammatory diseases (n=2) 
           
Neuropsych. systemic lupus 
erythematosus (n=2) 
2/2 
(100%) 
2/2 
(100%) 
0/2  
(0%) 
2/2 
(100%) 
0/2  
(0%) 
2/2 
(100%) 
2/2 
(100%) 
- - 1/2 
(50%) 
2/2 (100%) MMF, 
2/2 (100%) AZA 
Undiagnosed complex autoimmune 
disorders (n=3) 
           
Undiagnosed complex 
autoimmune disorders (n=3) 
2/3 
(66.7%) 
- 
 
2/3 
(66.7%) 
2/3 
(66.7%) 
- 1/3 
(33.3%) 
- 1/3 
(33.3%) 
- - 1/3 (33.3%) MMF 
PNS INDICATIONS (n=83)            
Demyelinating neuropathies (n=64)            
Acute demyelinating neuropathies 
(n=55) 
14/55 
(25.4%) 
6/55 
(10.9%) 
8/55 
(14.5%) 
14/55 
(25.4%) 
- - - - - - - 
Chronic demyelinating 
neuropathies (n=9) 
5/7 
(71.4%) 
2/7 
(28.6%) 
3/7 
(42.5%) 
4/7 
(57.1%) 
1/7 
(14.3%) 
1/7 
(14.3%) 
- 1/7 
(14.3%) 
- - 1/7 (14.3%) AZA 
Disorders of the neuromuscular 
junction (n=12) 
           
Myastenia gravis (n=12) 11/12 
(91.7%) 
8/12 
(66.7%) 
3/12 
(25%) 
11/12 
(91.7%) 
2/12 
(16.7%) 
8/12 
(66.7%) 
1/12 
(8.3%) 
7/12 
(58.3%) 
- - 6/12 (50%) MMF, 
3/12 (25%) AZA 
Inflammatory myopathies (n=7)            
Inflammatory myopathies (n=7) 7/7 
(100%) 
7/7  
(100%) 
- 7/7 
(100%) 
- 5/7 
(71.4%) 
4/7 
(57.1%) 
1/7 
(14.3%) 
- - 5/7 (71.4%) MTX,  
2/7 (28.6%) MMF 
 
 
Supplementary Table 1. First-line and second-line immune therapies administered beside IVIG 
according to indication group. The columns before/with and after IVIG refer to the relative order of first 
administration of IVIG or other therapy. 
Legend: AZA: azathioprine; CNS: central nervous system; CYC: cyclophosphamide; IFN: interferon; 
IVIG: intravenous immunoglobulin; Mitox: mitoxantrone; MMF: mycophenolate mofetil; MTX: 
methotrexate; neuropsych: neuropsychiatric; NMDAR: N-methyl-D-aspartate receptor; PE: plasma 
exchange; PNS: peripheral nervous system; ROHHAD: rapid-onset obesity with hypothalamic 
dysfunction, hypoventilation, and autonomic dysregulation; RTX: rituximab; -: 0%. 
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Supplementary Table 2 
 
 
INDICATIONS FOR IVIG 
ADMINISTRATION 
 
mRS 
 
Type of ongoing problems 
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CNS INDICATIONS (n=113)               
Encephalitis (n=47)               
Infectious and infection-associated 
encephalitis (n=11) 
27.3
% 
0% 9.1% 45.4
% 
18.2
% 
0% 0% 27.3
% 
27.3
% 
0% 54.5
% 
0% 18.2
% 
27.3
% 
Anti-NMDAR encephalitis (n=8) 62.5
% 
0% 25% 12.5
% 
0% 0% 0% 62.5
% 
25% 25% 25% 0% 0% 25% 
Acute disseminated encephalomyelitis 
(n=7) 
0% 28.6
% 
42.5
% 
28.6
% 
0% 0% 0% 0% 14.3
% 
0% 28.6
% 
0% 28.6
% 
71.4
% 
Rasmussen’s encephalitis (n=5) 0% 0% 0% 100% 0% 0% 0% 0% 40% 0% 100% 40% 60% 40% 
Other autoimmune or immune-mediated 
encephalitis (n=16) 
6.2% 18.7
% 
43.7
% 
18.7
% 
12.5
% 
0% 0% 6.2% 50% 12.5
% 
25% 0% 43.7
% 
56.2
% 
Inflammatory demyelinating CNS diseases 
(n=29) 
              
Monophasic inflammatory demyelinating 
CNS diseases (n=22) 
22.7
% 
18.2
% 
13.6
% 
27.3
% 
18.2
% 
0% 0% 22.7
% 
4.5% 4.5% 68.2
% 
0% 4.5% 36.4
% 
Relapsing inflammatory demyelinating 
CNS diseases (n=7) 
28.6
% 
28.6
% 
28.6
% 
0% 14.3
% 
0% 0% 28.6
% 
0% 0% 14.3
% 
28.6
% 
0% 42.8
% 
Epilepsies (n=11)               
Epilepsies (n=11) 0% 9.1% 18.2
% 
45.4
% 
9.1% 0% 18.2
% 
0% 63.6
% 
18.2
% 
18.2
% 
0% 63.6
% 
36.4
% 
Autoimmune CNS syndromes (n=10)               
Opsoclonus myoclonus ataxia syndrome 
(n=9)  
0% 11.1
% 
66.7
% 
22.2
% 
0% 0% 0% 0% 33.3
% 
22.2
% 
55.5
% 
0% 0% 44.4
% 
ROHHAD syndrome (n=1) 0% 0% 0% 0% 100% 0% 0% 0% 100% 100% 100% 0% 0% 100% 
Postinfectious movement disorders (n=4)               
Sydenham chorea (n=4) 0% 50% 50% 0% 0% 0% 0% 0% 0% 25% 50% 0% 0% 50% 
Paediatric acute neuropsych. syndromes 
(n=3) 
              
Paediatric acute neuropsych. syndromes 
(n=3) 
0% 33.3
% 
0% 66.7
% 
0% 0% 0% 0% 33.3
% 
0% 0% 0% 33.3
% 
100% 
Genetic autoinflammation (n=2)               
Genetic autoinflammation (n=2) 0% 0% 0% 0% 50% 50% 0% 0% 50% 0% 100% 0% 0% 100% 
CNS involvement in systemic inflammatory 
diseases (n=2) 
              
Neuropsychiatric systemic lupus 
erythematosus (n=2) 
0% 0% 0% 100% 0% 0% 0% 0% 50% 0% 50% 0% 50% 100% 
Undiagnosed complex autoimmune disorders 
(n=3) 
              
Undiagnosed complex autoimmune 
disorders (n=3) 
0% 33.3
% 
66.7
% 
0% 0% 0% 0% 0% 33.3
% 
66.7
% 
0% 0% 0% 100% 
Other (n=2)               
Other (n=2)  0% 50% 0% 50% 0% 0% 0% 0% 50% 100% 0% 0% 50% 50% 
PNS INDICATIONS (n=83)               
Demyelinating neuropathies (n=64)               
Guillain-Barré syndrome (n=55) 36.4
% 
29.1
% 
14.5
% 
18.2
% 
1.8% 0% 0% 36.4
% 
10.9
% 
3.6% 47.3
% 
1.8% 0% 20% 
Chronic demyelinating neuropathies (n=9) 0% 22.2
% 
55.5
% 
22.2
% 
 0% 0% 0% 0% 0% 0% 88.9
% 
11.1
% 
0% 22.2
% 
Disorders of the neuromuscular junction 
(n=12) 
              
Myastenia gravis (n=12) 25% 33.3
% 
33.3
% 
8.3% 0% 0% 0% 25% 8.3% 0% 66.7
% 
0% 0% 25% 
Inflammatory myopathies (n=7)               
Inflammatory myopathies (n=7)  14.3
% 
14.3
% 
57.1
% 
0% 0% 0% 14.3
% 
14.3
% 
0% 0% 28.6
% 
14.3
% 
0% 57.1
% 
 
 
Supplementary Table 2. Detailed data on outcome at last follow-up by clinical indications. 
Legend: CNS: central nervous system; IVIG: intravenous immunoglobulin; mRS: modified Rankin 
Scale; neuropsych.: neuropsychiatric; NMDAR: N-methyl-D-aspartate receptor; PNS: peripheral 
nervous system; ROHHAD: rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and 
autonomic dysregulation. 
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Supplementary Table 3 
 
 
Role for IVIG according to the National Blood Authority Australia for the 
clinical indications in our cohort (the quantity of IVIG administered by 
clinical indication is detailed) 
Established 
therapeutic 
role 
Emerging 
therapeutic 
role 
Use in 
exceptional 
circumstances 
only 
Use not 
supported 
Not listed in 
the NBA 
criteria for 
IVIG use 
CENTRAL INDICATIONS (n=113)  
Encephalitis (n=47)  
Infectious and infection-associated encephalitis (n=11): Enterovirus 
(n=7), Mycoplasma (n=1), HSV (n=1), Influenza (n=1), Acute 
necrotising encephalopathy (n=1) 
    530 g 
Anti-NMDAR encephalitis (n=8)     1626.5 g 
Acute disseminated encephalomyelitis (n=7)  454 g    
Rasmussen’s encephalitis (n=5)   1147   
Basal ganglia (n=4)     426 g 
Anti-VGKC encephalitis (n=1)   60 g   
Other suspected autoimmune encephalitis (n=11)   2830 g*    
Inflammatory demyelinating diseases (n=29)      
Transverse myelitis (n=21)     1327 g 
Optic neuritis (n=1)    40 g  
Multiple sclerosis (n=4)  2203 g    
Neuromyelitis optica MOG+ or AQP4+ (n=3)   819 g   
Epilepsies (n=11)      
FIRES (n=3), Lennox-Gastaut (n=2), Landau-Kleffner (n=1), Other (n=5)   6748 g   
Autoimmune CNS syndromes (n=10)      
Opsoclonus myoclonus ataxia syndrome (n=9)   5237 g    
ROHHAD syndrome (n=1)     1200 g 
Postinfectious movement disorders (n=4)  
Sydenham chorea (n=4)     482 g 
Other (n=2): Acute cerebellar ataxia (n=1), Complex movement disorder 
(n=1) 
    129 g 
Paediatric acute neuropsychiatric syndromes (n=3)      
PANDAS/Tourette syndrome (n=2)   1596 g   
PANS (n=1)    321 g  
Genetic autoinflammation (n=2)      
Aicardi-Goutieres syndrome (n=1), Suspected autoinflammatory 
neurodegenerative brain disorder (n=1) 
    260 g 
CNS involvement in systemic inflammatory diseases (n=2)      
Neuropsychiatric systemic lupus erythematosus (n=2)    1707 g  
Undiagnosed complex autoimmune disorders (n=3)  
Undiagnosed complex autoimmune disorders (n=3)     2078 g 
Other (n=2)  
Acute cerebellar ataxia (n=1), Complex movement disorder (n=1)     129 g 
PERIPHERAL INDICATIONS (n=83)  
Demyelyinating neuropathies (n=64)      
Acute demyelinating neuropathy (Guillain-Barré syndrome) (n=55) 4081.5 g     
Chronic inflammatory demyelinating polyneuropathy (n=7) 12229 g     
Mononeuritis (n=2)     275 g 
Disorders of the neuromuscular junction( n=12)      
Myastenia gravis (n=12) 4886 g     
Inflammatory neuropathies (n=7)      
Dermatomyositis (n=6),  4529 g     
Orbital myositis (n=1)     81 g 
Quantity of IVIG (total: 57221 g) 25644.5 g 
(44.8%) 
7894 g 
(13.8%) 
13200 g 
(23.1%) 
2068 g 
(3.6%) 
8414.5 g 
(14.7%) 
Number of patients (total: 196) 80/196 
(40.8%) 
20/196 
(10.2%) 
33/196 
(16.8%) 
4/196  
(2%) 
59/196 
(30.1%) 
 
 
Supplementary Table 3. Role for IVIG in the clinical indications of our cohort according to the National 
Blood Authority Australia, Criteria for the clinical use of intravenous immunoglobulin in Australia, 2nd 
edition July 2012. http://www.blood.gov.au/ivig-criteria. Only for a minority of the diagnoses present in 
our cohort IVIG has an established (n=4 diagnoses, n=80 patients, total 25644.5 g administered in our 
cohort) or emerging (n=3 diagnoses, n=20 patients, total 7894 g administered in our cohort) therapeutic 
role according to the NBA recommendations, whereas for the remaining diagnoses the use of IVIG was 
recommended in exceptional circumstances only (n=6 diagnoses, n=33 patients, total 13200 g 
administered in our cohort), not supported (n=3 diagnoses, n=4 patients, total 2068 g administered in 
our cohort) or not listed in the NBA criteria (n=10 diagnoses, n=59 patients, total 8414.5 g administered 
in our cohort). 49% (96/196) of the patients in our cohort received IVIG for indications that are not 
listed in the NBA Criteria, or for which the use of IVIG is not supported or is recommended in 
exceptional circumstances only. Legend: CNS: central nervous system; IVIG: intravenous 
immunoglobulin; neuropsych.: neuropsychiatric; NMDAR: N-methyl-D-aspartate receptor; PNS: 
peripheral nervous system; ROHHAD: rapid-onset obesity with hypothalamic dysfunction, 
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hypoventilation, and autonomic dysregulation; VGKC: voltage-gated potassium channel; *Limbic 
encephalitis, non-paraneoplastic. 
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Supplementary information: Patients with undiagnosed complex autoimmune disorders 
 
The three cases included in the group “undiagnosed complex autoimmune disorders” were patients with 
a complex history not fitting a known pattern. In these children, alternative diagnoses had been 
excluded, and clues to an autoimmune etiology were represented by a combination of factors including 
the family history of autoimmunity, the presence of other known autoimmune diagnoses in the patient, 
the exacerbation of symptoms with infection, and the inflammatory CSF findings in one patient, and by 
the history and the positive response to IVIG in the two other patients.  
Of the three patients in the category “undiagnosed complex autoimmune disorder”, the first was a boy 
with type 1 diabetes, idiopathic thrombocytopenia and neutropenia, obstructive sleep apnoea, recurrent 
tonsillitis, recurrent paroxysmal episodes of neurological disturbance (mostly characterised by visual 
disturbances), and tics exacerbated by infections. He had normal brain MRI and EEG, and evidence of 
chronic inflammation in the CSF (persistent finding of pleocytosis and raised neopterin and ESR). The 
patient’s mother had possible Hashimoto's disease. 
The two other patients were two challenging twin boys with a very similar acute onset then progressive 
history of stereotypic hand movements, posturing, repetitive ritualistic behaviour associated with 
anxiety, obsessive-compulsive behaviours, social anxiety and withdrawal, bursts of anger and rage, 
progressive decline in functioning (soiling, inability to write, decline in ability to perform mathematical 
calculations, on a background of previously good academic ability). The boys had raised anti-DNAse 
and anti-streptolysin titres, normal CSF and EEG, and brain MRI demonstrating minor cerebellar 
atrophy, minor thinning of the corpus callosum and minor widening of the posterior horn of the lateral 
ventricles. A diagnosis of PANDAS had been considered, even though their clinical course was not 
completely typical. Given the reported mild improvement in symptoms after commencement of 
antibiotics, a trial with IVIG was done, which associated with sustained improvement based on the 
family's observations and clinical examination (decrease in anxiety and obsessive compulsive type 
behaviours, decreased defiance, decreased anger and rage, improved sleep, toileting and participation in 
family life, increased participation in clinical examination as opposed to a firm refuse and withdrawal 
before treatment, better performance in simple arithmetic). The cases had features reminiscent of 
PANDAS but were atypical, and therefore put in this ‘undiagnosed category’. 
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3.3.3 Therapeutic plasma exchange in paediatric anti-NMDAR encephalitis 
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Abstract
Objective: To clarify the most frequent modalities of use of plasma exchange (PE) in pediatric anti-N-methyl-D-aspartate
receptor (anti-NMDAR) encephalitis and to establish the most eﬀective association with other immunotherapies.
Methods: Systematic literature review on PE in pediatric anti-NMDAR encephalitis (2007–2015).
Results: Seventy-one articles were included (mostly retrospective), reporting a total of 242 subjects (73.2%, 93/127 females; med-
ian age at onset 12 years, range 1–18). Median time to immunotherapy was 21 days (range 0–190). In most cases, PE was given with
steroids and IVIG (69.5%, 89/128), or steroids only (18%, 23/128); in a minority, it was associated with IVIG only (7%, 9/128), or
was the only ﬁrst-line treatment (5.5%, 7/128). In 54.5% (65/119), PE was the third treatment after steroids and IVIG, in 31.1%
(37/119) the second after steroids or IVIG; only in 14.3% (17/119) was it the ﬁrst treatment. Second-line immunotherapies were
administered in 71.9% (100/139). Higher rates of full/substantial recovery at follow-up were observed with immunotherapy given
630 days from onset (69.4%, 25/36) compared to later (59.2%, 16/27), and when PE was associated with steroids (66.7%,
70/105) rather than not (46.7%, 7/15). Signiﬁcant adverse reactions to PE were reported in 6 patients.
Conclusion: Our review disclosed a paucity of quality data on PE in pediatric anti-NMDAR encephalitis. PE use in this condition
has been increasingly reported, most often with steroids and IVIG. Despite the limited number of patients, our data seem to conﬁrm
the trend towards a better outcome when PE was administered early, and when given with steroids.
 2016 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Since its description in 2007, anti-N-methyl-D-
aspartate receptor (anti-NMDAR) encephalitis has been
increasingly recognized also in pediatric age, even in the
absence of tumor. Although treatment strategies have
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been suggested in adults [1], to date there is no estab-
lished treatment algorithm in children.
A direct pathogenic role of antibodies against
the GluN1 subunit of the NMDAR has been demon-
strated in anti-NMDAR encephalitis, resulting in
immunoglobulin-induced NMDAR internalization
[2,3], and supporting the rationale of antibody removal
for the treatment of the disease.
Therapeutic plasma exchange (PE) is an established
intervention as a ﬁrst-line, often life-saving treatment
in several conditions [4]. In view of its potential for
removal of the pathogenic antibodies, PE is one of the
immune therapies so far commonly used in pediatric
anti-NMDAR encephalitis. Though, the extent of PE
use, timing, and therapeutic protocols in pediatric
anti-NMDAR encephalitis vary greatly in the literature.
The use of PE in children partly relies on the expertise of
the individual centers [1].
We searched the literature for children with
anti-NMDAR encephalitis treated with PE, in order to
clarify the most frequent modalities of use of PE in this
disease and to investigate the most eﬀective protocols,
especially as regards the association with other immune
therapies and the relative timing. In particular, we stud-
ied the relationship between outcome at last follow-up
and overall ﬁrst-line immune therapy strategy, use of
second-line immune therapy, and timing of initiation
of the ﬁrst immune therapy, regardless of the type.
2. Materials and methods
2.1. Systematic review criteria
We performed an extensive search of the literature for
children with anti-NMDAR encephalitis treated with
PE. The literature search was conducted through MED-
LINE, updated to December 2015, using the search
terms ‘‘NMDAR”, ‘‘Anti-N-methyl-D-Aspartate
Receptor Encephalitis”, ‘‘N-methyl-D-Aspartate
receptor”, ‘‘anti-NMDAR encephalitis” and ‘‘NMDA
receptor encephalitis”. No randomized controlled trials
are available on the use of PE for anti–NMDAR
encephalitis. Given the retrospective nature of published
data, and the variable reporting in the publications, the
data regarding treatment and timing was not always
available. Therefore, the number of reported patients
with available data is provided in brackets for each
criteria. When the same patients reported in diﬀerent
articles were clearly identiﬁable, we counted them only
once to avoid duplication.
2.2. Inclusion and exclusion criteria
We included in the present study published pediatric
patients (age 618 years) with anti-NMDAR encephalitis
treated with PE. Exclusion criteria were lack of
treatment with PE, negative search for anti-NMDAR
antibodies, or age >18 years.
2.3. Demographics and clinical data
Wesearched in the literature cohort a comprehensive set
of data, including gender, age at onset, presence of tumor
and symptoms of anti-NMDAR encephalitis. Based on
the pertinent literature, we categorized symptoms in: pro-
dromal ﬂu-like symptoms; behavioral/psychiatric symp-
toms; movement disorder; speech disturbances/aphasia;
psychomotor agitation; paroxysmal spells/epileptic sei-
zures; consciousness disturbances/unresponsiveness/bed
ridden/catatonia; autonomic instability.
2.4. Immune therapy
First-line immune therapy was deﬁned as steroids,
intravenous immunoglobulin (IVIG) and/or PE;
second-line immune therapy included cyclophos-
phamide, rituximab, mycophenolate mofetil, azathio-
prine, methotrexate or other. Timing of initiation of
immune therapy with respect to disease onset was regis-
tered, when explicitly reported in the original papers or
when it could be inferred with a certain degree of conﬁ-
dence from the available data.
To enable comparison between treatment strategies
involving PE, these were categorized according to the
timing of PE compared to other ﬁrst-line immune ther-
apies (PE as ﬁrst treatment; PE after steroids; PE after
IVIG; PE after steroids and IVIG), and to the overall
ﬁrst-line immune therapy strategy, regardless of the
order (PE + steroids + IVIG; PE + steroids; PE
+ IVIG; PE only). We deﬁned the time point for ‘‘early”
immune therapy as 30 days, in order to split the liter-
ature cohort in two similar sized subgroups – similar
time thresholds have been used in other previous studies
of autoimmune encephalitis [5–7].
2.5. Outcome
Based on the explicit comments of the authors, or to
the best of our interpretation of the case description, clin-
ical response to treatment in three major categories was
performed by MN: full/substantial recovery (modiﬁed
Rankin Scale (mRS) 0–2, asymptomatic or only mild
deﬁcits), similarly to the ‘‘good outcome” category used
in one of the major studies on treatment in this condition
[8]; partial improvement (mRS 3, moderate impair-
ments); and limited/no improvement (mRS 4–6, severe
deﬁcits or death). Outcome was assessed at three diﬀer-
ent time stages: immediately after PE (regardless of the
administration of other therapies), after completion of
all ﬁrst-line treatments, and at last available follow-up.
The clinical outcome was evaluated with respect to
overall ﬁrst-line immune therapy strategy, use of
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second-line immune therapy, and timing of initiation of
immune therapy (any) and of PE.
3. Results
3.1. Literature cohort
The literature search led to the identiﬁcation of 71
articles meeting inclusion criteria, published between
January 2007 and December 2015 (literature search
updated to 31.12.2015), reporting a total of 242 children
treated with PE for anti-NMDAR encephalitis
(‘literature cohort’) [7–77] (Supplementary Table 1).
The number of published patients treated with PE for
anti–NMDAR encephalitis has increased over the years:
18 in the years 2007–2009, 28 in the years 2010–2012,
and 196 in the years 2013–2015.
Most of these articles are case reports describing a
restricted number of patients treated with PE (mean
3.4 patients per article, median 1, range 1–50). In partic-
ular, 45 of the articles describe only 1 case, 20 articles
describe 2–9 cases, and only 6 of the articles are series
reporting more than 10 cases treated with PE. In this lat-
ter group of larger series [7,8,10,41,54,76], the structure
of the article did not allow access to speciﬁc data for
each patient, therefore a considerable amount of infor-
mation could not be retrieved. This also occurred in
some of the papers reporting a smaller number of
patients [20,34,38,72,75]. Therefore, in several cases data
was available only in a limited proportion of the total
cohort, and the number of cases with available data
was speciﬁed in brackets.
3.2. Demographics and clinical features
In the patients with available data, female gender was
prevalent (93/127, 73.2%), and mean age at disease onset
was 10.6 years (median 12, range 1–18; data calculated
in 125/242). All symptom categories were frequently
represented, with the most frequent ones being behav-
ioral or psychiatric disturbances (117/126, 92.8%),
movement disorder (110/120, 91.7%), epileptic or non-
epileptic paroxysm (100/119, 84%) and speech distur-
bances (79/116, 68.1%). Unresponsive phase/catatonia
was reported in 58.8% (70/119), and autonomic instabil-
ity in 50.8% (61/120). Prodromal symptoms were
described in 25.5% (26/102), and 3.7% of patients
(9/242) had a preceding episode of herpes simplex
encephalitis [44,49,53,54,61,62,64]. Tumor was detected
in 21.9% of patients with available data (35/160).
Patients with tumor were older (mean age 14.9 years,
median 16, range 2–18; data available in 19/35 patients
with tumor), than patients without tumor (mean age
9.6 years, median 10, range 1–18; data available in
81/120 patients without tumor), and a higher proportion
of females had tumor than males (17/75, 22.7% vs. 2/31,
6.4%). Further data on the patients included in the
literature cohort are provided in Supplementary Table 1.
3.3. Treatment
Data on treatment in the literature cohort are
detailed in Table 1.
3.4. Time from disease onset to initiation of immune
therapy
In the patients with available data, ﬁrst immune ther-
apy (any) was initiated 630 days from disease onset in
57.1% of the cases (36/63). According to available infor-
mation, mean time to initiation of ﬁrst immune therapy
(any) was 27.5 days (median 21, range 0–190, data
available in 37/242 patients).
3.5. Overall ﬁrst-line immune therapy
According to the inclusion criteria, all patients
received PE. The most common combination of ﬁrst-
line immune therapies (regardless of the order of admin-
istration) was the association of PE with steroids and
IVIG (89/128, 69.5%), followed by the association of
PE with steroids only (23/128, 18%) (Table 1).
3.6. Order of PE compared to other ﬁrst-line immune
therapies and to second-line immune therapy
In 54.6% of cases, PE was performed as third treat-
ment, after steroids and IVIG (65/119), in 31.1% as sec-
ond treatment after steroids (28/119, 23.5%) or after
IVIG (9/119, 7.6%), and in a minority of patients as ﬁrst
treatment (17/119, 14.3%). In the great majority of
cases, PE was done before initiation of any second-line
immune therapies (107/117, 91.4%), but in 10 patients
it was done after rituximab, cyclophosphamide,
mycophenolate mofetil or interferon-b (10/117, 8.5%)
(in 3/10 PE was performed after a subsequent relapse).
3.7. Number of PE exchanges
In the few patients with available data, mean number
of PE exchanges was 7.3 (median 6, range 3–21).
3.8. Second-line immune therapy
The majority of patients received second-line immune
therapy (100/139, 71.9%). In most cases, this consisted
of rituximab (26/82, 31.7%), cyclophosphamide (14/82,
17.1%), or the combination of the two (20/82, 24.4%).
Other medications administered were mycophenolate
mofetil, azathioprine, methotrexate and interferon-b
(Table 1). 41.5% of patients received two or more
second-line immune therapies (34/82).
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3.9. Outcome
With the limitations imposed by the availability of
information and the restricted number of cases, data
on the clinical outcome in the literature cohort are
detailed in Table 2.
3.10. Overall clinical outcome
Full/substantial recovery or partial improvement
immediately after PE compared to pre-PE status was
reported in 63.5% (33/52) of patients. The rate of full/
substantial recovery showed a steady rise along the time
Table 1
Treatment in the literature cohort: time to initiation of immune therapy, ﬁrst-line immune therapy strategy, number of PE sessions, order of PE
compared to other ﬁrst-line immune therapies and to second-line treatments, and second-line immune therapies.
Treatment
Time from disease onset to immune therapy
Initiation of immune therapy (any) before or after 30 days
from onset (data in 63/242)
630 days 36/63 (57.1%)
>30 days 27/63 (42.8%)
Time from disease onset to initiation of ﬁrst immune therapy
(any) (data in 37/242)
Mean 27.5 days (median 21,
range 0–190)
Time from disease onset to initiation of PE (data in 33/242) Mean 46.4 days (median 34,
range 0–200)
First-line immune therapy
Overall ﬁrst-line immune therapy strategy (data in 128/242)
PE + Steroids + IVIG (any order) 89/128 (69.5%)
PE + Steroids (any order) 23/128 (18%)
PE + IVIG (any order) 9/128 (7%)
PE only 7/128 (5.5%)
Data on PE
Number of exchanges (data available in 62/242) Mean 7.3 (median 6, range
3–21)
Order of PE compared to other ﬁrst-line immune therapies
(data in 119/242)
PE as third treatment after Steroids and IVIG 65/119 (54.6%)
PE as second treatment after Steroids or IVIG Steroids: 28/119 (23.5%); IVIG:
9/119 (7.6%)
PE as ﬁrst treatment 17/119 (14.3%)
Order of PE compared to second-line immune therapies
(data in 117/242)
PE before initiation of second-line treatments 107/117 (91.4%)
PE after initiation of second-line treatments 10/117 (8.5%)
Second-line immune therapy
Second-line immune therapy (data in 139/242) 100/139 (71.9%)
P2 second-line immune therapies (data in 82/100) 34/82 (41.5%)
Type of second-line immune therapy (data in 82/100)
Rituximab only 26/82 (31.7%)
Cyclophosphamide + rituximab (any order) 20/82 (24.4%)
Cyclophosphamide only 14/82 (17.1%)
Mycophenolate mofetil only 6/82 (7.3%)
Cyclophosphamide + mycophenolate mofetil
(any order)
3/82 (3.6%)
Cyclophosphamide + rituximab + azathioprine
(any order)
3/82 (3.6%)
Mycophenolate mofetil + rituximab (any order) 3/82 (3.6%)
Azathioprine only 2/82 (2.4%)
Rituximab + methotrexate (any order) 2/82 (2.4%)
Cyclophosphamide + rituximab
+ mycophenolate mofetil (any order)
1/82 (1.2%)
Interferon-b + cyclophosphamide (any order) 1/82 (1.2%)
Rituximab + cyclophosphamide + methotrexate
(any order)
1/82 (1.2%)
IVIG: intravenous immunoglobulin; PE: plasma exchange.
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Table 2
Clinical outcome in the study population at diﬀerent time stages and according to the presence of tumor, ﬁrst-line immune therapy strategy, second-line immune therapy, time of initiation of immune
therapy and of PE.
Clinical outcome Mean (median) length of follow-up (months)
Clinical outcome at different time stages
Full/substantial recovery Partial improvement Limited/no improvement Follow-up
Immediately after PE (data in 52/242) 11/52 (21.1%) 22/52 (42.3%) 19/52 (36.5%)
After ﬁrst-line immune therapy (data in 62/242) 15/62 (24.1%) 29/62 (46.8%) 18/62 (29%)
At last follow-up (data in 120/242) 77/120 (64.2%) 33/120 (27.5%) 10/120 (8.3%)** 18.5 (12) (range 1.7-120, data in 102/120)
Clinical outcome at last follow-up according to the presence of tumor
Full/substantial recovery Partial improvement Limited/no improvement Follow-up
Patients without tumor (data in 87/125) 56/87 (64.4%) 26/87 (29.9%) 5/87 (5.7%) 21 (17) (data in 70/87)
Patients with tumor (data in 19/35) 11/19 (57.9%) 4/19 (21%) 4/19 (21%)* 13.1 (8) (data in 19/19)
Clinical outcome at last follow-up according to overall ﬁrst-line immune therapy strategy
Full/substantial recovery Partial improvement Limited/no improvement Follow-up#
PE + Steroids + IVIG (any order) (data in 82/89) 55/82 (67.1%) 20/82 (24.4%) 7/82 (8.5%)** 19.5 (12) (data in 72/82)
PE + Steroids (any order) (data in 23/23) 15/23 (65.2%) 7/23 (30.4%) 1/23 (4.3%) 16.3 (8) (data in 21/23)
PE + IVIG (any order) (data in 8/9) 4/8 (50%) 3/8 (37.5%) 1/8 (12.5%) 23 (24) (data in 3/8)
PE only (data in 7/7) 3/7 (42.8%) 3/7 (42.8%) 1/7 (14.3%) 12 (9.5) (data in 6/7)
Clinical outcome at last follow-up according to second-line immune therapy
Full/substantial recovery Partial improvement Limited/no improvement Follow-up
First-line only immune therapy (data in 37/39) 24/37 (64.9%) 11/37 (29.7%) 2/37 (5.4%)* 17.2 (9.5) (data in 32/37)
First + second-line immune therapy (data in 83/100) 53/83 (63.8%) 22/83 (26.5%) 8/83 (9.6%)* 19.1 (12) (data in 70/83)
Clinical outcome at last follow-up according to time of initiation of immune therapy
Full/substantial recovery Partial improvement Limited/no improvement Follow-up
First immune therapy 6 30 days (data in 36/36) 25/36 (69.4%) 4/36 (11.1%) 7/36 (19.4%) 12.3 (8) (data in 29/36)
First immune therapy > 30 days (data in 27/27) 16/27 (59.2%) 10/27 (32.2%) 1/27 (3.2%) 14.7 (8.5) (data in 22/27)
Clinical outcome at last follow-up according to time of initiation of PE
Full/substantial recovery Partial improvement Limited/no improvement Follow-up
Initiation of PE 6 30 days (data in 15/15) 12/15 (80%) 1/15 (6.7%) 2/15 (13.3%) 13 (10) (data in 13/15)
Initiation of PE > 30 days (data in 18/18) 11/18 (61.1%) 7/18 (38.9%) 0/18 (0%) 8.9 (6) (data in 17/18)
f-u: follow-up; IVIG: intravenous immunoglobulin; PE: plasma exchange.
* One of these patients had died at last follow-up.
** Two of these patients had died at last follow-up.
# Length of follow-up in the patients who received steroids and PE (with or without IVIG): mean 19.2 months, median 12, range 1.7–120; data in 89/101). Length of follow-up in the patients who
received IVIG and PE or PE only: mean 15.7, median 12, range 5–36; data in 9/15).
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stages, from immediately after PE (11/52, 21.1%) to the
last follow-up (77/120, 64.2%). The overall outcome at
last follow-up was slightly better in the patients without
tumor than in those with tumor, with longer follow-up
in the patients without tumor (Table 2).
3.11. Clinical outcome at last follow-up according to
overall ﬁrst-line immune therapy strategy
A trend towards a higher rate of full/substantial
recovery at follow-up was observed with ﬁrst-line
immune therapy strategy (regardless of the order of
administration) consisting of PE, steroids and IVIG
(55/82, 67.1%), or PE and steroids (15/23, 65.2%), com-
pared to PE and IVIG (4/8, 50%) or PE alone (3/7,
42.8%) (similar median length of follow-up) (Table 2).
3.12. Clinical outcome at last follow-up according to
second-line immune therapy
Patients who received second-line immune therapies
had similar rates of full/substantial recovery to patients
treated with ﬁrst-line immune therapy only (53/83,
63.8%, vs. 24/37, 64.9%), with similar length of
follow-up (Table 2).
3.13. Clinical outcome at last follow-up according to time
of initiation of ﬁrst-line immune therapy (any) and of PE
A higher rate of full/substantial recovery at last
follow-up occurred in patients in whom immune therapy
was started within a month from disease onset (25/36,
69.4%) as opposed to patients in whom it was started
later (16/27, 59.2%) (Table 2) (with similar length of
follow-up). Similar trends were observed as regards the
timing of initiation of PE (12/15, 80%, vs. 11/18,
61.1%, respectively) (length of follow-up slightly longer
in the group who received PE early).
3.14. Adverse reactions to PE
Signiﬁcant side eﬀects to PE were described only in 6
cases, and consisted of transient hypotensive episodes
responding to either a ﬂuid bolus or a vasopressor treat-
ment in 2 patients [22], anaphylactic reaction in 1 patient
[51], worsening of autonomic instability resulting in
hypotensive shock in 1 patient [67], and pulmonary
artery thromboembolism in 1 patient [65] (in 1 case,
PE had to be stopped due to nontolerance, but the type
of reaction was not described [53]).
4. Discussion
In the absence of deﬁnite guidelines on the treatment
of pediatric anti-NMDAR encephalitis, we conducted a
literature review with the aim of clarifying the most
frequent modalities of use of PE in this condition and
the most eﬀective protocols as regards the association
with other immune therapies and the relative timing.
Our results show that schemes of utilization of PE are
greatly heterogeneous in the literature; though, we
observed that in the majority of cases PE is used after
steroids and IVIG. In the cases with available informa-
tion, our data seem to suggest a better outcome at
follow-up in patients in whom ﬁrst-line immune therapy
consisted of the association of PE with steroids (with or
without IVIG), as opposed to other treatment strategies
without steroids, possibly supporting a role of the com-
bination of immune therapies with peripheral and cen-
tral action. The potential role for antibody removal
via PE in anti-NMDAR encephalitis is supported by
the direct pathogenic role of anti-NMDAR antibodies
[2,3]. Though, since the production of antibodies occurs
intrathecally in this disease [78], the removal of antibod-
ies from the peripheral circulation via PE, while altering
peripheral immunology and possibly reducing to a cer-
tain extent the traffic of antibody and lymphocytes into
the central nervous system, should also be associated
with other therapies that modify the intrathecal immune
disease, such as steroids. However, in the subgroup of
patients who received PE and steroids, the possibility
that better outcome primarily due to steroids (rather
than PE) cannot be excluded.
Of primary importance in clinical practice, our results
also seem to point to the role of early initiation of
immune therapy in favoring a better outcome. Data in
the literature on this and other autoimmune encephalitis
are consistent with these observations [5,7,8,22,72,78–
80]. The possibility of a better outcome with early
immune therapy should encourage a high level of suspi-
cion towards this condition, whose prompt recognition
may be challenging in view of its rarity and of its some-
times subtle and variegated initial features, in order to
promote early diagnosis and initiation of therapy.
Previous data in the literature support the role of
second-line immune therapy in terms of improvement
of the neurological outcome and of reduction of subse-
quent relapses [8,80], even though in our review the out-
come was similar in patients who received second-line
treatments or not. This may be possibly ascribed to a
severity bias, with predominant use of second-line
immune therapies in more severe patients.
PE was administered after second-line immune ther-
apy only in a small proportion of the cases included in
our literature review, sometimes to treat a relapse, or
as a last resource in severe cases not responding to other
treatments. This may at least partly reﬂect the lack of
available evidence on PE efficacy and safety and
the absence of deﬁnite guidelines in pediatric
anti-NMDAR encephalitis.
Reﬂecting the complexity of the general picture and
the natural history of anti-NMDAR encephalitis, it
618 A. Suppiej et al. / Brain & Development 38 (2016) 613–622
should be noted that this condition may have diﬀerent
degrees of clinical severity, and a spontaneous gradual
and slow recovery may occur in the course of several
months [8]. In our study, the rate of full recovery was
remarkably higher at last follow-up as opposed to the
previous stages of disease (after PE and after ﬁrst-line
therapy), possibly reﬂecting these observations and the
crucial role of time in the recovery from this condition.
Overall, a considerable number of published patients
treated with PE were identiﬁed, mostly derived from
case reports, small case series and only few larger series.
We observed that the number of published pediatric
cases of anti-NMDAR encephalitis treated with PE
has been rising steadily; though, the proportion of use
of PE compared to other immune interventions cannot
be estimated in the present work.
Despite the general characteristics of the literature
cohort studied are in overall agreement with the perti-
nent pediatric literature, a relatively high rate of tumor
was reported in this cohort, similar to that reported in
adult cases [8,10,34]. A reporting bias in the original
reports may at least partly explain this observation, with
data on the presence of tumor explicitly reported more
frequently than its absence. Similarly to what observed
by other authors, patients with tumor were older than
those without, and had a higher proportion of females.
In the patients without tumor, the overall outcome at last
follow-up was slightly better than the oncologic cases, in
contrast with the literature stating that tumor patients
generally do better [21,81]; whether this may be ascribed
to the use of PE is not clear, since our study did not
include literature on patients not treated with PE.
The main limitation of the present study is the
restricted number of patients, largely dependent on the
relative rarity of this condition in children and the avail-
ability of information as reported in the original articles.
In relation to this, certain aspects relative to the treat-
ment with PE, such as side eﬀects, were subject to
reporting bias and were likely under-reported, and could
not be fully evaluated. As pointed out by other authors,
PE in children presents unique challenges and higher
complication rates compared to adults, especially in
patients who are poorly cooperative or have autonomic
instability, and should therefore be performed in special-
ized centers [1,64,66,82]. On the other hand, research on
PE use in other conditions suggests a relatively safe pro-
ﬁle also in the pediatric age [83,84]. Further studies
speciﬁcally investigating PE safety in children with
anti-NMDAR encephalitis are warranted.
The outcome in our study was evaluated retrospec-
tively by one of the authors, representing a methodolog-
ical limitation to our work – multiple raters would have
strengthened the data. In a recent pediatric case series
from the United Kingdom [75], 89% (8/9) patients
who received PE during their initial treatment made a
full eventual recovery compared with 47% receiving
IVIG and steroids. Similarly, compelling preliminary
data from another recent retrospective review compar-
ing intravenous methylprednisolone and PE suggested
that corticosteroids may not be as eﬀective compared
to steroids followed by PE [85]. Despite these recent
papers, data speciﬁcally comparing the outcome in sub-
groups of patients receiving PE are generally lacking in
the literature and would be of high clinical importance –
this aspect could not be addressed in our study due to
the selection criteria including only patients who
received PE, and represents one of the main limitations
of our work.
Despite the fact that we tried to avoid duplication
when the same patient reported in diﬀerent articles
was clearly identiﬁable, we cannot exclude the possibil-
ity that duplication of cases may have inadvertently
occurred in a few instances, though possibly in a limited
number of cases.
In conclusion, treatment with PE has been reported
in increasing numbers recently in pediatric anti-
NMDAR encephalitis; though, its extent of utilization,
timing, and therapeutic protocols vary greatly. Stronger
scientiﬁc evidence on the added clinical value of PE is
warranted. Our literature review, conducted only on
patients receiving PE, suggests improved efficacy of PE
when used with steroids, and conﬁrms other data in
the literature reporting a positive role of early com-
mencement of immune therapy in autoimmune
encephalitis.
Appendix A. Supplementary data
Supplementary data associated with this article can
be found, in the online version, at http://dx.doi.org/10.
1016/j.braindev.2016.01.009.
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Authors, year 
[reference] 
(nº of reported 
children with anti-
NMDAR encephalitis 
treated with PE) 
Sex 
Age 
(years) 
Prodromal 
cold or 
viral-like 
symptoms 
Behaviour 
/ 
Psychiatri
c disorder  
Movement 
disorder 
Speech 
problems 
Epileptic 
seizures / 
Paroxysm
al episodes 
Unrespon-
sive phase 
/ 
Catatonia 
Autonomic 
instability 
Tumour 
(type if 
availa-
ble) 
Anti-NMDAR 
antibodies 
Dalmau et al, 2007 
[9] (2 cases) 
F 17 Yes Yes Yes Yes Yes Yes Yes 
Yes  
(OT) 
Positive in serum 
and CSF 
F 14 Yes Yes Yes Yes Yes Yes Yes 
Yes  
(OT) 
Positive in serum 
and CSF 
Seki et al, 2008 [10] 
(1 case) 
F 18 Yes Yes Yes Yes Yes Yes Yes 
Yes  
(OT) 
Positive in serum 
and CSF 
Florance et al, 2009 
[11] (14 cases) 
NR NR NR NR NR NR NR NR NR NR 
Positive in CSF 
and/or serum* 
Schimmel et al, 2008 
[12] (1 case) 
F 12 Yes Yes Yes Yes Yes Yes Yes No 
Positive in serum 
and CSF 
Agrawal et al, 2010 
[13] (1 case) 
F 1.8 No Yes Yes Yes Yes Yes Yes No NR 
Kruer et al, 2010 [14] 
(1 case) 
F 15 Yes Yes Yes Yes Yes Yes Yes No 
Positive in CSF, 
negative in serum 
Schmiedeskamp et al, 
2010 [15] (1 case) 
F 17 No Yes Yes Yes Yes No Yes No 
Positive in serum 
and CSF 
Sonn et al, 2010 [16] 
(1 case) 
F 14 Yes Yes Yes Yes Yes Yes Yes 
Yes  
(OT) 
Positive CSF 
(serum NR) 
Consoli et al, 2011 
[17] (1 case) 
F 17 No Yes Yes Yes Yes Yes Yes No 
Positive in serum 
and CSF 
Gataullina et al, 2011 
[18] (1 case) 
M 8 Yes Yes Yes Yes Yes Yes Yes No 
Positive in serum 
and CSF 
Greiner et al, 2011 
[19] (1 case) 
F 11 Yes Yes Yes Yes Yes Yes Yes 
Yes  
(OT) 
Positive in CSF, 
negative in serum 
Hollódy et al, 2011 
[20] (1 case) 
F 15 NR NR NR NR NR NR NR No NR 
Mirza et al, 2011 [21] 
(1 case) 
F 14 No Yes Yes Yes Yes Yes Yes No 
Positive in CSF, 
negative in serum 
Pham et al, 2011 [22] 
(3 cases) 
F 18 Yes Yes NR NR NR Yes NR 
Yes  
(OT) 
Positive  in serum 
(CSF NR) 
F 17 No Yes NR NR Yes NR NR 
Yes  
(OT) 
Positive in serum 
(CSF NR) 
M 3 No NR NR NR NR NR NR No 
Positive in serum 
(CSF NR) 
Taguchi et al, 2011 
[23] (1 case) 
F 17 NR Yes NR NR NR NR NR 
Yes  
(OT) 
Positive in serum 
and CSF 
Tamma et al, 2011 
[24] (1 case) 
M 7 No Yes Yes Yes Yes Yes Yes No 
Positive in serum 
and CSF 
Sameshima et al, 
2011 [25] (1 case) 
F 17 Yes Yes No No No Yes No 
Yes  
(OT) 
Positive in  serum 
(CSF NR) 
Bseikri et al, 2012 
[26] (2 cases) 
F 15 Yes Yes Yes NR Yes Yes Yes 
Yes  
(OT) 
Positive  in CSF 
(serum NR) 
F 9 No Yes Yes Yes Yes No No No 
Positive  in CSF 
(serum NR) 
Frawley et al, 2012 
[27] (1 case) 
F 11 Yes Yes Yes Yes Yes Yes No 
Yes  
(OT) 
Positive in CSF, 
negative in serum 
Houtrow et al, 2012 
[28] (4 cases) 
F 2 No Yes Yes Yes Yes Yes No No 
Positive in serum 
or CSF* 
M 9 No Yes Yes Yes No Yes Yes No 
Positive in serum 
or CSF* 
F 9 No Yes Yes Yes Yes No No No 
Positive in serum 
or CSF* 
F 15 No Yes No Yes Yes Yes No 
Yes  
(OT) 
Positive in serum 
or CSF* 
Kashyape et al, 2012 
[29] (2 cases) 
F 2.3 No Yes Yes Yes Yes Yes Yes No 
Positive in  serum 
(CSF NR) 
F 14 No Yes Yes Yes Yes Yes Yes No 
Positive in  serum 
(CSF NR) 
Kataoka et al, 2012 
[30] (1 case) 
F 17 NR Yes Yes NR Yes NR Yes 
Yes  
(OT) 
Positive in CSF 
(serum NR) 
Mann et al, 2012 [31] 
(1 case) 
F 14 Yes Yes Yes Yes Yes Yes Yes No 
Positive  in CSF 
(serum NR) 
Nunez-Enamorado et 
al, 2012 [32] (1 case) 
M 2.5 NR Yes Yes Yes Yes NR Yes No 
Positive in serum 
or CSF* 
Slettedal et al, 2012 
[33] (1 case) 
F 
School 
age 
No Yes Yes Yes Yes Yes Yes No 
Positive in CSF 
and  serum 
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Armangue et al, 2013 
[34] (3 cases) 
NR < 12 NR NR NR NR NR NR NR No 
Positive in CSF 
(serum NR) 
NR 12-18 NR NR NR NR NR NR NR No 
Positive in CSF 
(serum NR) 
NR 12-18 NR NR NR NR NR NR NR No 
Positive in CSF 
(serum NR) 
Baizabal-Carvallo et 
al, 2013 [35] (3 
cases) 
F 13 No Yes Yes No Yes No Yes No 
Positive in serum 
and/or CSF* 
M 8 No Yes Yes Yes Yes Yes No No 
Positive in serum 
and/or CSF* 
F 8 No Yes Yes Yes Yes Yes Yes No 
Positive in CSF 
(serum NR) 
Finné Lenoir et al, 
2013 [36] (1 case) 
M 17 Yes Yes Yes Yes Yes Yes Yes No 
Positive in serum 
and CSF 
Kayser et al, 2013 
[37] (3 cases) 
F 12 NR Yes NR NR NR NR NR No 
Positive in CSF, 
negative in serum 
F 13 NR Yes NR NR NR NR NR No 
Positive in CSF 
and serum 
F 17 NR Yes NR NR NR NR NR No 
Positive in CSF 
and serum 
Pérez et al, 2013 [38] 
(2 cases) 
NR NR NR NR NR NR NR NR NR NR NR 
NR NR NR NR NR NR NR NR NR NR NR 
Titulaer et al, 201 [8]  
(50 cases) 
NR NR NR NR NR NR NR NR NR 
34/50:  
No 
16/50: 
Yes 
NR 
van de Riet et al, 
2013 [39] (1 case) 
F 17 Yes Yes Yes Yes Yes Yes Yes No 
Positive in serum 
and CSF 
Verfaillie et al, 
2013 [40] (1 case) 
NR 18 NR Yes Yes NR NR Yes Yes No 
Positive in serum 
or CSF* 
Adang et al, 2014 
[41] (20 cases) 
NR NR NR NR NR NR NR NR NR NR NR 
Appu et  al, 2014 [42] 
(1 case) 
F 16 Yes Yes Yes NR NR Yes Yes 
Yes  
(OT) 
Positive in CSF 
(serum NR) 
Barros et al, 2014 
[43] (1 case) 
M 7 Yes Yes Yes Yes Yes No  No No 
Positive in serum 
and CSF 
Bektaş et al, 2014 
[44] (1 case) 
F^ 1.7 No Yes Yes No No No No No 
Positive in serum 
and CSF 
Ben Azoun et al, 
2014 [45] (1 case) 
F 12 Yes Yes Yes Yes Yes Yes No No 
Positive in serum 
and CSF 
Byrne et al, 2014 [46] 
(1 case) 
F 11 Yes Yes Yes Yes Yes No Yes No 
Positive in serum 
and CSF 
Chakrabarty et al, 
2014 [47] (3 cases) 
F 10 NR No Yes Yes Yes No Yes No 
Positive in serum 
and CSF 
F 10 NR No Yes No Yes No No No 
Positive in serum 
and CSF 
F 5 NR Yes Yes Yes Yes No No No 
Positive in serum 
and CSF 
Cohen et al, 2014 
[48] (1 case) 
M 2 No Yes Yes Yes Yes No Yes No 
Positive in CSF 
(serum NR) 
Dale et al, 2014 [7] 
(11 cases) 
NR NR NR NR NR NR NR NR NR NR NR 
Desena et al, 2014 
[49] (1 case) 
M^ Infant No No Yes Yes Yes Yes No No 
Positive in CSF 
(serum NR) 
DeSena et al, 2014 
[50] (7 cases) 
M 11 No Yes Yes Yes Yes Yes No No 
Positive in CSF 
(serum NR) 
M 4 No Yes Yes Yes Yes No No No 
Positive  in serum 
(CSF NR) 
M 17 No Yes No No Yes No No No 
Positive in CSF, 
negative in serum 
F 4 No Yes Yes No Yes No No No 
Positive in serum 
(CSF NR) 
F 2 No Yes Yes Yes No No No No 
Positive in serum 
(CSF NR) 
M 2 No Yes Yes Yes Yes Yes Yes 
Yes 
(testicul
ar 
tumor, 
detecte
d after 
4 years) 
Positive in serum 
(CSF NR) 
F 5 No No Yes Yes Yes Yes No No 
Positive in serum 
and CSF 
Guo et al, 2014 [51] 
(1 case) 
F 3.1 NR Yes Yes Yes No Yes Yes No 
Positive in CSF 
(serum NR) 
Hayashi et al, 2014 
[52] (1 case) 
F 18 Yes Yes Yes Yes No Yes Yes Yes 
Positive in serum 
and CSF 
Hacohen et al, 2014 
[53] (1 case) 
F^ 3.1 No Yes Yes No Yes Yes No No 
Positive in serum 
(CSF NR) 
Hacohen et al, 2014 
[54] (14 cases) 
M 18 No Yes Yes No No Yes Yes No 
Positive in serum 
(CSF NR) 
M 5 No No No No No Yes No No 
Positive in CSF 
(serum NR) 
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F^ 16 No No Yes No No Yes No No 
Positive  in CSF 
and serum 
F 14 No Yes No Yes No No No 
Yes 
(OT) 
Positive in serum 
(CSF NR) 
F 2 No No Yes Yes Yes No No No 
Positive in serum 
(CSF NR) 
M 16 No Yes No Yes Yes No Yes No 
Positive in serum 
(CSF NR) 
F 17 No Yes Yes No No No Yes No 
Positive in serum 
and CSF 
F 16 No No No Yes Yes No No No 
Positive in serum 
(CSF NR) 
M 4 No Yes Yes Yes Yes No Yes No 
Positive in serum 
(CSF NR) 
F 13 No Yes Yes Yes Yes No Yes No 
Positive in serum 
(CSF NR) 
F 11 No Yes Yes No Yes No Yes No 
Positive in serum 
and CSF 
M 13 No Yes Yes No Yes No No No 
Positive in serum 
and CSF 
F 14 No Yes Yes Yes Yes No Yes No 
Positive in serum 
and CSF 
F 16 No Yes Yes Yes Yes No No No 
Positive in serum 
and CSF 
Le Moigno et al, 
2014 [55] (1 case) 
F 6 No Yes Yes Yes Yes Yes No No 
Positive in CSF 
(serum NR) 
Salvucci et al, 2014 
[56] (1 case) 
F 7 Yes Yes Yes Yes Yes Yes No No 
Positive  in CSF 
and serum 
Sommeling et al, 
2014 [57] (1 case) 
M 16 No Yes Yes Yes Yes Yes Yes 
Yes 
(mature 
terato-
ma) 
Positive in serum 
and CSF 
Titulaer et al, 2014 
[58] (2 cases) 
F 8 No Yes Yes Yes Yes Yes Yes NR 
Positive in serum 
and CSF 
F 18 Yes Yes Yes Yes Yes No No NR 
Positive in serum 
and CSF 
Venancio et al, 2014 
[59] (1 case) 
M 9 Yes Yes Yes Yes No Yes Yes No 
Positive in CSF 
(serum NR) 
Almuslamani et al, 
2015 [60] (1 case) 
F 13 No Yes Yes Yes Yes Yes Yes No 
Positive in CSF, 
negative in serum 
Armangue et al, 2015 
[61] (3 cases) 
M^ 1 No Yes Yes No Yes Yes No No 
Positive in CSF, 
negative in serum 
M^ 1.3 No Yes Yes No Yes Yes No No 
Positive in serum 
and CSF 
F^ 1.8 No Yes Yes No Yes Yes No No 
Positive in serum 
and CSF 
Bamford et al, 2015 
[62] (1 case) 
F^ 1.3 NR No Yes Yes Yes Yes Yes No 
Positive in serum 
and CSF 
Cleland et al, 2015 
[63] (1 case) 
F 16 No Yes Yes Yes Yes No No No 
Positive in CSF, 
negative in serum 
Ellul et al, 2015 [64] 
(1 case) 
M^ 3 Yes Yes Yes Yes No Yes Yes No 
Positive in serum 
and CSF 
Kramina et al, 2015 
[65] (1 case) 
F 15 No Yes Yes Yes No Yes Yes No 
Positive in serum 
and CSF 
Lagarde et al, 2015 
[66] (6 cases) 
F 10 NR Yes Yes Yes Yes No No No 
Positive in serum 
and CSF# 
F 17 NR Yes Yes Yes Yes Yes Yes No 
Positive in serum 
and CSF# 
F 14 NR Yes Yes Yes Yes Yes No No 
Positive in serum 
and CSF# 
M 3 NR Yes Yes Yes Yes Yes No No 
Positive in serum 
and CSF# 
F 11 NR Yes Yes Yes Yes Yes No No 
Positive in serum 
and CSF# 
M 5 NR Yes Yes Yes Yes Yes No No 
Positive in serum 
and CSF# 
Miyauchi et al, 2015 
[67] (1 case) 
M 11 Yes Yes Yes Yes Yes Yes Yes No 
Positive in serum 
and CSF 
Mohammad et al, 
2015 [68] (7 cases) 
F 14 NR Yes Yes No Yes No No NR 
Positive in serum 
or CSF* 
F 14 NR Yes Yes No Yes No No NR 
Positive in serum 
or CSF* 
F 5.1 NR Yes Yes No Yes No No NR 
Positive in serum 
or CSF* 
M 2.2 NR Yes Yes No Yes No No NR 
Positive in serum 
or CSF* 
F 16 NR Yes Yes No Yes No No NR 
Positive in serum 
or CSF* 
M 1.8 NR Yes Yes No Yes No No NR 
Positive in serum 
or CSF* 
M 15 NR Yes Yes No Yes No No NR 
Positive in serum 
or CSF* 
Nosadini et al, 2015 F 9 Yes Yes Yes Yes Yes Yes Yes No Positive in CSF 
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[69] (4 cases) (serum NR) 
M 12 No Yes Yes Yes Yes Yes Yes No 
Positive in CSF 
(serum NR) 
F 8 No Yes Yes Yes No Yes Yes No 
Positive in CSF 
(serum NR) 
M 6 No Yes Yes Yes No Yes Yes No 
Positive in CSF 
(serum NR) 
Reilly-Shapiro et al, 
2015 [70] (1 case) 
F 18 No Yes Yes Yes Yes Yes Yes No 
Positive in CSF 
(serum NR) 
Sands et al, 2015 [71] 
(3 cases) 
F 2 No Yes Yes No Yes No No NR 
Positive in CSF 
(serum NR) 
F 14 No Yes No No Yes No Yes NR 
Positive in CSF 
(serum NR) 
F 14 No Yes Yes No No No No NR 
Positive in CSF 
(serum NR) 
Sartori et al, 2015 
[72] (3 cases) 
M 3.8 Yes Yes Yes Yes Yes Yes Yes No 
Positive in serum 
and CSF 
F 4.3 No Yes Yes Yes Yes Yes Yes No 
Positive in serum 
and CSF 
F 12 No Yes Yes Yes Yes Yes Yes No 
Positive in serum 
(CSF NR) 
Sharko et al, 2015 
[73] (1 case) 
F 13 No Yes Yes Yes Yes Yes Yes No 
Positive in CSF 
(serum NR) 
Tatencloux et al, 
2015 [74] (3 cases) 
M 10 No Yes Yes Yes Yes Yes No No 
Positive in serum 
and CSF 
F 11 No Yes Yes No Yes No No No 
Positive in serum 
and CSF 
F 14 No Yes Yes Yes Yes Yes Yes No 
Positive in serum 
and CSF 
Wright et al, 2015 
[75] (9 cases) 
F n.a. No Yes Yes No Yes No No NR 
Positive in serum 
and/or CSF* 
F 14 No Yes Yes No Yes No No NR 
Positive in serum 
and/or CSF* 
F 14 No Yes Yes No Yes No No NR 
Positive in serum 
and/or CSF* 
F 2 No Yes Yes No Yes No No NR 
Positive in serum 
and/or CSF* 
F 14 No Yes Yes No Yes No No NR 
Positive in serum 
and/or CSF* 
F 3 No Yes Yes No Yes No No NR 
Positive in serum 
and/or CSF* 
F 2 No Yes Yes No No No No NR 
Positive in serum 
and/or CSF* 
F 17 No Yes No No Yes No No NR 
Positive in serum 
and/or CSF* 
F 15 No Yes No No No No No NR 
Positive in serum 
and/or CSF* 
Zekeridou et al, 2015 
[76] (14 cases) 
NR NR NR NR NR NR NR NR NR NR NR 
Zubkov et al, 2015 
[77] (1 case) 
F 17 NR Yes Yes No Yes Yes Yes 
Yes 
(OT) 
Positive in CSF 
(serum NR) 
 
 
 
Supplementary Table 1. Articles included in our literature review and relative reported pediatric patients 
treated with PE for anti-NMDAR encephalitis. Demographic and clinical features of the patients and 
data on anti-NMDAR antibodies are reported too. For the case series with >10 patients and in which 
most of the information was not available, we reported all the cases in a single row [7,8,11,41,73]. See 
main text for list of References. 
Legend: anti-NMDAR: anti-N-methyl-D-aspartate receptor; CSF: cerebrospinal fluid; NR: not reportde 
(data not available); OT: ovarian teratoma; PE: plasma exchange; 
*Not specified 
#All patients showed anti-NMDAR antibody positivity at low titre in serum and with relatively higher 
titre in CSF, suggesting an intrathecal synthesis of anti-NMDAR antibodies 
^Preceding episode of herpes simplex virus encephalitis 
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Rituximab monitoring and redosing in
pediatric neuromyelitis optica spectrum
disorder
ABSTRACT
Objective: To study rituximab in pediatric neuromyelitis optica (NMO)/NMO spectrum disorders
(NMOSD) and the relationship between rituximab, B cell repopulation, and relapses in order to
improve rituximab monitoring and redosing.
Methods: Multicenter retrospective study of 16 children with NMO/NMOSD receiving$2 rituximab
courses. According to CD19 counts, events during rituximab were categorized as “repopulation,”
“depletion,” or “depletion failure” relapses (repopulation threshold CD19 $10 3 106 cells/L).
Results: The 16 patients (14 girls; mean age 9.6 years, range 1.8–15.3) had a mean of 6.1 events
(range 1–11) during a mean follow-up of 6.1 years (range 1.6–13.6) and received a total of 76
rituximab courses (mean 4.7, range 2–9) in 42.6-year cohort treatment. Before rituximab, 62.5%
had received azathioprine, mycophenolate mofetil, or cyclophosphamide. Mean time from rituximab
to last documented B cell depletion and first repopulation was 4.5 and 6.8 months, respectively,
with large interpatient variability. Earliest repopulations occurred with the lowest doses. Significant
reduction between pre- and post-rituximab annualized relapse rate (ARR) was observed (p5 0.003).
During rituximab, 6 patientswere relapse-free, although21 relapses occurred in 10 patients, includ-
ing 13 “repopulation,” 3 “depletion,” and 4 “depletion failure” relapses. Of the 13 “repopulation”
relapses, 4 had CD19 10–50 3 106 cells/L, 10 had inadequate monitoring (#1 CD19 in the 4
months before relapses), and 5 had delayed redosing after repopulation detection.
Conclusion: Rituximab is effective in relapse prevention, but B cell repopulation creates a risk of
relapse. Redosing before B cell repopulation could reduce the relapse risk further.
Classification of evidence: This study provides Class IV evidence that rituximab significantly reduces
ARR in pediatricNMO/NMOSD. This study also demonstrates a relationship betweenBcell repopulation
and relapses. Neurol Neuroimmunol Neuroinflamm 2016;3:e188; doi: 10.1212/NXI.0000000000000188
GLOSSARY
AQP45 aquaporin-4; ARR5 annualized relapse rate; EDSS 5 Expanded Disability Status Scale; IVIg 5 IV immunoglobulin;
MS 5 multiple sclerosis; MOG 5 myelin oligodendrocyte glycoprotein; NMO 5 neuromyelitis optica; NMOSD 5 NMO spec-
trum disorders; ON 5 optic neuritis; TM 5 transverse myelitis.
Neuromyelitis optica (NMO) is an autoimmune inflammatory demyelinating disease of the
CNS.1 Although previously considered a multiple sclerosis (MS) variant, IgG autoantibody
targeting aquaporin-4 (AQP4) channel (NMO-IgG) has clearly demonstrated that NMO is a
separate entity.2 NMO lesions are characterized by humoral inflammatory response and astro-
cytic cell death with AQP4 loss, followed by inflammatory demyelination and axonal damage.3
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The course of NMO is characterized by a
high relapse rate with accumulation of
neurologic disability, potentially causing
permanent blindness and paralysis. There-
fore, relapse prevention is crucial. Differenti-
ation from MS is important because some
MS therapies fail to control or may aggravate
NMO.4–6 Even though the optimal thera-
peutic regimen has not been established,
acute NMO attacks are mainly treated
with corticosteroids, plasma exchange, and
IV immunoglobulin (IVIg); azathioprine,
methotrexate, mycophenolate mofetil, ritux-
imab, mitoxantrone, cyclophosphamide, and
tocilizumab have been used to prevent
relapses.7
Rituximab is an anti-CD20 chimeric
monoclonal antibody that depletes B cells
that is used in severe autoimmune and
inflammatory CNS disorders despite the risk
of infections, as recently demonstrated in a
large pediatric study.8 One prospective and
3 retrospective adult NMO studies demon-
strated reduced annualized relapse rate
(ARR) and significantly improved Expanded
Disability Status Scale (EDSS) score with rit-
uximab.9–12 Pediatric data are more limited
and retrospective.13–16 No study specifically
addresses optimal rituximab monitoring and
redosing to prevent relapses and reduce dis-
ability. To clarify these aspects, we retrospec-
tively studied 16 children with NMO who
received $2 rituximab courses in order to
establish rituximab efficacy, the time from
rituximab to B cell repopulation, and the
relationship between B cell repopulation
and relapses.
METHODS Patients. We identified 16 patients with NMO
who received $2 rituximab courses (,18 years at first dose)
from 9 international pediatric neuroimmunology centers.
NMO was defined according to the revised Wingerchuk cri-
teria for NMO17 and NMO spectrum disorders (NMOSD).18
In 13 of 16 patients, diagnosis of definite NMO was met based
on the presence of both optic neuritis (ON) and transverse
myelitis (TM).19 The remaining 3 children had NMOSD (1
had a single attack of isolated TM, 1 had an attack of TM and
brainstem manifestations, and 1 had recurrent ON), and these
patients were all NMO-IgG positive. Regarding serologic
status, 15 of 16 patients were positive for NMO-IgG or
AQP4 antibodies: 12 were tested and positive for NMO-
IgG using immunofluorescence, and 3 were tested and
positive for both NMO-IgG (using immunofluorescence)
and anti-AQP4 antibodies (using cell-based assay). One
patient was negative for NMO-IgG but positive for anti–
myelin oligodendrocyte glycoprotein (MOG) antibodies
using cell-based assay (not tested for anti-AQP4 antibodies)
(patient 7).
Data collection. Data were retrospectively collected by the
main investigator (R.C.D.) through telephone interviews to
the physicians using a structured questionnaire created for this
study. Information recorded included demographics, clinical
characteristics of disease, immune therapies received besides
rituximab, rituximab regimen, CD19 count measurements,
and outcome. Data collection focused on the relationship
between rituximab administration (timing, dose, number of
courses, adverse reactions), CD19 counts, and relapses.
First-line immune therapy was defined as corticosteroids,
IVIg, and plasma exchange, whereas second-line immune
therapy included rituximab, cyclophosphamide, azathioprine,
and mycophenolate mofetil. Disease duration pre-rituximab
was defined as the time between onset (first event) and
initiation of rituximab treatment. Rituximab treatment
duration was defined as the time between rituximab
initiation and last follow-up (for patients with ongoing
rituximab) or the date of final CD19 repopulation (for
patients who stopped rituximab).
CD19 values and relationship to relapses. The threshold for
B cell repopulation was defined as CD19 count $10 3 106
cells/L, as previously proposed.16,20 In order to study the B cell
status during relapses, we used the CD19 count closest to the
clinical event (mean 4.6 days before or after the event, median 1,
range 0–22). We categorized a relapse as a “repopulation” relapse
when it was associated with B cell repopulation $10 3 106
cells/L, as a “depletion” relapse when it occurred despite B cell
depletion ,10 3 106 cells/L, or as a “depletion failure” relapse
when it occurred following a rituximab course failing to deplete B
cells despite conventional rituximab doses and adequate CD19
monitoring. In order to examine the timing of CD19 repopula-
tion, we used data only from rituximab courses with evidence of
both B cell depletion and subsequent repopulation (31 courses
from 13 patients).
Therapeutic efficacy. We used ARR as a clinical indicator of
therapeutic efficacy by comparing the ARR pre-rituximab and
during rituximab. ARR was calculated only when a time span of
$6 months was available.12 One relapse (patient 13) occurred 14
days after the first rituximab course and was considered to occur
before treatment effect because B cell depletion may take up to
1 month after rituximab administration.21 Pre- and post-rituximab
ARR were compared using the Wilcoxon 2-sample test (only
patients with both pre- and post-rituximab ARR were included).
EDSS score was calculated retrospectively to assess the neurologic
outcome at the last follow-up. We used Spearman correlation
coefficient (nonparametric) for correlating relapse number with
EDSS score at last follow-up.
Research questions and classification of evidence. Our pri-
mary research objectives were to determine the efficacy of ritux-
imab using ARR and to determine the relationship of relapses
to B cell repopulation. Given the retrospective nature of our study
and lack of a control group, our study represents Class IV
evidence.
Standard protocol approvals, registrations, and patient
consents. Patient data were acquired after local ethical approval
or using preexisting approved studies to collect deidentified clin-
ical data.
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RESULTS Demographics. Sixteen children (14 girls)
with NMO or NMOSD treated with $2 rituximab
courses were included in our study (mean age 9.6
years, median 10.9, range 1.8–15.3). The patient race
was white (n 5 8), black or African American (n 5
5), Native Pacific Islander (n 5 1), mixed white and
Native Pacific Islander (n 5 1), and mixed African,
Asian, and white (n 5 1).
Clinical presentation and disease course. Disease onset
was between 2000 and 2012. Ten patients had ON
and/or TM at onset (ON: n 5 4; TM: n 5 4; both
ON and TM: n 5 2). The other presentations were
brainstem disease only (n 5 3), TM and brainstem
disease (n 5 2), and ON and brainstem disease (n 5
1). The mean total duration of disease (time from
onset to last follow-up) was 6.1 years (median 5.1,
range 1.6–13.6). In the 16 children, 98 total events
occurred (mean 6.1, median 5, range 1–11), most of
which (71 of 98) were monosymptomatic attacks
(isolated ON: n 5 29; isolated TM: n 5 38;
isolated brainstem disease: n 5 4). The remaining
attacks were concurrent ON and TM (n 5 13); TM
and brainstem disease (n 5 9); ON, TM, and
brainstem disease (n 5 2); ON and brainstem
disease (n 5 1); or other (n 5 2). Figure 1 illustrates
the clinical course of the 16 patients (clinical events,
second-line immune therapies, and rituximab courses).
Immune therapies before rituximab. Before rituximab, all
patients received IV methylprednisolone followed by
oral prednisolone tapers; 8 patients received plasma
exchange and 8 received IVIg. Ten patients received
other second-line immune treatments before
rituximab (figure 1 and table 1): mycophenolate
mofetil (n 5 5; 2 of 5 also received azathioprine),
azathioprine (n 5 5; 2 of 5 also received
mycophenolate mofetil and 1 of 5 also received
cyclophosphamide), and cyclophosphamide (n 5 3;
1 of 3 also received azathioprine).
Figure 1 Clinical course of the 16 patients: Clinical events, second-line immune treatments, and rituximab courses
AZA 5 azathioprine; CYC 5 cyclophosphamide; MMF 5 mycophenolate mofetil; RTX 5 rituximab.
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Rituximab administration. A total of 76 rituximab
courses were administered in the 16 patients (mean
4.7, median 4.5, range 2–9) (figure 1). The mean
time between the first infusion of the first and last
rituximab courses was 29.8 months (median 23.5,
range 5.7–93). The protocols for administration (in
descending order of frequency) were as follows: 1,000
mg 3 2 infusions 2–4 weeks apart (n 5 31 courses),
375 mg/m2 3 4 weekly infusions (n 5 19 courses),
375 mg/m2 3 1 infusion (n 5 10 courses), 375
mg/m2 3 2 infusions 2 weeks apart (n 5 9 courses),
750 mg/m2 3 2 infusions 2 weeks apart (n 5 5
courses), and 500 mg/m2 3 2 infusions 2 weeks apart
(n 5 2 courses). Rituximab was redosed at a mean of
7.9 months (median 7.6, range 2.2–28.3). In some
patients it was redosed after a relapse, in others after
detection of B cell repopulation, and in a minority at
regular intervals regardless of B cell status. At last avail-
able follow-up, rituximab was ongoing in 13 patients.
Rituximab was discontinued in the 3 remaining
patients because of difficulty coming to the hospital
(patient 1), treatment failure (patient 2), and relapse
freedom for $2 years (patient 10).
Infusion reactions and adverse events. Data on infusion
reactions to rituximab and adverse events were
available in 14 of 16 patients. Infusion reactions
occurred in 6 of 14 children (dyspnea: n 5 2; rash:
n 5 2; chest pain: n 5 1; lightheadedness: n 5 1;
tingling and stinging sensation in mouth and throat:
n 5 1). Other adverse reactions occurred in 3 of 14
children, including infections in 2 (skin infection: n 5
1; mastoiditis: n 5 1) and immunoglobulin deficiency
without infectious complications in 1 (this patient
received 4 rituximab courses of 750 mg/m2 3 2).
Rituximab efficacy. Six patients were relapse-free
during rituximab treatment (patients 9, 10, 11, 13,
14, and 15) (table 2; figure 1). In these 6 relapse-
free patients, the rate of use of other immune
therapies during rituximab (corticosteroids: n 5 4;
IVIg: n 5 2; plasma exchange: n 5 0; second-line
immune therapies: n 5 0) was similar to the rate in
the other 10 patients (corticosteroids: n 5 9; IVIg:
n 5 4; plasma exchange: n 5 4; mycophenolate
mofetil 1 cyclophosphamide: n 5 1; azathioprine:
n 5 1). In the 10 relapsing patients, a total of 21
events occurred during rituximab treatment (mean
2.1, median 1.5, range 1–5) (table 2). Relapses
occurred a mean of 9.1 months (median 8.1, range
1.2–27.8) after the last rituximab course (figure 2A).
There was a statistically significant reduction between
Table 1 First-line and second-line immune treatments administered before rituximab
Patient Sex
Age at disease
onset, yr
First-line immune treatments before RTX
Second-line immune
treatments before RTX
Age at RTX
initiation, yrIVMP OP PE IVIg MMF AZA CYC
1 F 7.25 1 (5 courses) 1 2 2 2 1 2 12.92
2 M 1.83 1 (5 courses) 1 1 (1 cycle) 1 (1 course) 2 2 1 13.33
3 F 15.33 1 (2 courses) 1 1 (1 cycle) 2 2 2 2 15.92
4 F 9.58 1 (2 courses) 1 2 1 (2 courses) 2 2 2 10.25
5 F 8.08 1 (1 course) 1 2 1 (1 course) 2 2 2 8.17
6 F 10.83 1 (8 courses) 1 2 2 2 1 1 14.58
7 F 11 1 (1 course) 1 2 1 (2 courses) 2 2 2 11.25
8 F 7.75 1 (8 courses) 1 1 (3 cycles) 2 1 1 2 14.58
9 F 3.92 1 (6 courses) 1 2 1 (1 course) 1 1 2 13.92
10 F 12.42 1 (1 course) 1 2 2 2 2 2 12.67
11 F 11.75 1 (2 courses) 1 1 (1 cycle) 1 (1 course) 1 2 2 12.58
12 F 14.08 1 (2 courses) 1 1 (1 cycle) 2 1 2 2 15.33
13 M 11.17 1 (3 courses) 1 1 (1 cycle) 1 (8 courses) 1 2 2 11.75
14 F 5.67 1 (7 courses) 1 2 1 (1 course) 2 1 2 11.17
15 F 11.33 1 (3 courses) 1 1 (15 cycles) 2 2 2 2 13.67
16 F 11.25 1 (4 courses) 1 1 (3 cycles) 2 2 2 1 14
Abbreviations: AZA 5 azathioprine; CYC 5 cyclophosphamide; IVIg 5 IV immunoglobulin; IVMP 5 IV methylprednisolone; MMF 5 mycophenolate mofetil;
OP 5 oral prednisolone; PE 5 plasma exchange; RTX 5 rituximab.
When available, the number of treatment courses and cycles is provided in parentheses. Before rituximab, all patients received IV methylprednisolone (total
60 courses; mean 3.7 courses per patient, median 3, range 1–8) followed by oral prednisolone. Plasma exchange was administered in 8/16 patients (total
26 cycles; mean 3.2 cycles per patient, median 1, range 1–15; in data available, there were mean 5.2 exchanges per cycle, median 5, range 1–10). IVIg was
administered in 8/16 patients (total 17 courses; mean 2.1 courses per patient, median 1, range 1–8).
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pre- and post-rituximab ARR when first events were
included (p 5 0.003) or excluded (p 5 0.014) (table
2). There was also a significant reduction in the ARR
in the year after rituximab initiation compared to the
year before (p 5 0.002).
CD19 count monitoring and repopulation on rituximab.
During the total 42.6 years of cohort rituximab treat-
ment, a total of 196 CD19 counts were measured
(mean 12.2 per patient, median 9, range 1–36). All
patients had documented B cell depletion after at least
1 rituximab course. In the 31 rituximab courses (in
13 patients) with documented B cell depletion fol-
lowed by repopulation, the mean time from rituxi-
mab administration to the last demonstrated depleted
CD19 count was 4.5 months (median 5.1, range 0.9–
8.7), and the mean time to the first demonstrated
repopulated CD19 count was 6.8 months (median
6.7, range 2.7–12.2). The 2 shortest times to repo-
pulation occurred 2.7 and 2.9 months after rituximab
(375 mg/m2 3 1 and 375 mg/m2 3 2, respectively)
in 2 different patients. We observed notable interpa-
tient variability in the time to B cell repopulation and
some intrapatient variability (figure 2B). The mean
time to repopulation in the first rituximab courses
(mean 7.4 months, median 7.2, range 3.6–12.2;
calculated in 8 courses) was similar to that in subse-
quent courses (mean 6.7 months, median 6.8, range
2.7–11.2; calculated in 23 courses). Time to B cell
repopulation was faster in the younger patients (18
courses in 5 patients with adequate data; age range
8.2–11.7 years at rituximab initiation) than in the older
patients (12 courses in 7 patients; age range 13.3–15.9
years at rituximab initiation) (mean 5.9 vs 8.1 months,
median 5.6 vs 8.5 months). Where adequate data were
available (n 5 10 courses), once B cells repopulated
over the threshold of 10 3 106 cells/L, B cell counts
never redepleted spontaneously. In contrast, according
to available data (n 5 9 courses), only 22% of CD19
counts 1–93 106 cells/L were followed by repopulated
CD19 values $10 3 106 cells/L within 1 month.
CD19 count and relationship to relapses. The 21 relapses
that occurred in 10 children during rituximab treat-
ment are detailed in table e-1 at Neurology.org/nn
(adequate CD19 data in 20 of 21 relapses). Most of
the events (13 of 20) occurred with B cell
repopulation and are defined as “repopulation”
relapses. In these 13 “repopulation” relapses, the
mean CD19 value at relapse was 192.3 3 106 cells/
L (median 130, range 10–449), and in 4 of these 13
events the CD19 count was 10–50 3 106 cells/L
Table 2 Duration of disease, number of events, and ARR pre- and post-rituximab
Patient
Disease duration
pre-RTX, mo
Duration of RTX
treatment, mo
No. events
pre-RTX (including
first event)
No. events during
RTX treatment
ARR pre-RTX including
first event (excluding
first event)
ARR during
RTX
ARR in the
year before
RTX
ARR in the
year after
RTX
1 67.5 22 5 1 0.89 (0.71) 0.54 1 1
2 137 23 5 5 0.44 (0.35) 2.61 1 0
3 4 26 2 1 — 0.46 — 1
4 8 17.3 2 2 3.00 (1.50) 1.39 — 1
5 1.3 27.5 1 2 — 0.87 — 0
6 45 46 9 2 2.40 (2.13) 0.52 3 1
7 3.2 31 2 1 — 0.39 — 1
8 82.3 26 10 1 1.46 (1.31) 0.46 3 0
9 123.7 39.5 9 0 0.88 (0.78) 0 1 0
10 2.5 33.5 1 0 — 0 — 0
11 9.7 9.2 2 0 2.47 (1.24) 0 — 0
12 15 7 3 1 2.40 (1.60) 1.71 2 1
13 7.5 22.7 4 0 6.40 (4.80) 0 — 0
14 66 30 10 0 1.82 (1.64) 0 1 0
15 28 52.7 7 0 3.00 (2.57) 0 3 0
16 33 98 5 5 1.82 (1.45) 0.61 1 0
Mean 39.6 Mean 32 Mean 4.8 Mean 1.3 Mean 2.2 (1.5) Mean 0.6 Mean 1.7 Mean 0.4
Median 21.5 Median 26.7 Median 4.5 Median 1 Median 2.1 (1.5) Median 0.5 Median 1 Median 0
Range 1.3–137 Range 7–98 Range 1–10 Range 0–5 Range 0.4–6.4 (0.3–3.2) Range 0–2.6 Range 1–3 Range 0–1
Abbreviations: ARR 5 annualized relapse rate; RTX 5 rituximab.
There was a statistically significant reduction between pre- and post-rituximab ARR when first events were included (p 5 0.003) or excluded (p 5 0.014).
There was also a significant reduction in the ARR in the year before and after rituximab initiation (p 5 0.002).
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(10, 16, 37, and 40 3 106 cells/L). Of the 13
“repopulation” relapses, there was a lack of monitoring
(defined as#1 CD19 count in the 4 months preceding
the relapse) in 10, a delay in redosing (defined as
$10 days between detection of repopulation and
rituximab redosing) during which the relapse
occurred in 5, and there was no inadequate
monitoring or delayed redosing in 2.
The remaining 7 clinical events occurred in 2 pa-
tients: 3 relapses in patient 2 (rituximab 750 mg/m2 3
2 infusions 2 weeks apart) occurred despite B cell
depletion and were defined as “depletion” relapses,
whereas the 4 relapses in patient 16 (rituximab
1,000 mg3 2 infusions 4 weeks apart) occurred with
documented persistent nondepleted CD19 counts
(mean 6.2 CD19 counts/relapse, median 6, range
2–11) and were defined as “depletion failure” relap-
ses. Examples of relapse freedom after treatment and
of “repopulation,” “depletion,” and “depletion fail-
ure” relapses are presented in figures 3 and e-1.
Outcome. At a mean follow-up of 6.1 years from
disease onset (median 5.1 years, range 1.6–13.6),
mean EDSS score was 2.4 (median 2.5, range 0–
6.5), and no ongoing problems (EDSS 0) were
reported in 5 patients. There was a trend of worse
EDSS scores at follow-up in the patients who had
more relapses during the disease course, but this
was not statistically significant (r 5 0.49, p 5
0.051). The most common neurologic problem at
follow-up was reduced visual acuity, reported in 10
of 16 cases; in 6 of these 10 patients visual acuity was
severely reduced (worse eye with maximal visual
acuity corrected less than 20/200). Pyramidal signs
in the lower limbs were reported in 2 of 16 cases,
upper limb involvement in 0 of 16, and bowel or
bladder impairment in 1 of 16.
DISCUSSION We retrospectively studied 16 chil-
dren with NMO treated with $2 rituximab courses
with the aim of optimizing rituximab monitoring and
Figure 2 Time to relapse and time to B cell repopulation after rituximab
(A) Relapses during rituximab (RTX) treatment according to the time from last rituximab course (total 21 relapses in 10 pa-
tients). (B) Inter- and intraindividual variability in the time to B cell repopulation after rituximab in 9 patients. To assess the
variability in the intraindividual time to repopulation, these 9 patients were selected based on the availability of at least 2
rituximab courses with evidence of a repopulated CD19 count after demonstrated depletion and the fact that the same
dose regimen was administered (rituximab regimen specified for each patient next to the bar). The horizontal bars represent
the range of intraindividual variability in the time to repopulation, and the dots represent the actual measurements. There is
significant variability between patients, although the intrapatient variability appears to be less.
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Figure 3 Summary figure exemplifying 4 different types of response to rituximab treatment observed in our patients
Relapse freedom with rituximab (RTX) (A, B), occurrence of relapses with a repopulated B cell count (“repopulation” relapses; C, D), occurrence of relapses with a
depleted B cell count (“depletion” relapses; E), occurrence of relapses in association with failure to reach B cell depletion (“depletion failure” relapses; F). (A) Relapse
freedom (no relapses during rituximab): rituximab redosing after B cell repopulation (patient 14). (B) Relapse freedom (no relapses during rituximab): rituximab
redosing before B cell repopulation (patient 10). (C) “Repopulation” relapses (relapses with B cell repopulation): repopulation was detected only at the time of the
relapse (third and fourth relapses); subsequent rituximab courses were administered after the relapse (second and third rituximab courses) (patient 4). (D) “Repo-
pulation” relapses (relapses with B cell repopulation): repopulation was noticed at CD19 count monitoring and rituximab was administered, but clinical relapse
occurred a fewdays after rituximab, before depletionwas achieved (second and third relapses) (patient 5). (E) “Depletion” relapses (relapses despite B cell depletion in
Continued
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redosing to prevent relapses. This represents the larg-
est reported therapeutic study of pediatric NMO.
Confirming published literature, there was a
female predominance in our cohort, and most of
the clinical events were monosymptomatic TM,
ON, and brainstem events. Our patients had a high
relapse rate and a long disease course before rituximab
initiation. Fifteen of the 16 patients were NMO-IgG
positive, although the single MOG-IgG-positive
patient had 2 events in the 3 months preceding ritux-
imab initiation and 1 relapse during rituximab,
suggesting a highly relapsing disease. Although
long-term data regarding MOG-IgG-associated dis-
ease are lacking, early reports suggest that MOG-
IgG-associated NMOSD is more reversible and less
severe and carries less risk of permanent disability
compared to NMO-IgG-associated NMOSD.19,22
All patients received immunosuppressive therapies
before rituximab: all received IV methylprednisolone
and oral steroids, half received IVIg, half received
plasma exchange, and 62.5% were given other
second-line immune therapies before rituximab. Rit-
uximab was generally initiated after $2 events,
although it was started after the first event in 3 cases.
Overall, our cohort likely represents a more severe
end of the pediatric NMO spectrum.
In our cohort, the protocols of rituximab induc-
tion, redosing, and monitoring were heterogeneous,
reflecting the multicenter nature of our cohort and
the lack of guidelines and consensus opinion. Ritux-
imab was redosed at a mean of 7.9 months, although
with considerable variability (range 2.2–28.3
months). Redosing occurred for different reasons,
including occurrence of relapses, detection of B cell
repopulation, or, more rarely, planned redosing (fig-
ures 3 and e-1).
Rituximab treatment was relatively well tolerated
with no major complications in 42.6-year cohort treat-
ment. There was evidence of efficacy in our cohort; 6
of the patients were relapse-free during treatment
(figures 3, A and B and e-1). There was a significant
reduction in ARR using all measures, although it is
important to note that the ARR may decline during
the course of disease regardless of treatment.23 The use
of other immune therapies was similar in the 6 relapse-
free patients compared to the other patients, suggesting
that the lack of relapses was not due to other concom-
itant therapies administered with rituximab.
The clinical events during rituximab occurred a mean
of 9.1 months after the last rituximab course, although
the timing of relapses was very widely distributed.
We chose a CD19 count of 10 3 106 cells/L as a
threshold for B cell repopulation, as previously used,16,20
partly because absolute values (rather than percentages)
would allow adequate comparison across centers. The
observation that 4 of the 13 “repopulation” relapses
in our cohort occurred during early repopulation
(10–50 3 106 cells/L) confirms the clinical validity of
10 3 106 cells/L as a threshold. We also observed that
once B cells repopulated beyond 10 3 106 cells/L,
CD19 counts continued to rise and there was no spon-
taneous return to B cell redepletion.
We confirmed a relationship between B cell repo-
pulation and relapses. Most relapses occurred with
CD19 repopulation, and only 1 patient had relapses
with depleted CD19 counts, confirming that deple-
tion appears to be protective in most patients. In most
of the 13 “repopulation” relapses, CD19 monitoring
was inadequate and B cell repopulation went unno-
ticed until subsequent clinical relapse. In 5 of the
“repopulation” relapses, there was delayed rituximab
redosing after detection of B cell repopulation and
relapses occurred while waiting to admit the patient
for redosing. Furthermore, B cell depletion can take
up to 1 month after rituximab administration,21
allowing for a “window of vulnerability” for relapses
(as shown in figure 3D). The remaining 7 relapses
occurred in 2 patients, defined as “depletion” relapse
in one patient (figure 3E) and “depletion failure”
relapse in the other (figure 3F). Therefore, only 1 of
the 16 patients (patient 2) had relapses despite ade-
quate monitoring and documented B cell depletion
and can therefore be defined as having true rituximab
failure. The reason for the different response to ritux-
imab in these 2 patients with “depletion” and “deple-
tion failure” relapses is not clear, although some
investigators have suggested that B cell activating
factor of the tumor necrosis factor family may be
relevant.20,24–26 Some studies in adult patients have
shown a relationship of anti-AQP4 antibodies with
B cell status and clinical relapses,11,27,28 although
others have not found a convincing relationship.20
Unfortunately, longitudinal anti-AQP4 antibodies
were not available in our cohort.
In light of the above considerations on the rela-
tionship between B cell repopulation and relapses,
understanding the timing of repopulation after ritux-
imab is critical for preventing relapses. The mean
time for B cell repopulation in our cohort was
between 4.5 (mean time of last depletion) and 6.8
months (mean time of first repopulation) after the last
rituximab course. However, repopulation as early as
Figure 3 legend, continued:
the last 3 relapses) (patient 2). (F). “Depletion failure” relapses (relapses associated with failure to reach B cell depletion in the first, second, and third
rituximab courses). In this patient, B cell depletion was achieved in subsequent rituximab courses (total 9 courses; same rituximab regimen used in all the
courses, 1,000 mg 3 2). The figure shows only the first 5 courses; no relapses occurred subsequently.
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2.7 months post-rituximab and persistent B cell
depletion up to 8.7 months were observed, suggesting
large interpatient variability in CD19 count effects
(figure 2B), similar to other published data.29 In
contrast, the intrapatient variability appeared to be
smaller, implying a relative predictability of B cell re-
population in individuals, which will help monitoring.
We noted that the shortest time to repopulation
occurred with the lowest rituximab doses and the lon-
gest with the highest doses, as previously observed,29
although other variables likely play a role in B cell
repopulation. We also observed that younger patients
repopulated faster than older patients.
In our study, we observed that genuine treatment
failure with rituximab occurred in only 1 patient,
whereas relapses were otherwise attributable to the
challenges associated with monitoring and redosing.
We confirm that rituximab efficacy is associated with
CD19 depletion, and our data suggest that the detec-
tion of repopulation over 10 3 106 cells/L should
alert the clinician to the likely possibility of further
B cell rise and relapse risk. Considering the significant
variability observed in the time to B cell repopulation,
further efforts should be made to optimize rituximab
monitoring. A possible individualized strategy
to minimize relapses involves rigorous CD19 moni-
toring (i.e., monthly, especially after the third
month), particularly during first courses, and rapid
redosing on repopulation detection. Given the
latency of B cell depletion after rituximab infusion,
there is a risk of relapse during this repopulated
period, especially when there is delay in redosing.
In view of this, an alternative strategy involves
planned rituximab redosing at regular intervals,
before B cell repopulation occurs, as previously
described9,10,20 and shown in figure 3B, which may
reduce the relapse risk but will result in increased
therapy cost. As shown in figure 2B, there is signifi-
cant variability in B cell repopulation between pa-
tients, including early repopulation (3–6 months)
even for higher dose regimens (375 mg/m2 3 4 and
1,000 mg/m2 3 2). Therefore, planned redosing
would need to be at short intervals (3–4 months)
to minimize the chance of B cell repopulation.
The retrospective design, the lack of standardiza-
tion, and the relatively small number of patients are
the main limitations of our study. However, we have
confirmed rituximab efficacy, demonstrated chal-
lenges in monitoring, and provided data on B cell re-
population. This will improve redosing of rituximab
in children with NMO and other serious autoim-
mune disorders of the CNS.
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Supplementary material 
 
Supplementary figure e-1 
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Table e-1 
 
# Relapse number 
(including the first 
event) 
RTX regimen at last 
course 
Time from last RTX course 
to relapse (months) 
CD19 count at relapse  
(timing relative to event) 
Repopulation relapse 
Depletion relapse   
Depletion failure relapse 
1 6 375 mg/m2 x 2 6.7 340 x 106/L (7 days after relapse) Repopulation relapseº 
2 
 
6 750 mg/m2 x 2 12.6 388 x 106/L (11 days before relapse) Repopulation relapse 
7 750 mg/m2 x 2 13 388 x 106/L (22 days before relapse) Repopulation relapse 
8 750 mg/m2 x 2 4.5 2 x 106/L (same day as relapse) Depletion relapse 
9 750 mg/m2 x 2 5.5 3 x 106/L (9 days before relapse) Depletion relapse 
10 750 mg/m2 x 2 2.3 0 x 106/L (same day as relapse) Depletion relapse 
3 3 375 mg/m2 x 4 10 10 x 106/L (same day as relapse) Repopulation relapse 
4 3 375 mg/m2 x 4 5.6 320 x 106/L (same day as relapse) Repopulation relapse 
4 375 mg/m2 x 4 7.8 100 x 106/L (same day as relapse) Repopulation relapse 
5 2 375 mg/m2 x 4 8.1 40 x 106/L (2 days before relapse) Repopulation relapse 
3 500 mg/m2 x 2 7.2 130 x 106/L (6 days before relapse) Repopulation relapse 
6 
 
10 375 mg/m2 x 2 5 259 x 106/L (same day as relapse) Repopulation relapse 
11 375 mg/m2 x 2 14.7 16 x 106/L (7 days after relapse) Repopulation relapse 
7 3 375 mg/m2 x 4 9 60 x 106/L (1 day before relapse) Repopulation relapse 
8 11 1000 mg x 2 6.3 449 x 106/L (same day as relapse) Repopulation relapseº 
12 4 1000 mg x 2 1.3 n.a. n.a.* 
16 
 
6 1000 mg x 2 27.8 182 x 106/L (1 day after relapse) Depletion failure relapse 
7 1000 mg x 2 10.8 68 x 106/L (same day as relapse) Depletion failure relapse 
8 1000 mg x 2 11.5 68 x 106/L (20 days before relapse) Depletion failure relapse 
9 1000 mg x 2 10.4 115 x 106/L (same day as relapse) Depletion failure relapse 
10 1000 mg x 2 10.2 37 x 106/L (7 days before relapse) Repopulation relapse 
 
 
Table e-1 (adapted from [11]). Characteristics of the 21 relapses in 10 patients during rituximab 
treatment. The clinical events were analysed relative to the preceding rituximab course and CD19 
counts. Four of the relapses occurred between 2 and 22 days after rituximab, in the time window when 
rituximab effect may not be complete yet (patient #3 event number 3, patient #5 event number 3, and 
patient #16 events number 8 and 10), and were therefore analysed with respect to the previous rituximab 
course. 
Legend: #: patient number; RTX: rituximab. 
*For 1 of the 21 clinical events (patient #12) there were inadequate CD19 count data. 
ºIn all cases of ‘repopulation relapse’ there was demonstrated B cell depletion followed by repopulation 
except in cases #1 and #8, in whom only a single count was performed after rituximab course which 
showed repopulated B cells, but there was no demonstrated B cell depletion. 
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3.3.5 Mycophenolate mofetil, azathioprine and methotrexate in paediatric anti-NMDAR 
encephalitis 
 
In progress 
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Highlights 
 The use of steroid sparers for paediatric anti-NMDAR encephalitis is heterogenous  
 Severe adverse reactions seem to be rare, although a reporting bias is possible 
 Our review highlights the need for improved data in larger cohorts, focused on efficacy and 
tolerability 
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Abstract 
Background. While first and second-line immune therapy have been increasingly used in paediatric-
onset anti-NMDAR encephalitis, expert recommendations and physicians’ treating behaviours are still 
heterogeneous regarding the use of maintenance steroid sparers.  
Methods. Systematic literature review on steroid sparers mycophenolate mofetil (MMF), azathioprine 
(AZA) and methotrexate (MTX) for paediatric-onset anti-NMDAR encephalitis. 
Results. 76 patients treated with MMF/AZA/MTX for paediatric-onset anti-NMDAR encephalitis were 
included (age range at onset 0.8-18 years; 69.7% females; 49.1% had ≥1 relapse), reported in 37 
articles. MMF was used in 53.9%, AZA in 25%, MTX in 15.8%; an additional 5.3% received two 
among MMF/AZA/MTX. MMF/AZA/MTX were not preceded by any second-line therapy 
(rituximab/cyclophosphamide) in 47.7%, and were administered only after relapses in 46.8%. Among 
the subgroup treated with MMF/AZA/MTX after the first event, relapses occurred in 8.3% only. Time 
on MMF/AZA/MTX was median 9 months (range 1-48). Median annualised relapse rate was 0.45 
(mean 1, range 0-6.67) before MMF/AZA/MTX (excluding onset), and 0 (mean 0.06, range 0-1.3) 
during/after MMF/AZA/MTX. Adverse reactions were reported only for MMF (cytomegalovirus colitis 
and respiratory infection; grade 3 CTCAEv4.0). Relapse rate was significantly higher in patients started 
on first immune therapy (any) >30 days after onset (85.7%) compared to those treated early (31.2% 
(p=0.0272). 
Discussion. Our literature review disclosed heterogeneity in the use of steroid sparers 
(MMF/AZA/MTX) in paediatric-onset anti-NMDAR encephalitis. Severe adverse reactions were rare, 
although a reporting bias is possible. While treatment seemed to associate to a slightly lower relapse 
rate especially when given early, focused data on large prospective cohorts are warranted to study safety 
and efficacy of MMF/AZA/MTX in paediatric anti-NMDAR encephalitis. 
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Introduction 
Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is an autoimmune syndrome 
characterised by a constellation of symptoms with multistage progression (psychiatric changes, 
movement disorder, epileptic seizures, consciousness and vigilance disturbances, sleep-wake cycle 
disruption, dysautonomias), and the presence of neuronal surface antibodies in the cerebrospinal fluid 
and serum targeting the anti-N-methyl-D-aspartate receptor [Dalmau, 2007]. Despite the absence of 
definite guidelines, in recent years a number of expert recommendations have been published on 
immune therapy for anti-NMDAR encephalitis [Dalmau, 2011; Zuliani, 2012; McKeon, 2013; Gastaldi, 
2016; Lancaster, 2016; Dale, 2017; Shin, 2017]. First-line treatments usually include intravenous 
methylprednisolone, intravenous immunoglobulin (IVIG) [Nosadini, 2015; Nosadini, 2016; Gadian, 
2017] and plasma exchange [Suppiej, 2016]. In case of unsatisfactory response or in potentially 
relapsing disease, second-line therapies are advised, such as rituximab and/or cyclophosphamide. This 
approach is generally becoming more and more uniform, although major differences between centers 
and physicians do exist, especially in the use of second-line treatments [Bartolini, 2017; Kahn, 2017]. 
When it comes to maintenance immune therapy, expert recommendations are less definite and 
physicians' approaches vary widely as regards the use of maintenance therapy or not, the type of agent, 
and the duration of treatment [Bartolini, 2017; Kahn, 2017]. Most frequently used agents for 
maintenance therapy in autoimmune encephalitis include mycophenolate mofetil, azathioprine and 
methotrexate. These drugs are generally referred to as steroid sparers, and are widely used for 
prevention of transplant rejection and in a large array of autoimmune diseases, including rheumatologic, 
dermatologic, gastrointestinal and neurologic conditions [Nosadini, 2017]. The utility and the safety of 
mycophenolate mofetil, azathioprine and methotrexate in paediatric autoimmune encephalitis have not 
been thoroughly explored yet. In this context, we carried out a systematic literature review with the aim 
of collecting available data on the use of steroid sparing agents in paediatric anti-NMDAR encephalitis, 
with focus on the most frequent modes of use, tolerability and efficacy. 
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Methods  
We conducted a systematic literature review on the use of steroid sparing agents (mycophenolate 
mofetil, azathioprine and methotrexate) for paediatric-onset anti-NMDAR encephalitis. The search was 
carried out in Pubmed, up to date to 30.10.2017, with the search terms “anti–N-methyl-D-aspartate 
receptor encephalitis” OR “N-methyl-D-aspartate antibody encephalitis” OR “anti-NMDAR 
encephalitis” OR “NMDA receptor encephalitis". The available articles were filtered manually for 
patients in paediatric age (≤18 years), and searched for “mycophenolate”, "azathioprine", and 
"methotrexate".  
Articles reporting patients who received mycophenolate mofetil, azathioprine and/or methotrexate for 
paediatric-onset anti-NMDAR encephalitis were included. Articles reporting mixed populations of 
children and adults, in which the age of the patients treated with mycophenolate mofetil, azathioprine 
and/or methotrexate was not clear, were excluded.  
Articles were searched for data on demographics, disease severity and course, treatment, efficacy and 
tolerability of mycophenolate mofetil, azathioprine and methotrexate. For disease severity, the modified 
Rankin Scale (mRS) [van Swieten, 1988] was used, as reported in the original article or scored by one 
of the main authors (MN), when not available in the text. The annualised relapse rate (ARR) was 
calculated as number of disease events multiplied by 12 (months), divided by the number of months 
during which the events occurred (calculated only for time intervals ≥6 months). ARR was calculated 
before (both including and excluding first events), during and after treatment with mycophenolate 
mofetil, azathioprine and methotrexate. 
Adverse reactions to mycophenolate mofetil, azathioprine and methotrexate were classified using the 
Common Terminology Criteria for Adverse Events (CTCAE v4.0), into grade 1 (mild), 2 (moderate), 3 
(severe or medically significant but not immediately life-threatening), 4 (life-threatening consequences) 
and 5 (death) [ref].  
Data collection was subject to data availability, therefore in the results section of this work 
denominators may differ.  
X2 or Fisher's tests were used for statistical analysis to compare risk of relapses between different 
subgroups of patients. The level of statistical significance was set at p<0.05. 
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Results  
37 articles reporting a total of 76 patients treated with mycophenolate mofetil, azathioprine and/or 
methotrexate for paediatric-onset anti-NMDAR encephalitis were included in the literature review 
[Agrawal, 2010; Kruer, 2010; Shah, 2011; Dale, 2013; Armangue, 2013; Baizabal-Carvallo, 2013; 
Suleiman, 2013; Kayser, 2013; Bravo-Oro, 2013; Hacohen, 2014; Titulaer, 2014; Hacohen, 2014; 
Salvucci, 2014; Sommeling, 2014; Guo, 2014; Tatencloux, 2015; Finke, 2015; Nosadini, 2015; Sartori, 
2015; Bravo-Oro, 2015; Wright, 2015; DeSena, 2015; Mohammad, 2015; Zekeridou, 2015; Matoq, 
2015; Lu, 2016; Suthar, 2016; Liba, 2016; Iizuka, 2016; Brenton, 2016; Hacohen, 2016; Foff, 2017; 
Hinkle, 2017; Zhang, 2017; Haberlandt, 2017; Jones, 2017; Goldberg, 2017]. Most of the articles were 
published between 2014 and 2017 (24/37, 64.9%). Data relative to the whole cohort of patients with 
paediatric-onset anti-NMDAR encephalitis treated with mycophenolate mofetil, azathioprine and/or 
methotrexate are detailed in Table 1, whereas Table 2 provides efficacy and tolerability data according 
to treatment group for each of these three agents.  
Demographics. Median age at onset of anti-NMDAR encephalitis was 11 years (mean 10.2, range 0.8-
18; data available in 65/76), and 69.7% (46/66) of the patients were females. Tumour was reported in 2 
patients [Brenton, 2016; Sommeling, 2016].  
Disease severity and disease course. In the acute phase, median mRS was 5 (mean 4.4, range 2-5; data 
available in 51/76), and 49.1% of the patients had relapses (28/57). In the cases with relapsing disease 
course, median number of total events per patient (including disease onset) was 3 (mean 3.3, range 2-
11; data available in 25/28). 
Treatment. Immune therapy was started within 30 days from disease onset in 59.2% of patients (16/27). 
All children in our literature cohort received steroids (65/65, 100%), 80% IVIG (52/65), and 49.2% 
underwent plasma exchange (32/65). Second-line treatments were used in 62.9% (39/62): rituximab in 
50% (31/62), and cyclophosphamide in 34.9% (22/63). As per inclusion criteria, all patients received 
maintenance immune therapy with steroid sparing agents (76/75, 100%): 53.9% received 
mycophenolate mofetil (41/76), 25% azathioprine (19/76) and 15.8% methotrexate (12/76); an 
additional 5.3% of patients received a combination of these treatments (4/76). Methotrexate was 
administered intrathecally in 3 patients [Tatencloux, 2015; Jones 2017]. 
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Table 1 
 
DEMOGRAPHICS IN THE WHOLE LITERATURE COHORT  
(patients with paediatric-onset anti-NMDAR encephalitis treated with MMF/AZA/MTX) 
Total number of articles  included in the literature review 
publishing year 2010-2013 
publishing year 2014-2017 
37  
13/37 (35.1%) 
24/37 (64.9%) 
Total number of patients 76*  
Proportion of females  46/66 (69.7%) (data available in 66/76) 
Age at disease onset (years)  Median 11, mean 10.2, range 0.8-18 (data available in 65/76) 
Tumour 2/76 (2.6%)° 
DISEASE COURSE IN THE WHOLE LITERATURE COHORT 
Worst mRS in the acute phase  Median 5, mean 4.4, range 2-5 (data available in 51/76) 
Relapsing disease course  28/57 (49.1%) (data available in 57/76) 
TREATMENT IN THE WHOLE LITERATURE COHORT 
Time to first immune therapy ≤30 days  16/27 (59.2%) (data available in 27/76) 
First and second-line immune therapies during the whole disease course  
Steroids 65/65 (100%) (data available in 65/76) 
IVIG 52/65 (80%) (data available in 65/76) 
PE 32/65 (49.2%) (data available in 65/76) 
Any second-line immune therapy (RTX and/or CYC) 39/62 (62.9%) (data available in 62/76) 
RTX 31/62 (50%) (data available in 62/76) 
CYC 22/63 (34.9%) (data available in 63/76) 
Maintenance treatment with steroid sparers MMF/AZA/MTX 76/76 (100%) 
MMF 41/76 (53.9%) 
AZA 19/76 (25%) 
MTX 12/76 (15.8%) 
AZA + MTX 2/76 (2.6%) 
MMF + AZA 1/76 (1.3%) 
MMF + MTX 1/76 (1.3%) 
MODES OF USE OF MMF, AZA, MTX 
Any second-line immune therapy (RTX and/or CYC) before MMF/AZA/MTX 34/65 (52.3%) (data available in 65/76) 
Number of events after which MMF/AZA/MTX were started  Median 1, mean 2, range 1-11 (data available in 47/76) 
After ≥2 events  22/47 (46.8%) (data available in 47/76) 
Timing of administration of MMF/AZA/MTX from disease onset ≤6 months 17/34 (50%) (data available in 34/76) 
 
 
Table 1. Demographics, disease course and treatment in the whole literature cohort of patients with 
paediatric-onset anti-NMDAR encephalitis treated with mycophenolate mofetil, azathioprine and/or 
methotrexate. 
Legend: anti-NMDAR: anti-N-methyl-D-aspartate receptor; AZA: azathioprine; CYC: 
clyclophosphamide; IVIG: intravenous immunoglobulin; MMF: mycophenolate mofetil; mRS: modified 
Rankin Scale; MTX: methotrexate; PE: plasma exchange; RTX: rituximab. 
*4/76 patients had associated demyelinating episodes: 2/76 patients also had a brainstem syndrome with 
demyelination [Hacohen, 2014; Titulaer, 2014]; 1/76 patients also had NMOSD [Titulaer, 2014]; 1/76 
patient had a single area of demyelination [Titulaer, 2014]) 
°1 girl had an ovatian teratoma [Brenton, 2016] and 1 boy had a mediastinal teratoma [Sommeling, 
2016] 
 
 
Modes of use of mycophenolate mofetil, azathioprine and methotrexate. Age at commencement of 
steroid sparing agents was <13 years in 42.8% of patients (24/56), and <6 years in 12.5% (7/56). 47.7% 
of patients (31/65) did not receive any second-line immune therapy (rituximab and/or 
cyclophosphamide) before mycophenolate mofetil, azathioprine and/or methotrexate. Timing of 
initiation of maintenance immune therapy with mycophenolate mofetil, azathioprine and/or 
methotrexate was within 6 months from onset in 50% only (17/34). In nearly half of the patients, steroid 
sparers were started only after relapses had occurred (22/47, 46.8%). Median treatment duration with 
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steroid sparers was highly variable (median 9 months, mean 12.9, range 1-48; data available in 30/76 
patients) (Table 2). 
 
 
Table 2 
 
DISEASE COURSE AND OUTCOME ACCORDING TO TYPE OF MAINTENANCE IMMUNE THERAPY WITH STEROID SPARERS 
(MMF/AZA/MTX) 
 MMF (n=43)* AZA (n=22)** MTX (n=15)*** 
Worst mRS in the acute phase  Median 5, mean 4.3, range 2-5 (data 
available in 28/43) 
Median 4.5, mean 4.3, range 3-5 
(data available in 14/22) 
Median 5, mean 4.5, range 3-5 (data 
available in 12/15) 
mRS 2-3 7/28 (25%) 3/14 (21.4%) 1/12 (8.3%) 
mRS 4-5 21/28 (75%) 11/14 (78.6%) 11/12 (91.7%) 
Relapsing disease course 21/42 (50%) (data available in 42/43) 6/12 (50%) (data available in 12/22) 3/7 (42.8%) (data available in 7/15) 
Onset to first immune therapy ≤30 
days  
10/14 (71.4%) (data available in 14/43) 6/10 (60%) (data available in 10/22) 2/5 (40%) (data available in 5/15) 
RTX and/or CYC during disease 
course 
21/41 (51.2%) (data available in 41/43)  9/14 (64.3%) (data available in 
14/22) 
12/13 (92.3%) (data available in 
13/15) 
RTX and/or CYC after 1st event 12/20 (60%) (data available in 20/21) 5/6 (83.3%) (data available in 6/9) 2/4 (50%) (data available in 4/12) 
Age at MMF/AZA/MTX 
administration (years) 
Median 8.2, mean 10.3, range 2.2-26 
(data available in 19/43) 
Median 16.4, mean 13.9, range 3.5-
18.5 (data available in 9/22) 
Median 12.2, mean 11.6, range 6-
17.1 (data available in 6/15) 
Disease course before treatment with MMF/AZA/MTX 
Time from disease onset to initiation 
of MMF/AZA/MTX (months) 
Median 9.5, mean 16.3, range 1.2-60 
(data available in 18/43) 
Median 5, mean 4.3, range 2-5 (data 
available in 13/29) 
Median 7.5, mean 16.2, range 5-45 
(data available in 4/15) 
≤6 months 8/21 (38.1%) (data available in 21/43) 5/10 (50%) (data available in 10/22) 4/6 (66.7%) (data available in 6/15) 
Number of events before 
MMF/AZA/MTX (including 1st 
events) 
Median 1.5, mean 2.2, range 1-11 (data 
available in 34/43) 
Median 1, mean 1.6, range 1-4  (data 
available in 10/22) 
Median 1.5, mean 2.2, range 1-5 
(data available in 6/15) 
MMF/AZA/MTX after 1st event 17/34 (50%) 6/10 (60%) 3/6 (50%) 
ARR before MMF/AZA/MTX 
(excluding 1st events)# 
Median 0.6, median 1.1, range 0-6.7 
(data available in 12/43) 
Median 0.5, mean 0.8, range 0-2 
(data available in 8/22) 
Median 0.5, mean 0.5, range 0-1.1 
(data available in 2/15) 
Disease course during treatment with MMF/AZA/MTX 
Duration of treatment with 
MMF/AZA/MTX (months) 
Median 9, mean 14, range 1-48 (data 
available in 19/43) 
Median 2, mean 13.3, range 1-36 
(data available in 7/22) 
Median 6, mean 6, range 2-12 (data 
available in 5/15) 
Proportion of patients who relapsed 
during treatment with 
MMF/AZA/MTX 
4/35 (11.4%) (data available in 35/43) 1/10 (10%) (data available in 10/22) 0/6 (0%) (data available in 6/15) 
ARR during treatment with 
MMF/AZA/MTX 
Median 0, mean 0.08, range 0-1.3 (data 
available in 16/43) 
Median 0, mean 0.2, range 0-1 (data 
available in 4/22) 
Median 0, mean 0, range 0-0  (data 
available in 4/15) 
Disease course after discontinuation of MMF/AZA/MTX (if applicable) 
Proportion of patients who 
discontinued treatment with 
MMF/AZA/MTX 
4/16 (25%) (data available in 16/43) 4/7 (57.1%) (data available in 7/22) 4/5 (80%) (data available in 5/15) 
 
Time between discontinuation to last 
follow-up (months) 
Median 14, mean 14, range 6-22 (data 
available in 2/4) 
Median 6, mean 8.3, range 1-18 
(data available in 3/4) 
Mean 13, median 13.2, range 2-25 
(data available in 4/4) 
Proportion of patients who relapsed 
after MMF/AZA/MTX 
discontinuation  
0/4 (0%) (data available in 4/4) 0/3 (0%) (data available in 3/4) 0/4 (0%) (data available in 4/4) 
ARR after MMF/AZA/MTX 
discontinuation 
Median 0, mean 0, range 0-0 (data 
available in 2/4) 
Median 0, mean 0, range 0-0 (data 
available in 2/4) 
Mean 0, median 0, range 0-0 (data 
available in 3/4) 
Adverse reactions to MMF/AZA/MTX and outcome 
Adverse reactions to 
MMF/AZA/MTX 
2/32 (6.2%) (data available in 32/43): 
CMV colitis; respiratory infection 
0/14 (0%) (data available in 14/22) 0/12 (0%) (data available in 12/15) 
Length of follow-up from disease 
onset (years) 
Median 1.9, mean 2.5, range 0.2-8.6 
(data available in 34/43) 
Median 2, median 2.4, range 0.7-5.2 
(data available in 25/29) 
Mean 2.1, median 2.6, range 1-5.2 
(data available in 5/11) 
mRS at last follow-up  (data available in 37/43) (data available in 14/22) (data available in 5/15) 
mRS 0-1 23/37 (62.2%) 8/14 (57.1%) 3/5 (60%) 
mRS 2-3 14/37 (37.8%) 4/14 (28.6%) 2/5 (40%) 
mRS 4-5 0/37 (0%) 2/14 (14.3%) 0/5 (0%) 
 
 
Table 2. Disease course and outcome according to type of maintenance immune therapy 
(mycophenolate mofetil / azathioprine / methotrexate) in the literature cohort of patients with paediatric-
onset anti-NMDAR encephalitis treated with mycophenolate mofetil, azathioprine and/or methotrexate. 
Denominators vary according to data availability. 
Legend: anti-NMDAR: anti-N-methyl-D-aspartate receptor; AZA: azathioprine; CMV: 
cytomegalovirus; CYC: cyclophosphamide; IVIG: intravenous immunoglobulin; MMF: mycophenolate 
mofetil; mRS: modified Rankin Scale; MTX: methotrexate; PE: plasma exchange; RTX: rituximab. 
*1/43 of these patients also received AZA, and 1/43 also received MTX 
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**2/22 of these patients also received MTX, and 1/22 also received MMF 
**2/15 of these patients also received AZA, and 1/15 also received MMF 
#In the 72/76 patients who received monotherapy with mycophenolate mofetil, azathioprine or 
methotrexate, the median ARR before steroid sparers was 1.4 (mean 2.1, range 0.6-7.3; data available in 
16/72) (including the first episode) (median 0.45, mean 1, range 0-6.67 after excluding the first episode; 
data available in 16/72) 
 
 
Efficacy of mycophenolate mofetil, azathioprine and methotrexate. Among the 25 patients in whom 
mycophenolate mofetil, azathioprine and/or methotrexate were given after the first event, relapses 
occurred in 8.3% (2/24; data available in 24/25). Among the 22 patients in whom mycophenolate 
mofetil, azathioprine and/or methotrexate were given after at least one relapse had occurred, further 
relapses occurred in 18.2% (4/22; data available in 22/22). 
Among the 28 patients with relapsing disease course, in only 8.3% (2/24; data available in 24/28) 
steroid sparers had been given after the first event. During treatment with these agents, relapses 
occurred in 10.4% (5/48) patients (total 6 relapses in 5 patients). Proportion of patients who had relapses 
whilst on treatment with mycophenolate mofetil, azathioprine and/or methotrexate was similar for 
mycophenolate mofetil (4/35, 11.4%) and azathioprine (1/10, 10%), whereas no patients relapsed whilst 
on methotrexate (0/6, 0%). 
In the 72/76 patients who received monotherapy with mycophenolate mofetil, azathioprine or 
methotrexate (rather than a combination of these agents), the median ARR before steroid sparers was 
0.45 (mean 1, range 0-6.67; data available in 16/72) (excluding the first episode), and median ARR 
during/after steroid sparers was 0 (mean 0.06, range 0-1.3; data available in 22/72). In the 9/72 patients 
with monotherapy and availability of both ARR pre and during/after steroid sparing agents, ARR before 
treatment (excluding first events) was median 0.5 (mean 1.14, range 0-6.67), and ARR during/after 
treatment was median 0 (mean 0.19, range 0-1.3). ARR data subdivided according to steroid sparing 
agent received are represented in Table 2, with the limitation imposed by the restricted number of cases.  
Tolerability of mycophenolate mofetil, azathioprine and methotrexate. Adverse reactions were reported 
only for mycophenolate mofetil in 2 cases, with grade 3 severity according to the Common 
Terminology Criteria for Adverse Events v4.0 (CTCAE) (severe or medically significant, but not 
immediately life-threatening) (cytomegalovirus colitis and respiratory infection, respectively). 
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Treatment-related factors influencing relapse risk. The proportion of patients who relapsed was 
significantly higher among patients in whom the first immune therapy (any) was started late (>30 days 
after onset) (6/7, 85.7%; second-line treatments used in 5/7 of these, 71.4%) than in patients who were 
treated early (5/16, 31.2%; second-line treatments used in 9/16 of these, 56.2%) (p=0.0272). Among the 
patients not treated with second-line immune therapy after the first event, further relapses after second-
line therapy occurred in 50% (5/10), while in patients treated with second-line immune therapy after the 
first event relapses occurred in 16.7% (3/18) (p=0.0913). Relapse rate was only marginally higher 
among patients in whom mycophenolate mofetil, azathioprine or methotrexate were started after 6 
months from onset (10/17, 58.8%; second-line treatments used in 11/17 of these, 64.7%), than in those 
treated within 6 months from onset (8/16, 50%; second-line treatments used in 6/16 of these, 37.5%) 
(p=0.7319). 
 
 
Discussion 
Our systematic literature review disclosed that the use of mycophenolate mofetil, azathioprine and 
methotrexate in paediatric-onset anti-NMDAR encephalitis is quite heterogeneous. Firstly, while all 
patients in our literature cohort received first-line immune therapy before steroid sparers, second-line 
treatments (rituximab and/or cyclophosphamide) were administered only in 52.3% (34/65). Secondly, 
there was a huge variability in the timing of initiation of maintenance immune therapy with 
mycophenolate mofetil, azathioprine and methotrexate, with only 50% (17/34) of the patients started on 
one of these agents within 6 months from onset. Similarly, only in 53.2% were these treatments started 
after the first event (25/47), whereas for the remaining part they were introduced only after one or more 
relapses had occurred. In this regard, the high relapse rate in our literature cohort (28/57, 49.1%), as 
compared to that of the largest series available so far (12%) [Titulaer, 2013], confirms that steroid 
sparers are often used only after relapses have occurred.  
The duration of maintenance treatment with steroid sparing agents was also highly variable in our 
literature cohort, reflecting the lack of recommendations [Shin, 2017]. Indeed, it is unclear how long the 
inflammatory component of disease lasts for. In this respect, the correlation between anti-NMDAR 
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antibodies and clinical course is unclear [Mariotto, 2017], while there is some correlation of CXCL13 
and disease severity and relapse [Kothur, 2016; Kothur, 2017] that may be useful in guiding treatment.  
It is still unclear in the available literature whether long-term immunosuppression with oral agents is 
effective in reducing the relapse rate of autoimmune encephalitis [Shin, 2017]. In the subset of patients 
who were started on maintenance immune therapy after the first event, relapse rate (2/24, 8.3%) 
appeared to be slightly lower than that reported in some of the main literature series, where this figure 
mostly ranges between 12% [Titulaer, 2013] and 22.7% [Irani, 2010; Wright 2015; Shin, 2017]. 
Although, our result is limited by the very small number of cases in this subgroup of patients.  
In our literature cohort, there was a higher relapse rate among patients in whom the first immune 
therapy was started late (>30 days after onset) (6/7, 85.7%) than in patients who were treated early 
(5/16, 31.2%). Similarly, a late start of mycophenolate mofetil, azathioprine or methotrexate (after 6 
months from onset) seemed to associate with a slightly higher proportion of patients who relapsed 
(10/17, 58.8%), as compared to those treated early (8/16, 50%). These results are consistent with 
previous data in the literature, supporting early commencement of immune therapy [Nosadini, 2015].    
In our literature cohort, the use of mycophenolate mofetil prevailed over azathioprine and methotrexate. 
These agents were administered also in young ages, especially as regards mycophenolate mofetil and 
azathioprine. Adverse reactions were reported only for mycophenolate mofetil in 2 cases 
(cytomegalovirus colitis and respiratory infection) [Brenton, 2016]. Although, it should be noticed that 
side effects were probably under-reported and lacking in details in our review, since none of the articles 
were focused on drug tolerability.  
Our literature review is limited by several factors. The retrospective nature of data collection 
unavoidably impacts on data accuracy and completeness. Several pieces of information, such as drug 
doses and monitoring, could not be retrieved in the great majority of papers and therefore were omitted. 
Severity of disease was estimated via the mRS score, although this scale was not designed to detect and 
render the vast array of disturbances that characterise anti-NMDAR encephalitis, especially as regards 
movement disorder, autonomic disturbances, psychiatric symptoms and neuropsychological changes 
[Matricardi, 2016]. Moreover, when not given in the original report, the mRS was scored by only one of 
the main authors (MN). ARR (Table 2) was calculated in order to provide data on the tendency to 
relapse before, during and after treatment with mycophenolate mofetil, azathioprine, or methotrexate; 
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although, the utility of ARR in this setting is strongly limited by the consideration that, although 
recurrences are possible, anti-NMDAR encephalitis is typically not a chronic relapsing disease. The 
analysis of the results of our literature review is also limited by the restricted number of patients, 
especially when subdivided according to treatment type; therefore, a comparison between efficacy of 
mycophenolate mofetil, azathioprine and methotrexate could not be carried out. In view of the inclusion 
criteria, also a direct comparison between disease course in the patients who did and did not receive one 
of these agents could not be performed; this would be of great clinical interest and warrants further 
studies. Similarly, the efficacy of steroid sparers for sustained remission and relapse prevention should 
be explored further in comparison to other approaches proposed in the literature, such as monthly 
rituximab, IVIG or plasma exchange, or sustained use of oral corticosteroids [Shin, 2017; Dale, 2017]. 
Despite these important limitations, our literature review is the first work exploring most frequent 
current treatment modes, efficacy and tolerability of mycophenolate mofetil, azathioprine, and 
methotrexate in paediatric-onset anti-NMDAR encephalitis. Our review disclosed a huge heterogeneity 
in the use of these agent in paediatric-onset anti-NMDAR encephalitis, especially as regards the overall 
associated immune therapies, the timing and the duration of treatment.  
Our review highlights the need for improved data in larger cohorts. While paediatric anti-NMDAR 
encephalitis is usually characterised by a relatively good outcome, relapses are possible. Likewise as 
highlighted in this review, some clinicians use steroid sparing agents early in disease course, and 
without relapse, presumably to potentially reduce the steroid burden. However, the ‘risk versus benefit’ 
of this practice, as this review demonstrates, is unclear.  
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Abstract  
Background. Recommendations and data on mycophenolate mofetil (MMF) use, safety and efficacy in 
paediatric neuroimmunology are limited, and information is mostly derived from other fields of 
paediatrics.  
Methods. Retrospective, international study on children treated with MMF for autoimmune or immune-
mediated CNS conditions, with focus on MMF modes of use, efficacy and safety. 
Results. 44 children were included (30/44, 68.2% females). 43.2% (19/44) had proven or suspected 
autoimmune encephalitis, 31.8% (14/44) autoimmune inflammatory demyelinating CNS diseases, and 
25% (11/44) other autoimmune/immune-mediated CNS conditions. Worst mRS was median 4 (range 2-
6). Disease course was relapsing in 52.3% (23/44), monophasic in 38.6% (17/44), and chronic/chronic-
progressive in 9.1% (4/44). Before MMF, all patients received first-line (steroids: 44/44, 100%; 
intravenous immunoglobulin: 23/44, 52.3%; plasma exchange: 14/44, 31.8%) and 38.6% (17/44) 
second-line immune therapies (cyclophosphamide: 12/44, 27.3%; rituximab: 6/44, 13.6%). Median age 
at MMF commencement was 9.3 years (range 1.4-16.4). MMF was started at median 9.5 months from 
onset (range 1-127; ≤6 months in 31.8%, 14/44). In 55% (22/40) of patients, MMF was started only 
after ≥2 events had occurred. Median duration of MMF treatment was 18 months (mean 23.2, range 0.3-
73). Median annualised relapse rate (excluding patients with chronic/chronic-progressive disease) was 
0.52 (mean 0.86, range 0-3) before MMF (excluding first events), and 0 (mean 0.36, range 0-4.64) 
during MMF. 20.5% (8/39) patients relapsed during MMF; compared to patients who did not relapse 
(31/49, 79.5%), these patients were younger (median age at onset 4.2 years versus 7.6), were more 
frequently females (8/8, 100% versus 21/31, 67.7%), had lower rate of second-line treatments before 
MMF (1/8, 12.5% versus 15/31, 48.4%), a later commencement of MMF (>6 months after onset in 7/8, 
87.5% versus 22/35, 58.1%), and more frequently they were started on MMF only after ≥2 events had 
occurred (7/8, 87.5% versus 14/35, 45.2%). Adverse reactions to MMF occurred in 18.2% (8/44) of 
cases (6/8: grade 2, 2/8: grade 3 CTCAE v4.0). 
Significance. MMF modes of use in paediatric neuroimmunology are heterogenous, although relatively 
safe. Second-line treatments before MMF and early MMF commencement after onset seem to associate 
with lower probability of relapsing during MMF. Larger studies on MMF efficacy and safety should be 
warranted. 
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Introduction 
Mycophenolate mofetil (MMF) is an immunosuppressive agent approved for transplant rejection 
prophylaxis in the United States and Europe in the mid-1990s. MMF is a prodrug of mycophenolic acid, 
an inhibitor of the rate-limiting enzyme in de novo synthesis of purine nucleotides. [Nosadini, 2017; 
Filler, 2017], and it exerts a specific and potent cytostatic effect on T and B lymphocytes, blocking their 
proliferative response [Filler, 2017]. Beside its wide use as a maintenance anti-rejection drug in 
transplants, MMF is also largely used as a steroid-sparing agent for chronic immunosuppression in 
rheumatology and in neurologic autoimmune and immune-mediated conditions. MMF has been used for 
nearly two decades in myasthenia gravis [Gotterer, 2016], and has been reported to reduce disease in 
dermatomyositis and polymyositis [Marie, 2011; Johnson, 2015], while its utility in multifocal motor 
neuropathy and chronic inflammatory demyelinating polyneuropathy is still to be clarified [Umapathi, 
2015; Cocito, 2011]. In central nervous system (CNS) autoimmune and immune-mediated conditions, 
MMF has been increasingly used in relapsing demyelinating diseases such as neuromyelitis optica 
[Chen, 2017; Xu, 2016; Montcuquet, 2017] and MOG-associated disease [Montcuquet, 2017], while its 
role in multiple sclerosis has not been completely clarified yet [Frohman, 2010; Etemadifar; 2011; 
Pandit, 2014; Xiao, 2014]. Other uses in CNS disease include autoimmune/immune-mediated 
encephalitis [Nosadini, 2015; Titulaer, 2013] and cerebral vasculitis [Pagnoux, 2016; Rosati, 2017]; on 
the other hand, a limited utility of MMF has been reported in opsoclonus myoclonus ataxia syndrome 
[Pranzatelli, 2009].  
Most of available data on MMF efficacy and tolerability in neurology are derived from adult studies, as 
information in children is limited. In this context, we carried out a retrospective study on paediatric 
patients treated with MMF for autoimmune or immune-mediated CNS conditions, in order to gather 
data on safety and efficacy of MMF in this clinical context.  
 
 
Methods 
Study design and setting. Retrospective, multicenter study based on four paediatric neurology centers: 
The Children's Hospital at Westmead in Sydney (Australia) (RCD, MN), KK Women’s & Children’s 
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Hospital in Singapore (Singapore) (TT), Evelina London Children's Hospital in London (England) (ML, 
JG) and Department of Women's and Children's Health in Padua (Italy) (MN, SS).  
Inclusion criteria. Paediatric patients (<18 years) treated with MMF for autoimmune or immune-
mediated CNS conditions in one of the four centers participating to the study. Both 
monophasic/relapsing and chronic/chronic-progressive diseases were included. 
Data collection. Data collection was carried out between April 2016 and September 2017 via an ad hoc 
questionnaire created for the present study (RCD, MN) (Supplementary material). The questionnaire 
was filled in by the treating physician (RCD, MN, ML, JG, TT), and subsequently discussed on the 
phone when clarifications were necessary. The clinical indications for MMF administration were 
grouped into encephalitis, inflammatory demyelinating CNS diseases, epilepsies, and other 
autoimmune/immune-mediated CNS conditions (Table 1). Other therapies received beside MMF were 
categorised into first-line (corticosteroids, intravenous immunoglobulin, plasma exchange), second-line 
(cyclophosphamide, rituximab) and maintenance treatments (azathioprine, methotrexate). The modified 
Rankin Scale (mRS) [van Swieten, 1988] was scored by the treating physician to measure disease 
severity in the acute phase and neurological outcome at last follow-up. Patients with chronic/chronic-
progressive disease course were excluded from calculation of number of disease events, proportion of 
patients who relapsed during and after MMF treatment, and annualised relapse rate (ARR). ARR was 
calculated as the number of disease events multiplied by 12 (months), divided by the number of months 
during which the events occurred (calculated only for time intervals ≥6 months). ARR was calculated 
before (excluding first events), during and after treatment with MMF. Adverse reactions to MMF were 
classified using the Common Terminology Criteria for Adverse Events (CTCAE v4.0), into grade 1 
(mild), 2 (moderate), 3 (severe or medically significant but not immediately life-threatening), 4 (life-
threatening consequences) and 5 (death) [ref]. Data collection was subject to data availability, therefore 
in the results section of this work denominators may differ.  
 
 
Results 
Demographics, clinical characteristics, disease course and outcome. 44 patients treated with MMF for 
autoimmune or immune-mediated CNS conditions were included (30/44, 68.2% females) (Table 1). The 
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most frequent diagnosis was proven or suspected autoimmune encephalitis (19/44, 43.2%), followed by 
autoimmune inflammatory demyelinating CNS diseases (14/44, 31.8%) and other autoimmune or 
immune-mediated CNS conditions (11/44, 25%). Worst mRS at any stage of disease was median 4 
(mean 4.1, range 2-6; data available in 44/44 patients). Overall, 52.3% of the patients had a relapsing 
disease course (23/44), 38.6% (17/44) had monophasic disease, and 9.1% (4/44) had a chronic/chronic-
progressive course (Table 1). Relapsing disease course was more frequent in patients with inflammatory 
demyelinating CNS diseases (11/14, 78.6%) than in patients with encephalitis (8/19, 42.1%) and other 
autoimmune or immune-mediated CNS conditions 36.4% (4/11). A total 130 disease events occurred in 
40 patients (40 first events and 90 subsequent relapses) (Supplementary Table 1): 113 events in 23 
patients with relapsing disease (including first events) (median 4 events per patient, mean 4.9, range 2-
25), and 17 events in 17 patients with monophasic disease. Disease severity was worse at first events 
(median mRS 4, mean 4, range 2-5; data available in 36/40 first events) as compared to subsequent 
events (median mRS 3, mean 2.9, range 1-5; data available in 58/90 subsequent events). At a median 
follow-up of 3.8 years (mean 4.8, range 1-14.3; data available in 44/46 patients), median mRS was 1 
(mean 1.5, range 0-6; data available in 44/44 patients). 
Data on treatment and MMF use. As per inclusion criteria, all children in the study population received 
MMF. All patients received other immune therapies before MMF (44/44, 100%); second-line immune 
treatments (cyclophosphamide and/or rituximab) were used in 38.6% of patients before MMF (17/44), 
and in 47.7% (21/44) during the whole disease course (Table 2). Median time from onset to first 
immune therapy was 24 days (mean 107, range 3-2190; data available in 37/44 patients). Median age at 
MMF commencement was 9.3 years (mean 9.4, range 1.4-16.4); 68.2% of patients were ≤12 years old 
when started on MMF (30/44). MMF was started at median 9.5 months from disease onset (mean 21.4, 
range 1-127; data in 44/44 patients); only in 31.8% was MMF started within 6 months from onset 
(14/44). In 55% of patients, MMF was started only after ≥2 events had occurred (22/40) (excluding 
patients with chronic/chronic-progressive disease). Duration of MMF treatment was median 18 months 
(mean 23.2, range 0.3-73; ≥6 months in 40/43, 93%; data available in 43/44 patients). 50% (22/44) of 
the patients discontinued MMF: of these, 66.7% (14/21) discontinued it due to absence of relapses, 
23.8% (5/21) for possible inefficacy, and 9.5% (2/21) due to side effects.  
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Table 1 
 
DEMOGRAPHICS AND CLINICAL CHARACTERISTICS IN THE TOTAL COHORT (n=44) 
Demographics  
Age at disease onset (years) Median 7, mean 7.7, range 0.9-15.7 (data available in 44/44) 
Gender 30/44 (68.2%) females 
Referring Center 17/44 (38.6%) Sydney; 10/44 (22.7%) Padova; 9/44 (20.4%) London; 8/44 (18.2%) 
Singapore 
Diagnosis  
Encephalitis 19/44 (43.2%) 
Anti-NMDAR encephalitis 12/44 (27.3%) 
Seronegative suspected autoimmune encephalitis 5/44 (11.4%) 
Anti-D2R encephalitis 1/44 (2.3%) 
Anti-GAD encephalitis  1/44 (2.3%) 
Inflammatory demyelinating CNS diseases 14/44 (31.8%) 
MOG-associated demyelinating disease 9/44 (20.4%)* 
Neuromyelitis optica spectrum disorders (NMOSD) 3/44 (6.8%) (3/3 NMO-IgG or anti-AQP4 antibody positive) 
Multiple sclerosis 1/44 (2.3%) 
Chronic relapsing inflammatory optic neuropathy (CRION) 1/44 (2.3%) 
Other autoimmune/immune-mediated CNS conditions 11/44 (25%) 
Neuropsychiatric systemic lupus erythematosus 3/44 (6.8%) 
Cerebral vasculitis 3/44 (6.8%) 
Paediatric acute-onset neuropsychiatric syndrome 
(PANS/PANDAS) 
2/44 (4.5%) 
Relapsing autoimmune chorea 1/44 (2.3%) 
Opsoclonus myoclonus ataxia syndrome (OMAS) 1/44 (2.3%) 
Genetic autoinflammation 1/44 (2.3%) 
Disease course  
Multiphasic (relapsing) 23/44 (52.3%) (total events/patient: median 4, mean 4.9 events, range 2-25; data available 
in 23/23)  
Monophasic 17/44 (38.6%) 
Chronic/chronic-progressive 4/44 (9.1%)** 
Disease severity  
Worst mRS during the disease course Median 4, mean 4.1, range 2-6 (data available in 44/44)# 
Admission to paediatric intensive care unit in the acute phase 14/43 (32.5%) (data available in 43/44) 
Outcome  
Length of follow-up (years) Median 3.8, mean  4.8, range 1-14.3 (data available in 44/44) 
mRS at last follow-up Median 1, mean 1.5, range 0-6 (data available in 44/44)# 
No ongoing problems 10/43 (23.2%) 
Ongoing cognitive or learning problems 21/43 (48.8%) 
Ongoing behavioural problems 11/43 (25.6%) 
Ongoing motor problems 6/43 (13.9%) 
Ongoing visual impairment 5/43 (11.6%) 
Ongoing epilepsy 7/43 (16.3%) 
Other ongoing problem 8/43 (18.6%) 
Ongoing immune therapy at last follow-up 30/43 (69.8%) 
MMF 14/30 (46.7%) 
MMF + Oral steroids 6/30 (20%) (prednisone 5/6, dexamethasone 1/6) 
Intravenous immunoglobulin + Oral steroids 2/30 (6.7%) (hydrocortisone 1/2, prednisone 1/2) 
Other 8/30 (26.7%): IVIG 1/30 (3.3%); Oral steroids 1/30 (3.3%); MMF + RTX 1/30 (3.3%); 
MMF + Hydroxychloroquine 1/30 (3.3%); Sirolimus + Oral steroids 1/30 (3.3%); MMF + 
Tacrolimus + Oral steroids 1/30 (3.3%); MMF + Intravenous and oral steroids 1/30 (3.3%); 
MMF + IVIG + Oral steroids 1/30 (3.3%) 
 
Table 1. Demographics and clinical characteristics of 44 paediatric patients with central nervous system 
autoimmune or immune-mediated inflammatory diseases treated with mycophenolate mofetil. 
Legend: Anti-NMDAR: anti-N-methyl-D-Aspartate; AQP4: aquaporin-4; CNS: central nervous system; 
CRION: chronic relapsing inflammatory optic neuropathy; D2R: dopamine 2 receptor; GAD: glutamate 
decarboxylase; IVIG: intravenous immunoglobulin; MMF: mycophenolate mofetil; MOG: 
myelin oligodendrocyte glycoprotein; mRS: modified Rankin Scale; NMOSD: neuromyelitis optica 
spectrum disorder; OMAS: opsoclonus myoclonus ataxia syndrome; RTX: rituximab. 
*Phenotype in the 9 MOG positive patients: 2/9 multiphasic ADEM, 2/9 NMOSD, 2/9 CRION, 2/9 
other relapsing MOG-associated demyelinating disease, 1/9 other monophasic MOG-associated 
demyelinating disease. 
**The 4 patients with chronic/chronic-progressive disease course were: 1 boy with seronegative 
suspected autoimmune encephalitis with onset at 3.3 years; 1 boy with neuropsychiatric systemic lupus 
erythematosus with onset at 9.1 years; 1 boy with paediatric acute-onset neuropsychiatric syndrome 
with onset at 7 years; 1 boy with suspected genetic autoinflammatory disease with onset at 11 months, 
who died at 7.7 years. 
#1 patient with genetic autoinflammation and chronic-progressive disease course died 7.7 years from 
onset. 
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Table 2 
 
DATA ON TREATMENT, 
MMF USE AND EFFICACY 
ACCORDING TO DIAGNOSIS 
All patients  
(n=44) 
Encephalitis  
(n=19) 
Inflammatory 
demyelinating CNS 
diseases (n=14) 
Other 
autoimmune/immune-
mediated CNS conditions 
(n=11) 
Treatments other than MMF Before MMF During the 
whole 
disease 
course 
Before MMF During the 
whole 
disease 
course 
Before MMF During the 
whole 
disease 
course 
Before MMF During the 
whole 
disease 
course 
Any steroids 44/44 
(100%) 
44/44 
(100%) 
19/19 
(100%) 
19/19 
(100%) 
14/14 
(100%) 
14/14 
(100%) 
11/11 
(100%) 
11/11 
(100%) 
Intravenous steroids 39/44 (88.6 
%) 
41/44 
(93.2%)* 
18/19 
(94.7%) 
19/19 
(100%) 
13/14 
(93.8%) 
13/14 
(93.8%) 
8/11 (72.7%) 9/11 (81.8%) 
Oral steroids 44/44 
(100%) 
44/44 
(100%) 
19/19 
(100%) 
19/19 
(100%) 
14/14 
(100%) 
14/14 
(100%) 
11/11 
(100%) 
11/11 
(100%) 
Intravenous immunoglobulin 23/44 
(52.3%) 
28/44 
(63.6%) 
14/19 
(73.7%) 
14/19 
(73.7%) 
5/14 (35.7%) 8/14 (57.1%) 4/11 (36.4%) 6/11 (54.5%) 
Plasma exchange 14/44 
(31.8%) 
14/44 
(31.8%) 
11/19 
(57.9%) 
11/19 
(57.9%) 
3/14 (21.4%) 3/14 (21.4%) 0/11 (0%) 0/11 (0%) 
Second-line therapy 
(Cyclophosphamide and/or 
Rituximab) 
17/44 
(38.6%) 
21/44 
(47.7%) 
10/19 
(52.6%) 
13/19 
(68.4%) 
2/14 (14.3%) 2/14 (14.3%) 5/11 (45.4%) 6/11 (54.5%) 
Cyclophosphamide 12/44 
(27.3%) 
14/44 
(31.8%) 
7/19 (36.8%) 7/19 (36.8%) 1/14 (7.1%) 1/14 (7.1%) 4/11 (36.4%) 6/11 (54.5%) 
Rituximab 6/44 (13.6%) 9/44 (20.4%) 3/19 (15.8%) 6/19 (31.6%) 1/14 (7.1%) 1/14 (7.1%) 2/11 (18.2%) 2/11 (18.2%) 
Azathioprine 4/44 (9.1%) 4/44 (9.1%) 1/19 (5.3%) 1/19 (5.3%) 0/14 (0%) 0/14 (0%) 3/11 (27.3%) 3/11 (27.3%) 
Other 1/44 (2.3%) 3/44 
(6.8%)** 
0/19 (0%) 0/19 (0%) 0/14 (0%) 0/14 (0%) 1/11 (9.1%) 3/11 (27.3%) 
Time from disease onset to first 
immune therapy (any) 
    
Days from disease onset to first 
immune therapy 
Median 24, mean 107, range 
3-2190 (data available in 
37/44) 
Median 25, mean 52.5, 
range 6-365 (data available 
in 18/19) 
Median 15, mean 55.6, 
range 3-221 (data available 
in 11/14) 
Median 19, mean 300.4, 
range 4-2190 (data available 
in 8/11) 
First immune therapy ≤30 days 
from onset 
28/40 (70%) (data available 
in 40/44) 
14/19 (73.7%) (data 
available in 19/19) 
8/12 (66.7%) (data available 
in 12/14) 
6/9 (66.7%) (data available 
in 9/11) 
Age at MMF commencement 
(years) 
Median 9.3, mean 9.4, range 
1.4-16.4 (data available in 
44/44) 
Median 8.8, mean 8.3, range 
1.9-16.4 (data available in 
19/19) 
Median 8.7, mean 9.7, range 
3.6-15.6 (data available in 
14/14) 
Median 12.8, mean 10.9, 
range 1.4-16 (data available 
in 11/11) 
≤6 years 14/44 (31.8%) 7/19 (36.8%) 4/14 (28.6%) 3/11 (27.3%) 
7-12 years 16/44 (36.4%) 7/19 (36.8%) 6/14 (42.8%) 3/11 (27.3%) 
≥13 years 14/44 (31.8%) 5/19 (26.3%) 4/14 (28.6%) 5/11 (45.4%) 
Time from disease onset to MMF 
(months) 
Median 9.5, mean 21.4, 
range 1-127 (data in 44/44) 
Median 8, mean 17.3, range 
2-117 (data available in 
19/119) 
Median 12.7, mean 28, 
range 1-127 (data available 
in 14/14) 
Median 11, mean 20.1, 
range 2-96 (data available in 
11/11) 
≤6 months 14/44 (31.8%) 5/19 (26.3%) 5/14 (35.7%) 4/11 (36.4%) 
7-12 months 13/44 (29.5%) 8/19 (42.1%) 2/14 (14.3%) 3/11 (27.3%) 
≥13 months 17/44 (38.6%) 6/19 (31.6%) 7/14 (50%) 4/11 (36.4%) 
Number of events before MMF 
commencement (including first 
events)# 
Median 2, mean 2.2, range 
1-6 (data available in 40/44) 
Median 1, mean 1.9, range 
1-5 (data available in 18/19) 
Median 3, mean 2.8, range 
1-6 (data available in 14/14) 
Median 1, mean 1.9, range 
1-4 (data available in 8/11) 
1 event 18/40 (45%) 10/19 (52.6%) 3/14 (21.4%) 5/8 (62.5%) 
2 events 7/40 (17.5%) 5/19 (26.3%) 2/14 (14.3%) 0/8 (0%) 
≥3 events 15/40 (37.5 %) 3/19 (15.8%) 9/14 (64.3%) 3/8 (37.5%) 
Time on MMF (months) Median 18, mean 23.2, 
range 0.3-73 (data available 
in 43/44) 
Median 16, mean 22.7, 
range 7-62 (data available in 
19/19) 
Median 17.5, mean 20.1, 
range 0.3-40 (data available 
in 14/14) 
Median 25, mean 25.5, 
range 1-73 (data available in 
10/11) 
≤6 months 3/43 (7%) 0/19 (0%) 1/14 (7.1%) 2/10 (20%) 
7-12 months 10/43 (23.2%) 6/19 (31.6%) 3/14 (21.4%) 1/10 (10%) 
13-24 months 12/43 (27.9%) 6/19 (31.6%) 5/14 (35.7%) 1/10 (10%) 
≥25 months 18/43 (41.9%) 7/19 (36.8%) 5/14 (35.7%) 6/10 (60%) 
Number of patients who relapsed 
during MMF# 
8/39 (20.5%) 4/18 (22.2%) 3/14 (21.4%)  1/7 (14.3%) 
Proportion of patients who 
discontinued MMF at any time 
during disease course  
23/44 (52.3%) (4/23 
subsequently were restarted 
on MMF) 
10/19 (52.6%) 8/14 (57.1%) 5/11 (45.4%) 
Time after MMF discontinuation Median 12, mean 16.2, 
range 0-46 (data available in 
22/23 patients) 
Median 19, mean 19.3, 
range 0-38 (data available in 
10/10 patients) 
Median 9, mean 12.4, range 
0-46 (data available in 8/8) 
Median 15.5, mean 15.7, 
range 2-30 (data available in 
4/5) 
≤6 months 7/22 (31.8%) 2/10 (20%) 3/8 (37.5%) 2/4 (50%) 
7-12 months 4/22 (18.2%) 1/10 (10%) 3/8 (37.5%) 0/4 (0%) 
≥13 months 11/22 (50%) 7/10 (70%) 2/8 (25%) 2/4 (50%) 
Number of patients who relapsed 
after MMF discontinuation# 
4/21 (19%) (3/4 had also 
relapsed whilst on MMF) 
1/10 (10%) 2/8 (25%) 1/3 (33.3%) 
Efficacy     
ARR before MMF (excluding first 
events)# 
Median 0.52, mean 0.86, 
range 0-3 (data available in 
29/44) 
Median 0.45, mean 0.78, 
range 0-3 (data available in 
14/19) 
Median 0.52, mean 0.86, 
range 0-2.18 (data available 
in 9/14) 
Median 1, mean 1.05, range 
0-2.18 (data available in 
6/11) 
ARR during MMF# Median 0, mean 0.36, range 
0-4.64 (data available in 
37/44) 
Median 0, mean 0.43, range 
0-4.6 (data available in 
18/19) 
Median 0, mean 0.42, range 
0-3 (data available in 13/14) 
Median 0, mean 0.06, range 
0-0.37 (data available in 
6/11) 
ARR after MMF discontinuation# Median 0, mean 0.15, range 
0-1.5 (data available in 
13/19) 
Median 0, mean 0, range 0-0 
(data available in 6/9) 
Median 0, mean 0.3, range 
0-1.5 (data available in 5/7) 
Median 0.21, mean 0.21, 
range 0-0.43 (data available 
in 2/11) 
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Table 2. Data on mycophenolate mofetil use, efficacy and safety in 44 paediatric patients with central 
nervous system autoimmune or immune-mediated inflammatory diseases treated with mycophenolate 
mofetil, according to diagnosis. 
Legend: ARR: annualized relapse rate; CNS: central nervous system; CTCAE: common terminology 
criteria for adverse events; MMF: mycophenolate mofetil. 
*Intravenous steroids were: intravenous methylprednisolone in 40/41; intravenous dexamethasone in 
1/41 
**Other immune therapies received in 3/44 patients were: cyclosporine and rapamycin in 1/3; 
hydroxychloroquine in 1/3; tacrolimus in 1/3 
#Excluding 4 patients with chronic/chronic-progressive disease course. 
 
 
MMF efficacy. Median ARR (excluding patients with chronic/chronic-progressive disease) was 0.52 
(mean 0.86, range 0-3; data available in 29/44) before MMF (excluding first events), and 0 (mean 0.36, 
range 0-4.64; data available in 37/44) during MMF (Table 2). After MMF, median ARR was 0 (mean 
0.15, range 0-1.5; data available in 13/19 patients who discontinued MMF).  
20.5% patients relapsed during treatment with MMF (8/39), and 19% after MMF discontinuation (4/21; 
3/4 of these had also relapsed whilst on MMF) (excluding patients with chronic/chronic-progressive 
disease). In the 8 patients who relapsed whilst on MMF, a total of 34 events occurred on MMF (median 
1.5, mean 4.2, range 1-23) (Table 3). Time from MMF commencement to the clinical event was median 
6 months (mean 12.8, range 2-49; data available in 11/34 events). 72.7% (8/11) of the events occurred 
whilst on MMF and with available information were during tapering or within 2 months from cessation 
of immune therapy: 4/8 occurred during tapering of oral steroids, 2/8 within 2 months after cessation of 
oral steroids, and 2/7 during MMF weaning. The remaining 3/11 events on MMF, that did not occur 
whilst tapering immune therapy, occurred in 2 patients: 2 events in a 2 year-old girl with highly 
relapsing MOG-associated demyelinating disease (7 total events), respectively at 5 and 13 months after 
MMF initiation (this patient also had a further event 4 months after discontinuation of MMF); and 1 
event in a 14.1 year old girl with cerebral vasculitis, 24 months after MMF commencement (total 
disease events: 4).  
 
 
 
 
194 
 
Table 3 
 
STUDY OF 34 DISEASE EVENTS OCCURRED IN 8 PATIENTS WHILST ON MMF  
Gender, age at onset (diagnosis) Event 
number 
(includin
g 1st 
event) 
Time from 
MMF 
commencement 
to the event 
MMF dose at the event Other 
immune 
therapy at 
the event 
Medication weaning 
F, 3.2 y (MOG-associated 
demyelinating disease: ADEM)      
4 8 mo 20 mg/kg/day (200 mg BD; bw 20 kg) No No, but OP stopped 2 mo prior to 
the event 
F, 5.2 y (MOG-associated 
demyelinating disease: CRION)     
4 2 mo 22 mg/kg/day (500 mg BD, bw 45 kg) OP 5 mg 
OD 
OP tapering 
5 5.5 mo 22 mg/kg/day (500 mg BD, bw 45 kg) OP 15 mg 
alt. days 
OP tapering (last dose lowering: 
2 weeks prior to the event) 
*F, 14.1 y (Cerebral vasculitis)       3 24 mo 48 mg/kg/day (1000 mg BD; bw 42 kg) No No 
4 49 mo 18.9 mg/kg/day (500 mg BD, bw 53 
kg) 
No MMF tapering (started 5 mo 
prior to the event; last dose 
lowering: 1 month prior to the 
event) 
~F, 1.6 y (Seronegative 
suspected autoimmune 
encephalitis) 
3 20 mo 16 mg/kg/day (150 mg BD; bw 19 kg) No MMF tapering (started 1 mo 
prior to the event) 
F, 9.7 y (anti-NMDAR 
encephalitis) 
3 6 mo Dose/kg/day n.a. (600 mg/m2; bw 48 
kg) 
OP 5 mg 
alternate 
days 
OP tapering (started 9 mo prior 
to the event; last dose lowering: 1 
wk prior to the event) 
#F, 2 y (MOG-associated 
demyelinating disease)   
4 n.a. 55 mg/kg/day (400 mg BD; bw 14.5 
kg)  
No OP stopped <1 mo prior to the 
event 
5 n.a. 55 mg/kg/day (400 mg BD; bw 14.5 
kg) 
No No 
6 13 mo Dose/kg/day n.a. (400 mg BD; bw n.a) No No 
F, 2.2 y (seronegative suspected 
autoimmune encephalitis)               
3 n.a. Dose/kg/day n.a. (500 mg BD; bw n.a.) OP, IVIG n.a. 
4 n.a. Dose/kg/day n.a. (500 mg BD; bw n.a.) OP, IVIG n.a. 
5 n.a. Dose/kg/day n.a. (500 mg BD; bw n.a.) OP, IVIG n.a. 
6 n.a. Dose/kg/day n.a. (500 mg BD; bw n.a.) OP, IVIG n.a. 
7 n.a. Dose/kg/day n.a. (500 mg BD; bw n.a.) OP, IVIG n.a. 
8 n.a. Dose/kg/day n.a. (500 mg BD; bw n.a.) OP, IVIG n.a. 
9 n.a. Dose/kg/day n.a. (500 mg BD; bw n.a.) OP, IVIG n.a. 
10 n.a. Dose/kg/day n.a. (500 mg BD; bw n.a.) OP, IVIG n.a. 
11 n.a. Dose/kg/day n.a. (500 mg BD; bw n.a.) OP, IVIG n.a. 
12 n.a. Dose/kg/day n.a. (500 mg BD; bw n.a.) OP, IVIG n.a. 
13 n.a. Dose/kg/day n.a. (500 mg BD; bw n.a.) OP, IVIG n.a. 
14 n.a. Dose/kg/day n.a. (500 mg BD; bw n.a.) OP, IVIG n.a. 
15 n.a. Dose/kg/day n.a. (500 mg BD; bw n.a.) OP, IVIG n.a. 
16 n.a. Dose/kg/day n.a. (500 mg BD; bw n.a.) OP, IVIG n.a. 
17 n.a. Dose/kg/day n.a. (500 mg BD; bw n.a.) OP, IVIG n.a. 
18 n.a. Dose/kg/day n.a. (500 mg BD; bw n.a.) OP, IVIG n.a. 
19 n.a. Dose/kg/day n.a. (500 mg BD; bw n.a.) OP, IVIG n.a. 
20 n.a. Dose/kg/day n.a. (500 mg BD; bw n.a.) OP, IVIG n.a. 
21 n.a. Dose/kg/day n.a. (500 mg BD; bw n.a.) OP, IVIG n.a. 
22 n.a. Dose/kg/day n.a. (500 mg BD; bw n.a.) OP, IVIG n.a. 
23 n.a. Dose/kg/day n.a. (500 mg BD; bw n.a.) OP, IVIG n.a. 
24 n.a. Dose/kg/day n.a. (500 mg BD; bw n.a.) OP, IVIG n.a. 
25 n.a. Dose/kg/day n.a. (500 mg BD; bw n.a.) OP, IVIG n.a. 
F, 8 y (seronegative suspected 
autoimmune encephalitis) 
5 4 mo 31 mg/kg/day (750 mg BD; bw 48 kg) Oral DEX; 
IVIG 
DEX tapering 
STUDY OF 3 DISEASE EVENTS OCCURRED IN 3 PATIENTS AFTER DISCONTINUATION OF MMF  
Gender, age at onset (diagnosis) Event number 
(including first 
event) 
Time from MMF discontinuation to the 
event 
Immune 
therapy at 
the event 
Medication weaning 
F, 5.2 y (MOG-associated 
demyelinating disease: CRION) 
7 5 d OP 25 mg 
OD 
OP tapering (started <1 month 
prior to the event) 
~F, 1.6 y (Seronegative 
suspected autoimmune 
encephalitis) 
4 8 mo Pulsed DEX No 
#F, 2 y (MOG-associated 
demyelinating disease)     
4 4 mo No No 
*F, 14.1 y (Cerebral vasculitis)       2 4 mo No No (OP stopped 8 months prior 
to the event) 
 
Table 3. Study of the disease events occurred during and after treatment with MMF. 
Legend: BD: bis in die; bw: body weight; d: day; DEX: dexamethasone; F: female; IVIG: intravenous 
immunoglobulin; mo: month; n.a.: not available; OD: once per day; OP: oral prednisone; wk: week; y: 
year. ~The two cases with this symbol were the same patient. #The two cases with this symbol were the 
same patient. *The two cases with this symbol were the same patient. 
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A comparison between demographics, clinical characteristics and treatment data in the subgroups of 
patients who relapsed and who did not relapse during/after treatment with MMF is presented in Table 4. 
Diagnosis distribution and disease severity were similar in the two subgroups. Patients who relapsed 
during MMF (8/39, 20.5%), compared to patients who did not relapse (31/39, 79.5%), were younger 
(median age 4.2 years, mean 5.7, range 1.6-14.1; data in 8/8; versus median 7.6, mean 8.3, range 1.2-
15.7; data in 31/31 patients), had higher proportion of females (8/8, 100% versus 21/31, 67.7%), had 
lower rate of treatment with second-line therapies (cyclophosphamide and/or rituximab) before MMF 
(1/8, 12.5% versus 15/31, 48.4%), a later commencement of MMF (>6 months after disease onset in 
7/8, 87.5% versus 18/31, 58.1%), and more frequently they were started  on MMF only after ≥2 events 
had occurred (7/8, 87.5% versus 14/31, 45.2%). 
Safety. Adverse reactions to MMF occurred in 18.2% of cases (8/44) (Table 5): gastrointestinal adverse 
reactions included abdominal pain in 2 patients, not requiring medications, and appetite suppression in 1 
(grade 2 CTCAE v4.0); infectious adverse reactions occurred in 2 patients: 1 patient had herpes zoster 
(2.75 years after commencement of MMF), and another one required admission for pneumonia (1.4 
years after commencement of MMF) (grade 3 CTCAE v4.0); 1 patient had a maculopapular rash 7 days 
after commencement of MMF (grade 2 CTCAE v4.0); 2 patients had movement disorders: 1 had 
tremor, and 1 developed jerking and stiffness of legs on MMF dose escalation (grade 2 CTCAE v4.0). 
Time from MMF commencement to adverse reaction was median 1 month (mean 9.2, range 0.25-33; 
data available in 7/8 patients). 42.8% (3/7) patients were on other medications at the time of the adverse 
event. In 37.5% (3/8) cases was MMF discontinued due to side effects: one 5.2 year old girl with MOG-
associated CRION discontinued MMF 3 weeks after commencement (at the dose of 55 mg/kg/day) due 
to crampy abdominal pain (she relapsed 5 days after discontinuation, and MMF was resumed 1.5 
months after the relapse, still ongoing at last follow-up); one 14.7 year old girl with MOG-associated 
NMOSD discontinued MMF 10 days after commencement (at the dose of 13 mg/kg/day) due to tremor; 
one 2 year old girl with MOG-associated demyelinating disease discontinued MMF 17 months after 
commencement (at the dose of 13 mg/kg/day) due to inefficacy and appetite suppression. An additional 
4 year old girl with MOG-associated demyelinating disease developed jerking and stiffness of legs on 
dose escalation, 1 month after MMF commencement, and benefitted from dose reduction (dose was 
increased again later in the absence of adverse reactions).  
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Table 4 
 
COMPARISON BETWEEN PATIENTS WHO DID AND 
DID NOT RELAPSE DURING TREATMENT WITH 
MMF (excluding 4 patients with chronic/chronic-
progressive course) 
Patients who relapsed during  
MMF (n=8) 
Patients who did not relapse during MMF 
(n=31) 
Demographics   
Age at disease onset (years) Median 4.2, mean 5.7, range 1.6-14.1 (data 
available in 8/8 patients) 
Median 7.6, mean 8.3, range 1.2-15.7 (data 
available in 31/31 patients) 
Gender 8/8 (100%) females 21/31 (67.7%) females 
Diagnosis   
Encephalitis 4/8 (50%) 14/31 (45.2%) 
Anti-NMDAR encephalitis 1/8 (12.5%) 11/31 (35.5%) 
Seronegative suspected autoimmune encephalitis 3/8 (37.5%) 1/31 (3.2%) 
Anti-D2R encephalitis 0/8 (0%) 1/31 (3.2%) 
Anti-GAD encephalitis  0/8 (0%) 1/31 (3.2%) 
Inflammatory demyelinating CNS diseases 3/8 (37.5%) 11/31 (35.5%) 
MOG-associated demyelinating disease 3/8 (37.5%) 6/31 (19.3%) 
Neuromyelitis optica spectrum disorders (NMOSD) 0/8 (0%) 3/31 (9.7%) 
Multiple sclerosis 0/8 (0%) 1/31 (3.2%) 
Chronic relapsing inflammatory optic neuropathy (CRION) 0/8 (0%) 1/31 (3.2%) 
Other 1/8 (12.5%) 6/31 (19.3%) 
Neuropsychiatric systemic lupus erythematosus 1/8 (12.5%) 1/31 (3.2%) 
Cerebral vasculitis 0/8 (0%) 2/31 (6.4%) 
Pediatric acute-onset neuropsychiatric syndrome 
(PANS/PANDAS) 
0/8 (0%) 1/31 (3.2%) 
Relapsing autoimmune chorea 0/8 (0%) 1/31 (3.2%) 
Opsoclonus myoclonus ataxia syndrome (OMAS) 0/8 (0%) 1/31 (3.2%) 
Genetic autoinflammation 0/8 (0%) 0/31 (0%) 
Disease course   
Multiphasic (relapsing) 8/8 (100%) 17/31 (54.8%) 
Monophasic 0/8 (0%) 14/31 (45.2%) 
Disease severity   
Worst mRS during the disease course Median 4, mean 4.1, range 3-5 (data 
available in 8/8) 
Median 4, mean 4.1, range 2-5 (data 
available in 31/31) 
Admission to paediatric intensive care unit 2/7 (87.5%) 11/31 (35.5%) 
Treatments other than MMF Before MMF During the whole 
disease course 
Before MMF During the whole 
disease course 
Any steroids 8/8 (100%) 8/8 (100%) 31/31 (100%) 31/31 (100%) 
Intravenous steroids 7/8 (87.5%) 8/8 (100%) 29/31 (93.5%) 29/31 (93.5%) 
Oral steroids 8/8 (100%) 8/8 (100%) 31/31 (100%) 31/31 (100%) 
Intravenous immunoglobulin 5/8 (62.5%) 6/8 (75%) 15/31 (48.4%) 17/31 (54.8%) 
Plasma exchange 2/8 (25%) 2/8 (25%) 12/31 (38.7%) 12/31 (38.7%) 
Any second-line treatment (Cyclophosphamide and/or 
Rituximab) 
1/8 (12.5%) 3/8 (37.5%) 15/31 (48.4%) 15/31 (48.4%) 
Cyclophosphamide 1/8 (12.5%) 1/8 (12.5%) 11/31 (35.5%) 11/31 (35.5%) 
Rituximab 0/8 (0%) 2/8 (25%) 5/31 (16.1%) 5/31 (16.1%) 
Azathioprine 1/8 (12.5%) 1/8 (12.5%) 1/31 (3.2%) 1/31 (3.2%) 
Other 0/8 (0%) 0/8 (0%) 1/31 (3.2%) 2/31 (6.4%) 
Time from disease onset to first immune therapy (any)   
Days from disease onset to first immune therapy Median 26, mean 82, range 5-221 (data 
available in 5/8) 
Median 22, mean 42.3, range 3-365 (data 
available in 30/31) 
First immune therapy ≤30 days from onset 5/7 (71.4%) 22/30 (73.3%) 
Time from disease onset to MMF (months) Median 14.2, mean 16.8, range 6-46.2 (data 
available in 8/8) 
Median 7, mean 20.4, range 1-127 (data 
available in 31/31) 
≤6 months 1/8 (12.5%) 13/31 (41.9%) 
7-12 months 2/8 (25%) 9/31 (29%) 
≥13 months 5/8 (62.5%) 9/31 (29%) 
Age at MMF commencement (years) Median 6.4, mean 7.2, range 2.2-14.7 (data 
available in 8/8) 
Median 9.5, mean 9.8, range 1.4-16.4 (data 
available in 31/31) 
≤6 years 4/8 (50%) 8/31 (25.8%) 
7-12 years 3/8 (37.5%) 12/31 (38.7%) 
≥13 years 1/8 (12.5%) 11/31 (35.5%) 
Number of events before MMF commencement Median 2.5, mean 2.5, range 1-4 (data 
available in 8/8) 
Median 1, mean 2.1, range 1-6 (data 
available in 31/31) 
1 event 1/8 (12.5%) 17/31 (54.8%) 
2 events 3/8 (37.5%) 4/31 (12.9%) 
≥3 events 4/8 (50%) 10/31 (32.2%) 
Time on MMF (months) Median 21.5, mean 29, range 7-64 (data 
available in 8/8) 
Median 18, mean 20.8, range 0.3-55 (data 
available in 31/31) 
Outcome   
Length of follow-up (years) Median 4.3, mean  4.4, range 1.6-6.4 (data 
available in 8/8) 
Median 3.2, mean 4.2, range 1-14.3 (data 
available in 31/31) 
mRS at last follow-up Median 2.5, mean 2, range 0-4 (data 
available in 8/8) 
Median 1, mean 1.1, range 0-3 (data 
available  in 31/31) 
No ongoing problems 2/8 (25%) 8/31 (23.5%) 
Ongoing cognitive or learning problems 6/8 (75%) 13/31 (41.9%) 
Ongoing behavioural problems 4/8 (50%) 6/31 (19.3%) 
Ongoing motor problems 1/8 (12.5%) 3/31 (9.7%) 
Ongoing visual impairment 1/8 (12.5%) 4/31 (12.9%) 
Ongoing epilepsy 1/8 (12.5%) 45/31 (16.1%) 
Other ongoing problem 1/8 (12.5%) 4/31 (12.9%) 
Ongoing immune therapy at last follow-up 7/8 (87.5%) 18/31 (58.1%) 
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Table 4. Comparison between demographics, clinical characteristics and treatment data in the subgroups 
of patients who relapsed and who did not relapse during treatment with mycophenolate mofetil, after 
exclusion of patients with chronic/cronic-progressive disease course. 
Legend: Anti-NMDAR: anti-N-methyl-D-Aspartate; AQP4: aquaporin-4; CNS: central nervous system; 
CRION: chronic relapsing inflammatory optic neuropathy; D2R: dopamine 2 receptor; GAD: glutamate 
decarboxylase; IVIG: intravenous immunoglobulin; MMF: mycophenolate mofetil; MOG: 
myelin oligodendrocyte glycoprotein; mRS: modified Rankin Scale; NMOSD: neuromyelitis optica 
spectrum disorder; OMAS: opsoclonus myoclonus ataxia syndrome; RTX: rituximab. 
 
 
 
Table 5 
 
ADVERSE REACTIONS TO MMF OCCURRED IN 8 PATIENTS 
Gender, age at onset 
(diagnosis) 
Adverse 
reaction 
Severity 
(CTCAE 
v4.0) 
Time from MMF 
commencement 
to adverse 
reaction 
MMF dose at the time 
of adverse reaction 
Intervention required Other concomitant 
medications 
F, 5.2 yr (MOG-
associated 
demyelinating 
disease: CRION) 
Gastrointestinal: 
crampy 
abdominal pain 
Grade 2 3 weeks 55 mg/kg/day (1000 mg 
+ 500 mg/day; bw 27 
kg) 
MMF discontinuation 3 weeks 
after commencement (5 days after 
discontinuation she relapsed; 
MMF was resumed 1.5 months 
after the relapse and was still 
ongoing at last follow-up) 
OP 25 mg OD; 
Omeprazole (IVMP 
3 weeks before 
MMF adverse 
reaction) 
F, 9.7 y (anti-
NMDAR 
encephalitis) 
Gastrointestinal: 
mild abdominal 
pain 
Grade 2 n.a. 600 mg/m2 (bw 40 kg) None (MMF discontinued due to 
inefficacy, not due to side effects) 
n.a. 
F, 2 y (MOG-
associated 
demyelinating 
disease)    
Gastrointestinal: 
appetite 
suppression 
Grade 2 12 months 53 mg/kg/day (400 mg 
BD; bw 15 kg) 
MMF discontinuation 17 months 
after commencement (due to 
inefficacy and appetite 
suppression) 
None 
F, 14.7 y (MOG-
associated 
demyelinating 
disease: NMOSD) 
Movement 
disorder: tremor 
Grade 2 10 days 13 mg/kg/day (500 mg 
BD; bw 78 kg) 
MMF discontinuation 10 days 
after commencement (not 
subsequently resumed) 
OP 50 mg OD 
(IVMP 2 weeks 
before MMF adverse 
reaction) 
F, 4 y (MOG-
associated 
demyelinating 
disease)  
Movement 
disorder: 
jerking and 
stiffness of legs 
Grade 2 1 month 500mg/m2 BD (bw 
n.a.) [on dose 
escalation: after 2 
weeks from 300mg/m2 
BD to 500mg/m2 BD] 
MMF dose reduction, with good 
tolerability (subsequently dose 
was increased without adverse 
events to 500mg/m2 BD; MMF 
still ongoing at last follow-up) 
OP tapering 
M, 4.3 y (anti-
NMDAR 
encephalitis) 
Dermatologic: 
maculopapular 
rash 
Grade 2 7 days 600 mg/m2/dose BD 
(bw 18 kg) 
None (MMF not discontinued, still 
ongoing at last follow-up) 
None (Steroids, 
IVIG, RTX 1 month 
prior to MMF 
adverse reaction) 
F, 14.1 y (Cerebral 
vasculitis)  
Infectious: 
herpes zoster 
 
Grade 3 33 months 48 mg/kg/day (1000 mg 
BD; bw 42 kg) 
None (MMF not discontinued, still 
ongoing at last follow-up) 
None (CYC up to 
2.5 years and IVMP 
up to 1.5 prior to 
adverse reaction) 
F; 2.2 y (anti-
NMDAR 
encephalitis)  
Infectious: 
pneumonia; 
recurrent 
infections 
Grade 3 17 months 600 mg/m2/dose BD 
(bw n.a.) 
Required admission for 
pneumonuia (no PICU, no 
ventilation) (MMF discontinued 
25 months after commencement 
due to absence of relapses) 
None 
 
Table 5. Adverse reactions to MMF occurred in 8 patients. 
Legend: BD: bis in die; bw: body weight; CTCAE v4.0: Common Terminology Criteria for Adverse 
Events; CYC: cyclophosphamide; F: female; IVIG: intravenous immunoglobulin; IVMP: intravenous 
methylprednisolone; M: male; MMF: mycophenolate mofetil; n.a.: not available; OD: once per day; OP: 
oral prednisone; PICU: paediatric intentive care unit; RTX: rituximab; wk: week; y: year. 
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Discussion 
Our retrospective study on paediatric patients treated with MMF for autoimmune or immune-mediated 
CNS disorders disclosed a great heterogeneity in MMF use, reflecting the lack of definite 
recommendations and the limited availability of literature data. While all patients received other 
immune therapies before MMF, second-line treatments (cyclophosphamide and/or rituximab) were 
administered only in 38.6% (17/44) before MMF (Table 2). Recent surveys on treatment of autoimmune 
encephalitis have documented the persistence of a vast heterogeneity in the use of second-line immune 
therapy and, even more, of maintenance immune suppression [Bartolini, 2017; Kahn, 2017]. Moreover, 
in our population MMF administration was delayed >6 months from onset in 68.2% (30/44), and in 55% 
(22/40) MMF was administered only after relapses had occurred. The duration of treatment with MMF 
was also highly heterogeneous, ranging between 0.3 and 73 months. Indeed, for many of the clinical 
conditions included in our population, it is unclear how long the inflammatory component of disease 
lasts for. In this respect, there is some correlation of CXCL13 and disease severity and relapse [Kothur, 
2016; Kothur, 2017] that may be useful in guiding treatment.  
In our population, the main indications for MMF use were encephalitis and inflammatory demyelinating 
CNS diseases, while a smaller, more heterogeneous group included other autoimmune/immune-
mediated CNS conditions (Table 1). MMF role in autoimmune or immune-mediated encephalitis, and 
its efficacy compared to other steroid sparers, has not been thoroughly explored yet [Nosadini and Dale, 
in progress], while its use is more consolidated in some inflammatory demyelinating CNS diseases. In 
recent studies on adults with neuromyelitis optica spectrum disorders, MMF was shown to be effective 
[Montcuquet, 2017], and both MMF and azathioprine significantly reduced relapse rate and disability 
scores [Chen, 2017; Xu, 2016]. During treatment with MMF, ARR was reduced in all diagnosis groups 
in our population (Table 2), although definite comparisons are hindered by the limited number of cases.  
While a comparison of patients who did and did not receive MMF was not possible in our population in 
view of the inclusion criteria, we tried to identify factors associated with lack of efficacy of MMF. In 
our population, the subgroup of patients who relapsed during MMF, compared to patients who did not 
relapse, were younger and more frequently females, had lower rate of second-line therapies before 
MMF, a later commencement of MMF, and more frequently they were started on MMF only after ≥2 
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events had occurred. These results seem to be in agreement with other data in the literature, supporting 
the role of early and aggressive immune therapy [Nosadini, 2015].   
Adverse reactions to MMF occurred in 18.2% (8/44) of cases in our population, mostly of moderate 
severity, although two patients had severe infections. While studies focused on MMF safety in 
paediatric neurology are not available, data derived from MMF use in subsets of children with 
neurologic conditions and other paediatric diosorders [Rosati, 2017; Hassan, 2013], seem to disclose a 
favorable safety profile. In a recent study on adults with neuromyelitis optica specturm disorders, MMF 
had a significantly better tolerability profile than azathioprine [Chen, 2017]. 
Our study is primarily limited by the retrospective design and the restricted number of patients. Severity 
of disease was estimated via the mRS score, although this scale was not designed to detect and render 
the vast array of disturbances that occur in some of the disorders included in the study. Similarly, the 
utility of ARR in this setting may be limited in some diagnosis group, such as anti N-methyl-D-
aspartate encephalitis. In view of the inclusion criteria, efficacy of MMF could not be studied with 
comparison to patients who did not receive MMF, which would be of utmost clinical interest and 
warrants further studies. Similarly, the efficacy of steroid sparers for sustained remission and relapse 
prevention should be explored further in comparison to other approaches proposed in the literature, such 
as monthly rituximab, IVIG or plasma exchange, or sustained use of oral corticosteroids [Shin, 2017; 
Dale, 2017]. 
Despite these limitations, our study contributes to addressing the lack of literature data on the use, 
efficacy and safety of MMF in paediatric autoimmune or immune-mediated CNS disorders. The utility 
of MMF as compared to other agents could not be investigated in our study, and remains to be clarified. 
Although, when MMF is used, our results seem to point to a better efficacy when MMF is preceded by 
second-line immune therapies, and MMF is given early in the disease course. Even if MMF safety 
profile appears relatively good, the possibility of adverse reactions, also severe, should not be 
overlooked, and weighted in a ‘risk versus benefit’ approach.  
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Supplementary Table 1 
 
STUDY OF DISEASE 
EVENTS (excluding 4 
patients with 
chronic/chronic-progressive 
disease course) 
All events (n=130) First events (n=40) Subsequent events (n=90) 
Event severity    
Worst mRS during event Median 3, mean 3.3, range 1-5 (data 
available in 94/130) 
Median 4, mean 4, range 2-5 (data 
available in 36/40) 
Median 3, mean 2.9, range 1-5 (data 
available in 58/90) 
Best mRS after event Median 1, mean 1.3, range 0-4 (data 
available in 92/130) 
Median 1, mean 1, range 0-4 (data 
available in 36/40) 
Median 1, mean 1.4, range 0-4 (data 
available in 56/90) 
Events occurred whilst on 
immune therapy 
58/130 (44.6%) 1/40* (2.5%) 57/90 (63.3%) 
Steroids + Intravenous 
immunoglobulin + MMF 
24/58 (41.4%) 0/40 (0%) 24/57 (42.1%) 
Steroids 16/58 (27.6%) (14/16: OP, 1/16 oral 
DEX, 1/16 IVDEX) 
0/40 (0%) 16/57 (28.1%) (14/16: OP, 1/16 oral 
DEX, 1/16 IVDEX) 
MMF 7/58 (12.1%) 0/40 (0%) 7/57 (12.3%) 
Steroids + Intravenous 
immunoglobulin 
3/58 (5.2%) 0/40 (0%) 3/57 (5.3%) 
Steroids + MMF 3/58 (5.2%) 0/40 (0%) 3/57 (5.3%) 
Steroids + Azathioprine + 
Tacrolimus 
3/58 (5.2%) 1/40 (2.5%) 2/57 (3.5%) 
Intravenous immunoglobulin 2/58 (3.4%) 0/40 (0%) 2/57 (3.5%) 
Events occurred whilst 
tapering or ≤2 months from 
discontinuation of immune 
therapy  
31/103 (30.1%) 0/40 (0%) 31/63 (49.2%) 
Oral steroids (Prednisone or 
Dexamethasone) 
22/31 (71%) 0/40 (0%) 22/31 (71%) 
Oral Prednisone + MMF 5/31 (16.1%) 0/40 (0%) 5/31 (16.1%) 
MMF  4/31 (12.9%) 0/40 (0%) 4/31 (12.9%) 
Immune therapy received at 
the event 
124/130 (95.4%) 37/40 (92.5%) 87/90 (96.7%) 
Time to treatment (days) Median 10, mean 25.6, range 0-426 
(data available in 73/124) 
Median 17.5, mean 25.8, range 3-137 
(data available in 32/37) 
Median 10, mean 25.4, range 0-426 
(data available in 41/90) 
Any steroids 116/130 (89.2%) 37/40 (92.5%) 79/90 (87.8%) 
Intravenous steroids 88/130 (67.7%) (84/88: IVMP; 4/88: 
IVDEX) 
32/40 (80%) (30/32: IVMP; 2/32: 
IVDEX) 
56/90 (62.2%) (54/56: IVMP; 2/56: 
IVDEX) 
Oral steroids 114/130 (87.7%) 37/40 (92.5%) 77/90 (85.5%) 
Intravenous immunoglobulin 66/130 (50.7%) 15/40 (37.5%) 51/90 (56.7%) 
Plasma exchange 15/130 (11.5%) 11/40 (27.5%) 4/90 (4.4%) 
Any second-line treatment 
(Cyclophosphamide and/or 
Rituximab) 
21/130 (16.1%) 15/40 (37.5%) 6/90 (6.7%) 
Cyclophosphamide 12/130 (9.2 %) 11/40 (27.5%)  1/90 (1.1%) 
Rituximab 10/130 (7.7%) 5/40 (12.5%) 5/90 (5.5%) 
Azathioprine 4/130 (3.1%) 1/40 (2.5%) 3/90 (3.3%) 
MMF 79/130 (60.8%) 18/40 (45%) 61/90 (67.8%) 
Other 4/130 (3.1%) (3/4 Tacrolimus, 1/4 
Hydroxychloroquine) 
2/40 (5%) (Hydroxychloroquine, 
Tacrolimus) 
2/90 (2.2%) (Tacrolimus) 
 
Supplementary Table 1. Study of disease events. 
A total 130 events occurred in 40 patients (excluding 4 patients with chronic/chronic-progressive 
disease course): 113 events in 23 patients with multiphasic (relapsing) disease (including first events) 
(median 4 events per patient, mean 4.9, range 2-25), and 17 events in 17 patients with monophasic 
disease. 
Legend: DEX: dexamethasone; IVDEX: intravenous dexamethasone; IVMP: intravenous 
methylprednisolone; MMF: mycophenolate mofetil; OP: oral prednisone. 
*1 patient was on low dose prednisone, azathioprine and tacrolimus for renal transplant before onset of 
PANS/PANDAS 
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4. DISCUSSION 
 
The present thesis is a collection of ten works exploring several aspects of the clinical and therapeutic 
decision-making in paediatric autoimmune and immune-mediated inflammatory conditions. This field 
includes a vast array of diseases with variable clinical manifestations and severity, and with a broad 
differential diagnosis. An additional challenge is represented by the fact that this is a quickly expanding 
field, thanks to a more and more accurate clinical phenotyping, and neuroradiology and laboratory 
advances. Therefore, classifications and disease groupings are being rearranged, and new clinical 
entities introduced. This is the case for the identification of anti-NMDAR antibodies in 2007, leading to 
the subsequent identification of an array of other antibodies targeting neuronal surface antigens 
associated to autoimmune encephalitis. Similarly, the identification of MOG antibodies has led to the 
definition of a group of demyelinating disorders whose clinical features are yet to be fully understood.  
Immune therapies, such as corticosteroids, have been used for a long time in neurology and in other 
fields of paediatrics, although their mechanism of action are not always fully understood, and it is 
possible that multiple, concomitant actions are responsible for the therapeutic effect [Nosadini, 2017]. 
With the new diagnostic categories introduced by advances in disease identification, “old” drugs are 
being used for “new” indications, but also new drugs are becoming more and more available: disease 
modifying drugs for multiple sclerosis introduced in the last decades have changed the natural history of 
this condition, and the utility of monoclonal antibodies is currently being broadly investigated. 
Although, the enthusiasm in the exploration of the effect and safety of immune therapeutic agents, is 
usually held back by the relative rarity of most autoimmune and inflammatory conditions, which, along 
with their recent identification in some cases, make for the lack of quality data, such as randomized 
controlled trials, in most paediatric autoimmune and inflammatory neurological conditions. Moreover, 
data in children are sometimes derived from adult studies.  
In this context, the present thesis aimed at gathering data and shedding more light on the available 
evidence on the use of immune therapy in the literature, and at investigating this aspect in different 
clinical situations. One of the main areas of our exploration focused on the category of autoimmune 
encephalitis with antibodies targeting neuronal surface antibodies [Nosadini, 2015]. This is a 
fascinating, relatively recent section in neuroimmunology, likely bound to quickly expand further in the 
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next years possibly leading to further diagnostic definition of some of those entities yet with poor 
serologic characterization, such as seronegative suspected autoimmune encephalitis [Graus, 2016]. The 
distinction between the categories of encephalitis with antibodies targeting neuronal surface antibodies 
and that associated to antibodies targeting intracellular antigens (paraneoplastic syndromes) can be done 
at different levels, where the relatively good response to immune therapy in the former group is central. 
Despite data are heterogeneous, there are common therapeutic themes emerging: firstly, patients given 
immune therapy do better and relapse less than patients given no treatment; secondly, patients given 
early treatment do better; and thirdly, when patients fail first-line therapy, second-line therapy improves 
outcomes and reduces relapses. This literature trend was confirmed also in out Italian cohort of 
paediatric anti-NMDAR encephalitis [Sartori, 2015], with a better neurological outcome in patients 
treated early. Still within the theme of autoimmune encephalitis, we explored the particular 
circumstance of anti-NMDAR encephalitis occurring after herpes simplex virus CNS infection 
[Nosadini, 2017]. The description of this phenomenon in 2012 [Prüss, 2012] gave a further insight on 
the pathogenesis of anti-NMDAR encephalitis, and it possibly provided arguments in favour of the 
rationale for the debated use of immune therapy in the acute phase of herpes simplex encephalitis. It is 
noteworthy that in this literature cohort none of the patients treated with immune therapy for herpes 
simplex virus-induced anti-NMDAR encephalitis were reported to have recurrence of herpes simplex 
encephalitis, suggesting immune therapy given for herpes simplex virus-induced anti-NMDAR 
encephalitis does not predispose to recurrence of herpes simplex encephalitis. 
The last part of the work for the present thesis focused on the study of individual immune therapies 
declined into different clinical situations. Intravenous immunoglobulin was studied through a 
retrospective cohort of children with a vast array of neuroimmunology conditions, who received 
intravenous immunoglobulin over the years 2000-2014. The analysis of this cohort of children also 
included health economics data and comparison with available recommendations on use of intravenous 
immunoglobulin in paediatric neurology, and results showed that intravenous immunoglobulin is a 
relatively safe treatment, although very expensive. This work also disclosed discrepancies between 
guidelines and clinical practice in paediatric neurology, suggesting both the need for greater adherence 
to current recommendations, and for recommendations to be updated to accommodate emerging 
indications.  
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Therapeutic plasma exchange is a procedure relatively frequently used at our University hospital of 
Padova, Italy, also in children - thanks to the expertise of the apheresis team – while its use in other 
centres in paediatric neurology is strongly influenced by the individual centres’ treating habits. The use 
of plasma exchange is regulated by the guidelines of the American Society for Apheresis, which include 
several neurological indications; it is noteworthy that anti-NMDAR encephalitis was included in the 
latest issue [Schwartz, 2016]. When we reviewed the use of therapeutic plasma exchange in a literature 
cohort of children with anti-NMDAR encephalitis [Suppiej, 2016], we observed a trend toward a better 
outcome when therapeutic plasma exchange was coupled with steroids in first-line treatments, possibly 
benefitting of the association with an agent acting centrally.  
One of the project of the present thesis focused on rituximab re-dosing in paediatric neuromyelitis 
optica spectrum disorder [Nosadini, 2016]. While another large study focused on rituximab safety has 
recently been published [Dale, 2014], this work aimed at identifying factors related to treatment efficacy 
or failure. Indeed, relapse prevention in neuromyelitis optica is key to avoid the accumulation of 
permanent neurological deficits, and the identification of factors able to maximise rituximab efficacy 
could be of invaluable utility in clinical practice, possibly also in other diseases. The association 
between B cell repopulation and relapse risk was studied thoroughly, confirming the relationship 
between CD19 repopulation and increased risk for relapses, and the validity of a previously proposed 
threshold for B cell repopulation (CD19 ≥10 x 106 cells/L). Therefore, suggestions were formulated on 
the need for a close CD19 monitoring in order to prevent relapses. 
Finally, two of the projects have been focusing on steroid sparing agents in paediatric autoimmune and 
immune-mediated conditions, disclosing huge heterogeneity in the use of these compounds and the need 
for quality studies to clarify their risk-benefit profile. 
The main limitations of the present work are represented by the retrospective nature of the studies and 
the limited number of patients. Despite this, the present project may help shed further light on some 
aspects of treatment in paediatric neurology that are still partly unexplored or incompletely clarified, 
and contribute to the growth and the shaping of this field. Most importantly, this thesis has helped me 
grow and gain perspective in the field of decision making in paediatric neuroimmunology, even though 
there are major areas that warrant further exploration.  
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Shifting the focus from the therapy to the disease, it should not be forgotten that an adequate 
understanding of the pathophysiology may allow for a more adequate treatment strategy. The blood 
brain barrier is a dynamic element those modifications, such as changes in permeability due to an 
inflammatory state, may play a role in the pathophysiology of the disease [Alvarez, 2015] as well as in 
the penetration of immune therapy to the CNS. Moreover, knowing if neuroinflammation is 
predominantly driven centrally or peripherally may influence how we choose or direct therapy [Dale, 
2016]. For example, in disease with intrathecal inflammation such as anti-NMDAR encephalitis, while 
immune therapies acting peripherally (i.e. plasma exchange) may help reducing the total circulating 
antibodies, lymphocytes and other inflammatory molecules, an immune therapeutic agent acting 
centrally, such as corticosteroids, should be warranted [Dale, 2016].  
The theme of clinical and therapeutic decision making in paediatric neurology goes far beyond a 
thorough knowledge of immune therapeutic agents and their action, modes of use, efficacy and safety 
profile, notwithstanding this certainly is a key element. Indeed, clinical practice often requires that this 
theoretical knowledge be declined into a variety of scenarios, and the ability to understand each clinical 
situation in all its facets. While difficult to be learnt on books, these aspects are mainly derived from 
each clinician’s personal experience, and are beautifully dealt with in a recent discussion paper by 
Russell Dale [Dale, 2016]. Neuroimmunology conditions in paediatric age represent a spectrum with a 
broad range of severity and that may include life-threatening situations, such as in anti-NMDAR 
encephalitis and ADEM. Severe clinical scenarios may justify more aggressive therapies to get past the 
acute phase, in a balanced approach that takes into consideration potential treatment’s side effects. 
Moreover, the natural history of different conditions may vary hugely, with the potential for relapses in 
many cases, suggesting the need for a long-term immune suppression. The risk for permanent disability 
is another pivotal element of discussion in the decision making process, such as in neuromyelitis optica 
spectrum disorders, where the minimization of neurological injury in the acute phase and the prevention 
of relapses are exponentially increased, as compared to other situations, in view of the possibility of 
accumulation of irreversible disability. Although, the recent literature has been pointing to the actual 
existence of “subtle” sequelae also in situations where overt neurological deficits are typically not 
observed, such as in anti-NMDAR encephalitis and ADEM [Matricardi, 2016; Suppiej, 2014; Pawela, 
2017], adding elements in favour of a more aggressive treatment regimen. Despite the considerable 
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clinical challenges encountered in the abovementioned situations, an even further level in the 
complexity of the clinical and decisional decision making process is represented by scenarios such as 
that of seronegative suspected autoimmune encephalitis [Graus, 2016], where the clinical definition and 
therefore the potential severity and natural history of the condition are less clear. 
In conclusion, a comprehensive understanding of the therapeutic aspects should not go without the 
ability to understand each clinical situation in all its facets, taking into considerations not only potential 
effects, adverse reactions and mechanisms of treatment agents, but also the pathophysiology, the 
severity of the acute disease, the risk of relapses and of permanent disability, in a complex ‘risk-versus-
benefit’ determination and a tailored approach (Figure 1) [Dale, 2016].   
 
 
Figure 1 
 
 
 
 
Figure 1 [Dale, 2016]. The complexity of therapeutic decision-making: Balancing the risk of disease 
with risk of drug side effects. The figure demonstrates some of the variables involved in therapeutic 
decision-making. 
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